<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY f021-001-9780702070280 SYSTEM "f021-001-9780702070280" NDATA IMAGE><!ENTITY f021-002-9780702070280 SYSTEM "f021-002-9780702070280" NDATA IMAGE><!ENTITY f021-003-9780702070280 SYSTEM "f021-003-9780702070280" NDATA IMAGE><!ENTITY f021-004-9780702070280 SYSTEM "f021-004-9780702070280" NDATA IMAGE><!ENTITY f021-005-9780702070280 SYSTEM "f021-005-9780702070280" NDATA IMAGE><!ENTITY f021-006-9780702070280 SYSTEM "f021-006-9780702070280" NDATA IMAGE><!ENTITY f021-007-9780702070280 SYSTEM "f021-007-9780702070280" NDATA IMAGE><!ENTITY f021-008-9780702070280 SYSTEM "f021-008-9780702070280" NDATA IMAGE><!ENTITY f021-009-9780702070280 SYSTEM "f021-009-9780702070280" NDATA IMAGE><!ENTITY f021-010-9780702070280 SYSTEM "f021-010-9780702070280" NDATA IMAGE><!ENTITY f021-011a-9780702070280 SYSTEM "f021-011a-9780702070280" NDATA IMAGE><!ENTITY f021-011b-9780702070280 SYSTEM "f021-011b-9780702070280" NDATA IMAGE><!ENTITY f021-012ac-9780702070280 SYSTEM "f021-012ac-9780702070280" NDATA IMAGE><!ENTITY f021-013ad-9780702070280 SYSTEM "f021-013ad-9780702070280" NDATA IMAGE><!ENTITY f021-014-9780702070280 SYSTEM "f021-014-9780702070280" NDATA IMAGE><!ENTITY f021-015a-9780702070280 SYSTEM "f021-015a-9780702070280" NDATA IMAGE><!ENTITY f021-015b-9780702070280 SYSTEM "f021-015b-9780702070280" NDATA IMAGE><!ENTITY f021-016-9780702070280 SYSTEM "f021-016-9780702070280" NDATA IMAGE><!ENTITY f021-017-9780702070280 SYSTEM "f021-017-9780702070280" NDATA IMAGE><!ENTITY f021-018-9780702070280 SYSTEM "f021-018-9780702070280" NDATA IMAGE><!ENTITY f021-019-9780702070280 SYSTEM "f021-019-9780702070280" NDATA IMAGE><!ENTITY f021-020a-9780702070280 SYSTEM "f021-020a-9780702070280" NDATA IMAGE><!ENTITY f021-020b-9780702070280 SYSTEM "f021-020b-9780702070280" NDATA IMAGE><!ENTITY f021-021-9780702070280 SYSTEM "f021-021-9780702070280" NDATA IMAGE><!ENTITY f021-022-9780702070280 SYSTEM "f021-022-9780702070280" NDATA IMAGE><!ENTITY f021-023-9780702070280 SYSTEM "f021-023-9780702070280" NDATA IMAGE><!ENTITY f021-024-9780702070280 SYSTEM "f021-024-9780702070280" NDATA IMAGE><!ENTITY f021-025-9780702070280 SYSTEM "f021-025-9780702070280" NDATA IMAGE><!ENTITY f021-026-9780702070280 SYSTEM "f021-026-9780702070280" NDATA IMAGE><!ENTITY f021-027ab-9780702070280 SYSTEM "f021-027ab-9780702070280" NDATA IMAGE><!ENTITY f021-028-9780702070280 SYSTEM "f021-028-9780702070280" NDATA IMAGE><!ENTITY f021-029-9780702070280 SYSTEM "f021-029-9780702070280" NDATA IMAGE><!ENTITY f021-030-9780702070280 SYSTEM "f021-030-9780702070280" NDATA IMAGE><!ENTITY f021-031ab-9780702070280 SYSTEM "f021-031ab-9780702070280" NDATA IMAGE><!ENTITY f021-032-9780702070280 SYSTEM "f021-032-9780702070280" NDATA IMAGE><!ENTITY f021-033-9780702070280 SYSTEM "f021-033-9780702070280" NDATA IMAGE><!ENTITY f021-034-9780702070280 SYSTEM "f021-034-9780702070280" NDATA IMAGE><!ENTITY f021-035-9780702070280 SYSTEM "f021-035-9780702070280" NDATA IMAGE><!ENTITY f021-036-9780702070280 SYSTEM "f021-036-9780702070280" NDATA IMAGE><!ENTITY f021-037-9780702070280 SYSTEM "f021-037-9780702070280" NDATA IMAGE><!ENTITY f021-038-9780702070280 SYSTEM "f021-038-9780702070280" NDATA IMAGE><!ENTITY f021-039-9780702070280 SYSTEM "f021-039-9780702070280" NDATA IMAGE><!ENTITY f021-040-9780702070280 SYSTEM "f021-040-9780702070280" NDATA IMAGE><!ENTITY f021-041-9780702070280 SYSTEM "f021-041-9780702070280" NDATA IMAGE><!ENTITY f021-042a-9780702070280 SYSTEM "f021-042a-9780702070280" NDATA IMAGE><!ENTITY f021-042b-9780702070280 SYSTEM "f021-042b-9780702070280" NDATA IMAGE><!ENTITY f021-043-9780702070280 SYSTEM "f021-043-9780702070280" NDATA IMAGE><!ENTITY f021-044-9780702070280 SYSTEM "f021-044-9780702070280" NDATA IMAGE><!ENTITY f021-045-9780702070280 SYSTEM "f021-045-9780702070280" NDATA IMAGE><!ENTITY f021-046-9780702070280 SYSTEM "f021-046-9780702070280" NDATA IMAGE><!ENTITY f021-047-9780702070280 SYSTEM "f021-047-9780702070280" NDATA IMAGE><!ENTITY f021-048a-9780702070280 SYSTEM "f021-048a-9780702070280" NDATA IMAGE><!ENTITY f021-048b-9780702070280 SYSTEM "f021-048b-9780702070280" NDATA IMAGE><!ENTITY f021-049-9780702070280 SYSTEM "f021-049-9780702070280" NDATA IMAGE><!ENTITY f021-050-9780702070280 SYSTEM "f021-050-9780702070280" NDATA IMAGE><!ENTITY f021-051-9780702070280 SYSTEM "f021-051-9780702070280" NDATA IMAGE><!ENTITY f021-052-9780702070280 SYSTEM "f021-052-9780702070280" NDATA IMAGE><!ENTITY f021-053-9780702070280 SYSTEM "f021-053-9780702070280" NDATA IMAGE><!ENTITY f021-054-9780702070280 SYSTEM "f021-054-9780702070280" NDATA IMAGE><!ENTITY f021-055a-9780702070280 SYSTEM "f021-055a-9780702070280" NDATA IMAGE><!ENTITY f021-055b-9780702070280 SYSTEM "f021-055b-9780702070280" NDATA IMAGE><!ENTITY f021-056-9780702070280 SYSTEM "f021-056-9780702070280" NDATA IMAGE><!ENTITY f021-057-9780702070280 SYSTEM "f021-057-9780702070280" NDATA IMAGE><!ENTITY f021-058-9780702070280 SYSTEM "f021-058-9780702070280" NDATA IMAGE><!ENTITY f021-059-9780702070280 SYSTEM "f021-059-9780702070280" NDATA IMAGE><!ENTITY f021-060ad-9780702070280 SYSTEM "f021-060ad-9780702070280" NDATA IMAGE><!ENTITY f021-061ac-9780702070280 SYSTEM "f021-061ac-9780702070280" NDATA IMAGE><!ENTITY f021-062-9780702070280 SYSTEM "f021-062-9780702070280" NDATA IMAGE><!ENTITY f021-063-9780702070280 SYSTEM "f021-063-9780702070280" NDATA IMAGE><!ENTITY f021-064-9780702070280 SYSTEM "f021-064-9780702070280" NDATA IMAGE><!ENTITY f021-065-9780702070280 SYSTEM "f021-065-9780702070280" NDATA IMAGE><!ENTITY f021-066-9780702070280 SYSTEM "f021-066-9780702070280" NDATA IMAGE><!ENTITY f021-067-9780702070280 SYSTEM "f021-067-9780702070280" NDATA IMAGE><!ENTITY f021-068a-9780702070280 SYSTEM "f021-068a-9780702070280" NDATA IMAGE><!ENTITY f021-068b-9780702070280 SYSTEM "f021-068b-9780702070280" NDATA IMAGE><!ENTITY f021-069-9780702070280 SYSTEM "f021-069-9780702070280" NDATA IMAGE><!ENTITY f021-070a-9780702070280 SYSTEM "f021-070a-9780702070280" NDATA IMAGE><!ENTITY f021-070b-9780702070280 SYSTEM "f021-070b-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY icon03-9780702070280 SYSTEM "icon03-9780702070280" NDATA IMAGE><!ENTITY icon04-9780702070280 SYSTEM "icon04-9780702070280" NDATA IMAGE><!ENTITY icon05-9780702070280 SYSTEM "icon05-9780702070280" NDATA IMAGE><!ENTITY icon06-9780702070280 SYSTEM "icon06-9780702070280" NDATA IMAGE><!ENTITY u021-001-9780702070280 SYSTEM "u021-001-9780702070280" NDATA IMAGE><!ENTITY u021-002-9780702070280 SYSTEM "u021-002-9780702070280" NDATA IMAGE><!ENTITY u021-003-9780702070280 SYSTEM "u021-003-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00021" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00021-4</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00021-4</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0025"><ce:label>Fig. 21.1</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">The oesophagus: anatomy and function.</ce:simple-para><ce:simple-para id="sp0015" role="caption">The swallowing wave.</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 21.1</ce:alt-text><ce:link id="ln0025" locator="f021-001-9780702070280" xlink:href="pii:B9780702070280000214/f021-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 21.2</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" role="title">Normal gastric and duodenal anatomy.</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 21.2</ce:alt-text><ce:link id="ln0030" locator="f021-002-9780702070280" xlink:href="pii:B9780702070280000214/f021-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 21.3</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0025" role="title">Control of acid secretion.</ce:simple-para><ce:simple-para id="sp0030" role="caption">Gastrin released from antral G cells in response to food (protein) binds to cholecystokinin receptors (CCK-2R) on the surface of enterochromaffin-like (ECL) cells, which in turn release histamine. The histamine binds to H<ce:inf loc="post">2</ce:inf> receptors on parietal cells and this leads to secretion of hydrogen ions in exchange for potassium ions at the apical membrane. Parietal cells also express CCK-2R and it is thought that activation of these receptors by gastrin is involved in regulatory proliferation of parietal cells. Cholinergic (vagal) activity and gastric distension also stimulate acid secretion; somatostatin, vasoactive intestinal polypeptide (VIP) and gastric inhibitory polypeptide (GIP) may inhibit it. (ACh-R = acetylcholine receptor; ATPase = adenosine triphosphatase)</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 21.3</ce:alt-text><ce:link id="ln0035" locator="f021-003-9780702070280" xlink:href="pii:B9780702070280000214/f021-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 21.4</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0035" role="title">Small intestine: anatomy.</ce:simple-para><ce:simple-para id="sp0040" role="caption">Epithelial cells are formed in crypts and differentiate as they migrate to the tip of the villi to form enterocytes (absorptive cells) and goblet cells.</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 21.4</ce:alt-text><ce:link id="ln0040" locator="f021-004-9780702070280" xlink:href="pii:B9780702070280000214/f021-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 21.5</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0045" role="title">Fat digestion.</ce:simple-para><ce:simple-para id="sp0050" role="caption"><ce:italic>Step 1: Luminal phase</ce:italic>. Fatty acids stimulate cholecystokinin (CCK) release from the duodenum and upper jejunum. The CCK stimulates release of amylase, lipase, colipase and proteases from the pancreas, causes gallbladder contraction and relaxes the sphincter of Oddi, allowing bile to flow into the intestine. <ce:italic>Step 2: Fat solubilisation</ce:italic>. Bile acids and salts combine with dietary fat to form mixed micelles, which also contain cholesterol and fat-soluble vitamins. <ce:italic>Step 3: Digestion</ce:italic>. Pancreatic lipase, in the presence of its co-factor, colipase, cleaves long-chain triglycerides, yielding fatty acids and monoglycerides. <ce:italic>Step 4: Absorption.</ce:italic> Mixed micelles diffuse to the brush border of the enterocytes. Within the brush border, long-chain fatty acids bind to proteins, which transport the fatty acids into the cell, whereas cholesterol, short-chain fatty acids, phospholipids and fat-soluble vitamins enter the cell directly. The bile salts remain in the small intestinal lumen and are actively transported from the terminal ileum into the portal circulation and returned to the liver (the enterohepatic circulation). <ce:italic>Step 5: Re-esterification</ce:italic>. Within the enterocyte, fatty acids are re-esterified to form triglycerides. Triglycerides combine with cholesterol ester, fat-soluble vitamins, phospholipids and apoproteins to form chylomicrons. <ce:italic>Step 6: Transport.</ce:italic> Chylomicrons leave the enterocytes by exocytosis, enter mesenteric lymphatics, pass into the thoracic duct and eventually reach the systemic circulation.</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 21.5</ce:alt-text><ce:link id="ln0045" locator="f021-005-9780702070280" xlink:href="pii:B9780702070280000214/f021-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 21.6</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0055" role="title">Protein digestion.</ce:simple-para><ce:simple-para id="sp0060" role="caption">(CCK = cholecystokinin)</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 21.6</ce:alt-text><ce:link id="ln0050" locator="f021-006-9780702070280" xlink:href="pii:B9780702070280000214/f021-006-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0055"><ce:label>Fig. 21.7</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0065" role="title">Fluid homeostasis in the gastrointestinal tract.</ce:simple-para></ce:caption><ce:alt-text id="atte0040" role="short">Fig. 21.7</ce:alt-text><ce:link id="ln0055" locator="f021-007-9780702070280" xlink:href="pii:B9780702070280000214/f021-007-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0060"><ce:label>Fig. 21.8</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0070" role="title">Intestinal defence mechanisms.</ce:simple-para><ce:simple-para id="sp0075" role="caption">See text for details.</ce:simple-para></ce:caption><ce:alt-text id="atte0045" role="short">Fig. 21.8</ce:alt-text><ce:link id="ln0060" locator="f021-008-9780702070280" xlink:href="pii:B9780702070280000214/f021-008-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0065"><ce:label>Fig. 21.9</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0080" role="title">Pancreatic structure and function.</ce:simple-para><ce:simple-para id="sp0085" role="caption">Ductular cells secrete alkaline fluid in response to secretin. Acinar cells secrete digestive enzymes from zymogen granules in response to a range of secretagogues. The photograph shows a normal pancreatic duct (PD) and side branches, as defined at magnetic resonance cholangiopancreatography (MRCP). Note the incidental calculi in the gallbladder and common bile duct (arrow). (CCK = cholecystokinin; VIP = vasoactive intestinal polypeptide)</ce:simple-para></ce:caption><ce:alt-text id="atte0050" role="short">Fig. 21.9</ce:alt-text><ce:link id="ln0070" locator="f021-009-9780702070280" xlink:href="pii:B9780702070280000214/f021-009-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0070"><ce:label>Fig. 21.10</ce:label><ce:caption id="ca0055"><ce:simple-para id="sp0090" role="title">The normal colon, rectum and anal canal.</ce:simple-para></ce:caption><ce:alt-text id="atte0055" role="short">Fig. 21.10</ce:alt-text><ce:link id="ln0075" locator="f021-010-9780702070280" xlink:href="pii:B9780702070280000214/f021-010-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0075"><ce:label>Fig. 21.11</ce:label><ce:caption id="ca0060"><ce:simple-para id="sp0095" role="title">Examples of plain X-rays.</ce:simple-para><ce:simple-para id="sp0100" role="caption"><ce:bold>A</ce:bold> Abdominal X-ray showing dilatation of loops of small bowel (arrows), which are indicative of obstruction (in this case due to adhesions from previous surgery). <ce:bold>B</ce:bold> Chest X-ray showing free air under both hemi-diaphragms (arrows), which is indicative of acute perforation of an abdominal viscus.</ce:simple-para></ce:caption><ce:alt-text id="atte0060" role="short">Fig. 21.11</ce:alt-text><ce:link id="ln0085" locator="f021-011a-9780702070280" xlink:href="pii:B9780702070280000214/f021-011a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0090" locator="f021-011b-9780702070280" xlink:href="pii:B9780702070280000214/f021-011b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0090"><ce:label>Fig. 21.14</ce:label><ce:caption id="ca0075"><ce:simple-para id="sp0125" role="title">Examples of therapeutic techniques in endoscopy.</ce:simple-para></ce:caption><ce:alt-text id="atte0065" role="short">Fig. 21.14</ce:alt-text><ce:link id="ln0125" locator="f021-014-9780702070280" xlink:href="pii:B9780702070280000214/f021-014-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0095"><ce:label>Fig. 21.15</ce:label><ce:caption id="ca0080"><ce:simple-para id="sp0130" role="title">Wireless capsule endoscopy.</ce:simple-para><ce:simple-para id="sp0135" role="caption"><ce:bold>A</ce:bold> Examples of capsules. <ce:bold>B</ce:bold> Capsule endoscopy image of bleeding jejunal vascular malformation.</ce:simple-para></ce:caption><ce:alt-text id="atte0070" role="short">Fig. 21.15</ce:alt-text><ce:source>A, Courtesy of Given Imaging.</ce:source><ce:link id="ln0135" locator="f021-015a-9780702070280" xlink:href="pii:B9780702070280000214/f021-015a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0140" locator="f021-015b-9780702070280" xlink:href="pii:B9780702070280000214/f021-015b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0100"><ce:label>Fig. 21.16</ce:label><ce:caption id="ca0085"><ce:simple-para id="sp0150" role="title">Investigation of dysphagia.</ce:simple-para></ce:caption><ce:alt-text id="atte0075" role="short">Fig. 21.16</ce:alt-text><ce:link id="ln0185" locator="f021-016-9780702070280" xlink:href="pii:B9780702070280000214/f021-016-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0105"><ce:label>Fig. 21.17</ce:label><ce:caption id="ca0090"><ce:simple-para id="sp0155" role="title">Investigation of dyspepsia.</ce:simple-para></ce:caption><ce:alt-text id="atte0080" role="short">Fig. 21.17</ce:alt-text><ce:link id="ln0200" locator="f021-017-9780702070280" xlink:href="pii:B9780702070280000214/f021-017-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0110"><ce:label>Fig. 21.18</ce:label><ce:caption id="ca0095"><ce:simple-para id="sp0160" role="title">Causes of vomiting.</ce:simple-para><ce:simple-para id="sp0165" role="caption">(NSAIDs = non-steroidal anti-inflammatory drugs)</ce:simple-para></ce:caption><ce:alt-text id="atte0085" role="short">Fig. 21.18</ce:alt-text><ce:link id="ln0205" locator="f021-018-9780702070280" xlink:href="pii:B9780702070280000214/f021-018-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0115"><ce:label>Fig. 21.19</ce:label><ce:caption id="ca0100"><ce:simple-para id="sp0170" role="title">Causes of acute upper gastrointestinal haemorrhage.</ce:simple-para><ce:simple-para id="sp0175" role="caption">Frequency is given in parentheses. (NSAIDs = non-steroidal anti-inflammatory drugs)</ce:simple-para></ce:caption><ce:alt-text id="atte0090" role="short">Fig. 21.19</ce:alt-text><ce:link id="ln0215" locator="f021-019-9780702070280" xlink:href="pii:B9780702070280000214/f021-019-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0120"><ce:label>Fig. 21.20</ce:label><ce:caption id="ca0105"><ce:simple-para id="sp0180" role="title">Major stigmata of recent haemorrhage and endoscopic treatment.</ce:simple-para><ce:simple-para id="sp0185" role="caption"><ce:bold>A</ce:bold> Active bleeding from a duodenal ulcer. <ce:bold>B</ce:bold> Haemostasis is achieved after endoscopic injection of adrenaline (epinephrine) and application of a heater probe.</ce:simple-para></ce:caption><ce:alt-text id="atte0095" role="short">Fig. 21.20</ce:alt-text><ce:link id="ln0220" locator="f021-020a-9780702070280" xlink:href="pii:B9780702070280000214/f021-020a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0225" locator="f021-020b-9780702070280" xlink:href="pii:B9780702070280000214/f021-020b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0125"><ce:label>Fig. 21.21</ce:label><ce:caption id="ca0110"><ce:simple-para id="sp0190" role="title">Jejunal angiodysplastic lesion seen at enteroscopy in a patient with recurrent obscure bleeding.</ce:simple-para></ce:caption><ce:alt-text id="atte0100" role="short">Fig. 21.21</ce:alt-text><ce:link id="ln0235" locator="f021-021-9780702070280" xlink:href="pii:B9780702070280000214/f021-021-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0130"><ce:label>Fig. 21.22</ce:label><ce:caption id="ca0115"><ce:simple-para id="sp0200" role="title">Possible physical consequences of malabsorption.</ce:simple-para></ce:caption><ce:alt-text id="atte0105" role="short">Fig. 21.22</ce:alt-text><ce:link id="ln0245" locator="f021-022-9780702070280" xlink:href="pii:B9780702070280000214/f021-022-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0135"><ce:label>Fig. 21.23</ce:label><ce:caption id="ca0120"><ce:simple-para id="sp0205" role="title">Investigation for suspected malabsorption.</ce:simple-para><ce:simple-para id="sp0210" role="caption">(CT = computed tomography; MRCP = magnetic resonance cholangiopancreatography; MRI = magnetic resonance imaging; <ce:sup loc="post">75</ce:sup>SeHCAT = <ce:sup loc="post">75</ce:sup>Se-homocholic acid taurine)</ce:simple-para></ce:caption><ce:alt-text id="atte0110" role="short">Fig. 21.23</ce:alt-text><ce:link id="ln0255" locator="f021-023-9780702070280" xlink:href="pii:B9780702070280000214/f021-023-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0140"><ce:label>Fig. 21.24</ce:label><ce:caption id="ca0125"><ce:simple-para id="sp0215" role="title">Some important causes of weight loss.</ce:simple-para></ce:caption><ce:alt-text id="atte0115" role="short">Fig. 21.24</ce:alt-text><ce:link id="ln0260" locator="f021-024-9780702070280" xlink:href="pii:B9780702070280000214/f021-024-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0145"><ce:label>Fig. 21.25</ce:label><ce:caption id="ca0130"><ce:simple-para id="sp0220" role="title">Management of acute abdominal pain: an algorithm.</ce:simple-para></ce:caption><ce:alt-text id="atte0120" role="short">Fig. 21.25</ce:alt-text><ce:link id="ln0275" locator="f021-025-9780702070280" xlink:href="pii:B9780702070280000214/f021-025-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0150"><ce:label>Fig. 21.26</ce:label><ce:caption id="ca0135"><ce:simple-para id="sp0225" role="title">Factors associated with the development of gastro-oesophageal reflux disease.</ce:simple-para></ce:caption><ce:alt-text id="atte0125" role="short">Fig. 21.26</ce:alt-text><ce:link id="ln0315" locator="f021-026-9780702070280" xlink:href="pii:B9780702070280000214/f021-026-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0155"><ce:label>Fig. 21.27</ce:label><ce:caption id="ca0140"><ce:simple-para id="sp0230" role="title">Types of hiatus hernia.</ce:simple-para><ce:simple-para id="sp0235" role="caption"><ce:bold>A</ce:bold> Rolling or para-oesophageal. Inset: Barium meal showing a large para-oesophageal hernia with intrathoracic stomach. <ce:bold>B</ce:bold> Sliding. Inset: Barium meal showing a gastric volvulus (small arrows) complicating a sliding hiatus hernia (large arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0130" role="short">Fig. 21.27</ce:alt-text><ce:link id="ln0325" locator="f021-027ab-9780702070280" xlink:href="pii:B9780702070280000214/f021-027ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0160"><ce:label>Fig. 21.28</ce:label><ce:caption id="ca0145"><ce:simple-para id="sp0240" role="title">Severe reflux oesophagitis.</ce:simple-para><ce:simple-para id="sp0245" role="caption">There is near-circumferential superficial ulceration and inflammation extending up the gullet.</ce:simple-para></ce:caption><ce:alt-text id="atte0135" role="short">Fig. 21.28</ce:alt-text><ce:link id="ln0330" locator="f021-028-9780702070280" xlink:href="pii:B9780702070280000214/f021-028-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0165"><ce:label>Fig. 21.29</ce:label><ce:caption id="ca0150"><ce:simple-para id="sp0250" role="title">Barrett's oesophagus.</ce:simple-para><ce:simple-para id="sp0255" role="caption">Tongues of pink columnar mucosa are seen extending upwards above the oesophago-gastric junction.</ce:simple-para></ce:caption><ce:alt-text id="atte0140" role="short">Fig. 21.29</ce:alt-text><ce:link id="ln0335" locator="f021-029-9780702070280" xlink:href="pii:B9780702070280000214/f021-029-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0170"><ce:label>Fig. 21.30</ce:label><ce:caption id="ca0155"><ce:simple-para id="sp0260" role="title">Treatment of gastro-oesophageal reflux disease: a ‘step-down’ approach.</ce:simple-para></ce:caption><ce:alt-text id="atte0145" role="short">Fig. 21.30</ce:alt-text><ce:link id="ln0340" locator="f021-030-9780702070280" xlink:href="pii:B9780702070280000214/f021-030-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0175"><ce:label>Fig. 21.31</ce:label><ce:caption id="ca0160"><ce:simple-para id="sp0265" role="title">Achalasia.</ce:simple-para><ce:simple-para id="sp0270" role="caption"><ce:bold>A</ce:bold> X-ray showing a dilated, barium-filled oesophagus (O) with fluid level and distal tapering, and a closed lower oesophageal sphincter (LOS). (D = diaphragm) <ce:bold>B</ce:bold> High-resolution manometry in achalasia showing absence of peristaltic swallowing wave in oesophageal body (black arrows) and raised LOS pressure with failure of relaxation on swallowing (white arrow). Compare with normal appearances in <ce:cross-ref id="crf0655" refid="f0025">Figure 21.1</ce:cross-ref> (<ce:cross-ref id="crf9010" refid="s0015">p. 766</ce:cross-ref>).</ce:simple-para></ce:caption><ce:alt-text id="atte0150" role="short">Fig. 21.31</ce:alt-text><ce:link id="ln0350" locator="f021-031ab-9780702070280" xlink:href="pii:B9780702070280000214/f021-031ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0180"><ce:label>Fig. 21.32</ce:label><ce:caption id="ca0165"><ce:simple-para id="sp0275" role="title">Adenocarcinoma of the lower oesophagus.</ce:simple-para><ce:simple-para id="sp0280" role="caption">A polypoidal adenocarcinoma in association with Barrett's oesophagus.</ce:simple-para></ce:caption><ce:alt-text id="atte0155" role="short">Fig. 21.32</ce:alt-text><ce:link id="ln0365" locator="f021-032-9780702070280" xlink:href="pii:B9780702070280000214/f021-032-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0185"><ce:label>Fig. 21.33</ce:label><ce:caption id="ca0170"><ce:simple-para id="sp0285" role="title">Positron emission tomography–computed tomography (PET-CT) staging of oesophageal carcinoma.</ce:simple-para><ce:simple-para id="sp0290" role="caption">Whole-body PET scan showing avid uptake in the primary tumour (thick arrow) but also in distant paratracheal (superior thin arrow) and gastro-oesophageal (inferior thin arrow) lymph nodes.</ce:simple-para></ce:caption><ce:alt-text id="atte0160" role="short">Fig. 21.33</ce:alt-text><ce:link id="ln0370" locator="f021-033-9780702070280" xlink:href="pii:B9780702070280000214/f021-033-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0190"><ce:label>Fig. 21.34</ce:label><ce:caption id="ca0175"><ce:simple-para id="sp0295" role="title">Endoscopic ultrasound staging of oesophageal carcinoma.</ce:simple-para><ce:simple-para id="sp0300" role="caption">There is a superficial adenocarcinoma of the oesophagus (T). The submucosa (white band, white arrows) is not involved but there is a small involved local lymph node (white arrow, inset). The tumour is therefore staged T1a, N1.</ce:simple-para></ce:caption><ce:alt-text id="atte0165" role="short">Fig. 21.34</ce:alt-text><ce:link id="ln0375" locator="f021-034-9780702070280" xlink:href="pii:B9780702070280000214/f021-034-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0195"><ce:label>Fig. 21.35</ce:label><ce:caption id="ca0180"><ce:simple-para id="sp0305" role="title">Factors that influence the virulence of <ce:italic>Helicobacter pylori</ce:italic>.</ce:simple-para></ce:caption><ce:alt-text id="atte0170" role="short">Fig. 21.35</ce:alt-text><ce:link id="ln0385" locator="f021-035-9780702070280" xlink:href="pii:B9780702070280000214/f021-035-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0200"><ce:label>Fig. 21.36</ce:label><ce:caption id="ca0185"><ce:simple-para id="sp0310" role="title">Sequence of events in the pathophysiology of duodenal ulceration.</ce:simple-para></ce:caption><ce:alt-text id="atte0175" role="short">Fig. 21.36</ce:alt-text><ce:link id="ln0390" locator="f021-036-9780702070280" xlink:href="pii:B9780702070280000214/f021-036-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0205"><ce:label>Fig. 21.37</ce:label><ce:caption id="ca0190"><ce:simple-para id="sp0315" role="title">Consequences of <ce:italic>Helicobacter pylori</ce:italic> infection.</ce:simple-para><ce:simple-para id="sp0320" role="caption">(CagA = cytotoxin-associated gene; IL-1β = interleukin-1 beta; NSAIDs = non-steroidal anti-inflammatory drugs; TNF-α = tumour necrosis factor alpha; VacA = vacuolating cytotoxin)</ce:simple-para></ce:caption><ce:alt-text id="atte0180" role="short">Fig. 21.37</ce:alt-text><ce:link id="ln0395" locator="f021-037-9780702070280" xlink:href="pii:B9780702070280000214/f021-037-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0210"><ce:label>Fig. 21.38</ce:label><ce:caption id="ca0195"><ce:simple-para id="sp0325" role="title">Endoscopic identification of a duodenal ulcer.</ce:simple-para><ce:simple-para id="sp0330" role="caption">The ulcer has a clean base and there are no stigmata of recent haemorrhage.</ce:simple-para></ce:caption><ce:alt-text id="atte0185" role="short">Fig. 21.38</ce:alt-text><ce:link id="ln0400" locator="f021-038-9780702070280" xlink:href="pii:B9780702070280000214/f021-038-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0215"><ce:label>Fig. 21.39</ce:label><ce:caption id="ca0200"><ce:simple-para id="sp0335" role="title">Gastric carcinogenesis: a possible mechanism.</ce:simple-para><ce:simple-para id="sp0340" role="caption">(CagA = cytotoxin-associated gene)</ce:simple-para></ce:caption><ce:alt-text id="atte0190" role="short">Fig. 21.39</ce:alt-text><ce:link id="ln0435" locator="f021-039-9780702070280" xlink:href="pii:B9780702070280000214/f021-039-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0220"><ce:label>Fig. 21.40</ce:label><ce:caption id="ca0205"><ce:simple-para id="sp0345" role="title">Gastric carcinoma.</ce:simple-para><ce:simple-para id="sp0350" role="caption">Endoscopic finding of a large polypoidal mass arising from the wall of the stomach.</ce:simple-para></ce:caption><ce:alt-text id="atte0195" role="short">Fig. 21.40</ce:alt-text><ce:link id="ln0445" locator="f021-040-9780702070280" xlink:href="pii:B9780702070280000214/f021-040-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0225"><ce:label>Fig. 21.41</ce:label><ce:caption id="ca0210"><ce:simple-para id="sp0355" role="title">Pathophysiology of coeliac disease.</ce:simple-para><ce:simple-para id="sp0360" role="caption">After being taken up by epithelial cells, gluten peptides are deamidated by the enzyme tissue transglutaminase in the subepithelial layer. They are then able to fit the antigen-binding motif on human leucocyte antigen (HLA)-DQ2-positive antigen-presenting cells. Recognition by CD4<ce:sup loc="post">+</ce:sup> T cells triggers a Th<ce:inf loc="post">1</ce:inf> immune response with generation of pro-inflammatory cytokines: interleukin-1 (IL-1), interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α). Lymphocytes infiltrate the lamina propria and an increase in intra-epithelial lymphocytes (IELs), crypt hyperplasia and villous atrophy ensue.</ce:simple-para></ce:caption><ce:alt-text id="atte0200" role="short">Fig. 21.41</ce:alt-text><ce:link id="ln0455" locator="f021-041-9780702070280" xlink:href="pii:B9780702070280000214/f021-041-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0230"><ce:label>Fig. 21.42</ce:label><ce:caption id="ca0215"><ce:simple-para id="sp0365" role="title">Jejunal mucosa.</ce:simple-para><ce:simple-para id="sp0370" role="caption"><ce:bold>A</ce:bold> Normal. <ce:bold>B</ce:bold> Subtotal villous atrophy in coeliac disease. There is blunting of villi (B), crypt hyperplasia (H) and inflammatory infiltration of the lamina propria (I).</ce:simple-para></ce:caption><ce:alt-text id="atte0205" role="short">Fig. 21.42</ce:alt-text><ce:link id="ln0470" locator="f021-042a-9780702070280" xlink:href="pii:B9780702070280000214/f021-042a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0475" locator="f021-042b-9780702070280" xlink:href="pii:B9780702070280000214/f021-042b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0235"><ce:label>Fig. 21.43</ce:label><ce:caption id="ca0220"><ce:simple-para id="sp0375" role="title">Consequences of ileal resection.</ce:simple-para></ce:caption><ce:alt-text id="atte0210" role="short">Fig. 21.43</ce:alt-text><ce:link id="ln0495" locator="f021-043-9780702070280" xlink:href="pii:B9780702070280000214/f021-043-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0240"><ce:label>Fig. 21.44</ce:label><ce:caption id="ca0225"><ce:simple-para id="sp0385" role="title">Pathogenesis of inflammatory bowel disease.</ce:simple-para><ce:simple-para id="sp0390" role="caption">(1) Bacterial antigens are taken up by specialised M cells, pass between leaky epithelial cells or enter the lamina propria through ulcerated mucosa. (2) After processing, they are presented to type 1 T-helper cells by antigen-presenting cells (APCs) in the lamina propria. (3) T-cell activation and differentiation results in a Th<ce:inf loc="post">1</ce:inf> T cell-mediated cytokine response (4) with secretion of cytokines, including interferon gamma (IFN-γ). Further amplification of T cells perpetuates the inflammatory process with activation of non-immune cells and release of other important cytokines, including interleukin 12 (IL-12), IL-23, IL-1, IL-6 and tumour necrosis factor alpha (TNF-α). These pathways occur in all normal individuals exposed to an inflammatory insult and this is self-limiting in healthy subjects. In genetically predisposed persons, dysregulation of innate immunity may trigger inflammatory bowel disease.</ce:simple-para></ce:caption><ce:alt-text id="atte0215" role="short">Fig. 21.44</ce:alt-text><ce:link id="ln0530" locator="f021-044-9780702070280" xlink:href="pii:B9780702070280000214/f021-044-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0245"><ce:label>Fig. 21.45</ce:label><ce:caption id="ca0230"><ce:simple-para id="sp0395" role="title">Common patterns of disease distribution in inflammatory bowel disease.</ce:simple-para></ce:caption><ce:alt-text id="atte0220" role="short">Fig. 21.45</ce:alt-text><ce:link id="ln0535" locator="f021-045-9780702070280" xlink:href="pii:B9780702070280000214/f021-045-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0250"><ce:label>Fig. 21.46</ce:label><ce:caption id="ca0235"><ce:simple-para id="sp0400" role="title">Pseudopolyposis in ulcerative colitis.</ce:simple-para></ce:caption><ce:alt-text id="atte0225" role="short">Fig. 21.46</ce:alt-text><ce:link id="ln0540" locator="f021-046-9780702070280" xlink:href="pii:B9780702070280000214/f021-046-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0255"><ce:label>Fig. 21.47</ce:label><ce:caption id="ca0240"><ce:simple-para id="sp0405" role="title">Histology of ulcerative colitis.</ce:simple-para><ce:simple-para id="sp0410" role="caption">There is surface ulceration and inflammation is confined to the mucosa with excess inflammatory cells in the lamina propria, loss of goblet cells, and crypt abscesses (arrows). (SM = submucosa)</ce:simple-para></ce:caption><ce:alt-text id="atte0230" role="short">Fig. 21.47</ce:alt-text><ce:link id="ln0545" locator="f021-047-9780702070280" xlink:href="pii:B9780702070280000214/f021-047-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0260"><ce:label>Fig. 21.48</ce:label><ce:caption id="ca0245"><ce:simple-para id="sp0415" role="title">Histology of Crohn's disease.</ce:simple-para><ce:simple-para id="sp0420" role="caption"><ce:bold>A</ce:bold> Inflammation is ‘transmural’; there is fissuring ulceration (arrow), with inflammation extending into the submucosa (SM). <ce:bold>B</ce:bold> At higher power, a characteristic non-caseating granuloma is seen.</ce:simple-para></ce:caption><ce:alt-text id="atte0235" role="short">Fig. 21.48</ce:alt-text><ce:link id="ln0550" locator="f021-048a-9780702070280" xlink:href="pii:B9780702070280000214/f021-048a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0555" locator="f021-048b-9780702070280" xlink:href="pii:B9780702070280000214/f021-048b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0265"><ce:label>Fig. 21.49</ce:label><ce:caption id="ca0250"><ce:simple-para id="sp0425" role="title">Ileal Crohn's disease.</ce:simple-para><ce:simple-para id="sp0430" role="caption">Small bowel magnetic resonance image showing a terminal ileum that is thickened, narrowed and enhancing (arrow), with dilatation immediately proximal to this.</ce:simple-para></ce:caption><ce:alt-text id="atte0240" role="short">Fig. 21.49</ce:alt-text><ce:link id="ln0565" locator="f021-049-9780702070280" xlink:href="pii:B9780702070280000214/f021-049-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0270"><ce:label>Fig. 21.50</ce:label><ce:caption id="ca0255"><ce:simple-para id="sp0435" role="title">Barium follow-through showing terminal ileal Crohn's disease.</ce:simple-para><ce:simple-para id="sp0440" role="caption">A long stricture is present (arrow A), and more proximally there is ulceration with characteristic ‘rose thorn’ ulcers (arrow B).</ce:simple-para></ce:caption><ce:alt-text id="atte0245" role="short">Fig. 21.50</ce:alt-text><ce:link id="ln0570" locator="f021-050-9780702070280" xlink:href="pii:B9780702070280000214/f021-050-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0275"><ce:label>Fig. 21.51</ce:label><ce:caption id="ca0260"><ce:simple-para id="sp0445" role="title">Plain abdominal X-ray showing a grossly dilated colon due to severe ulcerative colitis.</ce:simple-para><ce:simple-para id="sp0450" role="caption">There is also marked mucosal oedema and ‘thumb-printing’ (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0250" role="short">Fig. 21.51</ce:alt-text><ce:link id="ln0585" locator="f021-051-9780702070280" xlink:href="pii:B9780702070280000214/f021-051-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0280"><ce:label>Fig. 21.52</ce:label><ce:caption id="ca0265"><ce:simple-para id="sp0455" role="title">Systemic complications of inflammatory bowel disease.</ce:simple-para><ce:simple-para id="sp0460" role="caption">See also <ce:intra-ref id="ii0405" xlink:href="pii:B978-0-7020-7028-0.00017-2#c00017">Chapters 17</ce:intra-ref> and <ce:intra-ref id="ii0410" xlink:href="pii:B978-0-7020-7028-0.00018-4#c00018">18</ce:intra-ref>. (HLA = human leukocyte antigen)</ce:simple-para></ce:caption><ce:alt-text id="atte0255" role="short">Fig. 21.52</ce:alt-text><ce:link id="ln0590" locator="f021-052-9780702070280" xlink:href="pii:B9780702070280000214/f021-052-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0285"><ce:label>Fig. 21.53</ce:label><ce:caption id="ca0270"><ce:simple-para id="sp0465" role="title">Sigmoidoscopic view of moderately active ulcerative colitis.</ce:simple-para><ce:simple-para id="sp0470" role="caption">Mucosa is erythematous and friable with contact bleeding. Submucosal blood vessels are no longer visible.</ce:simple-para></ce:caption><ce:alt-text id="atte0260" role="short">Fig. 21.53</ce:alt-text><ce:link id="ln0595" locator="f021-053-9780702070280" xlink:href="pii:B9780702070280000214/f021-053-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0290"><ce:label>Fig. 21.54</ce:label><ce:caption id="ca0275"><ce:simple-para id="sp0480" role="title">Management of irritable bowel syndrome.</ce:simple-para><ce:simple-para id="sp0485" role="caption">(FODMAP = fermentable oligo-, di- and monosaccharides, and polyols)</ce:simple-para></ce:caption><ce:alt-text id="atte0265" role="short">Fig. 21.54</ce:alt-text><ce:link id="ln0645" locator="f021-054-9780702070280" xlink:href="pii:B9780702070280000214/f021-054-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0295"><ce:label>Fig. 21.55</ce:label><ce:caption id="ca0280"><ce:simple-para id="sp0490" role="title">Large rectal adenomatous polyp.</ce:simple-para><ce:simple-para id="sp0495" role="caption"><ce:bold>A</ce:bold> Before colonoscopic polypectomy. <ce:bold>B</ce:bold> After polypectomy.</ce:simple-para></ce:caption><ce:alt-text id="atte0270" role="short">Fig. 21.55</ce:alt-text><ce:link id="ln0665" locator="f021-055a-9780702070280" xlink:href="pii:B9780702070280000214/f021-055a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0670" locator="f021-055b-9780702070280" xlink:href="pii:B9780702070280000214/f021-055b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0300"><ce:label>Fig. 21.56</ce:label><ce:caption id="ca0285"><ce:simple-para id="sp0505" role="title">Familial adenomatous polyposis.</ce:simple-para><ce:simple-para id="sp0510" role="caption">There are hundreds of adenomatous polyps throughout the colon.</ce:simple-para></ce:caption><ce:alt-text id="atte0275" role="short">Fig. 21.56</ce:alt-text><ce:link id="ln0680" locator="f021-056-9780702070280" xlink:href="pii:B9780702070280000214/f021-056-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0305"><ce:label>Fig. 21.57</ce:label><ce:caption id="ca0290"><ce:simple-para id="sp0515" role="title">Peutz–Jeghers syndrome.</ce:simple-para><ce:simple-para id="sp0520" role="caption">Typical lip pigmentation.</ce:simple-para></ce:caption><ce:alt-text id="atte0280" role="short">Fig. 21.57</ce:alt-text><ce:link id="ln0690" locator="f021-057-9780702070280" xlink:href="pii:B9780702070280000214/f021-057-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0310"><ce:label>Fig. 21.58</ce:label><ce:caption id="ca0295"><ce:simple-para id="sp0525" role="title">Pathogenesis of colorectal cancer (CRC).</ce:simple-para><ce:simple-para id="sp0530" role="caption">(FAP = familial adenomatous polyposis; HNPCC = hereditary non-polyposis colon cancer; JPS = juvenile polyposis syndrome; MAP = <ce:italic>MUTYH</ce:italic>-associated polyposis; PJS = Peutz–Jeghers syndrome)</ce:simple-para></ce:caption><ce:alt-text id="atte0285" role="short">Fig. 21.58</ce:alt-text><ce:link id="ln0695" locator="f021-058-9780702070280" xlink:href="pii:B9780702070280000214/f021-058-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0315"><ce:label>Fig. 21.59</ce:label><ce:caption id="ca0300"><ce:simple-para id="sp0535" role="title">The multistep origin of cancer: molecular events implicated in colorectal carcinogenesis.</ce:simple-para><ce:simple-para id="sp0540" role="caption">(GTP = guanine triphosphate)</ce:simple-para></ce:caption><ce:alt-text id="atte0290" role="short">Fig. 21.59</ce:alt-text><ce:link id="ln0710" locator="f021-059-9780702070280" xlink:href="pii:B9780702070280000214/f021-059-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0320"><ce:label>Fig. 21.60</ce:label><ce:caption id="ca0305"><ce:simple-para id="sp0545" role="title">Modified Dukes classification and survival in colorectal cancer.</ce:simple-para></ce:caption><ce:alt-text id="atte0295" role="short">Fig. 21.60</ce:alt-text><ce:link id="ln0720" locator="f021-060ad-9780702070280" xlink:href="pii:B9780702070280000214/f021-060ad-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0325"><ce:label>Fig. 21.61</ce:label><ce:caption id="ca0310"><ce:simple-para id="sp0550" role="title">Placement of a colonic stent for an inoperable cancer with impending obstruction.</ce:simple-para><ce:simple-para id="sp0555" role="caption"><ce:bold>A</ce:bold> The contrast study demonstrates an obstruction. <ce:bold>B</ce:bold> The stent is deployed across the tumour. <ce:bold>C</ce:bold> A satisfactory position is demonstrated on subsequent CT scanning.</ce:simple-para></ce:caption><ce:alt-text id="atte0300" role="short">Fig. 21.61</ce:alt-text><ce:link id="ln0725" locator="f021-061ac-9780702070280" xlink:href="pii:B9780702070280000214/f021-061ac-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0330"><ce:label>Fig. 21.62</ce:label><ce:caption id="ca0315"><ce:simple-para id="sp0560" role="title">The human colon in diverticulosis.</ce:simple-para><ce:simple-para id="sp0565" role="caption">The colonic wall is weak between the taeniae. The blood vessels that supply the colon pierce the circular muscle and weaken it further by forming tunnels. Diverticula usually emerge through these points of least resistance.</ce:simple-para></ce:caption><ce:alt-text id="atte0305" role="short">Fig. 21.62</ce:alt-text><ce:link id="ln0730" locator="f021-062-9780702070280" xlink:href="pii:B9780702070280000214/f021-062-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0335"><ce:label>Fig. 21.63</ce:label><ce:caption id="ca0320"><ce:simple-para id="sp0570" role="title">Thrombosed prolapsed haemorrhoids.</ce:simple-para></ce:caption><ce:alt-text id="atte0310" role="short">Fig. 21.63</ce:alt-text><ce:link id="ln0755" locator="f021-063-9780702070280" xlink:href="pii:B9780702070280000214/f021-063-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0340"><ce:label>Fig. 21.64</ce:label><ce:caption id="ca0325"><ce:simple-para id="sp0575" role="title">Pathophysiology of acute pancreatitis.</ce:simple-para></ce:caption><ce:alt-text id="atte0315" role="short">Fig. 21.64</ce:alt-text><ce:link id="ln0775" locator="f021-064-9780702070280" xlink:href="pii:B9780702070280000214/f021-064-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0345"><ce:label>Fig. 21.65</ce:label><ce:caption id="ca0330"><ce:simple-para id="sp0580" role="title">Computed tomogram showing large pancreatic pseudocyst (C) compressing the stomach (S).</ce:simple-para><ce:simple-para id="sp0585" role="caption">The pancreas is atrophic and calcified (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0320" role="short">Fig. 21.65</ce:alt-text><ce:link id="ln0790" locator="f021-065-9780702070280" xlink:href="pii:B9780702070280000214/f021-065-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0350"><ce:label>Fig. 21.66</ce:label><ce:caption id="ca0335"><ce:simple-para id="sp0590" role="title">Pancreatic necrosis.</ce:simple-para><ce:simple-para id="sp0595" role="caption">Lack of vascular enhancement of the pancreas during contrast-enhanced computed tomography indicates necrosis (arrow). The presence of gas suggests that infection has occurred.</ce:simple-para></ce:caption><ce:alt-text id="atte0325" role="short">Fig. 21.66</ce:alt-text><ce:link id="ln0795" locator="f021-066-9780702070280" xlink:href="pii:B9780702070280000214/f021-066-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0355"><ce:label>Fig. 21.67</ce:label><ce:caption id="ca0340"><ce:simple-para id="sp0600" role="title">Pathophysiology of chronic pancreatitis.</ce:simple-para><ce:simple-para id="sp0605" role="caption">Alcohol and other risk factors may trigger acute pancreatitis through multiple mechanisms. The first (or ‘sentinel’) episode of acute pancreatitis initiates an inflammatory response involving T-helper (Th) cells. Ongoing exposure to alcohol drives further inflammation but this is modified by regulatory T cells (Treg) with subsequent fibrosis, via activation of pancreatic stellate cells. A cycle of inflammation and fibrosis ensues, with development of chronic pancreatitis. Alcohol is the most relevant risk factor, as it is involved at multiple steps.</ce:simple-para></ce:caption><ce:alt-text id="atte0330" role="short">Fig. 21.67</ce:alt-text><ce:link id="ln0805" locator="f021-067-9780702070280" xlink:href="pii:B9780702070280000214/f021-067-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0360"><ce:label>Fig. 21.68</ce:label><ce:caption id="ca0345"><ce:simple-para id="sp0610" role="title">Imaging in chronic pancreatitis.</ce:simple-para><ce:simple-para id="sp0615" role="caption"><ce:bold>A</ce:bold> Computed tomogram showing a grossly dilated and irregular duct with a calcified stone (arrow A). Note the calcification in the head of the gland (arrow B). <ce:bold>B</ce:bold> Magnetic resonance cholangiopancreatogram of the same patient showing marked ductal dilatation with abnormal dilated side branches (arrows A). A small cyst is also present (arrow B).</ce:simple-para></ce:caption><ce:alt-text id="atte0335" role="short">Fig. 21.68</ce:alt-text><ce:link id="ln0820" locator="f021-068a-9780702070280" xlink:href="pii:B9780702070280000214/f021-068a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0825" locator="f021-068b-9780702070280" xlink:href="pii:B9780702070280000214/f021-068b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0365"><ce:label>Fig. 21.69</ce:label><ce:caption id="ca0350"><ce:simple-para id="sp0620" role="title">Features of pancreatic cancer.</ce:simple-para></ce:caption><ce:alt-text id="atte0340" role="short">Fig. 21.69</ce:alt-text><ce:link id="ln0835" locator="f021-069-9780702070280" xlink:href="pii:B9780702070280000214/f021-069-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0370"><ce:label>Fig. 21.70</ce:label><ce:caption id="ca0355"><ce:simple-para id="sp0625" role="title">Carcinoma of the pancreas.</ce:simple-para><ce:simple-para id="sp0630" role="caption"><ce:bold>A</ce:bold> A computed tomogram showing a large, necrotic mass encasing the coeliac axis (arrows). <ce:bold>B</ce:bold> Endoscopic ultrasound was subsequently performed to enhance staging and to obtain a fine needle aspiration biopsy, which confirmed pancreatic ductal adenocarcinoma.</ce:simple-para></ce:caption><ce:alt-text id="atte0345" role="short">Fig. 21.70</ce:alt-text><ce:link id="ln0840" locator="f021-070a-9780702070280" xlink:href="pii:B9780702070280000214/f021-070a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0845" locator="f021-070b-9780702070280" xlink:href="pii:B9780702070280000214/f021-070b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0020" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0065" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0350" role="short">Image 1</ce:alt-text></ce:inline-figure> 21.1</ce:label><ce:alt-text id="atte0355" role="short">21.1</ce:alt-text><ce:textbox-head><ce:title id="tit0025">Pancreatic enzymes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0445"><ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte0360" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Enzyme</entry><entry align="left">Substrate</entry><entry align="left">Product</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Amylase</ce:bold></entry><entry align="left">Starch and glycogen</entry><entry align="left">Limit dextrans<ce:br/>Maltose<ce:br/>Maltriose</entry></row><row rowsep="1"><entry align="left"><ce:bold>Lipase</ce:bold><ce:br/><ce:bold>Colipase</ce:bold></entry><entry align="left">Triglycerides</entry><entry align="left">Monoglycerides and free fatty acids</entry></row><row><entry align="left"><ce:bold>Proteolytic enzymes</ce:bold><ce:br/>Trypsinogen<ce:br/>Chymotrypsinogen<ce:br/>Pro-elastase<ce:br/>Pro-carboxypeptidases</entry><entry align="left">Proteins and polypeptides</entry><entry align="left">Short polypeptides</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0025" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0080" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0365" role="short">Image 2</ce:alt-text></ce:inline-figure> 21.2</ce:label><ce:alt-text id="atte0370" role="short">21.2</ce:alt-text><ce:textbox-head><ce:title id="tit0030">Gut hormones and peptides</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0500"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte0375" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Hormone</entry><entry align="left">Origin</entry><entry align="left">Stimulus</entry><entry align="left">Action</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Gastrin</ce:bold></entry><entry align="left">Stomach (G cell)</entry><entry align="left">Products of protein digestion<ce:br/>Suppressed by acid and somatostatin</entry><entry align="left">Stimulates gastric acid secretion<ce:br/>Stimulates growth of gastrointestinal mucosa</entry></row><row rowsep="1"><entry align="left"><ce:bold>Somatostatin</ce:bold></entry><entry align="left">Throughout gastrointestinal tract (D cell)</entry><entry align="left">Fat ingestion</entry><entry align="left">Inhibits gastrin and insulin secretion<ce:br/>Decreases acid secretion<ce:br/>Decreases absorption<ce:br/>Inhibits pancreatic secretion</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cholecystokinin (CCK)</ce:bold></entry><entry align="left">Duodenum and jejunum (I cells); also ileal and colonic nerve endings</entry><entry align="left">Products of protein digestion<ce:br/>Fat and fatty acids<ce:br/>Suppressed by trypsin</entry><entry align="left">Stimulates pancreatic enzyme secretion<ce:br/>Stimulates gallbladder contraction<ce:br/>Relaxes sphincter of Oddi<ce:br/>Modulates satiety<ce:br/>Decreases gastric acid secretion<ce:br/>Reduces gastric emptying<ce:br/>Regulates pancreatic growth</entry></row><row rowsep="1"><entry align="left"><ce:bold>Secretin</ce:bold></entry><entry align="left">Duodenum and jejunum (S cells)</entry><entry align="left">Duodenal acid<ce:br/>Fatty acids</entry><entry align="left">Stimulates pancreatic fluid and bicarbonate secretion<ce:br/>Decreases acid secretion<ce:br/>Reduces gastric emptying</entry></row><row rowsep="1"><entry align="left"><ce:bold>Motilin</ce:bold></entry><entry align="left">Duodenum, small intestine and colon (Mo cells)</entry><entry align="left">Fasting<ce:br/>Dietary fat</entry><entry align="left">Regulates peristaltic activity, including migrating motor complexes (MMCs)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Gastric inhibitory polypeptide (GIP)</ce:bold></entry><entry align="left">Duodenum (K cells) and jejunum</entry><entry align="left">Glucose and fat</entry><entry align="left">Stimulates insulin release (also known as glucose-dependent insulinotrophic polypeptide)<ce:br/>Inhibits acid secretion<ce:br/>Enhances satiety</entry></row><row rowsep="1"><entry align="left"><ce:bold>Glucagon-like peptide-1 (GLP-1)</ce:bold></entry><entry align="left">Ileum and colon (L cells)</entry><entry align="left">Carbohydrates, protein and fat</entry><entry align="left">Stimulates insulin release<ce:br/>Inhibits acid secretion and gastric emptying<ce:br/>Enhances satiety</entry></row><row rowsep="1"><entry align="left"><ce:bold>Vasoactive intestinal peptide (VIP)</ce:bold></entry><entry align="left">Nerve fibres throughout gastrointestinal tract</entry><entry align="left">Unknown</entry><entry align="left">Has vasodilator action<ce:br/>Relaxes smooth muscle<ce:br/>Stimulates water and electrolyte secretion</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ghrelin</ce:bold></entry><entry align="left">Stomach</entry><entry align="left">Fasting<ce:br/>Inhibited by eating</entry><entry align="left">Stimulates appetite, acid secretion and gastric emptying</entry></row><row><entry align="left"><ce:bold>Peptide YY</ce:bold></entry><entry align="left">Ileum and colon</entry><entry align="left">Feeding</entry><entry align="left">Modulates satiety</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0030" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0095" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0380" role="short">Image 3</ce:alt-text></ce:inline-figure> 21.3</ce:label><ce:alt-text id="atte0385" role="short">21.3</ce:alt-text><ce:textbox-head><ce:title id="tit0035">Contrast radiology in the investigation of gastrointestinal disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0520"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte0390" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Barium swallow/meal</entry><entry align="left">Barium follow-through</entry><entry align="left">Barium enema</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Indications and major uses</ce:bold></entry><entry align="left">Motility disorders (achalasia and gastroparesis)<ce:br/>Perforation or fistula (non-ionic contrast)</entry><entry align="left">Diarrhoea and abdominal pain of small bowel origin<ce:br/>Possible obstruction by strictures<ce:br/>Suspected malabsorption<ce:br/>Assessment of Crohn's disease</entry><entry align="left">Altered bowel habit<ce:br/>Evaluation of strictures or diverticular disease<ce:br/>Megacolon<ce:br/>Chronic constipation</entry></row><row><entry align="left"><ce:bold>Limitations</ce:bold></entry><entry align="left">Risk of aspiration<ce:br/>Poor mucosal detail<ce:br/>Low sensitivity for early cancer<ce:br/>Inability to biopsy</entry><entry align="left">Time-consuming nature<ce:br/>Radiation exposure<ce:br/>Relative insensitivity</entry><entry align="left">Difficulty in frail or incontinent patients<ce:br/>Sigmoidoscopy needed to see rectum<ce:br/>Low sensitivity for lesions &#x003C; 1 cm</entry></row></tbody></tgroup></ce:table></ce:display><ce:display><ce:figure id="f0080"><ce:label>Fig. 21.12</ce:label><ce:caption id="ca0065"><ce:simple-para id="sp0105" role="title">Examples of contrast radiology.</ce:simple-para><ce:simple-para id="sp0110" role="caption"><ce:bold>A</ce:bold> Barium swallow showing a large pharyngeal pouch (P) with retained contrast creating an air–fluid level. <ce:bold>B</ce:bold> Barium follow-through. There are multiple diverticula (arrows) in this patient with jejunal diverticulosis. <ce:bold>C</ce:bold> Barium enema showing severe diverticular disease. There is tortuosity and narrowing of the sigmoid colon with multiple diverticula (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0395" role="short">Fig. 21.12</ce:alt-text><ce:link id="ln0100" locator="f021-012ac-9780702070280" xlink:href="pii:B9780702070280000214/f021-012ac-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0035" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0115" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0400" role="short">Image 4</ce:alt-text></ce:inline-figure> 21.4</ce:label><ce:alt-text id="atte0405" role="short">21.4</ce:alt-text><ce:textbox-head><ce:title id="tit0040">Imaging in gastroenterology</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0530"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0410" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Ultrasound</entry><entry align="left">Computed tomography (CT)</entry><entry align="left">Magnetic resonance imaging (MRI)</entry><entry align="left">CT–positron emission tomography (CT-PET)</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Indications and major uses</ce:bold></entry><entry align="left">Abdominal masses<ce:br/>Organomegaly<ce:br/>Ascites<ce:br/>Biliary tract dilatation<ce:br/>Gallstones<ce:br/>Guided biopsy of lesions<ce:br/>Small bowel imaging</entry><entry align="left">Assessment of pancreatic disease<ce:br/>Hepatic tumour deposits<ce:br/>CT colonography (‘virtual colonoscopy’)<ce:br/>Tumour staging<ce:br/>Assessment of lesion vascularity<ce:br/>Abscesses and collections</entry><entry align="left">Hepatic tumour staging<ce:br/>MRCP<ce:br/>Pelvic/perianal disease<ce:br/>Crohn's fistulae<ce:br/>Small bowel visualisation</entry><entry align="left">Detection of metastases not seen on ultrasound or CT<ce:br/>Images can be fused with CT to form composite image</entry></row><row><entry align="left"><ce:bold>Limitations</ce:bold></entry><entry align="left">Low sensitivity for small lesions<ce:br/>Little functional information<ce:br/>Operator-dependent<ce:br/>Gas and obesity may obscure view</entry><entry align="left">Cost<ce:br/>Radiation dose</entry><entry align="left">Claustrophobic patients<ce:br/>Contraindicated in presence of metallic prostheses, cardiac pacemaker, cochlear implants</entry><entry align="left">Signal detection depends on metabolic activity within tumour – not all are metabolically active</entry></row></tbody></tgroup></ce:table></ce:display><ce:display><ce:figure id="f0085"><ce:label>Fig. 21.13</ce:label><ce:caption id="ca0070"><ce:simple-para id="sp0115" role="title">Examples of ultrasound, CT and MRI.</ce:simple-para><ce:simple-para id="sp0120" role="caption"><ce:bold>A</ce:bold> Ultrasound showing large gallstone (arrow) with acoustic shadowing. <ce:bold>B</ce:bold> Multidetector coronal CT showing large solid and cystic malignant tumour in the pancreatic tail (arrow). (PV = portal vein; L = liver) <ce:bold>C</ce:bold> Pelvic MRI showing large pelvic abscess (arrow) posterior to the rectum in a patient with Crohn's disease. <ce:bold>D</ce:bold> Fused CT-PET image showing two liver metastases (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0415" role="short">Fig. 21.13</ce:alt-text><ce:link id="ln0120" locator="f021-013ad-9780702070280" xlink:href="pii:B9780702070280000214/f021-013ad-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0040" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0130" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0420" role="short">Image 5</ce:alt-text></ce:inline-figure> 21.5</ce:label><ce:alt-text id="atte0425" role="short">21.5</ce:alt-text><ce:textbox-head><ce:title id="tit0045">Upper gastrointestinal endoscopy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0170"><ce:section-title id="st0170">Indications</ce:section-title><ce:para id="p0545"><ce:list id="ulist0075"><ce:list-item id="u0360"><ce:label>•</ce:label><ce:para id="p0550">Dyspepsia in patients &#x003E; 55 years of age or with alarm symptoms</ce:para></ce:list-item><ce:list-item id="u0365"><ce:label>•</ce:label><ce:para id="p0555">Atypical chest pain</ce:para></ce:list-item><ce:list-item id="u0370"><ce:label>•</ce:label><ce:para id="p0560">Dysphagia</ce:para></ce:list-item><ce:list-item id="u0375"><ce:label>•</ce:label><ce:para id="p0565">Vomiting</ce:para></ce:list-item><ce:list-item id="u0380"><ce:label>•</ce:label><ce:para id="p0570">Weight loss</ce:para></ce:list-item><ce:list-item id="u0385"><ce:label>•</ce:label><ce:para id="p0575">Acute or chronic gastrointestinal bleeding</ce:para></ce:list-item><ce:list-item id="u0390"><ce:label>•</ce:label><ce:para id="p0580">Screening for oesophageal varices in chronic liver disease</ce:para></ce:list-item><ce:list-item id="u0395"><ce:label>•</ce:label><ce:para id="p0585">Abnormal CT scan or barium meal</ce:para></ce:list-item><ce:list-item id="u0400"><ce:label>•</ce:label><ce:para id="p0590">Duodenal biopsies in the investigation of malabsorption and confirmation of a diagnosis of coeliac disease prior to commencement of gluten-free diet</ce:para></ce:list-item><ce:list-item id="u0405"><ce:label>•</ce:label><ce:para id="p0595">Therapy, including treatment of bleeding lesions, banding/injection of varices, dilatation of strictures, insertion of stents, placement of percutaneous gastrostomies, ablation of Barrett's oesophagus and resection of high-grade dysplastic lesions and early neoplasia in the upper gastrointestinal tract</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0175"><ce:section-title id="st0175">Contraindications</ce:section-title><ce:para id="p0600"><ce:list id="ulist0080"><ce:list-item id="u0410"><ce:label>•</ce:label><ce:para id="p0605">Severe shock</ce:para></ce:list-item><ce:list-item id="u0415"><ce:label>•</ce:label><ce:para id="p0610">Recent myocardial infarction, unstable angina, cardiac arrhythmia<ce:cross-ref id="crf0405" refid="fn0010">*</ce:cross-ref><ce:footnote id="fn0010"><ce:label>*</ce:label><ce:note-para id="np0010">These are ‘relative’ contraindications; in experienced hands, endoscopy can be safely performed.</ce:note-para></ce:footnote></ce:para></ce:list-item><ce:list-item id="u0420"><ce:label>•</ce:label><ce:para id="p0615">Severe respiratory disease<ce:cross-ref id="crf0410" refid="fn0010">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0425"><ce:label>•</ce:label><ce:para id="p0620">Atlantoaxial subluxation<ce:cross-ref id="crf0415" refid="fn0010">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0430"><ce:label>•</ce:label><ce:para id="p0625">Possible visceral perforation</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0180"><ce:section-title id="st0180">Complications</ce:section-title><ce:para id="p0630"><ce:list id="ulist0085"><ce:list-item id="u0435"><ce:label>•</ce:label><ce:para id="p0635">Cardiorespiratory depression due to sedation</ce:para></ce:list-item><ce:list-item id="u0440"><ce:label>•</ce:label><ce:para id="p0640">Aspiration pneumonia</ce:para></ce:list-item><ce:list-item id="u0445"><ce:label>•</ce:label><ce:para id="p0645">Perforation</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0145" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0430" role="short">Image 6</ce:alt-text></ce:inline-figure> 21.6</ce:label><ce:alt-text id="atte0435" role="short">21.6</ce:alt-text><ce:textbox-head><ce:title id="tit0050">Wireless capsule endoscopy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0195"><ce:section-title id="st0195">Indications</ce:section-title><ce:para id="p0660"><ce:list id="ulist0090"><ce:list-item id="u0450"><ce:label>•</ce:label><ce:para id="p0665">Obscure gastrointestinal bleeding</ce:para></ce:list-item><ce:list-item id="u0455"><ce:label>•</ce:label><ce:para id="p0670">Small bowel Crohn's disease</ce:para></ce:list-item><ce:list-item id="u0460"><ce:label>•</ce:label><ce:para id="p0675">Assessment of coeliac disease and its complications</ce:para></ce:list-item><ce:list-item id="u0465"><ce:label>•</ce:label><ce:para id="p0680">Screening and surveillance in familial polyposis syndromes</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0200"><ce:section-title id="st0200">Contraindications</ce:section-title><ce:para id="p0685"><ce:list id="ulist0095"><ce:list-item id="u0470"><ce:label>•</ce:label><ce:para id="p0690">Known or suspected small bowel stricture (risk of capsule retention)</ce:para></ce:list-item><ce:list-item id="u0475"><ce:label>•</ce:label><ce:para id="p0695">Caution in people with pacemakers or implantable defibrillators</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0205"><ce:section-title id="st0205">Complications</ce:section-title><ce:para id="p0700"><ce:list id="ulist0100"><ce:list-item id="u0480"><ce:label>•</ce:label><ce:para id="p0705">Capsule retention (&#x003C; 1%)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0150" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0440" role="short">Image 7</ce:alt-text></ce:inline-figure> 21.7</ce:label><ce:alt-text id="atte0445" role="short">21.7</ce:alt-text><ce:textbox-head><ce:title id="tit0055">Double balloon enteroscopy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0215"><ce:section-title id="st0215">Indications</ce:section-title><ce:section id="s0220"><ce:section-title id="st0220">Diagnostic</ce:section-title><ce:para id="p0715"><ce:list id="ulist0105"><ce:list-item id="u0485"><ce:label>•</ce:label><ce:para id="p0720">Obscure gastrointestinal bleeding</ce:para></ce:list-item><ce:list-item id="u0490"><ce:label>•</ce:label><ce:para id="p0725">Malabsorption or unexplained diarrhoea</ce:para></ce:list-item><ce:list-item id="u0495"><ce:label>•</ce:label><ce:para id="p0730">Suspicious radiological findings</ce:para></ce:list-item><ce:list-item id="u0500"><ce:label>•</ce:label><ce:para id="p0735">Suspected small bowel tumour</ce:para></ce:list-item><ce:list-item id="u0505"><ce:label>•</ce:label><ce:para id="p0740">Surveillance of polyposis syndromes</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0225"><ce:section-title id="st0225">Therapeutic</ce:section-title><ce:para id="p0745"><ce:list id="ulist0110"><ce:list-item id="u0510"><ce:label>•</ce:label><ce:para id="p0750">Coagulation/diathermy of bleeding lesions</ce:para></ce:list-item><ce:list-item id="u0515"><ce:label>•</ce:label><ce:para id="p0755">Jejunostomy placement</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0230"><ce:section-title id="st0230">Contraindications</ce:section-title><ce:para id="p0760"><ce:list id="ulist0115"><ce:list-item id="u0520"><ce:label>•</ce:label><ce:para id="p0765">As for upper gastrointestinal endoscopy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0235"><ce:section-title id="st0235">Complications</ce:section-title><ce:para id="p0770"><ce:list id="ulist0120"><ce:list-item id="u0525"><ce:label>•</ce:label><ce:para id="p0775">As for upper gastrointestinal endoscopy</ce:para></ce:list-item><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0780">Post-procedure abdominal pain (≤ 20%)</ce:para></ce:list-item><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p0785">Pancreatitis (1–3%)</ce:para></ce:list-item><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p0790">Perforation (especially after resection of large polyps)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0155" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0450" role="short">Image 8</ce:alt-text></ce:inline-figure> 21.8</ce:label><ce:alt-text id="atte0455" role="short">21.8</ce:alt-text><ce:textbox-head><ce:title id="tit0060">Colonoscopy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0245"><ce:section-title id="st0245">Indications<ce:cross-ref id="crf9005" refid="fn9000">*</ce:cross-ref><ce:footnote id="fn9000"><ce:label>*</ce:label><ce:note-para id="np9000">Colonoscopy is not useful in the investigation of constipation.</ce:note-para></ce:footnote></ce:section-title><ce:para id="p0800"><ce:list id="ulist0125"><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p0805">Suspected inflammatory bowel disease</ce:para></ce:list-item><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p0810">Chronic diarrhoea</ce:para></ce:list-item><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p0815">Altered bowel habit</ce:para></ce:list-item><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p0820">Rectal bleeding or iron deficiency anaemia</ce:para></ce:list-item><ce:list-item id="u0565"><ce:label>•</ce:label><ce:para id="p0825">Assessment of abnormal CT colonogram or barium enema</ce:para></ce:list-item><ce:list-item id="u0570"><ce:label>•</ce:label><ce:para id="p0830">Colorectal cancer screening</ce:para></ce:list-item><ce:list-item id="u0575"><ce:label>•</ce:label><ce:para id="p0835">Colorectal adenoma and carcinoma follow-up</ce:para></ce:list-item><ce:list-item id="u0580"><ce:label>•</ce:label><ce:para id="p0840">Therapeutic procedures, including endoscopic resection, dilatation of strictures, laser, stent insertion and argon plasma coagulation</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0250"><ce:section-title id="st0250">Contraindications</ce:section-title><ce:para id="p0845"><ce:list id="ulist0130"><ce:list-item id="u0585"><ce:label>•</ce:label><ce:para id="p0850">Acute severe ulcerative colitis (unprepared flexible sigmoidoscopy is preferred)</ce:para></ce:list-item><ce:list-item id="u0590"><ce:label>•</ce:label><ce:para id="p0855">As for upper gastrointestinal endoscopy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0255"><ce:section-title id="st0255">Complications</ce:section-title><ce:para id="p0860"><ce:list id="ulist0135"><ce:list-item id="u0595"><ce:label>•</ce:label><ce:para id="p0865">Cardiorespiratory depression due to sedation</ce:para></ce:list-item><ce:list-item id="u0600"><ce:label>•</ce:label><ce:para id="p0870">Perforation</ce:para></ce:list-item><ce:list-item id="u0605"><ce:label>•</ce:label><ce:para id="p0875">Bleeding following polypectomy</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0060" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0160" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0460" role="short">Image 9</ce:alt-text></ce:inline-figure> 21.10</ce:label><ce:alt-text id="atte0465" role="short">21.10</ce:alt-text><ce:textbox-head><ce:title id="tit0065">Endoscopic retrograde cholangiopancreatography</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0270"><ce:section-title id="st0270">Indications</ce:section-title><ce:section id="s0275"><ce:section-title id="st0275">Diagnostic</ce:section-title><ce:para id="p0895"><ce:list id="ulist0140"><ce:list-item id="u0610"><ce:label>•</ce:label><ce:para id="p0900">Biliary or pancreatic disease where other imaging is equivocal or contraindicated</ce:para></ce:list-item><ce:list-item id="u0615"><ce:label>•</ce:label><ce:para id="p0905">Ampullary biopsy or biliary cytology</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0280"><ce:section-title id="st0280">Therapeutic</ce:section-title><ce:para id="p0910"><ce:list id="ulist0145"><ce:list-item id="u0620"><ce:label>•</ce:label><ce:para id="p0915">Biliary disease:<ce:list id="ulist0150"><ce:list-item id="u0625"><ce:para id="p0920">Removal of common bile duct calculi<ce:cross-ref id="crf0445" refid="fn0015">*</ce:cross-ref><ce:footnote id="fn0015"><ce:label>*</ce:label><ce:note-para id="np0015">Laparoscopic surgery is preferred in fit individuals who also require cholecystectomy.</ce:note-para></ce:footnote></ce:para></ce:list-item><ce:list-item id="u0630"><ce:para id="p0925">Palliation of malignant biliary obstruction</ce:para></ce:list-item><ce:list-item id="u0635"><ce:para id="p0930">Management of biliary leaks/damage complicating surgery</ce:para></ce:list-item><ce:list-item id="u0640"><ce:para id="p0935">Dilatation of benign strictures</ce:para></ce:list-item><ce:list-item id="u0645"><ce:para id="p0940">Primary sclerosing cholangitis</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0650"><ce:label>•</ce:label><ce:para id="p0945">Pancreatic disease:<ce:list id="ulist0155"><ce:list-item id="u0655"><ce:para id="p0950">Drainage of pancreatic pseudocysts and fistulae</ce:para></ce:list-item><ce:list-item id="u0660"><ce:para id="p0955">Removal of pancreatic calculi (selected cases)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0285"><ce:section-title id="st0285">Contraindications</ce:section-title><ce:para id="p0960"><ce:list id="ulist0160"><ce:list-item id="u0665"><ce:label>•</ce:label><ce:para id="p0965">Severe cardiopulmonary comorbidity</ce:para></ce:list-item><ce:list-item id="u0670"><ce:label>•</ce:label><ce:para id="p0970">Coagulopathy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0290"><ce:section-title id="st0290">Complications</ce:section-title><ce:para id="p0975"><ce:list id="ulist0165"><ce:list-item id="u0675"><ce:label>•</ce:label><ce:para id="p0980">Occur in 5–10% with a 30-day mortality of 0.5–1%</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0295"><ce:section-title id="st0295">General</ce:section-title><ce:para id="p0985"><ce:list id="ulist0170"><ce:list-item id="u0680"><ce:label>•</ce:label><ce:para id="p0990">As for upper endoscopy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0300"><ce:section-title id="st0300">Specific</ce:section-title><ce:para id="p0995"><ce:list id="ulist0175"><ce:list-item id="u0685"><ce:label>•</ce:label><ce:para id="p1000">Biliary disease:<ce:list id="ulist0180"><ce:list-item id="u0690"><ce:para id="p1005">Bleeding following sphincterotomy</ce:para></ce:list-item><ce:list-item id="u0695"><ce:para id="p1010">Cholangitis (if biliary obstruction is not relieved by ERCP)</ce:para></ce:list-item><ce:list-item id="u0700"><ce:para id="p1015">Gallstone impaction</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0705"><ce:label>•</ce:label><ce:para id="p1020">Pancreatic disease:<ce:list id="ulist0185"><ce:list-item id="u0710"><ce:para id="p1025">Acute pancreatitis</ce:para></ce:list-item><ce:list-item id="u0715"><ce:para id="p1030">Infection of pseudocyst</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0070" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0170" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0470" role="short">Image 10</ce:alt-text></ce:inline-figure> 21.11</ce:label><ce:alt-text id="atte0475" role="short">21.11</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Reasons for biopsy or cytological examination</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1065"><ce:list id="ulist0195"><ce:list-item id="u0740"><ce:label>•</ce:label><ce:para id="p1070">Suspected malignant lesions</ce:para></ce:list-item><ce:list-item id="u0745"><ce:label>•</ce:label><ce:para id="p1075">Assessment of mucosal abnormalities</ce:para></ce:list-item><ce:list-item id="u0750"><ce:label>•</ce:label><ce:para id="p1080">Diagnosis of infection (<ce:italic>Candida</ce:italic>, <ce:italic>Helicobacter pylori</ce:italic>, <ce:italic>Giardia lamblia</ce:italic>)</ce:para></ce:list-item><ce:list-item id="u0755"><ce:label>•</ce:label><ce:para id="p1085">Analysis of genetic mutations</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0075" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0175" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0480" role="short">Image 11</ce:alt-text></ce:inline-figure> 21.12</ce:label><ce:alt-text id="atte0485" role="short">21.12</ce:alt-text><ce:textbox-head><ce:title id="tit0080">Tests of gastrointestinal function</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1110"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0490" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Process</entry><entry align="left">Test</entry><entry align="left">Principle</entry><entry align="left">Comments</entry></row></thead><tbody><row rowsep="0"><entry align="left"><ce:bold>Absorption</ce:bold></entry><entry align="left"/><entry align="left"/><entry align="left"/></row><row rowsep="0"><entry align="left">Lactose</entry><entry align="left">Lactose H<ce:inf loc="post">2</ce:inf> breath test</entry><entry align="left">Measurement of breath H<ce:inf loc="post">2</ce:inf> content after 50 g oral lactose. Undigested sugar is metabolised by colonic bacteria in hypolactasia and expired hydrogen is measured</entry><entry align="left">Non-invasive and accurate. May provoke pain and diarrhoea in sufferers</entry></row><row><entry morerows="1" rowsep="1" align="left">Bile acids</entry><entry rowsep="0" align="left"><ce:sup loc="post">75</ce:sup>SeHCAT test</entry><entry rowsep="0" align="left">Isotopic quantification of 7-day whole-body retention of oral dose <ce:sup loc="post">75</ce:sup>Se-labelled homocholyltaurine (&#x003E; 15% = normal, 5–15% borderline, &#x003C; 5% = abnormal)</entry><entry rowsep="0" align="left">Accurate and specific but requires two visits and involves radiation. Results can be equivocal. Serum 7α-hydroxycholestenone is almost as sensitive and specific</entry></row><row rowsep="1"><entry align="left">Serum 7α-hydroxycholestenone</entry><entry align="left">Intermediate metabolite of the bile acid synthetic pathway. Serum levels indicate activity of the pathway and are elevated in bile acid diarrhoea</entry><entry align="left">Simple test to perform and only marginally less sensitive and specific than <ce:sup loc="post">75</ce:sup>SeHCAT test</entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Pancreatic exocrine function</ce:bold></entry><entry rowsep="0" align="left">Pancreolauryl test</entry><entry rowsep="0" align="left">Pancreatic esterases cleave fluorescein dilaurate after oral ingestion. Fluorescein is absorbed and quantified in urine</entry><entry rowsep="0" align="left">Accurate and avoids duodenal intubation Takes 2 days. Accurate urine collection essential. Rarely performed</entry></row><row rowsep="1"><entry align="left">Faecal elastase</entry><entry align="left">Immunoassay of pancreatic enzymes on stool sample</entry><entry align="left">Simple, quick and avoids urine collection. Does not detect mild disease</entry></row><row><entry align="left"><ce:bold>Mucosal inflammation/ permeability</ce:bold></entry><entry align="left">Faecal calprotectin</entry><entry align="left">A protein secreted non-specifically by neutrophils into the colon in response to inflammation or neoplasia</entry><entry align="left">Useful screening test for gastrointestinal inflammation and for monitoring patients with Crohn's disease and ulcerative colitis. Poor sensitivity for cancer</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0145">(<ce:sup loc="post">75</ce:sup>SeHCAT = <ce:sup loc="post">75</ce:sup>Se-homocholic acid taurine)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0080" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0180" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0495" role="short">Image 12</ce:alt-text></ce:inline-figure> 21.13</ce:label><ce:alt-text id="atte0500" role="short">21.13</ce:alt-text><ce:textbox-head><ce:title id="tit0085">Commonly used radioisotope tests in gastroenterology</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1125"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0505" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Test</entry><entry align="left">Isotope</entry><entry align="left">Major uses and principle of test</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Gastric emptying study</ce:bold></entry><entry align="left"><ce:sup loc="post">99m</ce:sup>Tc-sulphur<ce:br/><ce:sup loc="post">111</ce:sup>In-DTPA</entry><entry align="left">Assessment of gastric emptying, particularly for possible gastroparesis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Urea breath test</ce:bold></entry><entry align="left"><ce:sup loc="post">13</ce:sup>C-urea</entry><entry align="left">Non-invasive diagnosis of <ce:italic>Helicobacter pylori.</ce:italic> Bacterial urease enzyme splits urea to ammonia and CO<ce:inf loc="post">2</ce:inf>, which is detected in expired air</entry></row><row rowsep="1"><entry align="left"><ce:bold>Meckel's scan</ce:bold></entry><entry align="left"><ce:sup loc="post">99m</ce:sup>Tc-pertechnate</entry><entry align="left">Diagnosis of Meckel's diverticulum in cases of obscure gastrointestinal bleeding. Isotope is injected intravenously and localises in ectopic parietal mucosa within diverticulum</entry></row><row rowsep="1"><entry align="left"><ce:bold>Somatostatin receptor scintigraphy (SRS)</ce:bold></entry><entry align="left"><ce:sup loc="post">111</ce:sup>In-DTPA-octreotide</entry><entry align="left">Labelled somatostatin analogue binds to cell surface somatostatin receptors on pancreatic neuro-endocrine tumours</entry></row><row><entry align="left"><ce:bold>Positron emission tomography (PET)</ce:bold></entry><entry align="left"><ce:sup loc="post">18</ce:sup>F-fluorodeoxyglucose (FDG)<ce:sup loc="post">68</ce:sup>Gallium-labelled somatostatin analogue</entry><entry align="left">Staging high-grade cancersMore sensitive and specific than SRS for staging neuro-endocrine tumours</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0085" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0190" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0510" role="short">Image 13</ce:alt-text></ce:inline-figure> 21.14</ce:label><ce:alt-text id="atte0515" role="short">21.14</ce:alt-text><ce:textbox-head><ce:title id="tit0090">Causes of dyspepsia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1165"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0520" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Upper gastrointestinal disorders</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0200"><ce:list-item id="u0760"><ce:label>•</ce:label><ce:para id="p1170">Peptic ulcer disease</ce:para></ce:list-item><ce:list-item id="u0765"><ce:label>•</ce:label><ce:para id="p1175">Acute gastritis</ce:para></ce:list-item><ce:list-item id="u0770"><ce:label>•</ce:label><ce:para id="p1180">Gallstones</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0205"><ce:list-item id="u0775"><ce:label>•</ce:label><ce:para id="p1185">Oesophageal spasm</ce:para></ce:list-item><ce:list-item id="u0780"><ce:label>•</ce:label><ce:para id="p1190">Non-ulcer dyspepsia</ce:para></ce:list-item><ce:list-item id="u0785"><ce:label>•</ce:label><ce:para id="p1195">Irritable bowel syndrome</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other gastrointestinal disorders</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0210"><ce:list-item id="u0790"><ce:label>•</ce:label><ce:para id="p1200">Pancreatic disease (cancer, chronic pancreatitis)</ce:para></ce:list-item><ce:list-item id="u0795"><ce:label>•</ce:label><ce:para id="p1205">Colonic carcinoma</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0215"><ce:list-item id="u0800"><ce:label>•</ce:label><ce:para id="p1210">Hepatic disease (hepatitis, metastases)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Systemic disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0220"><ce:list-item id="u0805"><ce:label>•</ce:label><ce:para id="p1215">Renal failure</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0225"><ce:list-item id="u0810"><ce:label>•</ce:label><ce:para id="p1220">Hypercalcaemia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0230"><ce:list-item id="u0815"><ce:label>•</ce:label><ce:para id="p1225">Non-steroidal anti-inflammatory drugs (NSAIDs)</ce:para></ce:list-item><ce:list-item id="u0820"><ce:label>•</ce:label><ce:para id="p1230">Glucocorticoids</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0235"><ce:list-item id="u0825"><ce:label>•</ce:label><ce:para id="p1235">Iron and potassium supplements</ce:para></ce:list-item><ce:list-item id="u0830"><ce:label>•</ce:label><ce:para id="p1240">Digoxin</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Others</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0240"><ce:list-item id="u0835"><ce:label>•</ce:label><ce:para id="p1245">Psychological (anxiety, depression)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0245"><ce:list-item id="u0840"><ce:label>•</ce:label><ce:para id="p1250">Alcohol</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0090" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0195" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0525" role="short">Image 14</ce:alt-text></ce:inline-figure> 21.15</ce:label><ce:alt-text id="atte0530" role="short">21.15</ce:alt-text><ce:textbox-head><ce:title id="tit0095">Alarm features in dyspepsia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1255"><ce:list id="ulist0250"><ce:list-item id="u0845"><ce:label>•</ce:label><ce:para id="p1260">Weight loss</ce:para></ce:list-item><ce:list-item id="u0850"><ce:label>•</ce:label><ce:para id="p1265">Anaemia</ce:para></ce:list-item><ce:list-item id="u0855"><ce:label>•</ce:label><ce:para id="p1270">Vomiting</ce:para></ce:list-item><ce:list-item id="u0860"><ce:label>•</ce:label><ce:para id="p1275">Haematemesis and/or melaena</ce:para></ce:list-item><ce:list-item id="u0865"><ce:label>•</ce:label><ce:para id="p1280">Dysphagia</ce:para></ce:list-item><ce:list-item id="u0870"><ce:label>•</ce:label><ce:para id="p1285">Palpable abdominal mass</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0095" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0210" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0535" role="short">Image 15</ce:alt-text></ce:inline-figure> 21.16</ce:label><ce:alt-text id="atte0540" role="short">21.16</ce:alt-text><ce:textbox-head><ce:title id="tit0100">Modified Blatchford score: risk stratification in acute upper gastrointestinal bleeding</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1310"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0545" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Admission risk marker</entry><entry align="left">Score component value</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Blood urea</ce:bold></entry></row><row rowsep="0"><entry align="left">≥ 25 mmol/L (70 mg/dL)</entry><entry align="left">6</entry></row><row rowsep="0"><entry align="left">10–25 mmol/L (28–70 mg/dL)</entry><entry align="left">4</entry></row><row rowsep="0"><entry align="left">8–10 mmol/L (22.4–28 mg/dL)</entry><entry align="left">3</entry></row><row rowsep="0"><entry align="left">6.5–8 mmol/L (18.2–22.4 mg/dL)</entry><entry align="left">2</entry></row><row rowsep="1"><entry align="left">&#x003C; 6.5 mmol/L (18.2 mg/dL)</entry><entry align="left">0</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haemoglobin for men</ce:bold></entry></row><row rowsep="0"><entry align="left">&#x003C; 100 g/L (10 g/dL)</entry><entry align="left">6</entry></row><row rowsep="0"><entry align="left">100–119 g/L (10–11.9 g/dL)</entry><entry align="left">3</entry></row><row rowsep="0"><entry align="left">120–129 g/L (12–12.9 g/dL)</entry><entry align="left">1</entry></row><row rowsep="1"><entry align="left">≥ 130 g/L (13 g/dL)</entry><entry align="left">0</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haemoglobin for women</ce:bold></entry></row><row rowsep="0"><entry align="left">&#x003C; 100 g/L (10 g/dL)</entry><entry align="left">6</entry></row><row rowsep="0"><entry align="left">100–119 g/L (10–11.9 g/dL)</entry><entry align="left">1</entry></row><row rowsep="1"><entry align="left">≥ 120 g/L (12 g/dL)</entry><entry align="left">0</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Systolic blood pressure</ce:bold></entry></row><row rowsep="0"><entry align="left">&#x003C; 90 mmHg</entry><entry align="left">3</entry></row><row rowsep="0"><entry align="left">90–99 mmHg</entry><entry align="left">2</entry></row><row rowsep="0"><entry align="left">100–109 mmHg</entry><entry align="left">1</entry></row><row rowsep="1"><entry align="left">&#x003E; 109 mmHg</entry><entry align="left">0</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other markers</ce:bold></entry></row><row rowsep="0"><entry align="left">Presentation with syncope</entry><entry align="left">2</entry></row><row rowsep="0"><entry align="left">Hepatic disease</entry><entry align="left">2</entry></row><row rowsep="0"><entry align="left">Cardiac failure</entry><entry align="left">2</entry></row><row rowsep="0"><entry align="left">Pulse ≥ 100 beats/min</entry><entry align="left">1</entry></row><row rowsep="0"><entry align="left">Presentation with melaena</entry><entry align="left">1</entry></row><row><entry align="left">None of the above</entry><entry align="left">0</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0100" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0230" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0550" role="short">Image 16</ce:alt-text></ce:inline-figure> 21.17</ce:label><ce:alt-text id="atte0555" role="short">21.17</ce:alt-text><ce:textbox-head><ce:title id="tit0105">Causes of lower gastrointestinal bleeding</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1425"><ce:display><ce:table frame="topbot" id="t0050"><ce:alt-text id="atte0560" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Severe acute</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0265"><ce:list-item id="u0915"><ce:label>•</ce:label><ce:para id="p1430">Diverticular disease</ce:para></ce:list-item><ce:list-item id="u0920"><ce:label>•</ce:label><ce:para id="p1435">Angiodysplasia</ce:para></ce:list-item><ce:list-item id="u0925"><ce:label>•</ce:label><ce:para id="p1440">Ischaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0270"><ce:list-item id="u0930"><ce:label>•</ce:label><ce:para id="p1445">Meckel's diverticulum</ce:para></ce:list-item><ce:list-item id="u0935"><ce:label>•</ce:label><ce:para id="p1450">Inflammatory bowel disease (rarely)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Moderate, chronic/subacute</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0275"><ce:list-item id="u0940"><ce:label>•</ce:label><ce:para id="p1455">Fissure</ce:para></ce:list-item><ce:list-item id="u0945"><ce:label>•</ce:label><ce:para id="p1460">Haemorrhoids</ce:para></ce:list-item><ce:list-item id="u0950"><ce:label>•</ce:label><ce:para id="p1465">Inflammatory bowel disease</ce:para></ce:list-item><ce:list-item id="u0955"><ce:label>•</ce:label><ce:para id="p1470">Carcinoma</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0280"><ce:list-item id="u0960"><ce:label>•</ce:label><ce:para id="p1475">Large polyps</ce:para></ce:list-item><ce:list-item id="u0965"><ce:label>•</ce:label><ce:para id="p1480">Angiodysplasia</ce:para></ce:list-item><ce:list-item id="u0970"><ce:label>•</ce:label><ce:para id="p1485">Radiation enteritis</ce:para></ce:list-item><ce:list-item id="u0975"><ce:label>•</ce:label><ce:para id="p1490">Solitary rectal ulcer</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0105" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0240" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0565" role="short">Image 17</ce:alt-text></ce:inline-figure> 21.18</ce:label><ce:alt-text id="atte0570" role="short">21.18</ce:alt-text><ce:textbox-head><ce:title id="tit0110">Chronic or relapsing diarrhoea</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1530"><ce:display><ce:table frame="topbot" id="t0055"><ce:alt-text id="atte0575" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Colonic</entry><entry align="left">Malabsorption</entry><entry align="left">Small bowel</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Clinical features</ce:bold></entry><entry align="left">Blood and mucus in stool<ce:br/>Cramping lower abdominal pain</entry><entry align="left">Steatorrhoea<ce:br/>Undigested food in the stool<ce:br/>Weight loss and nutritional disturbances</entry><entry align="left">Large-volume, watery stool<ce:br/>Abdominal bloating<ce:br/>Cramping mid-abdominal pain</entry></row><row rowsep="1"><entry align="left"><ce:bold>Some causes</ce:bold></entry><entry align="left">Inflammatory bowel disease<ce:br/>Microscopic colitis<ce:br/>Neoplasia<ce:br/>Ischaemia<ce:br/>Irritable bowel syndrome</entry><entry align="left">Pancreatic:<ce:br/><ce:list id="ulist0285"><ce:list-item id="u0980"><ce:para id="p1535">Chronic pancreatitis</ce:para></ce:list-item><ce:list-item id="u0985"><ce:para id="p1540">Cancer of pancreas</ce:para></ce:list-item><ce:list-item id="u0990"><ce:para id="p1545">Cystic fibrosis</ce:para></ce:list-item></ce:list><ce:br/>Enteropathy:<ce:br/><ce:list id="ulist0290"><ce:list-item id="u0995"><ce:para id="p1550">Coeliac disease</ce:para></ce:list-item><ce:list-item id="u1000"><ce:para id="p1555">Tropical sprue</ce:para></ce:list-item><ce:list-item id="u1005"><ce:para id="p1560">Lymphoma</ce:para></ce:list-item></ce:list><ce:br/>Lymphangiectasia</entry><entry align="left">Crohn's disease<ce:br/>VIPoma<ce:br/>Drug-induced:<ce:br/><ce:list id="ulist0295"><ce:list-item id="u1010"><ce:para id="p1565">NSAIDs</ce:para></ce:list-item><ce:list-item id="u1015"><ce:para id="p1570">Aminosalicylates</ce:para></ce:list-item><ce:list-item id="u1020"><ce:para id="p1575">SSRIs</ce:para></ce:list-item></ce:list></entry></row><row><entry morerows="3" align="left"><ce:bold>Investigations</ce:bold></entry><entry morerows="3" align="left">Faecal calprotectin<ce:br/>Ileocolonoscopy with biopsies</entry><entry rowsep="0" align="left">Faecal elastase</entry><entry rowsep="0" align="left">Faecal calprotectin</entry></row><row rowsep="0"><entry align="left">Ultrasound, CT and MRCP</entry><entry align="left">Stool volume</entry></row><row rowsep="0"><entry align="left">Small-bowel biopsy</entry><entry align="left">Gut hormone profile</entry></row><row><entry align="left">Barium follow-through or small-bowel MRI</entry><entry align="left">Barium follow-through or small-bowel MRI</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0195">(CT = computed tomography; MRCP = magnetic resonance cholangiopancreatography; MRI = magnetic resonance imaging; NSAIDs = non-steroidal anti-inflammatory drugs; SSRIs = selective serotonin re-uptake inhibitors; VIP = vasoactive intestinal polypeptide)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0110" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0250" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0580" role="short">Image 18</ce:alt-text></ce:inline-figure> 21.19</ce:label><ce:alt-text id="atte0585" role="short">21.19</ce:alt-text><ce:textbox-head><ce:title id="tit0115">Routine blood test abnormalities in malabsorption</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0520"><ce:section-title id="st0510">Haematology</ce:section-title><ce:para id="p1610"><ce:list id="ulist0305"><ce:list-item id="u1040"><ce:label>•</ce:label><ce:para id="p1615">Microcytic anaemia (iron deficiency)</ce:para></ce:list-item><ce:list-item id="u1045"><ce:label>•</ce:label><ce:para id="p1620">Macrocytic anaemia (folate or B<ce:inf loc="post">12</ce:inf> deficiency)</ce:para></ce:list-item><ce:list-item id="u1050"><ce:label>•</ce:label><ce:para id="p1625">Increased prothrombin time (vitamin K deficiency)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0525"><ce:section-title id="st0515">Biochemistry</ce:section-title><ce:para id="p1630"><ce:list id="ulist0310"><ce:list-item id="u1055"><ce:label>•</ce:label><ce:para id="p1635">Hypoalbuminaemia</ce:para></ce:list-item><ce:list-item id="u1060"><ce:label>•</ce:label><ce:para id="p1640">Hypocalcaemia</ce:para></ce:list-item><ce:list-item id="u1065"><ce:label>•</ce:label><ce:para id="p1645">Hypomagnesaemia</ce:para></ce:list-item><ce:list-item id="u1070"><ce:label>•</ce:label><ce:para id="p1650">Hypophosphataemia</ce:para></ce:list-item><ce:list-item id="u1075"><ce:label>•</ce:label><ce:para id="p1655">Low serum zinc</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0115" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0265" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0590" role="short">Image 19</ce:alt-text></ce:inline-figure> 21.20</ce:label><ce:alt-text id="atte0595" role="short">21.20</ce:alt-text><ce:textbox-head><ce:title id="tit0120">Causes of constipation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1700"><ce:display><ce:table frame="topbot" id="t0060"><ce:alt-text id="atte0600" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gastrointestinal causes</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Dietary</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0315"><ce:list-item id="u1080"><ce:label>•</ce:label><ce:para id="p1705">Lack of fibre and/or fluid intake</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Motility</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0320"><ce:list-item id="u1085"><ce:label>•</ce:label><ce:para id="p1710">Slow-transit constipation</ce:para></ce:list-item><ce:list-item id="u1090"><ce:label>•</ce:label><ce:para id="p1715">Irritable bowel syndrome</ce:para></ce:list-item><ce:list-item id="u1095"><ce:label>•</ce:label><ce:para id="p1720">Drugs (see below)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0325"><ce:list-item id="u1100"><ce:label>•</ce:label><ce:para id="p1725">Chronic intestinal pseudo-obstruction</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Structural</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0330"><ce:list-item id="u1105"><ce:label>•</ce:label><ce:para id="p1730">Colonic carcinoma</ce:para></ce:list-item><ce:list-item id="u1110"><ce:label>•</ce:label><ce:para id="p1735">Diverticular disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0335"><ce:list-item id="u1115"><ce:label>•</ce:label><ce:para id="p1740">Hirschsprung's disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Defecation</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0340"><ce:list-item id="u1120"><ce:label>•</ce:label><ce:para id="p1745">Anorectal disease (Crohn's, fissures, haemorrhoids)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0345"><ce:list-item id="u1125"><ce:label>•</ce:label><ce:para id="p1750">Obstructed defecation</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Non-gastrointestinal causes</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0350"><ce:list-item id="u1130"><ce:label>•</ce:label><ce:para id="p1755">Opiates</ce:para></ce:list-item><ce:list-item id="u1135"><ce:label>•</ce:label><ce:para id="p1760">Anticholinergics</ce:para></ce:list-item><ce:list-item id="u1140"><ce:label>•</ce:label><ce:para id="p1765">Calcium antagonists</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0355"><ce:list-item id="u1145"><ce:label>•</ce:label><ce:para id="p1770">Iron supplements</ce:para></ce:list-item><ce:list-item id="u1150"><ce:label>•</ce:label><ce:para id="p1775">Aluminium-containing antacids</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neurological</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0360"><ce:list-item id="u1155"><ce:label>•</ce:label><ce:para id="p1780">Multiple sclerosis</ce:para></ce:list-item><ce:list-item id="u1160"><ce:label>•</ce:label><ce:para id="p1785">Spinal cord lesions</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0365"><ce:list-item id="u1165"><ce:label>•</ce:label><ce:para id="p1790">Cerebrovascular accidents</ce:para></ce:list-item><ce:list-item id="u1170"><ce:label>•</ce:label><ce:para id="p1795">Parkinsonism</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic/endocrine</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0370"><ce:list-item id="u1175"><ce:label>•</ce:label><ce:para id="p1800">Diabetes mellitus</ce:para></ce:list-item><ce:list-item id="u1180"><ce:label>•</ce:label><ce:para id="p1805">Hypercalcaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0375"><ce:list-item id="u1185"><ce:label>•</ce:label><ce:para id="p1810">Hypothyroidism</ce:para></ce:list-item><ce:list-item id="u1190"><ce:label>•</ce:label><ce:para id="p1815">Pregnancy</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Others</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0380"><ce:list-item id="u1195"><ce:label>•</ce:label><ce:para id="p1820">Any serious illness with immobility, especially in the elderly</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0385"><ce:list-item id="u1200"><ce:label>•</ce:label><ce:para id="p1825">Depression</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0120" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0270" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0605" role="short">Image 20</ce:alt-text></ce:inline-figure> 21.21</ce:label><ce:alt-text id="atte0610" role="short">21.21</ce:alt-text><ce:textbox-head><ce:title id="tit0125">Causes of acute abdominal pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1890"><ce:display><ce:table frame="topbot" id="t0065"><ce:alt-text id="atte0615" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammation</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0395"><ce:list-item id="u1225"><ce:label>•</ce:label><ce:para id="p1895">Appendicitis</ce:para></ce:list-item><ce:list-item id="u1230"><ce:label>•</ce:label><ce:para id="p1900">Diverticulitis</ce:para></ce:list-item><ce:list-item id="u1235"><ce:label>•</ce:label><ce:para id="p1905">Cholecystitis</ce:para></ce:list-item><ce:list-item id="u1240"><ce:label>•</ce:label><ce:para id="p1910">Pelvic inflammatory disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0400"><ce:list-item id="u1245"><ce:label>•</ce:label><ce:para id="p1915">Pancreatitis</ce:para></ce:list-item><ce:list-item id="u1250"><ce:label>•</ce:label><ce:para id="p1920">Pyelonephritis</ce:para></ce:list-item><ce:list-item id="u1255"><ce:label>•</ce:label><ce:para id="p1925">Intra-abdominal abscess</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Perforation/rupture</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0405"><ce:list-item id="u1260"><ce:label>•</ce:label><ce:para id="p1930">Peptic ulcer</ce:para></ce:list-item><ce:list-item id="u1265"><ce:label>•</ce:label><ce:para id="p1935">Diverticular disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0410"><ce:list-item id="u1270"><ce:label>•</ce:label><ce:para id="p1940">Ovarian cyst</ce:para></ce:list-item><ce:list-item id="u1275"><ce:label>•</ce:label><ce:para id="p1945">Aortic aneurysm</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Obstruction</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0415"><ce:list-item id="u1280"><ce:label>•</ce:label><ce:para id="p1950">Intestinal obstruction</ce:para></ce:list-item><ce:list-item id="u1285"><ce:label>•</ce:label><ce:para id="p1955">Biliary colic</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0420"><ce:list-item id="u1290"><ce:label>•</ce:label><ce:para id="p1960">Ureteric colic</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other (rare)</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0425"><ce:list-item id="u1295"><ce:label>•</ce:label><ce:para id="p1965">See <ce:cross-ref id="crf0570" refid="b0130">Box 21.23</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0130" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0285" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0620" role="short">Image 21</ce:alt-text></ce:inline-figure> 21.23</ce:label><ce:alt-text id="atte0625" role="short">21.23</ce:alt-text><ce:textbox-head><ce:title id="tit0135">Extra-intestinal causes of chronic or recurrent abdominal pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2070"><ce:display><ce:table frame="topbot" id="t0070"><ce:alt-text id="atte0630" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Retroperitoneal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0440"><ce:list-item id="u1335"><ce:label>•</ce:label><ce:para id="p2075">Aortic aneurysm</ce:para></ce:list-item><ce:list-item id="u1340"><ce:label>•</ce:label><ce:para id="p2080">Malignancy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0445"><ce:list-item id="u1345"><ce:label>•</ce:label><ce:para id="p2085">Lymphadenopathy</ce:para></ce:list-item><ce:list-item id="u1350"><ce:label>•</ce:label><ce:para id="p2090">Abscess</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Psychogenic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0450"><ce:list-item id="u1355"><ce:label>•</ce:label><ce:para id="p2095">Depression</ce:para></ce:list-item><ce:list-item id="u1360"><ce:label>•</ce:label><ce:para id="p2100">Anxiety</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0455"><ce:list-item id="u1365"><ce:label>•</ce:label><ce:para id="p2105">Hypochondriasis</ce:para></ce:list-item><ce:list-item id="u1370"><ce:label>•</ce:label><ce:para id="p2110">Somatisation</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Locomotor</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0460"><ce:list-item id="u1375"><ce:label>•</ce:label><ce:para id="p2115">Vertebral compression/fracture</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0465"><ce:list-item id="u1380"><ce:label>•</ce:label><ce:para id="p2120">Abdominal muscle strain</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic/endocrine</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0470"><ce:list-item id="u1385"><ce:label>•</ce:label><ce:para id="p2125">Diabetes mellitus</ce:para></ce:list-item><ce:list-item id="u1390"><ce:label>•</ce:label><ce:para id="p2130">Acute intermittent porphyria</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0475"><ce:list-item id="u1395"><ce:label>•</ce:label><ce:para id="p2135">Hypercalcaemia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs/toxins</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0480"><ce:list-item id="u1400"><ce:label>•</ce:label><ce:para id="p2140">Glucocorticoids</ce:para></ce:list-item><ce:list-item id="u1405"><ce:label>•</ce:label><ce:para id="p2145">Azathioprine</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0485"><ce:list-item id="u1410"><ce:label>•</ce:label><ce:para id="p2150">Lead</ce:para></ce:list-item><ce:list-item id="u1415"><ce:label>•</ce:label><ce:para id="p2155">Alcohol</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haematological</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0490"><ce:list-item id="u1420"><ce:label>•</ce:label><ce:para id="p2160">Sickle-cell disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0495"><ce:list-item id="u1425"><ce:label>•</ce:label><ce:para id="p2165">Haemolytic disorders</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neurological</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0500"><ce:list-item id="u1430"><ce:label>•</ce:label><ce:para id="p2170">Spinal cord lesions</ce:para></ce:list-item><ce:list-item id="u1435"><ce:label>•</ce:label><ce:para id="p2175">Tabes dorsalis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0505"><ce:list-item id="u1440"><ce:label>•</ce:label><ce:para id="p2180">Radiculopathy</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0135" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0290" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000214/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0635" role="short">Image 22</ce:alt-text></ce:inline-figure> 21.24</ce:label><ce:alt-text id="atte0640" role="short">21.24</ce:alt-text><ce:textbox-head><ce:title id="tit0140">How to assess abdominal pain</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2185"><ce:list id="ulist0510"><ce:list-item id="u1445"><ce:label>•</ce:label><ce:para id="p2190">Duration</ce:para></ce:list-item><ce:list-item id="u1450"><ce:label>•</ce:label><ce:para id="p2195">Site and radiation</ce:para></ce:list-item><ce:list-item id="u1455"><ce:label>•</ce:label><ce:para id="p2200">Severity</ce:para></ce:list-item><ce:list-item id="u1460"><ce:label>•</ce:label><ce:para id="p2205">Precipitating and relieving factors (food, drugs, alcohol, posture, movement, defecation)</ce:para></ce:list-item><ce:list-item id="u1465"><ce:label>•</ce:label><ce:para id="p2210">Nature (colicky, constant, sharp or dull, wakes patient at night)</ce:para></ce:list-item><ce:list-item id="u1470"><ce:label>•</ce:label><ce:para id="p2215">Pattern (intermittent or continuous)</ce:para></ce:list-item><ce:list-item id="u1475"><ce:label>•</ce:label><ce:para id="p2220">Associated features (vomiting, dyspepsia, altered bowel habit)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0140" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0295" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0645" role="short">Image 23</ce:alt-text></ce:inline-figure> 21.25</ce:label><ce:alt-text id="atte0650" role="short">21.25</ce:alt-text><ce:textbox-head><ce:title id="tit0145">Causes of oral ulceration</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2280"><ce:display><ce:table frame="topbot" id="t0075"><ce:alt-text id="atte0655" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Aphthous</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0520"><ce:list-item id="u1515"><ce:label>•</ce:label><ce:para id="p2285">Idiopathic</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0525"><ce:list-item id="u1520"><ce:label>•</ce:label><ce:para id="p2290">Premenstrual</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infection</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0530"><ce:list-item id="u1525"><ce:label>•</ce:label><ce:para id="p2295">Fungal (candidiasis)</ce:para></ce:list-item><ce:list-item id="u1530"><ce:label>•</ce:label><ce:para id="p2300">Viral (herpes simplex, HIV)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0535"><ce:list-item id="u1535"><ce:label>•</ce:label><ce:para id="p2305">Bacterial, including syphilis, tuberculosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gastrointestinal diseases</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0540"><ce:list-item id="u1540"><ce:label>•</ce:label><ce:para id="p2310">Crohn's disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0545"><ce:list-item id="u1545"><ce:label>•</ce:label><ce:para id="p2315">Coeliac disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Dermatological conditions</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0550"><ce:list-item id="u1550"><ce:label>•</ce:label><ce:para id="p2320">Lichen planus</ce:para></ce:list-item><ce:list-item id="u1555"><ce:label>•</ce:label><ce:para id="p2325">Immunobullous disorders (<ce:intra-ref id="ii0170" xlink:href="pii:B978-0-7020-7028-0.00029-9#s1360">p. 1255</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0555"><ce:list-item id="u1560"><ce:label>•</ce:label><ce:para id="p2330">Dermatitis herpetiformis</ce:para></ce:list-item><ce:list-item id="u1565"><ce:label>•</ce:label><ce:para id="p2335">Erythema multiforme</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0560"><ce:list-item id="u1570"><ce:label>•</ce:label><ce:para id="p2340">Nicorandil, NSAIDs, methotrexate, penicillamine, losartan, ACE inhibitors</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0565"><ce:list-item id="u1575"><ce:label>•</ce:label><ce:para id="p2345">Stevens–Johnson syndrome (<ce:intra-ref id="ii0175" xlink:href="pii:B978-0-7020-7028-0.00029-9#s1335">pp. 1254 and 1264</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u1580"><ce:label>•</ce:label><ce:para id="p2350">Cytotoxic drugs</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Systemic diseases</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0570"><ce:list-item id="u1585"><ce:label>•</ce:label><ce:para id="p2355">Systemic lupus erythematosus (<ce:intra-ref id="ii0180" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1310">p. 1034</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0575"><ce:list-item id="u1590"><ce:label>•</ce:label><ce:para id="p2360">Behçet's disease (<ce:intra-ref id="ii0185" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1580">p. 1043</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neoplasia</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0580"><ce:list-item id="u1595"><ce:label>•</ce:label><ce:para id="p2365">Carcinoma</ce:para></ce:list-item><ce:list-item id="u1600"><ce:label>•</ce:label><ce:para id="p2370">Leukaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0585"><ce:list-item id="u1605"><ce:label>•</ce:label><ce:para id="p2375">Kaposi's sarcoma</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p2380">(ACE = angiotensin-converting enzyme; NSAIDs = non-steroidal anti-inflammatory drugs)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0145" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0300" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0660" role="short">Image 24</ce:alt-text></ce:inline-figure> 21.26</ce:label><ce:alt-text id="atte0665" role="short">21.26</ce:alt-text><ce:textbox-head><ce:title id="tit0150">Symptoms and signs of oral cancer</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2400"><ce:list id="ulist0590"><ce:list-item id="u1610"><ce:label>•</ce:label><ce:para id="p2405">Solitary ulcer without precipitant, e.g. local trauma</ce:para></ce:list-item><ce:list-item id="u1615"><ce:label>•</ce:label><ce:para id="p2410">Solitary white patch (‘leukoplakia’) that fails to wipe off</ce:para></ce:list-item><ce:list-item id="u1620"><ce:label>•</ce:label><ce:para id="p2415">Solitary red patch</ce:para></ce:list-item><ce:list-item id="u1625"><ce:label>•</ce:label><ce:para id="p2420">Fixed lump</ce:para></ce:list-item><ce:list-item id="u1630"><ce:label>•</ce:label><ce:para id="p2425">Lip numbness in absence of trauma or infection</ce:para></ce:list-item><ce:list-item id="u1635"><ce:label>•</ce:label><ce:para id="p2430">Trismus (pain/difficulty in opening the mouth)</ce:para></ce:list-item><ce:list-item id="u1640"><ce:label>•</ce:label><ce:para id="p2435">Cervical lymphadenopathy</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0150" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0305" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0670" role="short">Image 25</ce:alt-text></ce:inline-figure> 21.27</ce:label><ce:alt-text id="atte0675" role="short">21.27</ce:alt-text><ce:textbox-head><ce:title id="tit0155">Causes of salivary gland swelling</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2450"><ce:list id="ulist0595"><ce:list-item id="u1645"><ce:label>•</ce:label><ce:para id="p2455">Infection:<ce:list id="ulist0600"><ce:list-item id="u1650"><ce:para id="p2460">Mumps</ce:para></ce:list-item><ce:list-item id="u1655"><ce:para id="p2465">Bacterial (post-operative)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1660"><ce:label>•</ce:label><ce:para id="p2470">Calculi</ce:para></ce:list-item><ce:list-item id="u1665"><ce:label>•</ce:label><ce:para id="p2475">Sjögren's syndrome (<ce:intra-ref id="ii0195" xlink:href="pii:B978-0-7020-7028-0.00024-X#p4940">p. 1038</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u1670"><ce:label>•</ce:label><ce:para id="p2480">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u1675"><ce:label>•</ce:label><ce:para id="p2485">Tumours:<ce:list id="ulist0605"><ce:list-item id="u1680"><ce:para id="p2490">Benign: pleomorphic adenoma (95% of cases)</ce:para></ce:list-item><ce:list-item id="u1685"><ce:para id="p2495">Intermediate: mucoepidermoid tumour</ce:para></ce:list-item><ce:list-item id="u1690"><ce:para id="p2500">Malignant: carcinoma</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0160" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0320" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0680" role="short">Image 26</ce:alt-text></ce:inline-figure> 21.29</ce:label><ce:alt-text id="atte0685" role="short">21.29</ce:alt-text><ce:textbox-head><ce:title id="tit0165">Important features of hiatus hernia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2560"><ce:list id="ulist0615"><ce:list-item id="u1720"><ce:label>•</ce:label><ce:para id="p2565">Herniation of the stomach through the diaphragm into the chest</ce:para></ce:list-item><ce:list-item id="u1725"><ce:label>•</ce:label><ce:para id="p2570">Occurs in 30% of the population over the age of 50 years</ce:para></ce:list-item><ce:list-item id="u1730"><ce:label>•</ce:label><ce:para id="p2575">Often asymptomatic</ce:para></ce:list-item><ce:list-item id="u1735"><ce:label>•</ce:label><ce:para id="p2580">Heartburn and regurgitation can occur</ce:para></ce:list-item><ce:list-item id="u1740"><ce:label>•</ce:label><ce:para id="p2585">Gastric volvulus may complicate large hernias</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0170" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0355" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0690" role="short">Image 27</ce:alt-text></ce:inline-figure> 21.31</ce:label><ce:alt-text id="atte0695" role="short">21.31</ce:alt-text><ce:textbox-head><ce:title id="tit0175">Causes of oesophageal stricture</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2800"><ce:list id="ulist0630"><ce:list-item id="u1775"><ce:label>•</ce:label><ce:para id="p2805">Gastro-oesophageal reflux disease</ce:para></ce:list-item><ce:list-item id="u1780"><ce:label>•</ce:label><ce:para id="p2810">Webs and rings</ce:para></ce:list-item><ce:list-item id="u1785"><ce:label>•</ce:label><ce:para id="p2815">Carcinoma of the oesophagus or cardia</ce:para></ce:list-item><ce:list-item id="u1790"><ce:label>•</ce:label><ce:para id="p2820">Eosinophilic oesophagitis</ce:para></ce:list-item><ce:list-item id="u1795"><ce:label>•</ce:label><ce:para id="p2825">Extrinsic compression from bronchial carcinoma</ce:para></ce:list-item><ce:list-item id="u1800"><ce:label>•</ce:label><ce:para id="p2830">Corrosive ingestion</ce:para></ce:list-item><ce:list-item id="u1805"><ce:label>•</ce:label><ce:para id="p2835">Post-operative scarring following oesophageal resection</ce:para></ce:list-item><ce:list-item id="u1810"><ce:label>•</ce:label><ce:para id="p2840">Post-radiotherapy</ce:para></ce:list-item><ce:list-item id="u1815"><ce:label>•</ce:label><ce:para id="p2845">Following long-term nasogastric intubation</ce:para></ce:list-item><ce:list-item id="u1820"><ce:label>•</ce:label><ce:para id="p2850">Bisphosphonates</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0175" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0360" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0700" role="short">Image 28</ce:alt-text></ce:inline-figure> 21.32</ce:label><ce:alt-text id="atte0705" role="short">21.32</ce:alt-text><ce:textbox-head><ce:title id="tit0180">Squamous carcinoma: aetiological factors</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2865"><ce:list id="ulist0635"><ce:list-item id="u1825"><ce:label>•</ce:label><ce:para id="p2870">Smoking</ce:para></ce:list-item><ce:list-item id="u1830"><ce:label>•</ce:label><ce:para id="p2875">Alcohol excess</ce:para></ce:list-item><ce:list-item id="u1835"><ce:label>•</ce:label><ce:para id="p2880">Chewing betel nuts or tobacco</ce:para></ce:list-item><ce:list-item id="u1840"><ce:label>•</ce:label><ce:para id="p2885">Achalasia of the oesophagus</ce:para></ce:list-item><ce:list-item id="u1845"><ce:label>•</ce:label><ce:para id="p2890">Coeliac disease</ce:para></ce:list-item><ce:list-item id="u1850"><ce:label>•</ce:label><ce:para id="p2895">Post-cricoid web</ce:para></ce:list-item><ce:list-item id="u1855"><ce:label>•</ce:label><ce:para id="p2900">Post-caustic stricture</ce:para></ce:list-item><ce:list-item id="u1860"><ce:label>•</ce:label><ce:para id="p2905">Tylosis (familial hyperkeratosis of palms and soles)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0180" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0380" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0710" role="short">Image 29</ce:alt-text></ce:inline-figure> 21.33</ce:label><ce:alt-text id="atte0715" role="short">21.33</ce:alt-text><ce:textbox-head><ce:title id="tit0185">Common causes of gastritis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0955"><ce:section-title id="st0915">Acute gastritis (often erosive and haemorrhagic)</ce:section-title><ce:para id="p2950"><ce:list id="ulist0640"><ce:list-item id="u1865"><ce:label>•</ce:label><ce:para id="p2955">Aspirin, NSAIDs</ce:para></ce:list-item><ce:list-item id="u1870"><ce:label>•</ce:label><ce:para id="p2960"><ce:italic>Helicobacter pylori</ce:italic> (initial infection)</ce:para></ce:list-item><ce:list-item id="u1875"><ce:label>•</ce:label><ce:para id="p2965">Alcohol</ce:para></ce:list-item><ce:list-item id="u1880"><ce:label>•</ce:label><ce:para id="p2970">Other drugs, e.g. iron preparations</ce:para></ce:list-item><ce:list-item id="u1885"><ce:label>•</ce:label><ce:para id="p2975">Severe physiological stress, e.g. burns, multi-organ failure, central nervous system trauma</ce:para></ce:list-item><ce:list-item id="u1890"><ce:label>•</ce:label><ce:para id="p2980">Bile reflux, e.g. following gastric surgery</ce:para></ce:list-item><ce:list-item id="u1895"><ce:label>•</ce:label><ce:para id="p2985">Viral infections, e.g. CMV, herpes simplex virus in HIV/AIDS (<ce:intra-ref id="ii0235" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0160">p. 316</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0960"><ce:section-title id="st0920">Chronic non-specific gastritis</ce:section-title><ce:para id="p2990"><ce:list id="ulist0645"><ce:list-item id="u1900"><ce:label>•</ce:label><ce:para id="p2995"><ce:italic>H. pylori</ce:italic> infection</ce:para></ce:list-item><ce:list-item id="u1905"><ce:label>•</ce:label><ce:para id="p3000">Autoimmune (pernicious anaemia)</ce:para></ce:list-item><ce:list-item id="u1910"><ce:label>•</ce:label><ce:para id="p3005">Post-gastrectomy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0965"><ce:section-title id="st0925">Chronic ‘specific’ forms (rare)</ce:section-title><ce:para id="p3010"><ce:list id="ulist0650"><ce:list-item id="u1915"><ce:label>•</ce:label><ce:para id="p3015">Infections, e.g. CMV, tuberculosis</ce:para></ce:list-item><ce:list-item id="u1920"><ce:label>•</ce:label><ce:para id="p3020">Gastrointestinal diseases, e.g. Crohn's disease</ce:para></ce:list-item><ce:list-item id="u1925"><ce:label>•</ce:label><ce:para id="p3025">Systemic diseases, e.g. sarcoidosis, graft-versus-host disease</ce:para></ce:list-item><ce:list-item id="u1930"><ce:label>•</ce:label><ce:para id="p3030">Idiopathic, e.g. granulomatous gastritis</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p3035">(CMV = cytomegalovirus; NSAIDs = non-steroidal anti-inflammatory drugs)</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0185" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0405" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0720" role="short">Image 30</ce:alt-text></ce:inline-figure> 21.34</ce:label><ce:alt-text id="atte0725" role="short">21.34</ce:alt-text><ce:textbox-head><ce:title id="tit0190">Methods for the diagnosis of <ce:italic>Helicobacter pylori</ce:italic> infection</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3100"><ce:display><ce:table frame="topbot" id="t0080"><ce:alt-text id="atte0730" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Test</entry><entry align="left">Advantages</entry><entry align="left">Disadvantages</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Non-invasive</ce:bold></entry></row><row rowsep="0"><entry align="left">Serology</entry><entry align="left">Rapid office kits available<ce:br/>Good for population studies</entry><entry align="left">Lacks specificity<ce:br/>Cannot differentiate current from past infection</entry></row><row rowsep="0"><entry align="left"><ce:sup loc="post">13</ce:sup>C-urea breath test</entry><entry align="left">High sensitivity and specificity</entry><entry align="left">Requires expensive mass spectrometer</entry></row><row rowsep="1"><entry align="left">Faecal antigen test</entry><entry align="left">Cheap, specific (&#x003E; 95%)</entry><entry align="left">Acceptability</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Invasive (antral biopsy)</ce:bold></entry></row><row rowsep="0"><entry align="left">Histology</entry><entry align="left">Specificity</entry><entry align="left">False negatives<ce:br/>Takes several days to process</entry></row><row rowsep="0"><entry align="left">Rapid urease test</entry><entry align="left">Cheap, quick, specific (&#x003E; 95%)</entry><entry align="left">Sensitivity 85%</entry></row><row><entry align="left">Microbiological culture</entry><entry align="left">‘Gold standard’<ce:br/>Defines antibiotic sensitivity</entry><entry align="left">Slow and laborious<ce:br/>Lacks sensitivity</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0190" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0410" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0735" role="short">Image 31</ce:alt-text></ce:inline-figure> 21.35</ce:label><ce:alt-text id="atte0740" role="short">21.35</ce:alt-text><ce:textbox-head><ce:title id="tit0195">Common side-effects of <ce:italic>Helicobacter pylori</ce:italic> eradication therapy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3115"><ce:list id="ulist0655"><ce:list-item id="u1935"><ce:label>•</ce:label><ce:para id="p3120">Diarrhoea: 30–50% of patients; usually mild but <ce:italic>Clostridium difficile</ce:italic>-associated diarrhoea can occur</ce:para></ce:list-item><ce:list-item id="u1940"><ce:label>•</ce:label><ce:para id="p3125">Flushing and vomiting when taken with alcohol (metronidazole)</ce:para></ce:list-item><ce:list-item id="u1945"><ce:label>•</ce:label><ce:para id="p3130">Nausea, vomiting</ce:para></ce:list-item><ce:list-item id="u1950"><ce:label>•</ce:label><ce:para id="p3135">Abdominal cramps</ce:para></ce:list-item><ce:list-item id="u1955"><ce:label>•</ce:label><ce:para id="p3140">Headache</ce:para></ce:list-item><ce:list-item id="u1960"><ce:label>•</ce:label><ce:para id="p3145">Rash</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0195" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0415" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0745" role="short">Image 32</ce:alt-text></ce:inline-figure> 21.36</ce:label><ce:alt-text id="atte0750" role="short">21.36</ce:alt-text><ce:textbox-head><ce:title id="tit0200">Indications for <ce:italic>Helicobacter pylori</ce:italic> eradication</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1035"><ce:section-title id="st0995">Definite</ce:section-title><ce:para id="p3160"><ce:list id="ulist0660"><ce:list-item id="u1965"><ce:label>•</ce:label><ce:para id="p3165">Peptic ulcer</ce:para></ce:list-item><ce:list-item id="u1970"><ce:label>•</ce:label><ce:para id="p3170">Extranodal marginal-zone lymphomas of MALT type</ce:para></ce:list-item><ce:list-item id="u1975"><ce:label>•</ce:label><ce:para id="p3175">Family history of gastric cancer</ce:para></ce:list-item><ce:list-item id="u1980"><ce:label>•</ce:label><ce:para id="p3180">Previous resection for gastric cancer</ce:para></ce:list-item><ce:list-item id="u1985"><ce:label>•</ce:label><ce:para id="p3185"><ce:italic>H. pylori</ce:italic>-positive dyspepsia</ce:para></ce:list-item><ce:list-item id="u1990"><ce:label>•</ce:label><ce:para id="p3190">Long-term NSAID or low-dose aspirin users</ce:para></ce:list-item><ce:list-item id="u1995"><ce:label>•</ce:label><ce:para id="p3195">Chronic (&#x003E; 1 year) PPI users</ce:para></ce:list-item><ce:list-item id="u2000"><ce:label>•</ce:label><ce:para id="p3200">Extragastric disorders:<ce:list id="ulist0665"><ce:list-item id="u2005"><ce:para id="p3205">Unexplained vitamin B<ce:inf loc="post">12</ce:inf> deficiency<ce:cross-ref id="crf0735" refid="fn0020">*</ce:cross-ref><ce:footnote id="fn0020"><ce:label>*</ce:label><ce:note-para id="np0020">If <ce:italic>H. pylori</ce:italic>-positive on testing.</ce:note-para></ce:footnote></ce:para></ce:list-item><ce:list-item id="u2010"><ce:para id="p3210">Idiopathic thrombocytopenic purpura<ce:cross-ref id="crf0740" refid="fn0020">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u2015"><ce:para id="p3215">Iron deficiency anaemia<ce:cross-ref id="crf0745" refid="fn0020">*</ce:cross-ref> (see text)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1040"><ce:section-title id="st1000">Not indicated</ce:section-title><ce:para id="p3220"><ce:list id="ulist0670"><ce:list-item id="u2020"><ce:label>•</ce:label><ce:para id="p3225">Gastro-oesophageal reflux disease</ce:para></ce:list-item><ce:list-item id="u2025"><ce:label>•</ce:label><ce:para id="p3230">Asymptomatic people without gastric cancer risk factors</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p3235">(MALT = mucosa-associated lymphoid tissue; NSAID = non-steroidal anti-inflammatory drug; PPI = proton pump inhibitor)</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0200" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0420" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0755" role="short">Image 33</ce:alt-text></ce:inline-figure> 21.37</ce:label><ce:alt-text id="atte0760" role="short">21.37</ce:alt-text><ce:textbox-head><ce:title id="tit0205">Indications for surgery in peptic ulcer</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1060"><ce:section-title id="st1020">Emergency</ce:section-title><ce:para id="p3255"><ce:list id="ulist0675"><ce:list-item id="u2030"><ce:label>•</ce:label><ce:para id="p3260">Perforation</ce:para></ce:list-item><ce:list-item id="u2035"><ce:label>•</ce:label><ce:para id="p3265">Haemorrhage</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1065"><ce:section-title id="st1025">Elective</ce:section-title><ce:para id="p3270"><ce:list id="ulist0680"><ce:list-item id="u2040"><ce:label>•</ce:label><ce:para id="p3275">Gastric outflow obstruction</ce:para></ce:list-item><ce:list-item id="u2045"><ce:label>•</ce:label><ce:para id="p3280">Persistent ulceration despite adequate medical therapy</ce:para></ce:list-item><ce:list-item id="u2050"><ce:label>•</ce:label><ce:para id="p3285">Recurrent ulcer following gastric surgery</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0210" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0430" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0765" role="short">Image 34</ce:alt-text></ce:inline-figure> 21.39</ce:label><ce:alt-text id="atte0770" role="short">21.39</ce:alt-text><ce:textbox-head><ce:title id="tit0215">Differential diagnosis and management of gastric outlet obstruction</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3370"><ce:display><ce:table frame="topbot" id="t0085"><ce:alt-text id="atte0775" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Cause</entry><entry align="left">Management</entry></row></thead><tbody><row rowsep="1"><entry align="left">Fibrotic stricture from duodenal ulcer (pyloric stenosis)</entry><entry align="left">Balloon dilatation or surgery</entry></row><row rowsep="1"><entry align="left">Oedema from pyloric channel or duodenal ulcer</entry><entry align="left">Proton pump inhibitor therapy</entry></row><row rowsep="1"><entry align="left">Carcinoma of antrum</entry><entry align="left">Surgery</entry></row><row><entry align="left">Adult hypertrophic pyloric stenosis</entry><entry align="left">Surgery</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0215" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0440" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0780" role="short">Image 35</ce:alt-text></ce:inline-figure> 21.40</ce:label><ce:alt-text id="atte0785" role="short">21.40</ce:alt-text><ce:textbox-head><ce:title id="tit0220">Risk factors for gastric cancer</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3470"><ce:list id="ulist0690"><ce:list-item id="u2075"><ce:label>•</ce:label><ce:para id="p3475"><ce:italic>Helicobacter pylori</ce:italic></ce:para></ce:list-item><ce:list-item id="u2080"><ce:label>•</ce:label><ce:para id="p3480">Smoking</ce:para></ce:list-item><ce:list-item id="u2085"><ce:label>•</ce:label><ce:para id="p3485">Alcohol</ce:para></ce:list-item><ce:list-item id="u2090"><ce:label>•</ce:label><ce:para id="p3490">Dietary associations (see text)</ce:para></ce:list-item><ce:list-item id="u2095"><ce:label>•</ce:label><ce:para id="p3495">Autoimmune gastritis (pernicious anaemia)</ce:para></ce:list-item><ce:list-item id="u2100"><ce:label>•</ce:label><ce:para id="p3500">Adenomatous gastric polyps</ce:para></ce:list-item><ce:list-item id="u2105"><ce:label>•</ce:label><ce:para id="p3505">Previous partial gastrectomy (&#x003E; 20 years)</ce:para></ce:list-item><ce:list-item id="u2110"><ce:label>•</ce:label><ce:para id="p3510">Ménétrier's disease</ce:para></ce:list-item><ce:list-item id="u2115"><ce:label>•</ce:label><ce:para id="p3515">Hereditary diffuse gastric cancer families (<ce:italic>CDH1</ce:italic> mutations)</ce:para></ce:list-item><ce:list-item id="u2120"><ce:label>•</ce:label><ce:para id="p3520">Familial adenomatous polyposis (<ce:cross-ref id="crf9015" refid="s1975">p. 828</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0220" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0450" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000214/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0790" role="short">Image 36</ce:alt-text></ce:inline-figure> 21.41</ce:label><ce:alt-text id="atte0795" role="short">21.41</ce:alt-text><ce:textbox-head><ce:title id="tit0225">How to insert a nasogastric tube</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1235"><ce:section-title id="st1195">Equipment</ce:section-title><ce:para id="p3550"><ce:list id="ulist0695"><ce:list-item id="u2125"><ce:label>•</ce:label><ce:para id="p3555">8–9F ‘fine-bore’ tube for feeding or 16–18F ‘wide-bore’ tube for drainage</ce:para></ce:list-item><ce:list-item id="u2130"><ce:label>•</ce:label><ce:para id="p3560">Lubricant jelly</ce:para></ce:list-item><ce:list-item id="u2135"><ce:label>•</ce:label><ce:para id="p3565">Cup of water and straw for sipping</ce:para></ce:list-item><ce:list-item id="u2140"><ce:label>•</ce:label><ce:para id="p3570">Adhesive tape</ce:para></ce:list-item><ce:list-item id="u2145"><ce:label>•</ce:label><ce:para id="p3575">pH (not litmus) paper</ce:para></ce:list-item><ce:list-item id="u2150"><ce:label>•</ce:label><ce:para id="p3580">Sickness bowl and tissues</ce:para></ce:list-item><ce:list-item id="u2155"><ce:label>•</ce:label><ce:para id="p3585">Catheter drainage bag and clamp (for drainage)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1240"><ce:section-title id="st1200">Technique</ce:section-title><ce:para id="p3590"><ce:list id="ulist0700"><ce:list-item id="u2160"><ce:label>•</ce:label><ce:para id="p3595">A clear explanation and a calm patient are essential</ce:para></ce:list-item><ce:list-item id="u2165"><ce:label>•</ce:label><ce:para id="p3600">Establish a ‘stop signal’ for the patient to use, if needed</ce:para></ce:list-item><ce:list-item id="u2170"><ce:label>•</ce:label><ce:para id="p3605">Ask the patient to sit semi-upright</ce:para></ce:list-item><ce:list-item id="u2175"><ce:label>•</ce:label><ce:para id="p3610">Examine the nose for deformity or blockage to determine which side to use</ce:para></ce:list-item><ce:list-item id="u2180"><ce:label>•</ce:label><ce:para id="p3615">Measure the distance from ear to xiphoid process via the nose and mark the position on the tube</ce:para></ce:list-item><ce:list-item id="u2185"><ce:label>•</ce:label><ce:para id="p3620">Advance the lubricated tube tip slowly along the floor of the nasal passage to the oropharynx</ce:para></ce:list-item><ce:list-item id="u2190"><ce:label>•</ce:label><ce:para id="p3625">Ask the patient to sip water and advance the tube 2–3 cm with each swallow</ce:para></ce:list-item><ce:list-item id="u2195"><ce:label>•</ce:label><ce:para id="p3630">Stop, withdraw and retry if the patient is distressed or coughing, as the tube may have entered the larynx</ce:para></ce:list-item><ce:list-item id="u2200"><ce:label>•</ce:label><ce:para id="p3635">Advance until the mark on the tube reaches the tip of the nose and secure with tape</ce:para></ce:list-item><ce:list-item id="u2205"><ce:label>•</ce:label><ce:para id="p3640">Aspirate the contents and check pH (gastric acid confirmed if pH &#x003C; 5). If in doubt, perform a chest X-ray to confirm tube position (usually necessary with feeding tubes)</ce:para></ce:list-item><ce:list-item id="u2210"><ce:label>•</ce:label><ce:para id="p3645">Attach the catheter drainage bag, if necessary, and clamp</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1245"><ce:section-title id="st1205">Aftercare</ce:section-title><ce:para id="p3650"><ce:list id="ulist0705"><ce:list-item id="u2215"><ce:label>•</ce:label><ce:para id="p3655">Flush the tube daily after feeding or drug dosing</ce:para></ce:list-item><ce:list-item id="u2220"><ce:label>•</ce:label><ce:para id="p3660">Check position regularly and look for signs of displacement</ce:para></ce:list-item><ce:list-item id="u2225"><ce:label>•</ce:label><ce:para id="p3665">Check with the pharmacist what drugs, if any, can be safely given via the tube</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0225" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0460" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0800" role="short">Image 37</ce:alt-text></ce:inline-figure> 21.42</ce:label><ce:alt-text id="atte0805" role="short">21.42</ce:alt-text><ce:textbox-head><ce:title id="tit0230">Disease associations of coeliac disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3720"><ce:list id="ulist0710"><ce:list-item id="u2230"><ce:label>•</ce:label><ce:para id="p3725">Type 1 diabetes mellitus (2–8%)</ce:para></ce:list-item><ce:list-item id="u2235"><ce:label>•</ce:label><ce:para id="p3730">Thyroid disease (5%)</ce:para></ce:list-item><ce:list-item id="u2240"><ce:label>•</ce:label><ce:para id="p3735">Primary biliary cholangitis (3%)</ce:para></ce:list-item><ce:list-item id="u2245"><ce:label>•</ce:label><ce:para id="p3740">Sjögren's syndrome (3%)</ce:para></ce:list-item><ce:list-item id="u2250"><ce:label>•</ce:label><ce:para id="p3745">Immunoglobulin A deficiency (2%)</ce:para></ce:list-item><ce:list-item id="u2255"><ce:label>•</ce:label><ce:para id="p3750">Pernicious anaemia</ce:para></ce:list-item><ce:list-item id="u2260"><ce:label>•</ce:label><ce:para id="p3755">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u2265"><ce:label>•</ce:label><ce:para id="p3760">Neurological complications:<ce:list id="ulist0715"><ce:list-item id="u2270"><ce:para id="p3765">Encephalopathy</ce:para></ce:list-item><ce:list-item id="u2275"><ce:para id="p3770">Cerebellar atrophy</ce:para></ce:list-item><ce:list-item id="u2280"><ce:para id="p3775">Peripheral neuropathy</ce:para></ce:list-item><ce:list-item id="u2285"><ce:para id="p3780">Epilepsy</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2290"><ce:label>•</ce:label><ce:para id="p3785">Myasthenia gravis</ce:para></ce:list-item><ce:list-item id="u2295"><ce:label>•</ce:label><ce:para id="p3790">Dermatitis herpetiformis</ce:para></ce:list-item><ce:list-item id="u2300"><ce:label>•</ce:label><ce:para id="p3795">Down's syndrome</ce:para></ce:list-item><ce:list-item id="u2305"><ce:label>•</ce:label><ce:para id="p3800">Enteropathy-associated T-cell lymphoma</ce:para></ce:list-item><ce:list-item id="u2310"><ce:label>•</ce:label><ce:para id="p3805">Small bowel carcinoma</ce:para></ce:list-item><ce:list-item id="u2315"><ce:label>•</ce:label><ce:para id="p3810">Squamous carcinoma of oesophagus</ce:para></ce:list-item><ce:list-item id="u2320"><ce:label>•</ce:label><ce:para id="p3815">Ulcerative jejunitis</ce:para></ce:list-item><ce:list-item id="u2325"><ce:label>•</ce:label><ce:para id="p3820">Pancreatic insufficiency</ce:para></ce:list-item><ce:list-item id="u2330"><ce:label>•</ce:label><ce:para id="p3825">Microscopic colitis</ce:para></ce:list-item><ce:list-item id="u2335"><ce:label>•</ce:label><ce:para id="p3830">Splenic atrophy</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0230" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0465" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0810" role="short">Image 38</ce:alt-text></ce:inline-figure> 21.43</ce:label><ce:alt-text id="atte0815" role="short">21.43</ce:alt-text><ce:textbox-head><ce:title id="tit0235">Important causes of subtotal villous atrophy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3845"><ce:list id="ulist0720"><ce:list-item id="u2340"><ce:label>•</ce:label><ce:para id="p3850">Coeliac disease</ce:para></ce:list-item><ce:list-item id="u2345"><ce:label>•</ce:label><ce:para id="p3855">Tropical sprue</ce:para></ce:list-item><ce:list-item id="u2350"><ce:label>•</ce:label><ce:para id="p3860">Dermatitis herpetiformis</ce:para></ce:list-item><ce:list-item id="u2355"><ce:label>•</ce:label><ce:para id="p3865">Lymphoma</ce:para></ce:list-item><ce:list-item id="u2360"><ce:label>•</ce:label><ce:para id="p3870">HIV-related enteropathy</ce:para></ce:list-item><ce:list-item id="u2365"><ce:label>•</ce:label><ce:para id="p3875">Giardiasis</ce:para></ce:list-item><ce:list-item id="u2370"><ce:label>•</ce:label><ce:para id="p3880">Hypogammaglobulinaemia</ce:para></ce:list-item><ce:list-item id="u2375"><ce:label>•</ce:label><ce:para id="p3885">Radiation</ce:para></ce:list-item><ce:list-item id="u2380"><ce:label>•</ce:label><ce:para id="p3890">Whipple's disease</ce:para></ce:list-item><ce:list-item id="u2385"><ce:label>•</ce:label><ce:para id="p3895">Zollinger–Ellison syndrome</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0235" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0480" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0820" role="short">Image 39</ce:alt-text></ce:inline-figure> 21.44</ce:label><ce:alt-text id="atte0825" role="short">21.44</ce:alt-text><ce:textbox-head><ce:title id="tit0240">Causes of small bowel bacterial overgrowth</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3970"><ce:display><ce:table frame="topbot" id="t0090"><ce:alt-text id="atte0830" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Mechanism</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Hypo- or achlorhydria</ce:bold></entry><entry align="left">Pernicious anaemia<ce:br/>Partial gastrectomy<ce:br/>Long-term proton pump inhibitor therapy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Impaired intestinal motility</ce:bold></entry><entry align="left">Systemic sclerosis<ce:br/>Diabetic autonomic neuropathy<ce:br/>Chronic intestinal pseudo-obstruction</entry></row><row rowsep="1"><entry align="left"><ce:bold>Structural abnormalities</ce:bold></entry><entry align="left">Gastric surgery (blind loop after Billroth II operation)<ce:br/>Jejunal diverticulosis<ce:br/>Enterocolic fistulae<ce:cross-ref id="crf0815" refid="tn0010">*</ce:cross-ref><ce:br/>Extensive small bowel resection<ce:br/>Strictures<ce:cross-ref id="crf0820" refid="tn0010">*</ce:cross-ref></entry></row><row><entry align="left"><ce:bold>Impaired immune function</ce:bold></entry><entry align="left">Hypogammaglobulinaemia</entry></row></tbody></tgroup><ce:table-footnote id="tn0010"><ce:label>*</ce:label><ce:note-para id="np0025">Most commonly caused by Crohn's disease.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0245" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0490" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0835" role="short">Image 40</ce:alt-text></ce:inline-figure> 21.46</ce:label><ce:alt-text id="atte0840" role="short">21.46</ce:alt-text><ce:textbox-head><ce:title id="tit0250">Clinical features of Whipple's disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4015"><ce:display><ce:table frame="topbot" id="t0095"><ce:alt-text id="atte0845" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gastrointestinal (&#x003E; 70%)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0730"><ce:list-item id="u2400"><ce:label>•</ce:label><ce:para id="p4020">Diarrhoea (75%)</ce:para></ce:list-item><ce:list-item id="u2405"><ce:label>•</ce:label><ce:para id="p4025">Steatorrhoea</ce:para></ce:list-item><ce:list-item id="u2410"><ce:label>•</ce:label><ce:para id="p4030">Weight loss (90%)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0735"><ce:list-item id="u2415"><ce:label>•</ce:label><ce:para id="p4035">Protein-losing enteropathy</ce:para></ce:list-item><ce:list-item id="u2420"><ce:label>•</ce:label><ce:para id="p4040">Ascites</ce:para></ce:list-item><ce:list-item id="u2425"><ce:label>•</ce:label><ce:para id="p4045">Hepatosplenomegaly (&#x003C; 5%)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Musculoskeletal (65%)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0740"><ce:list-item id="u2430"><ce:label>•</ce:label><ce:para id="p4050">Seronegative large joint arthropathy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0745"><ce:list-item id="u2435"><ce:label>•</ce:label><ce:para id="p4055">Sacroiliitis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cardiac (10%)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0750"><ce:list-item id="u2440"><ce:label>•</ce:label><ce:para id="p4060">Pericarditis</ce:para></ce:list-item><ce:list-item id="u2445"><ce:label>•</ce:label><ce:para id="p4065">Myocarditis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0755"><ce:list-item id="u2450"><ce:label>•</ce:label><ce:para id="p4070">Endocarditis</ce:para></ce:list-item><ce:list-item id="u2455"><ce:label>•</ce:label><ce:para id="p4075">Coronary arteritis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neurological (10–40%)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0760"><ce:list-item id="u2460"><ce:label>•</ce:label><ce:para id="p4080">Apathy</ce:para></ce:list-item><ce:list-item id="u2465"><ce:label>•</ce:label><ce:para id="p4085">Fits</ce:para></ce:list-item><ce:list-item id="u2470"><ce:label>•</ce:label><ce:para id="p4090">Dementia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0765"><ce:list-item id="u2475"><ce:label>•</ce:label><ce:para id="p4095">Myoclonus</ce:para></ce:list-item><ce:list-item id="u2480"><ce:label>•</ce:label><ce:para id="p4100">Meningitis</ce:para></ce:list-item><ce:list-item id="u2485"><ce:label>•</ce:label><ce:para id="p4105">Cranial nerve lesions</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Pulmonary (10–20%)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0770"><ce:list-item id="u2490"><ce:label>•</ce:label><ce:para id="p4110">Chronic cough</ce:para></ce:list-item><ce:list-item id="u2495"><ce:label>•</ce:label><ce:para id="p4115">Pleurisy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0775"><ce:list-item id="u2500"><ce:label>•</ce:label><ce:para id="p4120">Pulmonary infiltrates</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haematological (60%)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0780"><ce:list-item id="u2505"><ce:label>•</ce:label><ce:para id="p4125">Anaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0785"><ce:list-item id="u2510"><ce:label>•</ce:label><ce:para id="p4130">Lymphadenopathy</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other (40%)</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0790"><ce:list-item id="u2515"><ce:label>•</ce:label><ce:para id="p4135">Fever</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0795"><ce:list-item id="u2520"><ce:label>•</ce:label><ce:para id="p4140">Pigmentation</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0250" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0500" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0850" role="short">Image 41</ce:alt-text></ce:inline-figure> 21.47</ce:label><ce:alt-text id="atte0855" role="short">21.47</ce:alt-text><ce:textbox-head><ce:title id="tit0255">Chronic complications of intestinal irradiation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4195"><ce:list id="ulist0800"><ce:list-item id="u2525"><ce:label>•</ce:label><ce:para id="p4200">Proctocolitis</ce:para></ce:list-item><ce:list-item id="u2530"><ce:label>•</ce:label><ce:para id="p4205">Bleeding from telangiectasia</ce:para></ce:list-item><ce:list-item id="u2535"><ce:label>•</ce:label><ce:para id="p4210">Small bowel strictures</ce:para></ce:list-item><ce:list-item id="u2540"><ce:label>•</ce:label><ce:para id="p4215">Fistulae: rectovaginal, colovesical, enterocolic</ce:para></ce:list-item><ce:list-item id="u2545"><ce:label>•</ce:label><ce:para id="p4220">Adhesions</ce:para></ce:list-item><ce:list-item id="u2550"><ce:label>•</ce:label><ce:para id="p4225">Malabsorption: bacterial overgrowth, bile acid diarrhoea (ileal damage)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0255" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0505" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0860" role="short">Image 42</ce:alt-text></ce:inline-figure> 21.48</ce:label><ce:alt-text id="atte0865" role="short">21.48</ce:alt-text><ce:textbox-head><ce:title id="tit0260">Causes of chronic intestinal pseudo-obstruction</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1445"><ce:section-title id="st1405">Primary or idiopathic</ce:section-title><ce:para id="p4255"><ce:list id="ulist0805"><ce:list-item id="u2555"><ce:label>•</ce:label><ce:para id="p4260">Rare familial visceral myopathies or neuropathies</ce:para></ce:list-item><ce:list-item id="u2560"><ce:label>•</ce:label><ce:para id="p4265">Congenital aganglionosis</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1450"><ce:section-title id="st1410">Secondary</ce:section-title><ce:para id="p4270"><ce:list id="ulist0810"><ce:list-item id="u2565"><ce:label>•</ce:label><ce:para id="p4275">Drugs (opiates, tricyclic antidepressants, phenothiazines)</ce:para></ce:list-item><ce:list-item id="u2570"><ce:label>•</ce:label><ce:para id="p4280">Smooth muscle disorders (systemic sclerosis, amyloidosis, mitochondrial myopathies)</ce:para></ce:list-item><ce:list-item id="u2575"><ce:label>•</ce:label><ce:para id="p4285">Myenteric plexus disorders, e.g. paraneoplastic syndrome in small-cell lung cancer</ce:para></ce:list-item><ce:list-item id="u2580"><ce:label>•</ce:label><ce:para id="p4290">Central nervous system disorders (Parkinson's disease, autonomic neuropathy)</ce:para></ce:list-item><ce:list-item id="u2585"><ce:label>•</ce:label><ce:para id="p4295">Endocrine and metabolic disorders (hypothyroidism, phaeochromocytoma, acute intermittent porphyria)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0260" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0510" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0870" role="short">Image 43</ce:alt-text></ce:inline-figure> 21.49</ce:label><ce:alt-text id="atte0875" role="short">21.49</ce:alt-text><ce:textbox-head><ce:title id="tit0265">Causes of protein-losing enteropathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4320"><ce:display><ce:table frame="topbot" id="t0100"><ce:alt-text id="atte0880" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>With mucosal erosions or ulceration</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0815"><ce:list-item id="u2590"><ce:label>•</ce:label><ce:para id="p4325">Crohn's disease</ce:para></ce:list-item><ce:list-item id="u2595"><ce:label>•</ce:label><ce:para id="p4330">Ulcerative colitis</ce:para></ce:list-item><ce:list-item id="u2600"><ce:label>•</ce:label><ce:para id="p4335">Radiation damage</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0820"><ce:list-item id="u2605"><ce:label>•</ce:label><ce:para id="p4340">Oesophageal, gastric or colonic cancer</ce:para></ce:list-item><ce:list-item id="u2610"><ce:label>•</ce:label><ce:para id="p4345">Lymphoma</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Without mucosal erosions or ulceration</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0825"><ce:list-item id="u2615"><ce:label>•</ce:label><ce:para id="p4350">Ménétrier's disease</ce:para></ce:list-item><ce:list-item id="u2620"><ce:label>•</ce:label><ce:para id="p4355">Bacterial overgrowth</ce:para></ce:list-item><ce:list-item id="u2625"><ce:label>•</ce:label><ce:para id="p4360">Coeliac disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0830"><ce:list-item id="u2630"><ce:label>•</ce:label><ce:para id="p4365">Tropical sprue</ce:para></ce:list-item><ce:list-item id="u2635"><ce:label>•</ce:label><ce:para id="p4370">Eosinophilic gastroenteritis</ce:para></ce:list-item><ce:list-item id="u2640"><ce:label>•</ce:label><ce:para id="p4375">Systemic lupus erythematosus</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>With lymphatic obstruction</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0835"><ce:list-item id="u2645"><ce:label>•</ce:label><ce:para id="p4380">Intestinal lymphangiectasia</ce:para></ce:list-item><ce:list-item id="u2650"><ce:label>•</ce:label><ce:para id="p4385">Constrictive pericarditis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0840"><ce:list-item id="u2655"><ce:label>•</ce:label><ce:para id="p4390">Lymphoma</ce:para></ce:list-item><ce:list-item id="u2660"><ce:label>•</ce:label><ce:para id="p4395">Whipple's disease</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0265" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0515" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0885" role="short">Image 44</ce:alt-text></ce:inline-figure> 21.50</ce:label><ce:alt-text id="atte0890" role="short">21.50</ce:alt-text><ce:textbox-head><ce:title id="tit0270">Causes of small intestinal ulcers</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4410"><ce:list id="ulist0845"><ce:list-item id="u2665"><ce:label>•</ce:label><ce:para id="p4415">Idiopathic</ce:para></ce:list-item><ce:list-item id="u2670"><ce:label>•</ce:label><ce:para id="p4420">Inflammatory bowel disease</ce:para></ce:list-item><ce:list-item id="u2675"><ce:label>•</ce:label><ce:para id="p4425">Non-steroidal anti-inflammatory drugs</ce:para></ce:list-item><ce:list-item id="u2680"><ce:label>•</ce:label><ce:para id="p4430">Ulcerative jejuno-ileitis</ce:para></ce:list-item><ce:list-item id="u2685"><ce:label>•</ce:label><ce:para id="p4435">Lymphoma and carcinoma</ce:para></ce:list-item><ce:list-item id="u2690"><ce:label>•</ce:label><ce:para id="p4440">Infections (tuberculosis, typhoid, <ce:italic>Yersinia enterocolitica</ce:italic>)</ce:para></ce:list-item><ce:list-item id="u2695"><ce:label>•</ce:label><ce:para id="p4445">Others (radiation, vasculitis)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0270" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0520" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0895" role="short">Image 45</ce:alt-text></ce:inline-figure> 21.51</ce:label><ce:alt-text id="atte0900" role="short">21.51</ce:alt-text><ce:textbox-head><ce:title id="tit0275">Comparison of ulcerative colitis and Crohn's disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4610"><ce:display><ce:table frame="topbot" id="t0105"><ce:alt-text id="atte0905" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Ulcerative colitis</entry><entry align="left">Crohn's disease</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Age group</ce:bold></entry><entry align="left">Any</entry><entry align="left">Any</entry></row><row rowsep="1"><entry align="left"><ce:bold>Gender</ce:bold></entry><entry align="left">M = F</entry><entry align="left">Slight female preponderance</entry></row><row rowsep="1"><entry align="left"><ce:bold>Incidence</ce:bold></entry><entry align="left">Stable</entry><entry align="left">Increasing</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ethnic group</ce:bold></entry><entry align="left">Any</entry><entry align="left">Any; more common in Ashkenazi Jews</entry></row><row rowsep="1"><entry align="left"><ce:bold>Genetic factors</ce:bold></entry><entry align="left"><ce:italic>HLA-DR*103</ce:italic>; colonic epithelial barrier function (<ce:italic>HNF4α</ce:italic>, <ce:italic>LAMB1</ce:italic>, <ce:italic>CDH1</ce:italic>)</entry><entry align="left">Defective innate immunity and autophagy (<ce:italic>NOD2</ce:italic>, <ce:italic>ATG16L1</ce:italic>, <ce:italic>IRGM</ce:italic>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Risk factors</ce:bold></entry><entry align="left">More common in non-/ex-smokers<ce:br/>Appendicectomy protects</entry><entry align="left">More common in smokers</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anatomical distribution</ce:bold></entry><entry align="left">Colon only; begins at anorectal margin with variable proximal extension</entry><entry align="left">Any part of gastrointestinal tract; perianal disease common; patchy distribution, skip lesions</entry></row><row rowsep="1"><entry align="left"><ce:bold>Extra-intestinal manifestations</ce:bold></entry><entry align="left">Common</entry><entry align="left">Common</entry></row><row rowsep="1"><entry align="left"><ce:bold>Presentation</ce:bold></entry><entry align="left">Bloody diarrhoea</entry><entry align="left">Variable; pain, diarrhoea, weight loss all common</entry></row><row rowsep="1"><entry align="left"><ce:bold>Histology</ce:bold></entry><entry align="left">Inflammation limited to mucosa; crypt distortion, cryptitis, crypt abscesses, loss of goblet cells</entry><entry align="left">Submucosal or transmural inflammation common; deep fissuring ulcers, fistulae; patchy changes; granulomas</entry></row><row><entry align="left"><ce:bold>Management</ce:bold></entry><entry align="left">5-ASA; glucocorticoids; azathioprine; biological therapy (anti-TNF, anti-α4β7 integrin); colectomy is curative</entry><entry align="left">Glucocorticoids; azathioprine; methotrexate; biological therapy (anti-TNF, anti-α4β7 integrin); nutritional therapy; smoking cessation; surgery for complications is not curative; 5-ASA is not effective</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0380">(5-ASA = 5-aminosalicylic acid; TNF = tumour necrosis factor)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0275" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0525" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0910" role="short">Image 46</ce:alt-text></ce:inline-figure> 21.52</ce:label><ce:alt-text id="atte0915" role="short">21.52</ce:alt-text><ce:textbox-head><ce:title id="tit0280">Factors associated with the development of inflammatory bowel disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1625"><ce:section-title id="st1575">Genetic</ce:section-title><ce:para id="p4630"><ce:list id="ulist0850"><ce:list-item id="u2700"><ce:label>•</ce:label><ce:para id="p4635">Both CD and UC are common in Ashkenazi Jews</ce:para></ce:list-item><ce:list-item id="u2705"><ce:label>•</ce:label><ce:para id="p4640">10% have first-degree relative/1 or more close relative with IBD</ce:para></ce:list-item><ce:list-item id="u2710"><ce:label>•</ce:label><ce:para id="p4645">High concordance in identical twins (40–50% CD; 20–25% UC)</ce:para></ce:list-item><ce:list-item id="u2715"><ce:label>•</ce:label><ce:para id="p4650">163 susceptibility loci identified at genome-wide levels of significance; most confer susceptibility to both CD and UC; many are also susceptibility loci for other inflammatory conditions (especially ankylosing spondylosis and psoriasis)</ce:para></ce:list-item><ce:list-item id="u2720"><ce:label>•</ce:label><ce:para id="p4655">UC and CD are both associated with genetic variants at HLA locus, and with multiple genes involved with immune signalling (especially IL-23 and IL-10 pathways)</ce:para></ce:list-item><ce:list-item id="u2725"><ce:label>•</ce:label><ce:para id="p4660">CD is associated with genetic defects in innate immunity and autophagy (<ce:italic>NOD2</ce:italic>, <ce:italic>ATG16L1</ce:italic> and <ce:italic>IRGM</ce:italic> genes)</ce:para></ce:list-item><ce:list-item id="u2730"><ce:label>•</ce:label><ce:para id="p4665">UC is associated with genetic defects in barrier function</ce:para></ce:list-item><ce:list-item id="u2735"><ce:label>•</ce:label><ce:para id="p4670"><ce:italic>NOD2</ce:italic> is associated with ileal and stricturing disease, and hence a need for resectional surgery</ce:para></ce:list-item><ce:list-item id="u2740"><ce:label>•</ce:label><ce:para id="p4675"><ce:italic>HLA-DR*103</ce:italic> is associated with severe UC</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1630"><ce:section-title id="st1580">Environmental</ce:section-title><ce:para id="p4680"><ce:list id="ulist0855"><ce:list-item id="u2745"><ce:label>•</ce:label><ce:para id="p4685">UC is more common in non-smokers and ex-smokers</ce:para></ce:list-item><ce:list-item id="u2750"><ce:label>•</ce:label><ce:para id="p4690">CD is more common in smokers (relative risk = 3)</ce:para></ce:list-item><ce:list-item id="u2755"><ce:label>•</ce:label><ce:para id="p4695">CD is associated with a low-residue, high-refined-sugar diet</ce:para></ce:list-item><ce:list-item id="u2760"><ce:label>•</ce:label><ce:para id="p4700">Commensal gut microbiota are altered (dysbiosis) in CD and UC</ce:para></ce:list-item><ce:list-item id="u2765"><ce:label>•</ce:label><ce:para id="p4705">Appendicectomy protects against UC</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4710">(CD = Crohn's disease; HLA = human leucocyte antigen; IBD = inflammatory bowel disease; IL = interleukin; UC = ulcerative colitis)</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0280" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0560" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0920" role="short">Image 47</ce:alt-text></ce:inline-figure> 21.53</ce:label><ce:alt-text id="atte0925" role="short">21.53</ce:alt-text><ce:textbox-head><ce:title id="tit0285">Assessment of disease severity in ulcerative colitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4730"><ce:display><ce:table frame="topbot" id="t0110"><ce:alt-text id="atte0930" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Mild</entry><entry align="left">Moderate</entry><entry align="left">Severe</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Daily bowel frequency</ce:bold></entry><entry align="left">&#x003C; 4</entry><entry align="left">4–6</entry><entry align="left">≥ 6<ce:cross-ref id="crf0905" refid="tn0015">*</ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Blood in stools</ce:bold></entry><entry align="left">+/−</entry><entry align="left">+/++</entry><entry align="left">+++</entry></row><row rowsep="1"><entry align="left"><ce:bold>Stool volume</ce:bold></entry><entry align="left">&#x003C; 200 g/24 hrs</entry><entry align="left">200–400 g/24 hrs</entry><entry align="left">&#x003E; 400 g/24 hrs</entry></row><row rowsep="1"><entry align="left"><ce:bold>Pulse</ce:bold></entry><entry align="left">&#x003C; 90 beats/min</entry><entry align="left">&#x003C; 90 beats/min</entry><entry align="left">≥ 90 beats/min<ce:cross-ref id="crf0910" refid="tn0015">*</ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Temperature</ce:bold></entry><entry align="left">Normal</entry><entry align="left">Normal</entry><entry align="left">≥ 37.8°C<ce:cross-ref id="crf0915" refid="tn0015">*</ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Haemoglobin</ce:bold></entry><entry align="left">Normal</entry><entry align="left">Normal</entry><entry align="left">&#x003C; 100 g/L (&#x003C; 10 g/dL)<ce:cross-ref id="crf0920" refid="tn0015">*</ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold>Erythrocyte sedimentation rate</ce:bold></entry><entry align="left">Normal</entry><entry align="left">Normal</entry><entry align="left">&#x003E; 30 mm/hr<ce:cross-ref id="crf0925" refid="tn0015">*</ce:cross-ref> (or equivalent C-reactive protein)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Serum albumin</ce:bold></entry><entry align="left">&#x003E; 35 g/L (&#x003E; 3.5 g/dL)</entry><entry align="left"/><entry align="left">&#x003C; 30 g/L (&#x003C; 3 g/dL)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Abdominal X-ray</ce:bold></entry><entry align="left">Normal</entry><entry align="left">Normal</entry><entry align="left">Dilated bowel, mucosal islands, thumb-printing of mucosa, or absence of features</entry></row><row><entry align="left"><ce:bold>Sigmoidoscopy</ce:bold></entry><entry align="left">Normal or erythema/granular mucosa</entry><entry align="left"/><entry align="left">Severe mucosal inflammatory changes; ulceration; blood in lumen</entry></row></tbody></tgroup><ce:table-footnote id="tn0015"><ce:label>*</ce:label><ce:note-para id="np0030">The Truelove–Witts criteria for acute severe ulcerative colitis are ≥ 6 bloody stools/24 hrs plus one or more of: anaemia, fever, tachycardia and high inflammatory markers.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0285" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0575" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0935" role="short">Image 48</ce:alt-text></ce:inline-figure> 21.54</ce:label><ce:alt-text id="atte0940" role="short">21.54</ce:alt-text><ce:textbox-head><ce:title id="tit0290">Conditions that can mimic ulcerative or Crohn's colitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4750"><ce:display><ce:table frame="topbot" id="t0115"><ce:alt-text id="atte0945" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infective</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bacterial</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0860"><ce:list-item id="u2770"><ce:label>•</ce:label><ce:para id="p4755"><ce:italic>Salmonella</ce:italic></ce:para></ce:list-item><ce:list-item id="u2775"><ce:label>•</ce:label><ce:para id="p4760"><ce:italic>Shigella</ce:italic></ce:para></ce:list-item><ce:list-item id="u2780"><ce:label>•</ce:label><ce:para id="p4765"><ce:italic>Campylobacter jejuni</ce:italic></ce:para></ce:list-item><ce:list-item id="u2785"><ce:label>•</ce:label><ce:para id="p4770"><ce:italic>Escherichia coli</ce:italic> O157</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0865"><ce:list-item id="u2790"><ce:label>•</ce:label><ce:para id="p4775">Gonococcal proctitis</ce:para></ce:list-item><ce:list-item id="u2795"><ce:label>•</ce:label><ce:para id="p4780">Pseudomembranous colitis</ce:para></ce:list-item><ce:list-item id="u2800"><ce:label>•</ce:label><ce:para id="p4785">Chlamydia proctitis</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Viral</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0870"><ce:list-item id="u2805"><ce:label>•</ce:label><ce:para id="p4790">Herpes simplex proctitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0875"><ce:list-item id="u2810"><ce:label>•</ce:label><ce:para id="p4795">Cytomegalovirus</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Protozoal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0880"><ce:list-item id="u2815"><ce:label>•</ce:label><ce:para id="p4800">Amoebiasis</ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Non-infective</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0885"><ce:list-item id="u2820"><ce:label>•</ce:label><ce:para id="p4805">Ischaemic colitis</ce:para></ce:list-item><ce:list-item id="u2825"><ce:label>•</ce:label><ce:para id="p4810">Collagenous colitis</ce:para></ce:list-item><ce:list-item id="u2830"><ce:label>•</ce:label><ce:para id="p4815">Non-steroidal anti-inflammatory drugs</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0890"><ce:list-item id="u2835"><ce:label>•</ce:label><ce:para id="p4820">Diverticulitis</ce:para></ce:list-item><ce:list-item id="u2840"><ce:label>•</ce:label><ce:para id="p4825">Radiation proctitis</ce:para></ce:list-item><ce:list-item id="u2845"><ce:label>•</ce:label><ce:para id="p4830">Behçet's disease</ce:para></ce:list-item><ce:list-item id="u2850"><ce:label>•</ce:label><ce:para id="p4835">Colonic carcinoma</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0290" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0580" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0950" role="short">Image 49</ce:alt-text></ce:inline-figure> 21.55</ce:label><ce:alt-text id="atte0955" role="short">21.55</ce:alt-text><ce:textbox-head><ce:title id="tit0295">Differential diagnosis of small bowel Crohn's disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4840"><ce:list id="ulist0895"><ce:list-item id="u2855"><ce:label>•</ce:label><ce:para id="p4845">Other causes of right iliac fossa mass:<ce:list id="ulist0900"><ce:list-item id="u2860"><ce:para id="p4850">Caecal carcinoma<ce:cross-ref id="crf0950" refid="fn0025">*</ce:cross-ref><ce:footnote id="fn0025"><ce:label>*</ce:label><ce:note-para id="np0035">Common; other causes are rare.</ce:note-para></ce:footnote></ce:para></ce:list-item><ce:list-item id="u2865"><ce:para id="p4855">Appendix abscess<ce:cross-ref id="crf0955" refid="fn0025">*</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2870"><ce:label>•</ce:label><ce:para id="p4860">Infection (tuberculosis, <ce:italic>Yersinia</ce:italic>, actinomycosis)</ce:para></ce:list-item><ce:list-item id="u2875"><ce:label>•</ce:label><ce:para id="p4865">Mesenteric adenitis</ce:para></ce:list-item><ce:list-item id="u2880"><ce:label>•</ce:label><ce:para id="p4870">Pelvic inflammatory disease</ce:para></ce:list-item><ce:list-item id="u2885"><ce:label>•</ce:label><ce:para id="p4875">Lymphoma</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0295" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0600" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0960" role="short">Image 50</ce:alt-text></ce:inline-figure> 21.56</ce:label><ce:alt-text id="atte0965" role="short">21.56</ce:alt-text><ce:textbox-head><ce:title id="tit0300">Drugs used in the treatment of inflammatory bowel disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4930"><ce:display><ce:table frame="topbot" id="t0120"><ce:alt-text id="atte0970" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Class</entry><entry align="left">Mechanism of action</entry><entry align="left">Notes</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Aminosalicylates</ce:bold> (mesalazine (Asacol, Salofalk, Pentasa, Mezavant), olsalazine, sulfasalazine, balsalazide)</entry><entry align="left">Modulate cytokine release from mucosa<ce:br/>Different means of delivery to colon:<ce:br/> pH-dependent (Asacol, Salofalk)<ce:br/> time-dependent (Pentasa)<ce:br/> bacterial breakdown by colonic bacteria from a carrier molecule (sulfasalazine, balsalazide)</entry><entry align="left">No proven value in CD<ce:br/>Available as oral or topical (enema/suppository)<ce:br/>Sulfasalazine causes side-effects in 10–45%: headache, nausea, diarrhoea, blood dyscrasias<ce:br/>Other aminosalicylates better tolerated; diarrhoea, headache in 2–5%<ce:br/>Rarely, renal impairment (check urea and electrolytes 6-monthly)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Glucocorticoids</ce:bold> (prednisolone, hydrocortisone, budesonide)</entry><entry align="left">Anti-inflammatory<ce:br/>Budesonide is a potent glucocorticoid efficiently cleared from circulation by liver, thereby minimising adrenocortical suppression and steroid side-effects</entry><entry align="left">Topical, oral or IV, according to disease severity<ce:br/>Budesonide considered for active ileitis and ileocolitis<ce:br/>High vigilance for complications<ce:br/>Never used for maintenance therapy<ce:br/>Calcium/vitamin D supplements</entry></row><row rowsep="1"><entry align="left"><ce:bold>Thiopurines</ce:bold> (azathioprine, mercaptopurine)</entry><entry align="left">Immunomodulation by inducing T-cell apoptosis<ce:br/>Azathioprine is metabolised in liver to mercaptopurine, then by TPMT to thioguanine nucleotides</entry><entry align="left">Effective 12 weeks after starting therapy<ce:br/>Complications leading to drug withdrawal in approximately 20%: influenza-like syndrome with myalgia, nausea and vomiting; leucopenia in 3%, particularly in inherited TPMT deficiency; hepatotoxicity; pancreatitis<ce:br/>60% of those intolerant of azathioprine will tolerate mercaptopurine<ce:br/>Increase in lymphoma (approximately 2–3-fold) and non-melanoma skin cancer (life-long sun protection advised)<ce:br/>Check TPMT levels prior to starting treatment and avoid if deficient/very low due to risk of toxicity<ce:br/>Metabolite levels can be measured to tailor therapy<ce:br/>Use with caution for patients presenting over the age of 60 years due to risk of malignancy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Methotrexate</ce:bold></entry><entry align="left">Anti-inflammatory</entry><entry align="left">Intolerance in 10–18%<ce:br/>Maximal efficacy when given by SC injection once weekly<ce:br/>Nausea, stomatitis, diarrhoea, hepatotoxicity and pneumonitis<ce:br/>Co-prescription of folic acid and antiemetics.<ce:br/>Teratogenic; robust contraception required for males and females</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ciclosporin</ce:bold></entry><entry align="left">Inhibits T-cell activation</entry><entry align="left">Rescue therapy to prevent surgery in UC responding poorly to glucocorticoids. No value in CD<ce:br/>Major side-effects in 0–17%: nephrotoxicity, infections, neurotoxicity (including fits)<ce:br/>Minor complications in up to 50%: tremor, paraesthesiae, abnormal liver function tests, hirsutism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-TNF antibodies</ce:bold> (infliximab and adalimumab)</entry><entry align="left">Suppress inflammation and induce apoptosis of inflammatory cells</entry><entry align="left">Moderate to severe CD, including fistulating disease<ce:br/>Moderate to severe UC and acute severe UC as rescue therapy<ce:br/>Acute (anaphylactic) and delayed (serum sickness) infusion reactions after multiple infusions; anti-drug antibody titres and drug levels can be measured<ce:br/>Contraindicated in infection; reactivation of latent tuberculosis and moderate to severe cardiac failure<ce:br/>Increased risk of infections and possibly of malignancy<ce:br/>Rarely, neurological adverse events<ce:br/>Requires assessment for latent tuberculosis and hepatitis B and C prior to commencement<ce:br/>Continue until treatment failure or 12 months and reassess</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-α4β7 integrin</ce:bold> (vedolizumab)</entry><entry align="left">Blocks integrin expressed on leukocytes and inhibits interaction with gut-specific receptor on endothelium, reducing leukocyte migration to gut mucosa</entry><entry align="left">Moderate to severe CD or moderate to severe UC where treatment with anti-TNF has failed or is not tolerated<ce:br/>Side-effects include nasopharyngitis, arthralgia, headache<ce:br/>Progressive multifocal leukoencephalopathy risk is reduced due to gut specificity<ce:br/>Induction with 300 mg infusion at weeks 0, 2 and 6; maintenance 8-weekly infusions thereafter<ce:br/>Discontinue if no improvement after 14 weeks<ce:br/>Continue until treatment failure or 12 months and reassess</entry></row><row rowsep="1"><entry align="left"><ce:bold>Antibiotics</ce:bold></entry><entry align="left">Antibacterial</entry><entry align="left">Useful in perianal CD and pouchitis<ce:br/>Major concern is peripheral neuropathy with long-term metronidazole</entry></row><row><entry align="left"><ce:bold>Antidiarrhoeal agents</ce:bold> (loperamide, co-phenoxylate)</entry><entry align="left">Reduce gut motility and small bowel secretion<ce:br/>Loperamide improves anal function</entry><entry align="left">Avoided in acute flare-ups of disease<ce:br/>May precipitate colonic dilatation</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0475">(CD = Crohn's disease; IV = intravenous; SC = subcutaneous; TNF = tumour necrosis factor; TPMT = thiopurine methyltransferase; UC = ulcerative colitis)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0300" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0605" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000214/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0975" role="short">Image 51</ce:alt-text></ce:inline-figure> 21.57</ce:label><ce:alt-text id="atte0980" role="short">21.57</ce:alt-text><ce:textbox-head><ce:title id="tit0305">Medical management of fulminant ulcerative colitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4995"><ce:list id="ulist0915"><ce:list-item id="u2930"><ce:label>•</ce:label><ce:para id="p5000">Admit to hospital for intensive therapy and monitoring</ce:para></ce:list-item><ce:list-item id="u2935"><ce:label>•</ce:label><ce:para id="p5005">Give IV fluids and correct electrolyte imbalance</ce:para></ce:list-item><ce:list-item id="u2940"><ce:label>•</ce:label><ce:para id="p5010">Consider transfusion if haemoglobin is &#x003C; 100 g/L (&#x003C; 10 g/dL)</ce:para></ce:list-item><ce:list-item id="u2945"><ce:label>•</ce:label><ce:para id="p5015">Give IV methylprednisolone (60 mg daily) or hydrocortisone (400 mg daily)</ce:para></ce:list-item><ce:list-item id="u2950"><ce:label>•</ce:label><ce:para id="p5020">Give antibiotics until enteric infection is excluded</ce:para></ce:list-item><ce:list-item id="u2955"><ce:label>•</ce:label><ce:para id="p5025">Arrange nutritional support</ce:para></ce:list-item><ce:list-item id="u2960"><ce:label>•</ce:label><ce:para id="p5030">Give subcutaneous low-molecular-weight heparin for prophylaxis of venous thromboembolism</ce:para></ce:list-item><ce:list-item id="u2965"><ce:label>•</ce:label><ce:para id="p5035">Avoid opiates and antidiarrhoeal agents</ce:para></ce:list-item><ce:list-item id="u2970"><ce:label>•</ce:label><ce:para id="p5040">Consider infliximab (5 mg/kg) or ciclosporin (2 mg/kg) in stable patients not responding to 3–5 days of glucocorticoids</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0305" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0610" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0985" role="short">Image 52</ce:alt-text></ce:inline-figure> 21.58</ce:label><ce:alt-text id="atte0990" role="short">21.58</ce:alt-text><ce:textbox-head><ce:title id="tit0310">Monitoring of inflammatory bowel disease (IBD)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5060"><ce:list id="ulist0920"><ce:list-item id="u2975"><ce:label>•</ce:label><ce:para id="p5065">Assess symptoms, including extra-intestinal manifestations</ce:para></ce:list-item><ce:list-item id="u2980"><ce:label>•</ce:label><ce:para id="p5070">Examine for abdominal mass or perianal disease</ce:para></ce:list-item><ce:list-item id="u2985"><ce:label>•</ce:label><ce:para id="p5075">Perform full blood count, urea and electrolytes, liver function tests, albumin, C-reactive protein (CRP)</ce:para></ce:list-item><ce:list-item id="u2990"><ce:label>•</ce:label><ce:para id="p5080">Check haematinics (vitamin B<ce:inf loc="post">12</ce:inf>, folate, iron studies) at least annually</ce:para></ce:list-item><ce:list-item id="u2995"><ce:label>•</ce:label><ce:para id="p5085">Check faecal calprotectin (to monitor each disease flare/change in therapy and assess response)</ce:para></ce:list-item><ce:list-item id="u3000"><ce:label>•</ce:label><ce:para id="p5090">Perform stool cultures (at each flare to exclude infection)</ce:para></ce:list-item><ce:list-item id="u3005"><ce:label>•</ce:label><ce:para id="p5095">Assess mucosal healing: surrogate markers (CRP/calprotectin), ileocolonoscopy and/or small bowel magnetic resonance imaging</ce:para></ce:list-item><ce:list-item id="u3010"><ce:label>•</ce:label><ce:para id="p5100">Enrol patient in a dedicated IBD clinic (monitoring of stable, uncomplicated patients may be carried out by a nurse or phone clinic)</ce:para></ce:list-item><ce:list-item id="u3015"><ce:label>•</ce:label><ce:para id="p5105">Arrange IBD multidisciplinary meeting for acutely ill or complex patients</ce:para></ce:list-item><ce:list-item id="u3020"><ce:label>•</ce:label><ce:para id="p5110">Check vaccinations are up to date; ensure surveillance colonoscopy is scheduled where appropriate</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0310" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0615" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000214/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0995" role="short">Image 53</ce:alt-text></ce:inline-figure> 21.59</ce:label><ce:alt-text id="atte1000" role="short">21.59</ce:alt-text><ce:textbox-head><ce:title id="tit0315">How to give anti-tumour necrosis factor (TNF) therapy in inflammatory bowel disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5135"><ce:list id="ulist0925"><ce:list-item id="u3025"><ce:label>•</ce:label><ce:para id="p5140">Infliximab (5 mg/kg IV infusion) is given as three loading doses (at 0, 2 and 6 weeks), with 8-weekly maintenance thereafter</ce:para></ce:list-item><ce:list-item id="u3030"><ce:label>•</ce:label><ce:para id="p5145">Adalimumab is given as SC injections, which patients can be trained to give themselves. Loading dose is 160 mg, followed by 80 mg 2 weeks later and 40 mg every second week thereafter; some patients require dose escalation to 40 mg once weekly</ce:para></ce:list-item><ce:list-item id="u3035"><ce:label>•</ce:label><ce:para id="p5150">Concomitant immunosuppression with a thiopurine or methotrexate may be more efficacious than monotherapy but has more side-effects</ce:para></ce:list-item><ce:list-item id="u3040"><ce:label>•</ce:label><ce:para id="p5155">Anti-TNF therapy is contraindicated in the presence of active infection and latent tuberculosis without appropriate prophylaxis; it carries an increased risk of opportunistic infections and a possible increased risk of malignancy; rarely, multiple sclerosis may be unmasked in susceptible individuals. Counselling about the balance of risk and benefit for each patient is important</ce:para></ce:list-item><ce:list-item id="u3045"><ce:label>•</ce:label><ce:para id="p5160">Prior to therapy, latent tuberculosis must be excluded</ce:para></ce:list-item><ce:list-item id="u3050"><ce:label>•</ce:label><ce:para id="p5165">Live vaccines should not be given</ce:para></ce:list-item><ce:list-item id="u3055"><ce:label>•</ce:label><ce:para id="p5170">Certolizumab is effective for luminal Crohn's disease but is not licensed in Europe</ce:para></ce:list-item><ce:list-item id="u3060"><ce:label>•</ce:label><ce:para id="p5175">Etanercept is not effective in Crohn's disease</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0315" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0620" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1005" role="short">Image 54</ce:alt-text></ce:inline-figure> 21.60</ce:label><ce:alt-text id="atte1010" role="short">21.60</ce:alt-text><ce:textbox-head><ce:title id="tit0320">Indications for surgery in ulcerative colitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1780"><ce:section id="s1785"><ce:section-title id="st1730">Impaired quality of life</ce:section-title><ce:para id="p5195"><ce:list id="ulist0930"><ce:list-item id="u3065"><ce:label>•</ce:label><ce:para id="p5200">Loss of occupation or education</ce:para></ce:list-item><ce:list-item id="u3070"><ce:label>•</ce:label><ce:para id="p5205">Disruption of family life</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1790"><ce:section-title id="st1735">Failure of medical therapy</ce:section-title><ce:para id="p5210"><ce:list id="ulist0935"><ce:list-item id="u3075"><ce:label>•</ce:label><ce:para id="p5215">Dependence on oral glucocorticoids</ce:para></ce:list-item><ce:list-item id="u3080"><ce:label>•</ce:label><ce:para id="p5220">Complications of drug therapy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1795"><ce:section-title id="st1740">Fulminant colitis</ce:section-title><ce:para id="p5225">Disease complications unresponsive to medical therapy</ce:para><ce:para id="p5230"><ce:list id="ulist0940"><ce:list-item id="u3085"><ce:label>•</ce:label><ce:para id="p5235">Arthritis</ce:para></ce:list-item><ce:list-item id="u3090"><ce:label>•</ce:label><ce:para id="p5240">Pyoderma gangrenosum</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5245">Colon cancer or severe dysplasia</ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0320" role="alt4"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0625" locator="icon04-9780702070280" xlink:href="pii:B9780702070280000214/icon04-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1015" role="short">Image 55</ce:alt-text></ce:inline-figure> 21.61</ce:label><ce:alt-text id="atte1020" role="short">21.61</ce:alt-text><ce:textbox-head><ce:title id="tit0325">Inflammatory bowel disease in adolescence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5270"><ce:list id="ulist0945"><ce:list-item id="u3095"><ce:label>•</ce:label><ce:para id="p5275"><ce:bold>Delayed growth and pubertal development</ce:bold>: chronic active inflammation, malabsorption, malnutrition and long-term glucocorticoids contribute to short stature and delayed development, with physical and psychological consequences.</ce:para></ce:list-item><ce:list-item id="u3100"><ce:label>•</ce:label><ce:para id="p5280"><ce:bold>Metabolic bone disease</ce:bold>: more common with chronic disease beginning in childhood, resulting from chronic inflammation, dietary deficiency and malabsorption of calcium and vitamin D.</ce:para></ce:list-item><ce:list-item id="u3105"><ce:label>•</ce:label><ce:para id="p5285"><ce:bold>Drug side-effects and adherence issues</ce:bold>: young people are more likely to require azathioprine or biological therapy than adults. Poor adherence to therapy is more common than with adults, as younger patients may feel well, lack self-motivation to adhere and believe that drugs are ineffective or cause side-effects.</ce:para></ce:list-item><ce:list-item id="u3110"><ce:label>•</ce:label><ce:para id="p5290"><ce:bold>Loss of time from education</ce:bold>: physical illness, surgery, fatigue in chronic inflammatory bowel disease, privacy and dignity issues, and social isolation may all contribute.</ce:para></ce:list-item><ce:list-item id="u3115"><ce:label>•</ce:label><ce:para id="p5295"><ce:bold>Emotional difficulties</ce:bold>: may result from challenges in coping with illness, problems with forming interpersonal relationships, and issues relating to body image or sexual function.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0325" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0630" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000214/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1025" role="short">Image 56</ce:alt-text></ce:inline-figure> 21.62</ce:label><ce:alt-text id="atte1030" role="short">21.62</ce:alt-text><ce:textbox-head><ce:title id="tit0330">Pregnancy and inflammatory bowel disease (IBD)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1820"><ce:section-title id="st1765">Pre-conception</ce:section-title><ce:para id="p5305"><ce:list id="ulist0950"><ce:list-item id="u3120"><ce:label>•</ce:label><ce:para id="p5310">Outcomes are best when pregnancy is carefully planned and disease is in remission</ce:para></ce:list-item><ce:list-item id="u3125"><ce:label>•</ce:label><ce:para id="p5315">Methotrexate must be stopped 3 months prior to conception; other IBD drugs should be continued until discussed with a specialist</ce:para></ce:list-item><ce:list-item id="u3130"><ce:label>•</ce:label><ce:para id="p5320">Aminosalicylates and azathioprine are safe in pregnancy</ce:para></ce:list-item><ce:list-item id="u3135"><ce:label>•</ce:label><ce:para id="p5325">Glucocorticoids are probably safe</ce:para></ce:list-item><ce:list-item id="u3140"><ce:label>•</ce:label><ce:para id="p5330">Anti-tumour necrosis factor biological therapy in pregnancy can continue if established pre-pregnancy but should be withheld in the third trimester due to placental transfer of antibody</ce:para></ce:list-item><ce:list-item id="u3145"><ce:label>•</ce:label><ce:para id="p5335">No data are available for the use of vedolizumab in pregnancy</ce:para></ce:list-item><ce:list-item id="u3150"><ce:label>•</ce:label><ce:para id="p5340">Daily high-dose (&#x003E; 2 mg) folic acid supplements are recommended</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1825"><ce:section-title id="st1770">Pregnancy</ce:section-title><ce:para id="p5345"><ce:list id="ulist0955"><ce:list-item id="u3155"><ce:label>•</ce:label><ce:para id="p5350">Two-thirds of patients in remission will remain so in pregnancy</ce:para></ce:list-item><ce:list-item id="u3160"><ce:label>•</ce:label><ce:para id="p5355">Active disease is likely to remain active</ce:para></ce:list-item><ce:list-item id="u3165"><ce:label>•</ce:label><ce:para id="p5360">Severe active disease carries an increased risk of premature delivery and low birth weight</ce:para></ce:list-item><ce:list-item id="u3170"><ce:label>•</ce:label><ce:para id="p5365">Gentle flexible sigmoidoscopy is safe after the first trimester</ce:para></ce:list-item><ce:list-item id="u3175"><ce:label>•</ce:label><ce:para id="p5370">X-rays can be performed if clinically indicated but discuss with the radiologist first</ce:para></ce:list-item><ce:list-item id="u3180"><ce:label>•</ce:label><ce:para id="p5375">Colonoscopy can be performed safely if the potential benefits outweigh the risks</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1830"><ce:section-title id="st1775">Labour</ce:section-title><ce:para id="p5380"><ce:list id="ulist0960"><ce:list-item id="u3185"><ce:label>•</ce:label><ce:para id="p5385">This needs careful discussion between patient, gastroenterologist and obstetrician</ce:para></ce:list-item><ce:list-item id="u3190"><ce:label>•</ce:label><ce:para id="p5390">Normal labour and vaginal delivery are possible for most</ce:para></ce:list-item><ce:list-item id="u3195"><ce:label>•</ce:label><ce:para id="p5395">Caesarean section may be preferred for patients with perianal Crohn's or an ileo-anal pouch to reduce risks of pelvic floor damage, fistulation and late incontinence</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1835"><ce:section-title id="st1780">Breastfeeding</ce:section-title><ce:para id="p5400"><ce:list id="ulist0965"><ce:list-item id="u3200"><ce:label>•</ce:label><ce:para id="p5405">This is safe and does not exacerbate IBD</ce:para></ce:list-item><ce:list-item id="u3205"><ce:label>•</ce:label><ce:para id="p5410">Data on the risk to babies from drugs excreted in breast milk are limited; most of these drugs are probably safe</ce:para></ce:list-item><ce:list-item id="u3210"><ce:label>•</ce:label><ce:para id="p5415">Patients should discuss breastfeeding and drug therapy with their doctor</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0330" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0635" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1035" role="short">Image 57</ce:alt-text></ce:inline-figure> 21.63</ce:label><ce:alt-text id="atte1040" role="short">21.63</ce:alt-text><ce:textbox-head><ce:title id="tit0335">Rome III criteria for diagnosis of irritable bowel syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5470">Recurrent abdominal pain or discomfort on at least 3 days per month in the last 3 months, associated with <ce:italic>two or more</ce:italic> of the following:<ce:list id="ulist0970"><ce:list-item id="u3215"><ce:label>•</ce:label><ce:para id="p5475">Improvement with defecation</ce:para></ce:list-item><ce:list-item id="u3220"><ce:label>•</ce:label><ce:para id="p5480">Onset associated with a change in frequency of stool</ce:para></ce:list-item><ce:list-item id="u3225"><ce:label>•</ce:label><ce:para id="p5485">Onset associated with a change in form (appearance) of stool</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0335" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0640" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1045" role="short">Image 58</ce:alt-text></ce:inline-figure> 21.64</ce:label><ce:alt-text id="atte1050" role="short">21.64</ce:alt-text><ce:textbox-head><ce:title id="tit0340">Supporting diagnostic features and alarm features in irritable bowel syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5495"><ce:display><ce:table frame="topbot" id="t0125"><ce:alt-text id="atte1055" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Features supporting a diagnosis of IBS</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0975"><ce:list-item id="u3230"><ce:label>•</ce:label><ce:para id="p5500">Presence of symptoms for more than 6 months</ce:para></ce:list-item><ce:list-item id="u3235"><ce:label>•</ce:label><ce:para id="p5505">Frequent consultations for non-gastrointestinal problems</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0980"><ce:list-item id="u3240"><ce:label>•</ce:label><ce:para id="p5510">Previous medically unexplained symptoms</ce:para></ce:list-item><ce:list-item id="u3245"><ce:label>•</ce:label><ce:para id="p5515">Worsening of symptoms by stress</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Alarm features</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0985"><ce:list-item id="u3250"><ce:label>•</ce:label><ce:para id="p5520">Age &#x003E; 50 years; male gender</ce:para></ce:list-item><ce:list-item id="u3255"><ce:label>•</ce:label><ce:para id="p5525">Weight loss</ce:para></ce:list-item><ce:list-item id="u3260"><ce:label>•</ce:label><ce:para id="p5530">Nocturnal symptoms</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0990"><ce:list-item id="u3265"><ce:label>•</ce:label><ce:para id="p5535">Family history of colon cancer</ce:para></ce:list-item><ce:list-item id="u3270"><ce:label>•</ce:label><ce:para id="p5540">Anaemia</ce:para></ce:list-item><ce:list-item id="u3275"><ce:label>•</ce:label><ce:para id="p5545">Rectal bleeding</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0340" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0650" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1060" role="short">Image 59</ce:alt-text></ce:inline-figure> 21.65</ce:label><ce:alt-text id="atte1065" role="short">21.65</ce:alt-text><ce:textbox-head><ce:title id="tit0345">Dietary management of irritable bowel syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5555"><ce:list id="ulist0995"><ce:list-item id="u3280"><ce:label>•</ce:label><ce:para id="p5560">Eat regularly and avoid missing meals</ce:para></ce:list-item><ce:list-item id="u3285"><ce:label>•</ce:label><ce:para id="p5565">Take time to eat</ce:para></ce:list-item><ce:list-item id="u3290"><ce:label>•</ce:label><ce:para id="p5570">Ensure adequate hydration and avoid carbonated and caffeinated drinks</ce:para></ce:list-item><ce:list-item id="u3295"><ce:label>•</ce:label><ce:para id="p5575">Reduce alcohol intake</ce:para></ce:list-item><ce:list-item id="u3300"><ce:label>•</ce:label><ce:para id="p5580">Reduce intake of ‘resistant’ starch and insoluble fibre</ce:para></ce:list-item><ce:list-item id="u3305"><ce:label>•</ce:label><ce:para id="p5585">Avoid foods with artificial sweeteners</ce:para></ce:list-item><ce:list-item id="u3310"><ce:label>•</ce:label><ce:para id="p5590">Consider a wheat-free diet</ce:para></ce:list-item><ce:list-item id="u3315"><ce:label>•</ce:label><ce:para id="p5595">Consider a lactose exclusion diet</ce:para></ce:list-item><ce:list-item id="u3320"><ce:label>•</ce:label><ce:para id="p5600">Consider a diet low in FODMAPs</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5605">(FODMAPs = fermentable oligo-, di- and monosaccharides, and polyols)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0345" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0655" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1070" role="short">Image 60</ce:alt-text></ce:inline-figure> 21.66</ce:label><ce:alt-text id="atte1075" role="short">21.66</ce:alt-text><ce:source>From Hussain Z, Quigley EMM. Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23:465–471.</ce:source><ce:textbox-head><ce:title id="tit0350">Complementary and alternative therapies for irritable bowel syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1905"><ce:section-title id="st1840">Manipulative and body-based</ce:section-title><ce:para id="p5630"><ce:list id="ulist1000"><ce:list-item id="u3325"><ce:label>•</ce:label><ce:para id="p5635">Massage, chiropractic</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1910"><ce:section-title id="st1845">Mind–body interventions</ce:section-title><ce:para id="p5640"><ce:list id="ulist1005"><ce:list-item id="u3330"><ce:label>•</ce:label><ce:para id="p5645">Meditation, hypnosis<ce:cross-ref id="crf1060" refid="fn0030">*</ce:cross-ref><ce:footnote id="fn0030"><ce:label>*</ce:label><ce:note-para id="np0040">Some evidence for benefit exists.</ce:note-para></ce:footnote>, cognitive therapy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1915"><ce:section-title id="st1850">Biologically based</ce:section-title><ce:para id="p5650"><ce:list id="ulist1010"><ce:list-item id="u3335"><ce:label>•</ce:label><ce:para id="p5655">Herbal products<ce:cross-ref id="crf1065" refid="fn0030">*</ce:cross-ref>, dietary additives, probiotics<ce:cross-ref id="crf1070" refid="fn0030">*</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1920"><ce:section-title id="st1855">Energy healing</ce:section-title><ce:para id="p5660"><ce:list id="ulist1015"><ce:list-item id="u3340"><ce:label>•</ce:label><ce:para id="p5665">Biofield therapies (reiki), bio-electromagnetic field therapies</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1925"><ce:section-title id="st1860">Alternative medical systems</ce:section-title><ce:para id="p5670"><ce:list id="ulist1020"><ce:list-item id="u3345"><ce:label>•</ce:label><ce:para id="p5675">Ayurveda, homeopathy, traditional Chinese medicine</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0350" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0660" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1080" role="short">Image 61</ce:alt-text></ce:inline-figure> 21.67</ce:label><ce:alt-text id="atte1085" role="short">21.67</ce:alt-text><ce:textbox-head><ce:title id="tit0355">Risk factors for malignant change in colonic polyps</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5725"><ce:list id="ulist1025"><ce:list-item id="u3350"><ce:label>•</ce:label><ce:para id="p5730">Large size (&#x003E; 2 cm)</ce:para></ce:list-item><ce:list-item id="u3355"><ce:label>•</ce:label><ce:para id="p5735">Multiple polyps</ce:para></ce:list-item><ce:list-item id="u3360"><ce:label>•</ce:label><ce:para id="p5740">Villous architecture</ce:para></ce:list-item><ce:list-item id="u3365"><ce:label>•</ce:label><ce:para id="p5745">High-grade dysplasia</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0355" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0675" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1090" role="short">Image 62</ce:alt-text></ce:inline-figure> 21.68</ce:label><ce:alt-text id="atte1095" role="short">21.68</ce:alt-text><ce:textbox-head><ce:title id="tit0360">Gastrointestinal polyposis syndromes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5770"><ce:display><ce:table frame="topbot" id="t0130"><ce:alt-text id="atte1100" role="short">Unlabelled table</ce:alt-text><tgroup cols="6"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><colspec colname="col6" colnum="6"/><thead><row rowsep="1"><entry morerows="1" align="left"/><entry align="center">Neoplastic</entry><entry namest="col3" nameend="col6" align="center">Non-neoplastic<ce:cross-ref id="crf1090" refid="tn0020"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry></row><row role="tcolhead1" rowsep="1"><entry align="left">Familial adenomatous polyposis</entry><entry align="left">Peutz–Jeghers syndrome</entry><entry align="left">Juvenile polyposis</entry><entry align="left">Cronkhite–Canada syndrome</entry><entry align="left">Cowden's disease</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Inheritance</ce:bold></entry><entry align="left">Autosomal dominant<ce:cross-ref id="crf1095" refid="tn0025"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">Autosomal dominant</entry><entry align="left">Autosomal dominant in one-third</entry><entry align="left">None</entry><entry align="left">Autosomal dominant</entry></row><row rowsep="1"><entry align="left"><ce:bold>Oesophageal polyps</ce:bold></entry><entry align="left">−</entry><entry align="left">−</entry><entry align="left">−</entry><entry align="left">+</entry><entry align="left">+</entry></row><row rowsep="1"><entry align="left"><ce:bold>Gastric polyps</ce:bold></entry><entry align="left">+</entry><entry align="left">+</entry><entry align="left">+</entry><entry align="left">+++</entry><entry align="left">+++</entry></row><row rowsep="1"><entry align="left"><ce:bold>Small bowel polyps</ce:bold></entry><entry align="left">++</entry><entry align="left">+++</entry><entry align="left">++</entry><entry align="left">++</entry><entry align="left">++</entry></row><row rowsep="1"><entry align="left"><ce:bold>Colonic polyps</ce:bold></entry><entry align="left">+++</entry><entry align="left">++</entry><entry align="left">++</entry><entry align="left">+++</entry><entry align="left">+</entry></row><row><entry align="left"><ce:bold>Other features</ce:bold></entry><entry align="left">Colorectal cancer, bleeding, extra-intestinal features (see <ce:cross-ref id="crf1100" refid="b0360">Box 21.69</ce:cross-ref>)</entry><entry align="left">Pigmentation, bleeding, intussusception, bowel and other cancers</entry><entry align="left">Colorectal cancer</entry><entry align="left">Hair loss, pigmentation, nail dystrophy, malabsorption</entry><entry align="left">Many congenital anomalies, oral and cutaneous hamartomas, thyroid and breast tumours</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0500">− absent; + may occur; ++ common; +++ very common.</ce:simple-para></ce:legend><ce:table-footnote id="tn0020"><ce:label>1</ce:label><ce:note-para id="np0045">The polyps themselves are not neoplastic but cancer risk is increased in several syndromes.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0025"><ce:label>2</ce:label><ce:note-para id="np0050">Rare autosomal recessive variant <ce:italic>MUTYH</ce:italic> (see text).</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0360" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0685" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1105" role="short">Image 63</ce:alt-text></ce:inline-figure> 21.69</ce:label><ce:alt-text id="atte1110" role="short">21.69</ce:alt-text><ce:textbox-head><ce:title id="tit0365">Extra-intestinal features of familial adenomatous polyposis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5795"><ce:list id="ulist1030"><ce:list-item id="u3370"><ce:label>•</ce:label><ce:para id="p5800">Congenital hypertrophy of the retinal pigment epithelium (CHRPE, 70–80%)</ce:para></ce:list-item><ce:list-item id="u3375"><ce:label>•</ce:label><ce:para id="p5805">Epidermoid cysts (extremities, face, scalp)<ce:cross-ref id="crf1115" refid="fn0035">*</ce:cross-ref><ce:footnote id="fn0035"><ce:label>*</ce:label><ce:note-para id="np0055">Gardner's syndrome.</ce:note-para></ce:footnote> (50%)</ce:para></ce:list-item><ce:list-item id="u3380"><ce:label>•</ce:label><ce:para id="p5810">Benign osteomas, especially skull and angle of mandible<ce:cross-ref id="crf1120" refid="fn0035">*</ce:cross-ref> (50–90%)</ce:para></ce:list-item><ce:list-item id="u3385"><ce:label>•</ce:label><ce:para id="p5815">Dental abnormalities (15–25%)<ce:cross-ref id="crf1125" refid="fn0035">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u3390"><ce:label>•</ce:label><ce:para id="p5820">Desmoid tumours (10–15%)</ce:para></ce:list-item><ce:list-item id="u3395"><ce:label>•</ce:label><ce:para id="p5825">Other malignancies (brain, thyroid, liver, 1–3%)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0365" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0700" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1115" role="short">Image 64</ce:alt-text></ce:inline-figure> 21.70</ce:label><ce:alt-text id="atte1120" role="short">21.70</ce:alt-text><ce:textbox-head><ce:title id="tit0370">Dietary risk factors for colorectal cancer</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5900"><ce:display><ce:table frame="topbot" id="t0135"><ce:alt-text id="atte1125" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Risk factor</entry><entry align="left">Comments</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Increased risk</ce:bold></entry></row><row rowsep="0"><entry align="left">Red meat<ce:cross-ref id="crf1145" refid="tn0030">*</ce:cross-ref></entry><entry align="left">High saturated fat and protein content<ce:br/>Carcinogenic amines formed during cooking</entry></row><row rowsep="1"><entry align="left">Saturated animal fat<ce:cross-ref id="crf1150" refid="tn0030">*</ce:cross-ref></entry><entry align="left">High faecal bile acid and fatty acid levels<ce:br/>May affect colonic prostaglandin turnover</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Decreased risk</ce:bold></entry></row><row rowsep="0"><entry align="left">Dietary fibre<ce:cross-ref id="crf1155" refid="tn0030">*</ce:cross-ref></entry><entry align="left">Effects vary with fibre type; shortened transit time, binding of bile acids and effects on bacterial flora proposed</entry></row><row rowsep="0"><entry align="left">Fruit and vegetables</entry><entry align="left">Green vegetables contain anticarcinogens, such as flavonoids<ce:br/>Little evidence for protection from vitamins A, C and E</entry></row><row rowsep="0"><entry align="left">Calcium</entry><entry align="left">Binds and precipitates faecal bile acids</entry></row><row rowsep="0"><entry align="left">Folic acid</entry><entry align="left">Reverses DNA hypomethylation</entry></row><row><entry align="left">Omega-3 fatty acids</entry><entry align="left">May be of modest benefit</entry></row></tbody></tgroup><ce:table-footnote id="tn0030"><ce:label>*</ce:label><ce:note-para id="np0060">Evidence is inconsistent and a clear relationship is unproven.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0370" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0705" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1130" role="short">Image 65</ce:alt-text></ce:inline-figure> 21.71</ce:label><ce:alt-text id="atte1135" role="short">21.71</ce:alt-text><ce:textbox-head><ce:title id="tit0375">Non-dietary risk factors for colorectal cancer</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2000"><ce:section-title id="st1930">Medical conditions</ce:section-title><ce:para id="p5905"><ce:list id="ulist1045"><ce:list-item id="u3430"><ce:label>•</ce:label><ce:para id="p5910">Colorectal adenomas (<ce:cross-ref id="crf9020" refid="s1935">p. 827</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u3435"><ce:label>•</ce:label><ce:para id="p5915">Long-standing extensive ulcerative colitis or Crohn's colitis (<ce:cross-ref id="crf9025" refid="s1565">p. 813</ce:cross-ref>), especially if associated with primary sclerosing cholangitis</ce:para></ce:list-item><ce:list-item id="u3440"><ce:label>•</ce:label><ce:para id="p5920">Ureterosigmoidostomy</ce:para></ce:list-item><ce:list-item id="u3445"><ce:label>•</ce:label><ce:para id="p5925">Acromegaly</ce:para></ce:list-item><ce:list-item id="u3450"><ce:label>•</ce:label><ce:para id="p5930">Pelvic radiotherapy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2005"><ce:section-title id="st1935">Others</ce:section-title><ce:para id="p5935"><ce:list id="ulist1050"><ce:list-item id="u3455"><ce:label>•</ce:label><ce:para id="p5940">Obesity and sedentary lifestyle – may be related to diet</ce:para></ce:list-item><ce:list-item id="u3460"><ce:label>•</ce:label><ce:para id="p5945">Smoking (relative risk 1.5–3.0)</ce:para></ce:list-item><ce:list-item id="u3465"><ce:label>•</ce:label><ce:para id="p5950">Alcohol (weak association)</ce:para></ce:list-item><ce:list-item id="u3470"><ce:label>•</ce:label><ce:para id="p5955">Cholecystectomy (effect of bile acids in right colon)</ce:para></ce:list-item><ce:list-item id="u3475"><ce:label>•</ce:label><ce:para id="p5960">Type 2 diabetes (hyperinsulinaemia)</ce:para></ce:list-item><ce:list-item id="u3480"><ce:label>•</ce:label><ce:para id="p5965">Use of aspirin or NSAIDs (COX-2 inhibition) and perhaps statins associated with <ce:italic>reduced</ce:italic> risk</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5970">(COX-2 = cyclo-oxygenase 2; NSAIDs = non-steroidal anti-inflammatory drugs)</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0375" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0715" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1140" role="short">Image 66</ce:alt-text></ce:inline-figure> 21.72</ce:label><ce:alt-text id="atte1145" role="short">21.72</ce:alt-text><ce:textbox-head><ce:title id="tit0380">Modified Amsterdam criteria<ce:cross-ref id="crf1175" refid="fn0040">*</ce:cross-ref><ce:footnote id="fn0040"><ce:label>*</ce:label><ce:note-para id="np0065">These criteria are strict and may miss some families with mutations. Hereditary non-polyposis colon cancer should also be considered in individuals with colorectal or endometrial cancer under 45 years of age.</ce:note-para></ce:footnote> for hereditary non-polyposis colon cancer</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6005"><ce:list id="ulist1060"><ce:list-item id="u3500"><ce:label>•</ce:label><ce:para id="p6010">Three or more relatives with colon cancer (at least one first-degree)</ce:para></ce:list-item><ce:list-item id="u3505"><ce:label>•</ce:label><ce:para id="p6015">Colorectal cancer in two or more generations</ce:para></ce:list-item><ce:list-item id="u3510"><ce:label>•</ce:label><ce:para id="p6020">At least one member affected under 50 years of age</ce:para></ce:list-item><ce:list-item id="u3515"><ce:label>•</ce:label><ce:para id="p6025">Familial adenomatous polyposis excluded</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0380" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0735" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1150" role="short">Image 67</ce:alt-text></ce:inline-figure> 21.73</ce:label><ce:alt-text id="atte1155" role="short">21.73</ce:alt-text><ce:textbox-head><ce:title id="tit0385">Laxatives</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6130"><ce:display><ce:table frame="topbot" id="t0140"><ce:alt-text id="atte1160" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Class</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Bulk-forming laxatives</ce:bold></entry><entry align="left">Ispaghula husk, methylcellulose</entry></row><row rowsep="1"><entry align="left"><ce:bold>Stimulants</ce:bold></entry><entry align="left">Bisacodyl, dantron (only for terminally ill patients), docusate, senna</entry></row><row rowsep="1"><entry align="left"><ce:bold>Faecal softeners</ce:bold></entry><entry align="left">Docusate, arachis oil enema</entry></row><row rowsep="1"><entry align="left"><ce:bold>Osmotic laxatives</ce:bold></entry><entry align="left">Lactulose, lactitol, magnesium salts</entry></row><row><entry align="left"><ce:bold>Others</ce:bold></entry><entry align="left">Polyethylene glycol (PEG)<ce:cross-ref id="crf1215" refid="tn0035">*</ce:cross-ref>, phosphate enema<ce:cross-ref id="crf1220" refid="tn0035">*</ce:cross-ref></entry></row></tbody></tgroup><ce:table-footnote id="tn0035"><ce:label>*</ce:label><ce:note-para id="np0070">Also used for bowel preparation prior to investigation or surgery.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0390" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0745" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1165" role="short">Image 68</ce:alt-text></ce:inline-figure> 21.75</ce:label><ce:alt-text id="atte1170" role="short">21.75</ce:alt-text><ce:textbox-head><ce:title id="tit0395">Causes of acute colonic pseudo-obstruction</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6205"><ce:list id="ulist1075"><ce:list-item id="u3565"><ce:label>•</ce:label><ce:para id="p6210">Trauma, burns</ce:para></ce:list-item><ce:list-item id="u3570"><ce:label>•</ce:label><ce:para id="p6215">Recent surgery</ce:para></ce:list-item><ce:list-item id="u3575"><ce:label>•</ce:label><ce:para id="p6220">Drugs (opiates, phenothiazines)</ce:para></ce:list-item><ce:list-item id="u3580"><ce:label>•</ce:label><ce:para id="p6225">Respiratory failure</ce:para></ce:list-item><ce:list-item id="u3585"><ce:label>•</ce:label><ce:para id="p6230">Electrolyte and acid–base disorders</ce:para></ce:list-item><ce:list-item id="u3590"><ce:label>•</ce:label><ce:para id="p6235">Diabetes mellitus</ce:para></ce:list-item><ce:list-item id="u3595"><ce:label>•</ce:label><ce:para id="p6240">Uraemia</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0395" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0750" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1175" role="short">Image 69</ce:alt-text></ce:inline-figure> 21.76</ce:label><ce:alt-text id="atte1180" role="short">21.76</ce:alt-text><ce:textbox-head><ce:title id="tit0400">Causes of faecal incontinence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6260"><ce:list id="ulist1080"><ce:list-item id="u3600"><ce:label>•</ce:label><ce:para id="p6265">Obstetric trauma: childbirth, hysterectomy</ce:para></ce:list-item><ce:list-item id="u3605"><ce:label>•</ce:label><ce:para id="p6270">Severe diarrhoea</ce:para></ce:list-item><ce:list-item id="u3610"><ce:label>•</ce:label><ce:para id="p6275">Faecal impaction</ce:para></ce:list-item><ce:list-item id="u3615"><ce:label>•</ce:label><ce:para id="p6280">Congenital anorectal anomalies</ce:para></ce:list-item><ce:list-item id="u3620"><ce:label>•</ce:label><ce:para id="p6285">Anorectal disease: haemorrhoids, rectal prolapse, Crohn's disease</ce:para></ce:list-item><ce:list-item id="u3625"><ce:label>•</ce:label><ce:para id="p6290">Neurological disorders: spinal cord or cauda equina lesions, dementia</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0400" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0760" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1185" role="short">Image 70</ce:alt-text></ce:inline-figure> 21.77</ce:label><ce:alt-text id="atte1190" role="short">21.77</ce:alt-text><ce:textbox-head><ce:title id="tit0405">Causes of pruritus ani</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6315"><ce:display><ce:table frame="topbot" id="t0145"><ce:alt-text id="atte1195" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Local anorectal conditions</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1085"><ce:list-item id="u3630"><ce:label>•</ce:label><ce:para id="p6320">Haemorrhoids</ce:para></ce:list-item><ce:list-item id="u3635"><ce:label>•</ce:label><ce:para id="p6325">Fistula, fissures</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1090"><ce:list-item id="u3640"><ce:label>•</ce:label><ce:para id="p6330">Poor hygiene</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infections</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1095"><ce:list-item id="u3645"><ce:label>•</ce:label><ce:para id="p6335">Threadworms</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1100"><ce:list-item id="u3650"><ce:label>•</ce:label><ce:para id="p6340">Candidiasis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Skin disorders</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1105"><ce:list-item id="u3655"><ce:label>•</ce:label><ce:para id="p6345">Contact dermatitis</ce:para></ce:list-item><ce:list-item id="u3660"><ce:label>•</ce:label><ce:para id="p6350">Psoriasis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1110"><ce:list-item id="u3665"><ce:label>•</ce:label><ce:para id="p6355">Lichen planus</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1115"><ce:list-item id="u3670"><ce:label>•</ce:label><ce:para id="p6360">Diarrhoea or incontinence of any cause</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1120"><ce:list-item id="u3675"><ce:label>•</ce:label><ce:para id="p6365">Irritable bowel syndrome</ce:para></ce:list-item><ce:list-item id="u3680"><ce:label>•</ce:label><ce:para id="p6370">Anxiety</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0405" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0765" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1200" role="short">Image 71</ce:alt-text></ce:inline-figure> 21.78</ce:label><ce:alt-text id="atte1205" role="short">21.78</ce:alt-text><ce:textbox-head><ce:title id="tit0410">Glasgow criteria for prognosis in acute pancreatitis<ce:cross-ref id="crf1250" refid="fn0045">*</ce:cross-ref><ce:footnote id="fn0045"><ce:label>*</ce:label><ce:note-para id="np0075">Severity and prognosis worsen as the number of these factors increases. More than three implies severe disease.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6440"><ce:list id="ulist1125"><ce:list-item id="u3685"><ce:label>•</ce:label><ce:para id="p6445">Age &#x003E; 55 years</ce:para></ce:list-item><ce:list-item id="u3690"><ce:label>•</ce:label><ce:para id="p6450"><ce:italic>P</ce:italic>O<ce:inf loc="post">2</ce:inf> &#x003C; 8 kPa (60 mmHg)</ce:para></ce:list-item><ce:list-item id="u3695"><ce:label>•</ce:label><ce:para id="p6455">White blood cell count &#x003E; 15 × 10<ce:sup loc="post">9</ce:sup>/L</ce:para></ce:list-item><ce:list-item id="u3700"><ce:label>•</ce:label><ce:para id="p6460">Albumin &#x003C; 32 g/L (3.2 g/dL)</ce:para></ce:list-item><ce:list-item id="u3705"><ce:label>•</ce:label><ce:para id="p6465">Serum calcium &#x003C; 2 mmol/L (8 mg/dL) (corrected)</ce:para></ce:list-item><ce:list-item id="u3710"><ce:label>•</ce:label><ce:para id="p6470">Glucose &#x003E; 10 mmol/L (180 mg/dL)</ce:para></ce:list-item><ce:list-item id="u3715"><ce:label>•</ce:label><ce:para id="p6475">Urea &#x003E; 16 mmol/L (45 mg/dL) (after rehydration)</ce:para></ce:list-item><ce:list-item id="u3720"><ce:label>•</ce:label><ce:para id="p6480">Alanine aminotransferase &#x003E; 200 U/L</ce:para></ce:list-item><ce:list-item id="u3725"><ce:label>•</ce:label><ce:para id="p6485">Lactate dehydrogenase &#x003E; 600 U/L</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0410" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0770" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1210" role="short">Image 72</ce:alt-text></ce:inline-figure> 21.79</ce:label><ce:alt-text id="atte1215" role="short">21.79</ce:alt-text><ce:textbox-head><ce:title id="tit0415">Features that predict severe pancreatitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2195"><ce:section-title id="st2120">Initial assessment</ce:section-title><ce:para id="p6490"><ce:list id="ulist1130"><ce:list-item id="u3730"><ce:label>•</ce:label><ce:para id="p6495">Clinical impression of severity</ce:para></ce:list-item><ce:list-item id="u3735"><ce:label>•</ce:label><ce:para id="p6500">Body mass index &#x003E; 30 kg/m<ce:sup loc="post">2</ce:sup></ce:para></ce:list-item><ce:list-item id="u3740"><ce:label>•</ce:label><ce:para id="p6505">Pleural effusion on chest X-ray</ce:para></ce:list-item><ce:list-item id="u3745"><ce:label>•</ce:label><ce:para id="p6510">APACHE II score &#x003E; 8 (see <ce:intra-ref id="ii0540" xlink:href="pii:B978-0-7020-7028-0.00010-X#b0260">Box 10.50</ce:intra-ref>, <ce:intra-ref id="ii0545" xlink:href="pii:B978-0-7020-7028-0.00010-X#u2115">p. 214</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2200"><ce:section-title id="st2125">24 hours after admission</ce:section-title><ce:para id="p6515"><ce:list id="ulist1135"><ce:list-item id="u3750"><ce:label>•</ce:label><ce:para id="p6520">Clinical impression of severity</ce:para></ce:list-item><ce:list-item id="u3755"><ce:label>•</ce:label><ce:para id="p6525">APACHE II score &#x003E; 8</ce:para></ce:list-item><ce:list-item id="u3760"><ce:label>•</ce:label><ce:para id="p6530">Glasgow score &#x003E; 3 (see <ce:cross-ref id="crf1260" refid="b0405">Box 21.78</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u3765"><ce:label>•</ce:label><ce:para id="p6535">Persisting organ failure, especially if multiple</ce:para></ce:list-item><ce:list-item id="u3770"><ce:label>•</ce:label><ce:para id="p6540">CRP &#x003E; 150 mg/L</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2205"><ce:section-title id="st2130">48 hours after admission</ce:section-title><ce:para id="p6545"><ce:list id="ulist1140"><ce:list-item id="u3775"><ce:label>•</ce:label><ce:para id="p6550">Clinical impression of severity</ce:para></ce:list-item><ce:list-item id="u3780"><ce:label>•</ce:label><ce:para id="p6555">Glasgow score &#x003E; 3</ce:para></ce:list-item><ce:list-item id="u3785"><ce:label>•</ce:label><ce:para id="p6560">CRP &#x003E; 150 mg/L</ce:para></ce:list-item><ce:list-item id="u3790"><ce:label>•</ce:label><ce:para id="p6565">Persisting organ failure for 48 hours</ce:para></ce:list-item><ce:list-item id="u3795"><ce:label>•</ce:label><ce:para id="p6570">Multiple or progressive organ failure</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p6575">(CRP = C-reactive protein)</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0415" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0780" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1220" role="short">Image 73</ce:alt-text></ce:inline-figure> 21.80</ce:label><ce:alt-text id="atte1225" role="short">21.80</ce:alt-text><ce:textbox-head><ce:title id="tit0420">Causes of acute pancreatitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2220"><ce:section-title id="st2140">Common (90% of cases)</ce:section-title><ce:para id="p6585"><ce:list id="ulist1145"><ce:list-item id="u3800"><ce:label>•</ce:label><ce:para id="p6590">Gallstones</ce:para></ce:list-item><ce:list-item id="u3805"><ce:label>•</ce:label><ce:para id="p6595">Alcohol</ce:para></ce:list-item><ce:list-item id="u3810"><ce:label>•</ce:label><ce:para id="p6600">Idiopathic causes</ce:para></ce:list-item><ce:list-item id="u3815"><ce:label>•</ce:label><ce:para id="p6605">Post-ERCP</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2225"><ce:section-title id="st2145">Rare</ce:section-title><ce:para id="p6610"><ce:list id="ulist1150"><ce:list-item id="u3820"><ce:label>•</ce:label><ce:para id="p6615">Post-surgical (abdominal, cardiopulmonary bypass)</ce:para></ce:list-item><ce:list-item id="u3825"><ce:label>•</ce:label><ce:para id="p6620">Trauma</ce:para></ce:list-item><ce:list-item id="u3830"><ce:label>•</ce:label><ce:para id="p6625">Drugs (azathioprine/mercaptopurine, thiazide diuretics, sodium valproate)</ce:para></ce:list-item><ce:list-item id="u3835"><ce:label>•</ce:label><ce:para id="p6630">Metabolic (hypercalcaemia, hypertriglyceridaemia)</ce:para></ce:list-item><ce:list-item id="u3840"><ce:label>•</ce:label><ce:para id="p6635">Pancreas divisum (<ce:cross-ref id="crf9030" refid="s2330">p. 842</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u3845"><ce:label>•</ce:label><ce:para id="p6640">Sphincter of Oddi dysfunction</ce:para></ce:list-item><ce:list-item id="u3850"><ce:label>•</ce:label><ce:para id="p6645">Infection (mumps, Coxsackie virus)</ce:para></ce:list-item><ce:list-item id="u3855"><ce:label>•</ce:label><ce:para id="p6650">Hereditary factors</ce:para></ce:list-item><ce:list-item id="u3860"><ce:label>•</ce:label><ce:para id="p6655">Renal failure</ce:para></ce:list-item><ce:list-item id="u3865"><ce:label>•</ce:label><ce:para id="p6660">Organ transplantation (kidney, liver)</ce:para></ce:list-item><ce:list-item id="u3870"><ce:label>•</ce:label><ce:para id="p6665">Severe hypothermia</ce:para></ce:list-item><ce:list-item id="u3875"><ce:label>•</ce:label><ce:para id="p6670">Petrochemical exposure</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p6675">(ERCP = endoscopic retrograde cholangiopancreatography)</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0420" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0785" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1230" role="short">Image 74</ce:alt-text></ce:inline-figure> 21.81</ce:label><ce:alt-text id="atte1235" role="short">21.81</ce:alt-text><ce:textbox-head><ce:title id="tit0425">Complications of acute pancreatitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6685"><ce:display><ce:table frame="topbot" id="t0150"><ce:alt-text id="atte1240" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Complication</entry><entry align="left">Cause</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Systemic</ce:bold></entry></row><row rowsep="0"><entry align="left">Systemic inflammatory response syndrome (SIRS)</entry><entry align="left">Increased vascular permeability from cytokine, platelet-aggregating factor and kinin release</entry></row><row rowsep="0"><entry align="left">Hypoxia</entry><entry align="left">Acute respiratory distress syndrome (ARDS) due to microthrombi in pulmonary vessels</entry></row><row rowsep="0"><entry align="left">Hyperglycaemia</entry><entry align="left">Disruption of islets of Langerhans with altered insulin/glucagon release</entry></row><row rowsep="0"><entry align="left">Hypocalcaemia</entry><entry align="left">Sequestration of calcium in fat necrosis, fall in ionised calcium</entry></row><row rowsep="1"><entry align="left">Reduced serum albumin concentration</entry><entry align="left">Increased capillary permeability</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Pancreatic</ce:bold></entry></row><row rowsep="0"><entry align="left">Necrosis</entry><entry align="left">Non-viable pancreatic tissue and peripancreatic tissue death; frequently infected</entry></row><row rowsep="0"><entry align="left">Abscess</entry><entry align="left">Circumscribed collection of pus close to the pancreas and containing little or no pancreatic necrotic tissue</entry></row><row rowsep="0"><entry align="left">Pseudocyst</entry><entry align="left">Disruption of pancreatic ducts</entry></row><row rowsep="1"><entry align="left">Pancreatic ascites or pleural effusion</entry><entry align="left">Disruption of pancreatic ducts</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gastrointestinal</ce:bold></entry></row><row rowsep="0"><entry align="left">Upper gastrointestinal bleeding</entry><entry align="left">Gastric or duodenal erosions</entry></row><row rowsep="0"><entry align="left">Variceal haemorrhage</entry><entry align="left">Splenic or portal vein thrombosis</entry></row><row rowsep="0"><entry align="left">Erosion into colon</entry><entry align="left">Erosion by pancreatic pseudocyst</entry></row><row rowsep="0"><entry align="left">Duodenal obstruction</entry><entry align="left">Compression by pancreatic mass</entry></row><row><entry align="left">Obstructive jaundice</entry><entry align="left">Compression of common bile duct</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0425" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0800" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1245" role="short">Image 75</ce:alt-text></ce:inline-figure> 21.82</ce:label><ce:alt-text id="atte1250" role="short">21.82</ce:alt-text><ce:textbox-head><ce:title id="tit0430">Causes of chronic pancreatitis<ce:cross-ref id="crf1305" refid="fn0050">*</ce:cross-ref><ce:footnote id="fn0050"><ce:label>*</ce:label><ce:note-para id="np0080">These can be memorised by the mnemonic ‘TIGARO’. Gallstones do not cause chronic pancreatitis but may be observed as an incidental finding.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6770"><ce:display><ce:table frame="topbot" id="t0155"><ce:alt-text id="atte1255" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Toxic–metabolic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1160"><ce:list-item id="u3900"><ce:label>•</ce:label><ce:para id="p6775">Alcohol</ce:para></ce:list-item><ce:list-item id="u3905"><ce:label>•</ce:label><ce:para id="p6780">Tobacco</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1165"><ce:list-item id="u3910"><ce:label>•</ce:label><ce:para id="p6785">Hypercalcaemia</ce:para></ce:list-item><ce:list-item id="u3915"><ce:label>•</ce:label><ce:para id="p6790">Chronic kidney disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Idiopathic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1170"><ce:list-item id="u3920"><ce:label>•</ce:label><ce:para id="p6795">Tropical</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1175"><ce:list-item id="u3925"><ce:label>•</ce:label><ce:para id="p6800">Early-/late-onset types</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Genetic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1180"><ce:list-item id="u3930"><ce:label>•</ce:label><ce:para id="p6805">Hereditary pancreatitis (cationic trypsinogen mutation)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1185"><ce:list-item id="u3935"><ce:label>•</ce:label><ce:para id="p6810"><ce:italic>SPINK-1</ce:italic> mutation</ce:para></ce:list-item><ce:list-item id="u3940"><ce:label>•</ce:label><ce:para id="p6815">Cystic fibrosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Autoimmune</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1190"><ce:list-item id="u3945"><ce:label>•</ce:label><ce:para id="p6820">In isolation or as part of multi-organ problem</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Recurrent and severe acute pancreatitis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1195"><ce:list-item id="u3950"><ce:label>•</ce:label><ce:para id="p6825">Recurrent acute pancreatitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1200"><ce:list-item id="u3955"><ce:label>•</ce:label><ce:para id="p6830">Post-necrotic</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Obstructive</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1205"><ce:list-item id="u3960"><ce:label>•</ce:label><ce:para id="p6835">Ductal adenocarcinoma</ce:para></ce:list-item><ce:list-item id="u3965"><ce:label>•</ce:label><ce:para id="p6840">Intraductal papillary mucinous neoplasia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1210"><ce:list-item id="u3970"><ce:label>•</ce:label><ce:para id="p6845">Pancreas divisum</ce:para></ce:list-item><ce:list-item id="u3975"><ce:label>•</ce:label><ce:para id="p6850">Sphincter of Oddi stenosis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0430" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0810" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1260" role="short">Image 76</ce:alt-text></ce:inline-figure> 21.83</ce:label><ce:alt-text id="atte1265" role="short">21.83</ce:alt-text><ce:textbox-head><ce:title id="tit0435">Complications of chronic pancreatitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6860"><ce:list id="ulist1215"><ce:list-item id="u3980"><ce:label>•</ce:label><ce:para id="p6865">Pseudocysts and pancreatic ascites, which occur in both acute and chronic pancreatitis</ce:para></ce:list-item><ce:list-item id="u3985"><ce:label>•</ce:label><ce:para id="p6870">Obstructive jaundice due to benign stricture of the common bile duct as it passes through the diseased pancreas</ce:para></ce:list-item><ce:list-item id="u3990"><ce:label>•</ce:label><ce:para id="p6875">Duodenal stenosis</ce:para></ce:list-item><ce:list-item id="u3995"><ce:label>•</ce:label><ce:para id="p6880">Portal or splenic vein thrombosis leading to segmental portal hypertension and gastric varices</ce:para></ce:list-item><ce:list-item id="u4000"><ce:label>•</ce:label><ce:para id="p6885">Peptic ulcer</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0435" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0815" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1270" role="short">Image 77</ce:alt-text></ce:inline-figure> 21.84</ce:label><ce:alt-text id="atte1275" role="short">21.84</ce:alt-text><ce:textbox-head><ce:title id="tit0440">Investigations in chronic pancreatitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2270"><ce:section-title id="st2185">Tests to establish the diagnosis</ce:section-title><ce:para id="p6895"><ce:list id="ulist1220"><ce:list-item id="u4005"><ce:label>•</ce:label><ce:para id="p6900">Ultrasound</ce:para></ce:list-item><ce:list-item id="u4010"><ce:label>•</ce:label><ce:para id="p6905">Computed tomography (may show atrophy, calcification or ductal dilatation)</ce:para></ce:list-item><ce:list-item id="u4015"><ce:label>•</ce:label><ce:para id="p6910">Abdominal X-ray (may show calcification)</ce:para></ce:list-item><ce:list-item id="u4020"><ce:label>•</ce:label><ce:para id="p6915">Magnetic resonance cholangiopancreatography</ce:para></ce:list-item><ce:list-item id="u4025"><ce:label>•</ce:label><ce:para id="p6920">Endoscopic ultrasound</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2275"><ce:section-title id="st2190">Tests to define pancreatic function</ce:section-title><ce:para id="p6925"><ce:list id="ulist1225"><ce:list-item id="u4030"><ce:label>•</ce:label><ce:para id="p6930">Collection of pure pancreatic juice after secretin injection (gold standard but invasive and seldom used)</ce:para></ce:list-item><ce:list-item id="u4035"><ce:label>•</ce:label><ce:para id="p6935">Pancreolauryl test (see <ce:cross-ref id="crf1325" refid="b0075">Box 21.12</ce:cross-ref>, <ce:cross-ref id="crf9035" refid="s0310">p. 777</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u4040"><ce:label>•</ce:label><ce:para id="p6940">Faecal pancreatic elastase</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2280"><ce:section-title id="st2195">Tests to demonstrate anatomy prior to surgery</ce:section-title><ce:para id="p6945"><ce:list id="ulist1230"><ce:list-item id="u4045"><ce:label>•</ce:label><ce:para id="p6950">Magnetic resonance cholangiopancreatography</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0440" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0830" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000214/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1280" role="short">Image 78</ce:alt-text></ce:inline-figure> 21.85</ce:label><ce:alt-text id="atte1285" role="short">21.85</ce:alt-text><ce:textbox-head><ce:title id="tit0445">Intervention in chronic pancreatitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2305"><ce:section-title id="st2215">Endoscopic therapy</ce:section-title><ce:para id="p6980"><ce:list id="ulist1240"><ce:list-item id="u4065"><ce:label>•</ce:label><ce:para id="p6985">Dilatation or stenting of pancreatic duct strictures</ce:para></ce:list-item><ce:list-item id="u4070"><ce:label>•</ce:label><ce:para id="p6990">Removal of calculi (mechanical or shock-wave lithotripsy)</ce:para></ce:list-item><ce:list-item id="u4075"><ce:label>•</ce:label><ce:para id="p6995">Drainage of pseudocysts</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2310"><ce:section-title id="st2220">Surgical methods</ce:section-title><ce:para id="p7000"><ce:list id="ulist1245"><ce:list-item id="u4080"><ce:label>•</ce:label><ce:para id="p7005">Partial pancreatic resection, preserving the duodenum</ce:para></ce:list-item><ce:list-item id="u4085"><ce:label>•</ce:label><ce:para id="p7010">Pancreatico-jejunostomy</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>21</ce:label><ce:title id="tit0010">Gastroenterology</ce:title><ce:author-group id="aug0010"><ce:author author-id="B9780702070280000214-3b9a18e671d59215c03cb9454b53e812" id="au0010"><ce:given-name>E</ce:given-name><ce:surname>El-Omar</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0015"><ce:author author-id="B9780702070280000214-6d359d87d0ca897e7830ac51c8670ec8" id="au0015"><ce:given-name>MH</ce:given-name><ce:surname>McLean</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Clinical examination of the gastrointestinal tract</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>764</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>Functional anatomy and physiology</ce:bold> <ce:cross-ref id="crf0015" refid="s0015"><ce:bold>766</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0020"><ce:para id="p0020">Oesophagus, stomach and duodenum <ce:cross-ref id="crf0020" refid="s0020">766</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025">Small intestine <ce:cross-ref id="crf0025" refid="s0040">767</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0030"><ce:para id="p0030">Pancreas <ce:cross-ref id="crf0030" refid="s0090">770</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0035"><ce:para id="p0035">Colon <ce:cross-ref id="crf0035" refid="s0095">770</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0040"><ce:para id="p0040">Intestinal microbiota <ce:cross-ref id="crf0040" refid="s0100">771</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="o9000"><ce:para id="p9000">Control of gastrointestinal function <ce:cross-ref id="crf9000" refid="s0105">771</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0045"><ce:para id="p0045">Gut hormones <ce:cross-ref id="crf0045" refid="s0130">772</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0050"><ce:para id="p0050"><ce:bold>Investigation of gastrointestinal disease</ce:bold> <ce:cross-ref id="crf0050" refid="s0135"><ce:bold>772</ce:bold></ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0055"><ce:para id="p0055">Imaging <ce:cross-ref id="crf0055" refid="s0140">772</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060">Tests of infection <ce:cross-ref id="crf0060" refid="s0310">777</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0065"><ce:para id="p0065">Tests of function <ce:cross-ref id="crf0065" refid="s0330">777</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0070"><ce:para id="p0070">Radioisotope tests <ce:cross-ref id="crf0070" refid="s0350">778</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0075"><ce:para id="p0075">Gut hormone testing <ce:cross-ref id="crf0075" refid="s0355">778</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0080"><ce:para id="p0080"><ce:bold>Presenting problems in gastrointestinal disease</ce:bold> <ce:cross-ref id="crf0080" refid="s0360"><ce:bold>778</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0085"><ce:para id="p0085">Dysphagia <ce:cross-ref id="crf0085" refid="s0365">778</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0090"><ce:para id="p0090">Dyspepsia <ce:cross-ref id="crf0090" refid="s0380">779</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095">Heartburn and regurgitation <ce:cross-ref id="crf0095" refid="s0385">779</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0100"><ce:para id="p0100">Vomiting <ce:cross-ref id="crf0100" refid="s0390">780</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0105"><ce:para id="p0105">Gastrointestinal bleeding <ce:cross-ref id="crf0105" refid="s0395">780</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Diarrhoea <ce:cross-ref id="crf0110" refid="s0485">783</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0115"><ce:para id="p0115">Malabsorption <ce:cross-ref id="crf0115" refid="s0500">783</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0120"><ce:para id="p0120">Weight loss <ce:cross-ref id="crf0120" refid="s0530">785</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0125"><ce:para id="p0125">Constipation <ce:cross-ref id="crf0125" refid="s0575">786</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0130"><ce:para id="p0130">Abdominal pain <ce:cross-ref id="crf0130" refid="s0605">787</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0135"><ce:para id="p0135"><ce:bold>Diseases of the mouth and salivary glands</ce:bold> <ce:cross-ref id="crf0135" refid="s0670"><ce:bold>790</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0140"><ce:para id="p0140"><ce:bold>Diseases of the oesophagus</ce:bold> <ce:cross-ref id="crf0140" refid="s0700"><ce:bold>791</ce:bold></ce:cross-ref><ce:list id="ulist0030"><ce:list-item id="u0145"><ce:para id="p0145">Gastro-oesophageal reflux disease <ce:cross-ref id="crf0145" refid="s0705">791</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0150"><ce:para id="p0150">Motility disorders <ce:cross-ref id="crf0150" refid="s0845">794</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0155"><ce:para id="p0155">Tumours of the oesophagus <ce:cross-ref id="crf0155" refid="s0905">796</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0160"><ce:para id="p0160">Perforation of the oesophagus <ce:cross-ref id="crf0160" refid="s0935">797</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0165"><ce:para id="p0165"><ce:bold>Diseases of the stomach and duodenum</ce:bold> <ce:cross-ref id="crf0165" refid="s0940"><ce:bold>797</ce:bold></ce:cross-ref><ce:list id="ulist0035"><ce:list-item id="u0170"><ce:para id="p0170">Gastritis <ce:cross-ref id="crf0170" refid="s0945">797</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0175"><ce:para id="p0175">Peptic ulcer disease <ce:cross-ref id="crf0175" refid="s0985">798</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0180"><ce:para id="p0180">Functional disorders <ce:cross-ref id="crf0180" refid="s1155">802</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0185"><ce:para id="p0185">Tumours of the stomach <ce:cross-ref id="crf0185" refid="s1195">803</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0190"><ce:para id="p0190"><ce:bold>Diseases of the small intestine</ce:bold> <ce:cross-ref id="crf0190" refid="s1260"><ce:bold>805</ce:bold></ce:cross-ref><ce:list id="ulist0040"><ce:list-item id="u0195"><ce:para id="p0195">Disorders causing malabsorption <ce:cross-ref id="crf0195" refid="s1265">805</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0200"><ce:para id="p0200">Motility disorders <ce:cross-ref id="crf0200" refid="s1435">810</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0205"><ce:para id="p0205">Miscellaneous disorders of the small intestine <ce:cross-ref id="crf0205" refid="s1470">811</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0210"><ce:para id="p0210">Adverse food reactions <ce:cross-ref id="crf0210" refid="s1515">812</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0215"><ce:para id="p0215">Infections of the small intestine <ce:cross-ref id="crf0215" refid="s1540">812</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0220"><ce:para id="p0220">Tumours of the small intestine <ce:cross-ref id="crf0220" refid="s1570">813</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0225"><ce:para id="p0225"><ce:bold>Inflammatory bowel disease</ce:bold> <ce:cross-ref id="crf0225" refid="s1605"><ce:bold>813</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0230"><ce:para id="p0230"><ce:bold>Irritable bowel syndrome</ce:bold> <ce:cross-ref id="crf0230" refid="s1855"><ce:bold>824</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0235"><ce:para id="p0235"><ce:bold>HIV/AIDS and the gastrointestinal tract</ce:bold> <ce:cross-ref id="crf0235" refid="s1930"><ce:bold>826</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0240"><ce:para id="p0240"><ce:bold>Ischaemic gut injury</ce:bold> <ce:cross-ref id="crf0240" refid="s1935"><ce:bold>827</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0245"><ce:para id="p0245"><ce:bold>Disorders of the colon and rectum</ce:bold> <ce:cross-ref id="crf0245" refid="s1960"><ce:bold>827</ce:bold></ce:cross-ref><ce:list id="ulist0045"><ce:list-item id="u0250"><ce:para id="p0250">Tumours of the colon and rectum <ce:cross-ref id="crf0250" refid="s1965">827</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0255"><ce:para id="p0255">Diverticulosis <ce:cross-ref id="crf0255" refid="s2045">833</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0260"><ce:para id="p0260">Constipation and disorders of defecation <ce:cross-ref id="crf0260" refid="s2075">834</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0265"><ce:para id="p0265">Anorectal disorders <ce:cross-ref id="crf0265" refid="s2115">835</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0270"><ce:para id="p0270"><ce:bold>Diseases of the peritoneal cavity</ce:bold> <ce:cross-ref id="crf0270" refid="s2155">836</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0275"><ce:para id="p0275"><ce:bold>Other disorders</ce:bold> <ce:cross-ref id="crf0275" refid="s2170">837</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0280"><ce:para id="p0280"><ce:bold>Diseases of the pancreas</ce:bold> <ce:cross-ref id="crf0280" refid="s2185"><ce:bold>837</ce:bold></ce:cross-ref><ce:list id="ulist0050"><ce:list-item id="u0285"><ce:para id="p0285">Acute pancreatitis <ce:cross-ref id="crf0285" refid="s2190">837</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0290"><ce:para id="p0290">Chronic pancreatitis <ce:cross-ref id="crf0290" refid="s2245">839</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0295"><ce:para id="p0295">Congenital abnormalities affecting the pancreas <ce:cross-ref id="crf0295" refid="s2330">842</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0300"><ce:para id="p0300">Tumours of the pancreas <ce:cross-ref id="crf0300" refid="s2355">842</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:section id="s0010"><ce:section-title id="st0010">Clinical examination of the gastrointestinal tract</ce:section-title><ce:para id="p0305"><ce:display><ce:figure id="f0010"><ce:alt-text id="atte1290" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0010" locator="u021-001-9780702070280" xlink:href="pii:B9780702070280000214/u021-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:display><ce:textbox id="b0010" role="alt7"><ce:label>4</ce:label><ce:alt-text id="atte1295" role="short">4</ce:alt-text><ce:textbox-head><ce:title id="tit0015">Abdominal examination: possible findings</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0310"><ce:display><ce:figure id="f0015"><ce:alt-text id="atte1300" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0015" locator="u021-002-9780702070280" xlink:href="pii:B9780702070280000214/u021-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0015" role="alt7"><ce:label>6</ce:label><ce:alt-text id="atte1305" role="short">6</ce:alt-text><ce:textbox-head><ce:title id="tit0020">Rectal examination: common findings</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0315"><ce:display><ce:figure id="f0020"><ce:alt-text id="atte1310" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0020" locator="u021-003-9780702070280" xlink:href="pii:B9780702070280000214/u021-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display>Diseases of the gastrointestinal tract are a major cause of morbidity and mortality. Approximately 10% of all GP consultations in the UK are for indigestion and 1 in 14 is for diarrhoea. Infective diarrhoea and malabsorption are responsible for much ill health and many deaths in the developing world. The gastrointestinal tract is the most common site for cancer development. Colorectal cancer is the third most common cancer in men and women and population-based screening programmes exist in many countries. Functional bowel disorders affect up to 10–15% of the population and consume considerable health-care resources. The inflammatory bowel diseases, Crohn's disease and ulcerative colitis, together affect 1 in 250 people in the Western world, with substantial associated morbidity.</ce:para></ce:section><ce:section id="s0015"><ce:section-title id="st0015">Functional anatomy and physiology</ce:section-title><ce:section id="s0020"><ce:section-title id="st0020">Oesophagus, stomach and duodenum</ce:section-title><ce:para id="p0320">The oesophagus is a muscular tube that extends 25 cm from the cricoid cartilage to the cardiac orifice of the stomach. It has an upper and a lower sphincter. A peristaltic swallowing wave propels the food bolus into the stomach (<ce:cross-ref id="crf0305" refid="f0025">Fig. 21.1</ce:cross-ref><ce:float-anchor refid="f0025"/>).</ce:para><ce:para id="p0325">The stomach acts as a ‘hopper’, retaining and grinding food, and then actively propelling it into the upper small bowel (<ce:cross-ref id="crf0310" refid="f0030">Fig. 21.2</ce:cross-ref><ce:float-anchor refid="f0030"/>).</ce:para><ce:section id="s0025"><ce:section-title id="st0025">Gastric secretion</ce:section-title><ce:para id="p0330">Gastrin, histamine and acetylcholine are the key stimulants of acid secretion. Hydrogen and chloride ions are secreted from the apical membrane of gastric parietal cells into the lumen of the stomach by a hydrogen–potassium adenosine triphosphatase (ATPase) (‘proton pump’) (<ce:cross-ref id="crf0315" refid="f0035">Fig. 21.3</ce:cross-ref><ce:float-anchor refid="f0035"/>). The hydrochloric acid sterilises the upper gastrointestinal tract and converts pepsino­gen, which is secreted by chief cells, to pepsin. The glycoprotein intrinsic factor, secreted in parallel with acid, is necessary for vitamin B<ce:inf loc="post">12</ce:inf> absorption.</ce:para></ce:section><ce:section id="s0030"><ce:section-title id="st0030">Gastrin, somatostatin and ghrelin</ce:section-title><ce:para id="p0335">The hormone gastrin is produced by G cells in the antrum, whereas somatostatin is secreted from D cells throughout the stomach. Gastrin stimulates acid secretion and mucosal growth while somatostatin suppresses it. Ghrelin, secreted from oxyntic glands, stimulates acid secretion but also appetite and gastric emptying.</ce:para></ce:section><ce:section id="s0035"><ce:section-title id="st0035">Protective factors</ce:section-title><ce:para id="p0340">Bicarbonate ions, stimulated by prostaglandins, mucins and trefoil factor family (TFF) peptides, together protect the gastro­duodenal mucosa from the ulcerative properties of acid and pepsin.</ce:para></ce:section></ce:section><ce:section id="s0040"><ce:section-title id="st0040">Small intestine</ce:section-title><ce:para id="p0345">The small bowel extends from the ligament of Treitz to the ileocaecal valve (<ce:cross-ref id="crf0320" refid="f0040">Fig. 21.4</ce:cross-ref><ce:float-anchor refid="f0040"/>). During fasting, a wave of peristaltic activity passes down the small bowel every 1–2 hours. Entry of food into the gastrointestinal tract stimulates small bowel peristaltic activity. Functions of the small intestine are:<ce:list id="ulist0055"><ce:list-item id="u0305"><ce:label>•</ce:label><ce:para id="p0350">digestion (mechanical, enzymatic and peristaltic)</ce:para></ce:list-item><ce:list-item id="u0310"><ce:label>•</ce:label><ce:para id="p0355">absorption – the products of digestion, water, electrolytes and vitamins</ce:para></ce:list-item><ce:list-item id="u0315"><ce:label>•</ce:label><ce:para id="p0360">protection against ingested toxins</ce:para></ce:list-item><ce:list-item id="u0320"><ce:label>•</ce:label><ce:para id="p0365">immune regulation.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0045"><ce:section-title id="st0045">Digestion and absorption</ce:section-title><ce:section id="s0050"><ce:section-title id="st0050">Fat</ce:section-title><ce:para id="p0370">Dietary lipids comprise long-chain triglycerides, cholesterol esters and lecithin. Lipids are insoluble in water and undergo lipolysis and incorporation into mixed micelles before they can be absorbed into enterocytes along with the fat-soluble vitamins A, D, E and K. The lipids are processed within enterocytes and pass via lymphatics into the systemic circulation. Fat absorption and digestion can be considered as a stepwise process, as outlined in <ce:cross-ref id="crf0325" refid="f0045">Figure 21.5</ce:cross-ref><ce:float-anchor refid="f0045"/>.</ce:para></ce:section><ce:section id="s0055"><ce:section-title id="st0055">Carbohydrates</ce:section-title><ce:para id="p0375">Starch is hydrolysed by salivary and pancreatic amylases to:<ce:list id="ulist0060"><ce:list-item id="u0325"><ce:label>•</ce:label><ce:para id="p0380">α-limit dextrins containing 4–8 glucose molecules</ce:para></ce:list-item><ce:list-item id="u0330"><ce:label>•</ce:label><ce:para id="p0385">the disaccharide maltose</ce:para></ce:list-item><ce:list-item id="u0335"><ce:label>•</ce:label><ce:para id="p0390">the trisaccharide maltotriose.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0395">Disaccharides are digested by enzymes fixed to the microvillous membrane to form the monosaccharides glucose, galactose and fructose. Glucose and galactose enter the cell by an energy-requiring process involving a carrier protein, and fructose enters by simple diffusion.</ce:para></ce:section><ce:section id="s0060"><ce:section-title id="st0060">Protein</ce:section-title><ce:para id="p0400">The steps involved in protein digestion are shown in <ce:cross-ref id="crf0330" refid="f0050">Figure 21.6</ce:cross-ref><ce:float-anchor refid="f0050"/>. Intragastric digestion by pepsin is quantitatively modest but important because the resulting polypeptides and amino acids stimulate cholecystokinin (CCK) release from the mucosa of the proximal jejunum, which in turn stimulates release of pancreatic proteases, including trypsinogen, chymotrypsinogen, pro-elastases and procarboxypeptidases, from the pancreas. On exposure to brush border enterokinase, inert trypsinogen is converted to the active proteolytic enzyme trypsin, which activates the other pancreatic pro-enzymes. Trypsin digests proteins to produce oligopeptides, peptides and amino acids. Oligopeptides are further hydrolysed by brush border enzymes to yield dipeptides, tripeptides and amino acids. These small peptides and the amino acids are actively transported into the enterocytes, where intracellular peptidases further digest peptides to amino acids. Amino acids are then actively transported across the basal cell membrane of the enterocyte into the portal circulation and the liver.</ce:para></ce:section><ce:section id="s0065"><ce:section-title id="st0065">Water and electrolytes</ce:section-title><ce:para id="p0405">Absorption and secretion of electrolytes and water occur throughout the intestine. Electrolytes and water are transported by two pathways:<ce:list id="ulist0065"><ce:list-item id="u0340"><ce:label>•</ce:label><ce:para id="p0410"><ce:italic>the paracellular route</ce:italic>, in which passive flow through tight junctions between cells is a consequence of osmotic, electrical or hydrostatic gradients</ce:para></ce:list-item><ce:list-item id="u0345"><ce:label>•</ce:label><ce:para id="p0415"><ce:italic>the transcellular route</ce:italic> across apical and basolateral membranes by energy-requiring specific active transport carriers (pumps).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0420">In healthy individuals, fluid balance is tightly controlled, such that only 100 mL of the 8 litres of fluid entering the gastrointestinal tract daily is excreted in stools (<ce:cross-ref id="crf0335" refid="f0055">Fig. 21.7</ce:cross-ref><ce:float-anchor refid="f0055"/>).</ce:para></ce:section><ce:section id="s0070"><ce:section-title id="st0070">Vitamins and trace elements</ce:section-title><ce:para id="p0425">Water-soluble vitamins are absorbed throughout the intestine. The absorption of folic acid, vitamin B<ce:inf loc="post">12</ce:inf>, calcium and iron is described on <ce:intra-ref id="ii0010" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0660">page 943</ce:intra-ref>.</ce:para></ce:section></ce:section><ce:section id="s0075"><ce:section-title id="st0075">Protective function of the small intestine</ce:section-title><ce:section id="s0080"><ce:section-title id="st0080">Physical defence mechanisms</ce:section-title><ce:para id="p0430">There are several levels of defence in the small bowel (<ce:cross-ref id="crf0340" refid="f0060">Fig. 21.8</ce:cross-ref><ce:float-anchor refid="f0060"/>). Firstly, the gut lumen contains host bacteria (see below), mucins and secreted antibacterial products, including defensins and immunoglobulins that help combat pathogenic infections. Secondly, epithelial cells have relatively impermeable brush border membranes and passage between cells is prevented by tight and adherens junctions. These cells can react to foreign peptides (‘innate immunity’) using pattern recognition receptors found on cell surfaces (Toll receptors) or intracellularly. Lastly, in the subepithelial layer, immune responses occur under control of the adaptive immune system in response to pathogenic compounds.</ce:para></ce:section><ce:section id="s0085"><ce:section-title id="st0085">Immunological defence mechanisms</ce:section-title><ce:para id="p0435">Gastrointestinal mucosa-associated lymphoid tissue (MALT) constitutes 25% of the total lymphatic tissue of the body and is at the heart of adaptive immunity. Within Peyer's patches, B lymphocytes differentiate to plasma cells following exposure to antigens and these migrate to mesenteric lymph nodes to enter the blood stream via the thoracic duct. The plasma cells return to the lamina propria of the gut through the circulation and release immunoglobulin A (IgA), which is transported into the lumen of the intestine. Intestinal T lymphocytes help localise plasma cells to the site of antigen exposure, as well as producing inflammatory mediators. Macrophages in the gut phagocytose foreign materials and secrete a range of cytokines, which mediate inflammation. Similarly, activation of mast-cell surface IgE receptors leads to degranulation and release of other molecules involved in inflammation.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0090"><ce:section-title id="st0090">Pancreas</ce:section-title><ce:para id="p0440">The exocrine pancreas (<ce:cross-ref id="crf0345" refid="b0020">Box 21.1</ce:cross-ref><ce:float-anchor refid="b0020"/>) is necessary for the digestion of fat, protein and carbohydrate. Pro-enzymes are secreted from pancreatic acinar cells in response to circulating gastrointestinal hormones (<ce:cross-ref id="crf0350" refid="f0065">Fig. 21.9</ce:cross-ref><ce:float-anchor refid="f0065"/>) and are activated by trypsin. Bicarbonate-rich fluid is secreted from ductular cells to produce an optimum alkaline pH for enzyme activity. The endocrine pancreas is discussed in <ce:intra-ref id="ii0015" xlink:href="pii:B978-0-7020-7028-0.00018-4#c00018">Chapters 18</ce:intra-ref> and <ce:intra-ref id="ii0020" xlink:href="pii:B978-0-7020-7028-0.00020-2#c00020">20</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0095"><ce:section-title id="st0095">Colon</ce:section-title><ce:para id="p0450">The colon (<ce:cross-ref id="crf0355" refid="f0070">Fig. 21.10</ce:cross-ref><ce:float-anchor refid="f0070"/>) absorbs water and electrolytes. It also acts as a storage organ and has contractile activity. Two types of contraction occur. The first of these is segmentation (ring contraction), which leads to mixing but not propulsion; this promotes absorption of water and electrolytes. Propulsive (peristaltic contraction) waves occur several times a day and propel faeces to the rectum. All activity is stimulated after meals through the gastrocolic reflex in response to release of hormones such as 5-hydroxytryptamine (5-HT, serotonin), motilin and CCK. Faecal continence depends on maintenance of the anorectal angle and tonic contraction of the external anal sphincters. On defecation, there is relaxation of the anorectal muscles, increased intra-abdominal pressure from the Valsalva manœuvre and contraction of abdominal muscles, and relaxation of the anal sphincters.</ce:para></ce:section><ce:section id="s0100"><ce:section-title id="st0100">Intestinal microbiota</ce:section-title><ce:para id="p0455">The human microbiota comprises 10<ce:sup loc="post">14</ce:sup> microbial residents in the human body, vastly outnumbering host cells. Indeed, the number of bacterial genes in the microbiota genome exceeds that of the host by 100-fold or more. This represents a vast ecosystem that is central to health and homeostasis, and is disordered in disease. In terms of nomenclature, ‘microbiota’ refers to the microorganisms that live in a particular niche, while ‘microbiome’ refers to the collective genomes of these microbiota. The metabolic capacity of the gut microbiota is equivalent to that of the liver. The Human Microbiome Project revealed that there are unique communities at different body sites and in the gut particular phyla predominate: namely, Firmicutes, Bacteriodetes, Proteobacteria and Actinobacteria. There is a degree of heritability of this microbiota, as shown in twin studies, but it is clear that there are many environmental factors that can impact, including diet, drugs, physical activity, smoking, stress and natural ageing. Generally, we acquire our adult intestinal microbiota by the age of 2 years. A dysbiosis or imbalance between the different components of the intestinal microbiota has been associated with diseases of the gastrointestinal tract, such as inflammatory bowel disease and colorectal cancer; liver disease, including hepatocellular carcinoma; and pathologies outside the gastrointestinal tract, such as diabetes, obesity, cardiovascular disorders, cerebrovascular disorders, asthma and psychiatric disorders, such as depression. Many challenges remain in understanding the intestinal microbiota and how it impacts on health and disease. It is not clear what constitutes a ‘healthy’ phenotype; there are questions over best sampling practice from either the faecal stream or the mucosa; and there are technical considerations to ensure consistency in methodologies and data analysis.</ce:para></ce:section><ce:section id="s0105"><ce:section-title id="st0105">Control of gastrointestinal function</ce:section-title><ce:para id="p0460">Secretion, absorption, motor activity, growth and differentiation of the gut are all modulated by a combination of neuronal and hormonal factors.</ce:para><ce:section id="s0110"><ce:section-title id="st0110">The nervous system and gastrointestinal function</ce:section-title><ce:para id="p0465">The central nervous system (CNS), the autonomic system (ANS) and the enteric nervous system (ENS) interact to regulate gut function. The ANS comprises:<ce:list id="ulist0070"><ce:list-item id="u0350"><ce:label>•</ce:label><ce:para id="p0470"><ce:italic>parasympathetic pathways</ce:italic> (vagal and sacral efferent), which are cholinergic, and increase smooth muscle tone and promote sphincter relaxation</ce:para></ce:list-item><ce:list-item id="u0355"><ce:label>•</ce:label><ce:para id="p0475"><ce:italic>sympathetic pathways</ce:italic>, which release noradrenaline (norepinephrine), reduce smooth muscle tone and stimulate sphincter contraction.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0115"><ce:section-title id="st0115">The enteric nervous system</ce:section-title><ce:para id="p0480">In conjunction with the ANS, the ENS senses gut contents and conditions, and regulates motility, fluid exchange, secretion, blood flow and other key gut functions. It comprises two major networks intrinsic to the gut wall. The myenteric (Auerbach's) plexus in the smooth muscle layer regulates motor control; and the submucosal (Meissner's) plexus exerts secretory control over the epithelium, entero-endocrine cells and submucosal vessels. Together, these plexuses form a two-layered neuronal mesh along the length of the gut. Although connected centrally via the ANS, the ENS can function autonomously using a variety of transmitters, including acetylcholine, noradrenaline (norepinephrine), 5-HT, nitric oxide, substance P and calcitonin gene-related peptide (CGRP). There are local reflex loops within the ENS but also loops involving the coeliac and mesenteric ganglia and the paravertebral ganglia. The parasympathetic system generally stimulates motility and secretion, while the sympathetic system generally acts in an inhibitory manner.</ce:para></ce:section><ce:section id="s0120"><ce:section-title id="st0120">Peristalsis</ce:section-title><ce:para id="p0485">Peristalsis is a reflex triggered by gut wall distension, which consists of a wave of circular muscle contraction to propel contents from the oesophagus to the rectum. It can be influenced by innervation but functions independently. It results from a basic electrical rhythm originating from the interstitial cells of Cajal in the circular layer of intestinal smooth muscle. These are stellate cells of mesenchymal origin with smooth muscle features, which act as the ‘pacemaker’ of the gut.</ce:para></ce:section><ce:section id="s0125"><ce:section-title id="st0125">Migrating motor complexes</ce:section-title><ce:para id="p0490">Migrating motor complexes (MMCs) are waves of contraction spreading from the stomach to the ileum, occurring at a frequency of about 5 per minute every 90 minutes or so, between meals and during fasting. They may serve to sweep intestinal contents distally in preparation for the next meal and are inhibited by eating.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0130"><ce:section-title id="st0130">Gut hormones</ce:section-title><ce:para id="p0495">The origin, action and control of the major gut hormones, peptides and non-peptide signalling transmitters are summarised in <ce:cross-ref id="crf0360" refid="b0025">Box 21.2</ce:cross-ref><ce:float-anchor refid="b0025"/>.</ce:para></ce:section></ce:section><ce:section id="s0135"><ce:section-title id="st0135">Investigation of gastrointestinal disease</ce:section-title><ce:para id="p0505">A wide range of tests is available for the investigation of patients with gastrointestinal symptoms. These can be classified broadly into tests of structure, tests for infection and tests of function.</ce:para><ce:section id="s0140"><ce:section-title id="st0140">Imaging</ce:section-title><ce:section id="s0145"><ce:section-title id="st0145">Plain X-rays</ce:section-title><ce:para id="p0510">Plain X-rays of the abdomen are useful in the diagnosis of intestinal obstruction or paralytic ileus, where dilated loops of bowel and (in the erect position) fluid levels may be seen (<ce:cross-ref id="crf0365" refid="f0075">Fig. 21.11</ce:cross-ref><ce:float-anchor refid="f0075"/>). Calcified lymph nodes, gallstones and renal stones can also be detected. Chest X-ray (performed with the patient in erect position) is useful in the diagnosis of suspected perforation, as it shows subdiaphragmatic free air (<ce:cross-ref id="crf0370" refid="f0075">Fig. 21.11</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0150"><ce:section-title id="st0150">Contrast studies</ce:section-title><ce:para id="p0515">X-rays with contrast medium are usually performed to assess not only anatomical abnormalities but also motility. Barium sulphate provides good mucosal coating and excellent opacification but can precipitate impaction proximal to an obstructive lesion. Water-soluble contrast is used to opacify bowel prior to abdominal computed tomography and in cases of suspected perforation. The double contrast technique improves mucosal visualisation by using gas to distend the barium-coated intestinal surface. Contrast studies are useful for detecting filling defects, such as tumours, strictures, ulcers and motility disorders, but are inferior to endoscopic procedures and more sophisticated cross-sectional imaging techniques, such as computed tomography and magnetic resonance imaging. The major uses and limitations of various contrast studies are shown in <ce:cross-ref id="crf0375" refid="b0030">Box 21.3</ce:cross-ref><ce:float-anchor refid="b0030"/> and <ce:cross-ref id="crf0380" refid="f0080">Figure 21.12</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0155"><ce:section-title id="st0155">Ultrasound, computed tomography and magnetic resonance imaging</ce:section-title><ce:para id="p0525">Ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI) are key tests in the evaluation of intra-abdominal disease. They are non-invasive and offer detailed images of the abdominal contents. Fluorodeoxyglucose–positron emission tomography (FDG-PET) is increasingly used in the staging of malignancies and images may be fused with CT to enhance localisation. Their main applications are summarised in <ce:cross-ref id="crf0385" refid="b0035">Box 21.4</ce:cross-ref><ce:float-anchor refid="b0035"/> and <ce:cross-ref id="crf0390" refid="f0085">Figure 21.13</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0160"><ce:section-title id="st0160">Endoscopy</ce:section-title><ce:para id="p0535">Videoendoscopes provide high-definition imaging and accessories can be passed down the endoscope to allow both diagnostic and therapeutic procedures, some of which are illustrated in <ce:cross-ref id="crf0395" refid="f0090">Figure 21.14</ce:cross-ref><ce:float-anchor refid="f0090"/>. Endoscopes with magnifying lenses allow almost microscopic detail to be observed, and imaging modalities, such as confocal endomicroscopy, autofluorescence and ‘narrow-band imaging’, are increasingly used to detect subtle abnormalities not visible by standard ‘white light’ endoscopy.</ce:para><ce:section id="s0165"><ce:section-title id="st0165">Upper gastrointestinal endoscopy</ce:section-title><ce:para id="p0540">This is performed under light intravenous benzodiazepine sedation, or using only local anaesthetic throat spray after the patient has fasted for at least 4 hours. With the patient in the left lateral position, the entire oesophagus (excluding pharynx), stomach and first two parts of duodenum can be seen. Indications, contraindications and complications are given in <ce:cross-ref id="crf0400" refid="b0040">Box 21.5</ce:cross-ref><ce:float-anchor refid="b0040"/>.</ce:para></ce:section><ce:section id="s0185"><ce:section-title id="st0185">Endoscopic ultrasound</ce:section-title><ce:para id="p0650">Endoscopic ultrasound (EUS) combines endoscopy with intraluminal ultrasonography using a high-frequency transducer to produce high-resolution ultrasound images. This allows visualisation through the wall of the gastrointestinal tract and into surrounding tissues, e.g. the pancreas or lymph nodes. It can therefore be used to perform fine needle aspiration or biopsy of mass lesions. EUS is helpful in the diagnosis of pancreatic tumours, chronic pancreatitis, pancreatic cysts, cholangiocarcinoma, common bile duct stones, ampullary lesions and submucosal tumours. It also plays an important role in the staging of certain cancers, e.g. those of oesophagus and pancreas. EUS can also be therapeutic, as in drainage of pancreatic fluid collections and coeliac plexus block for pain management. Possible complications of EUS include bleeding, infection, cardiopulmonary events and perforation.</ce:para></ce:section><ce:section id="s0190"><ce:section-title id="st0190">Capsule endoscopy</ce:section-title><ce:para id="p0655">Capsule endoscopy (<ce:cross-ref id="crf0420" refid="f0095">Fig. 21.15</ce:cross-ref><ce:float-anchor refid="f0095"/>) uses a capsule containing an imaging device, battery, transmitter and antenna; as it traverses the small intestine, it transmits images to a battery-powered recorder worn on a belt round the patient's waist. After approximately 8 hours, the capsule is excreted. Images from the capsule are analysed as a video sequence and it is usually possible to localise the segment of small bowel in which lesions are seen. Abnormalities detected usually require enteroscopy for confirmation and therapy. Indications, contraindications and complications are listed in <ce:cross-ref id="crf0425" refid="b0045">Box 21.6</ce:cross-ref><ce:float-anchor refid="b0045"/>.</ce:para></ce:section><ce:section id="s0210"><ce:section-title id="st0210">Double balloon enteroscopy</ce:section-title><ce:para id="p0710">While endoscopy can reach the proximal small intestine in most patients, a technique called double balloon enteroscopy is also available, which uses a long endoscope with a flexible overtube. Sequential and repeated inflation and deflation of balloons on the tip of the overtube and enteroscope allow the operator to push and pull along the entire length of the small intestine to the terminal ileum, in order to diagnose or treat small bowel lesions detected by capsule endoscopy or other imaging modalities. Indications, contraindications and complications are listed in <ce:cross-ref id="crf0430" refid="b0050">Box 21.7</ce:cross-ref><ce:float-anchor refid="b0050"/>.</ce:para></ce:section><ce:section id="s0240"><ce:section-title id="st0240">Sigmoidoscopy and colonoscopy</ce:section-title><ce:para id="p0795">Sigmoidoscopy can be carried out either in the outpatient clinic using a 20 cm rigid plastic sigmoidoscope or in the endoscopy suite using a 60 cm flexible colonoscope following bowel preparation. When sigmoidoscopy is combined with proctoscopy, accurate detection of haemorrhoids, ulcerative colitis and distal colorectal neoplasia is possible. After full bowel cleansing, it is possible to examine the entire colon and the terminal ileum using a longer colonoscope. Indications, contraindications and complications of colonoscopy are listed in <ce:cross-ref id="crf0435" refid="b0055">Box 21.8</ce:cross-ref><ce:float-anchor refid="b0055"/>.</ce:para></ce:section><ce:section id="s0260"><ce:section-title id="st0260">Magnetic resonance cholangiopancreatography</ce:section-title><ce:para id="p0885">Magnetic resonance cholangiopancreatography (MRCP) has largely replaced endoscopic retrograde cholangiopancreatography (ERCP) in the evaluation of obstructive jaundice since it produces comparable images of the biliary tree and pancreas, providing information that complements that obtained from CT and endoscopic ultrasound examination (EUS).</ce:para></ce:section><ce:section id="s0265"><ce:section-title id="st0265">Endoscopic retrograde cholangiopancreatography</ce:section-title><ce:para id="p0890">Using a side-viewing duodenoscope, it is possible to cannulate the main pancreatic duct and common bile duct. Nowadays, ERCP is used mainly in the treatment of a range of biliary and pancreatic diseases that have been identified by other imaging techniques such as MRCP, EUS and CT. Indications for and risks of ERCP are listed in <ce:cross-ref id="crf0440" refid="b0060">Box 21.10</ce:cross-ref><ce:float-anchor refid="b0060"/>.<ce:display><ce:textbox id="b0065" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0165" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000214/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1315" role="short">Image 79</ce:alt-text></ce:inline-figure> 21.9</ce:label><ce:alt-text id="atte1320" role="short">21.9</ce:alt-text><ce:textbox-head><ce:title id="tit0070">Endoscopy in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1035"><ce:list id="ulist0190"><ce:list-item id="u0720"><ce:label>•</ce:label><ce:para id="p1040"><ce:bold>Tolerance</ce:bold>: endoscopic procedures are generally well tolerated, even in very old people.</ce:para></ce:list-item><ce:list-item id="u0725"><ce:label>•</ce:label><ce:para id="p1045"><ce:bold>Side-effects from sedation</ce:bold>: older people are more sensitive, and respiratory depression, hypotension and prolonged recovery times are more common.</ce:para></ce:list-item><ce:list-item id="u0730"><ce:label>•</ce:label><ce:para id="p1050"><ce:bold>Bowel preparation for colonoscopy</ce:bold>: can be difficult in frail, immobile people. Sodium phosphate-based preparations can cause dehydration or hypotension and should be avoided in those with underlying cardiac or renal failure. Minimal-preparation CT colonograms provide an excellent alternative in these individuals.</ce:para></ce:list-item><ce:list-item id="u0735"><ce:label>•</ce:label><ce:para id="p1055"><ce:bold>Antiperistaltic agents</ce:bold>: hyoscine should be avoided in those with glaucoma and can also cause tachyarrhythmias. Glucagon is preferred if an antiperistaltic agent is needed.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section></ce:section><ce:section id="s0305"><ce:section-title id="st0305">Histology</ce:section-title><ce:para id="p1060">Biopsy material obtained endoscopically or percutaneously can provide useful information (<ce:cross-ref id="crf0450" refid="b0070">Box 21.11</ce:cross-ref><ce:float-anchor refid="b0070"/>).</ce:para></ce:section></ce:section><ce:section id="s0310"><ce:section-title id="st0310">Tests of infection</ce:section-title><ce:section id="s0315"><ce:section-title id="st0315">Bacterial cultures</ce:section-title><ce:para id="p1090">Stool cultures are essential in the investigation of diarrhoea, especially when it is acute or bloody, in order to identify pathogenic organisms (<ce:intra-ref id="ii0025" xlink:href="pii:B978-0-7020-7028-0.00011-1#c00011">Ch. 11</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0320"><ce:section-title id="st0320">Serology</ce:section-title><ce:para id="p1095">Detection of antibodies plays a limited role in the diagnosis of gastrointestinal infection caused by organisms such as <ce:italic>Helicobacter pylori</ce:italic>, <ce:italic>Salmonella</ce:italic> species and <ce:italic>Entamoeba histolytica</ce:italic>.</ce:para></ce:section><ce:section id="s0325"><ce:section-title id="st0325">Breath tests</ce:section-title><ce:para id="p1100">Non-invasive breath tests for <ce:italic>H. pylori</ce:italic> infection are discussed on <ce:cross-ref id="crf9040" refid="s1030">page 800</ce:cross-ref> and breath tests for suspected small intestinal bacterial overgrowth on <ce:cross-ref id="crf9045" refid="p3960">page 808</ce:cross-ref>.</ce:para></ce:section></ce:section><ce:section id="s0330"><ce:section-title id="st0330">Tests of function</ce:section-title><ce:para id="p1105">A number of dynamic tests can be used to investigate aspects of gut function, including digestion, absorption, inflammation and epithelial permeability. Some of the more common ones are listed in <ce:cross-ref id="crf0455" refid="b0075">Box 21.12</ce:cross-ref><ce:float-anchor refid="b0075"/>. In the assessment of suspected malabsorption, blood tests (full blood count, erythrocyte sedimentation rate (ESR), and measurement of C-reactive protein (CRP), folate, vitamin B<ce:inf loc="post">12</ce:inf>, iron status, albumin, calcium and phosphate) are essential, and endoscopy is undertaken to obtain mucosal biopsies. Faecal calprotectin is very sensitive at detecting mucosal inflammation.</ce:para><ce:section id="s0335"><ce:section-title id="st0335">Oesophageal motility</ce:section-title><ce:para id="p1115">A barium swallow can give useful information about oesophageal motility. Videofluoroscopy, with joint assessment by a speech and language therapist and a radiologist, may be necessary in difficult cases. Oesophageal manometry (see <ce:cross-ref id="crf0460" refid="f0025">Fig. 21.1</ce:cross-ref>), often in conjunction with 24-hour pH measurements, is of value in diagnosing cases of refractory gastro-oesophageal reflux, achalasia and non-cardiac chest pain. Oesophageal impedance testing is useful for detecting non-acid or gas reflux events, especially in patients with atypical symptoms or those who respond poorly to acid suppression.</ce:para></ce:section><ce:section id="s0340"><ce:section-title id="st0340">Gastric emptying</ce:section-title><ce:para id="p1120">This involves administering a test meal containing solids and liquids labelled with different radioisotopes and measuring the amount retained in the stomach afterwards (<ce:cross-ref id="crf0465" refid="b0080">Box 21.13</ce:cross-ref><ce:float-anchor refid="b0080"/>). It is useful in the investigation of suspected delayed gastric emptying (gastroparesis) when other studies are normal.</ce:para></ce:section><ce:section id="s0345"><ce:section-title id="st0345">Colonic and anorectal motility</ce:section-title><ce:para id="p1130">A plain abdominal X-ray taken on day 5 after ingestion of different-shaped inert plastic pellets on days 1–3 gives an estimate of whole-gut transit time. The test is useful in the evaluation of chronic constipation, when the position of any retained pellets can be observed, and helps to differentiate cases of slow transit from those due to obstructed defecation. The mechanism of defecation and anorectal function can be assessed by anorectal manometry, electrophysiological tests and defecating proctography.</ce:para></ce:section></ce:section><ce:section id="s0350"><ce:section-title id="st0350">Radioisotope tests</ce:section-title><ce:para id="p1135">Many different radioisotope tests are used (<ce:cross-ref id="crf0470" refid="b0080">Box 21.13</ce:cross-ref>). In some, structural information is obtained, such as the localisation of a Meckel's diverticulum. Others provide functional information, such as the rate of gastric emptying or ability to reabsorb bile acids. Yet others are tests of infection and rely on the presence of bacteria to hydrolyse a radio-labelled test substance followed by detection of the radioisotope in expired air, such as the urea breath test for <ce:italic>H. pylori.</ce:italic></ce:para></ce:section><ce:section id="s0355"><ce:section-title id="st0355">Gut hormone testing</ce:section-title><ce:para id="p1140">Excess gut hormone secretion by some gastrointestinal and pancreatic neuro-endocrine tumours can be assessed by measuring levels in blood. Commonly measured hormones include gastrin, somatostatin, vasoactive intestinal polypeptide (VIP) and pancreatic polypeptide.</ce:para></ce:section></ce:section><ce:section id="s0360"><ce:section-title id="st0360">Presenting problems in gastrointestinal disease</ce:section-title><ce:section id="s0365"><ce:section-title id="st0365">Dysphagia</ce:section-title><ce:para id="p1145">Dysphagia is defined as difficulty in swallowing. It may coexist with heartburn or vomiting but should be distinguished from both globus sensation (in which anxious people feel a lump in the throat without organic cause) and odynophagia (pain during swallowing, usually from gastro-oesophageal reflux or candidiasis).</ce:para><ce:para id="p1150">Dysphagia can occur due to problems in the oropharynx or oesophagus (<ce:cross-ref id="crf0475" refid="f0100">Fig. 21.16</ce:cross-ref><ce:float-anchor refid="f0100"/>). Oropharyngeal disorders affect the initiation of swallowing at the pharynx and upper oesophageal sphincter. The patient has difficulty initiating swallowing and complains of choking, nasal regurgitation or tracheal aspiration. Drooling, dysarthria, hoarseness and cranial nerve or other neurological signs may be present. Oesophageal disorders cause dysphagia by obstructing the lumen or by affecting motility. Patients with oesophageal disease complain of food ‘sticking’ after swallowing, although the level at which this is felt correlates poorly with the true site of obstruction. Swallowing of liquids is normal until strictures become extreme.</ce:para><ce:section id="s0370"><ce:section id="s0375"><ce:section-title id="st0370">Investigations</ce:section-title><ce:para id="p1155">Dysphagia should always be investigated urgently. Endoscopy is the investigation of choice because it allows biopsy and dilatation of strictures. Even if the appearances are normal, biopsies should be taken to look for eosinophilic oesophagitis. If no abnormality is found, then barium swallow with videofluoroscopic swallowing assessment is indicated to detect major motility disorders. In some cases, oesophageal manometry is required. High-resolution manometry allows accurate classification of abnormalities. <ce:cross-ref id="crf0480" refid="f0100">Figure 21.16</ce:cross-ref> summarises a diagnostic approach to dysphagia and lists the major causes.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0380"><ce:section-title id="st0375">Dyspepsia</ce:section-title><ce:para id="p1160">Dyspepsia describes symptoms such as discomfort, bloating and nausea, which are thought to originate from the upper gastrointestinal tract. There are many causes (<ce:cross-ref id="crf0485" refid="b0085">Box 21.14</ce:cross-ref><ce:float-anchor refid="b0085"/>), including some arising outside the digestive system. Heartburn and other ‘reflux’ symptoms are separate entities and are considered elsewhere. Although symptoms often correlate poorly with the underlying diagnosis, a careful history is important to detect ‘alarm’ features requiring urgent investigation (<ce:cross-ref id="crf0490" refid="b0090">Box 21.15</ce:cross-ref><ce:float-anchor refid="b0090"/>) and to detect atypical symptoms that might be due to problems outside the gastrointestinal tract.</ce:para><ce:para id="p1290">Dyspepsia affects up to 80% of the population at some time in life and most patients have no serious underlying disease. People who present with new dyspepsia at an age of more than 55 years and younger patients unresponsive to empirical treatment require investigation to exclude serious disease. An algorithm for the investigation of dyspepsia is outlined in <ce:cross-ref id="crf0495" refid="f0105">Figure 21.17</ce:cross-ref><ce:float-anchor refid="f0105"/>.</ce:para></ce:section><ce:section id="s0385"><ce:section-title id="st0380">Heartburn and regurgitation</ce:section-title><ce:para id="p1295">Heartburn describes retrosternal, burning discomfort, often rising up into the chest and sometimes accompanied by regurgitation of acidic or bitter fluid into the throat. These symptoms often occur after meals, on lying down or with bending, straining or heavy lifting. They are classical symptoms of gastro-oesophageal reflux but up to 50% of patients present with other symptoms, such as chest pain, belching, halitosis, chronic cough or sore throats. In young patients with typical symptoms and a good response to dietary changes, antacids or acid suppression investigation is not required, but in patients over 55 years of age and those with alarm symptoms or atypical features urgent endoscopy is necessary.</ce:para></ce:section><ce:section id="s0390"><ce:section-title id="st0385">Vomiting</ce:section-title><ce:para id="p1300">Vomiting is a complex reflex involving both autonomic and somatic neural pathways. Synchronous contraction of the diaphragm, intercostal muscles and abdominal muscles raises intra-abdominal pressure and, combined with relaxation of the lower oesophageal sphincter, results in forcible ejection of gastric contents. It is important to distinguish true vomiting from regurgitation and to elicit whether the vomiting is acute or chronic (recurrent), as the underlying causes may differ. The major causes are shown in <ce:cross-ref id="crf0500" refid="f0110">Figure 21.18</ce:cross-ref><ce:float-anchor refid="f0110"/>.</ce:para></ce:section><ce:section id="s0395"><ce:section-title id="st0390">Gastrointestinal bleeding</ce:section-title><ce:section id="s0400"><ce:section-title id="st0395">Acute upper gastrointestinal haemorrhage</ce:section-title><ce:para id="p1305">This is the most common gastrointestinal emergency, accounting for 50–170 admissions to hospital per 100 000 of the population each year in the UK. The mortality of patients admitted to hospital is about 10% but there is some evidence that outcome is better when individuals are treated in specialised units. Risk scoring systems have been developed to stratify the risk of needing endoscopic therapy or of having a poor outcome (<ce:cross-ref id="crf0505" refid="b0095">Box 21.16</ce:cross-ref><ce:float-anchor refid="b0095"/>). The advantage of the Blatchford score is that it may be used before endoscopy to predict the need for intervention to treat bleeding. Low scores (2 or less) are associated with a very low risk of adverse outcome. The common causes are shown in <ce:cross-ref id="crf0510" refid="f0115">Figure 21.19</ce:cross-ref><ce:float-anchor refid="f0115"/>.</ce:para><ce:section id="s0405"><ce:section-title id="st0400">Clinical assessment</ce:section-title><ce:para id="p1315">Haematemesis is red with clots when bleeding is rapid and profuse, or black (‘coffee grounds’) when less severe. Syncope may occur and is caused by hypotension from intravascular volume depletion. Symptoms of anaemia suggest chronic bleeding. Melaena is the passage of black, tarry stools containing altered blood; it is usually caused by bleeding from the upper gastrointestinal tract, although haemorrhage from the right side of the colon is occasionally responsible. The characteristic colour and smell are the result of the action of digestive enzymes and of bacteria on haemoglobin. Severe acute upper gastrointestinal bleeding can sometimes cause maroon or bright red stool.</ce:para></ce:section><ce:section id="s0410"><ce:section-title id="st0405">Management</ce:section-title><ce:para id="p1320">The principles of emergency management of non-variceal bleeding are discussed in detail below. Management of variceal bleeding is discussed on <ce:intra-ref id="ii0040" xlink:href="pii:B978-0-7020-7028-0.00022-6#p2500">page 869</ce:intra-ref>.</ce:para><ce:section id="s0415"><ce:label>1</ce:label><ce:section-title id="st0410">Intravenous access</ce:section-title><ce:para id="p1325">The first step is to gain intravenous access using at least one large-bore cannula.</ce:para></ce:section><ce:section id="s0420"><ce:label>2</ce:label><ce:section-title id="st0415">Initial clinical assessment</ce:section-title><ce:para id="p1330"><ce:list id="ulist0255"><ce:list-item id="u0875"><ce:label>•</ce:label><ce:para id="p1335"><ce:italic>Define circulatory status</ce:italic>. Severe bleeding causes tachycardia, hypotension and oliguria. The patient is cold and sweating, and may be agitated.</ce:para></ce:list-item><ce:list-item id="u0880"><ce:label>•</ce:label><ce:para id="p1340"><ce:italic>Seek evidence of liver disease</ce:italic> (<ce:intra-ref id="ii0045" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0010">p. 846</ce:intra-ref>). Jaundice, cutaneous stigmata, hepatosplenomegaly and ascites may be present in decompensated cirrhosis.</ce:para></ce:list-item><ce:list-item id="u0885"><ce:label>•</ce:label><ce:para id="p1345"><ce:italic>Identify comorbidity</ce:italic>. The presence of cardiorespiratory, cerebrovascular or renal disease is important, both because these may be worsened by acute bleeding and because they increase the hazards of endoscopy and surgical operations.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1350">These factors can be combined using the Blatchford score (<ce:cross-ref id="crf0515" refid="b0095">Box 21.16</ce:cross-ref>), which can be calculated at the bedside. A score of 2 or less is associated with a good prognosis, while progressively higher scores are associated with poorer outcomes.</ce:para></ce:section><ce:section id="s0425"><ce:label>3</ce:label><ce:section-title id="st0420">Basic investigations</ce:section-title><ce:para id="p1355"><ce:list id="ulist0260"><ce:list-item id="u0890"><ce:label>•</ce:label><ce:para id="p1360"><ce:italic>Full blood count.</ce:italic> Chronic or subacute bleeding leads to anaemia but the haemoglobin concentration may be normal after sudden, major bleeding until haemodilution occurs. Thrombocytopenia may be a clue to the presence of hypersplenism in chronic liver disease.</ce:para></ce:list-item><ce:list-item id="u0895"><ce:label>•</ce:label><ce:para id="p1365"><ce:italic>Urea and electrolytes.</ce:italic> This test may show evidence of renal failure. The blood urea rises as the absorbed products of luminal blood are metabolised by the liver; an elevated blood urea with normal creatinine concentration implies severe bleeding.</ce:para></ce:list-item><ce:list-item id="u0900"><ce:label>•</ce:label><ce:para id="p1370"><ce:italic>Liver function tests.</ce:italic> These may show evidence of chronic liver disease.</ce:para></ce:list-item><ce:list-item id="u0905"><ce:label>•</ce:label><ce:para id="p1375"><ce:italic>Prothrombin time.</ce:italic> Check when there is a clinical suggestion of liver disease or patients are anticoagulated.</ce:para></ce:list-item><ce:list-item id="u0910"><ce:label>•</ce:label><ce:para id="p1380"><ce:italic>Cross-matching</ce:italic>. At least 2 units of blood should be cross-matched if a significant bleed is suspected.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0430"><ce:label>4</ce:label><ce:section-title id="st0425">Resuscitation</ce:section-title><ce:para id="p1385">Intravenous crystalloid fluids should be given to raise the blood pressure, and blood should be transfused when the patient is actively bleeding with low blood pressure and tachycardia. Comorbidities should be managed as appropriate. Patients with suspected chronic liver disease should receive broad-spectrum antibiotics.</ce:para></ce:section><ce:section id="s0435"><ce:label>5</ce:label><ce:section-title id="st0430">Oxygen</ce:section-title><ce:para id="p1390">This should be given to all patients in shock.</ce:para></ce:section><ce:section id="s0440"><ce:label>6</ce:label><ce:section-title id="st0435">Endoscopy</ce:section-title><ce:para id="p1395">This should be carried out after adequate resuscitation, ideally within 24 hours, and will yield a diagnosis in 80% of cases. Patients who are found to have major endoscopic stigmata of recent haemorrhage (<ce:cross-ref id="crf0520" refid="f0120">Fig. 21.20</ce:cross-ref><ce:float-anchor refid="f0120"/>) can be treated endoscopically using a thermal or mechanical modality, such as a ‘heater probe’ or endoscopic clips, combined with injection of dilute adrenaline (epinephrine) into the bleeding point (‘dual therapy’). A biologically inert haemostatic mineral powder (TC325, ‘haemospray’) can be used as rescue therapy when standard therapy fails. This may stop active bleeding and, combined with intravenous proton pump inhibitor (PPI) therapy, may prevent rebleeding, thus avoiding the need for surgery. Patients found to have bled from varices should be treated by band ligation (<ce:intra-ref id="ii0050" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0530">p. 870</ce:intra-ref>); if this fails, balloon tamponade is another option, while arrangements are made for a transjugular intrahepatic portosystemic shunt (TIPSS).</ce:para></ce:section><ce:section id="s0445"><ce:label>7</ce:label><ce:section-title id="st0440">Monitoring</ce:section-title><ce:para id="p1400">Patients should be closely observed, with hourly measurements of pulse, blood pressure and urine output.</ce:para></ce:section><ce:section id="s0450"><ce:label>8</ce:label><ce:section-title id="st0445">Surgery</ce:section-title><ce:para id="p1405">Surgery is indicated when endoscopic haemostasis fails to stop active bleeding and if rebleeding occurs on one occasion in an elderly or frail patient, or twice in a younger, fitter patient. If available, angiographic embolisation is an effective alternative to surgery in frail patients.</ce:para><ce:para id="p1410">The choice of operation depends on the site and diagnosis of the bleeding lesion. Duodenal ulcers are treated by under-running, with or without pyloroplasty. Under-running for gastric ulcers can also be carried out (a biopsy must be taken to exclude carcinoma). Local excision may be performed, but when neither is possible, partial gastrectomy is required.</ce:para></ce:section><ce:section id="s0455"><ce:label>9</ce:label><ce:section-title id="st0450">Eradication</ce:section-title><ce:para id="p1415">Following treatment for ulcer bleeding, all patients should avoid non-steroidal anti-inflammatory drugs (NSAIDs) and those who test positive for <ce:italic>H. pylori</ce:italic> infection should receive eradication therapy (<ce:cross-ref id="crf9050" refid="s1030">p. 800</ce:cross-ref>). Successful eradication should be confirmed by urea breath or faecal antigen testing.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0460"><ce:section-title id="st0455">Lower gastrointestinal bleeding</ce:section-title><ce:para id="p1420">This may be caused by haemorrhage from the colon, anal canal or small bowel. It is useful to distinguish those patients who present with profuse, acute bleeding from those who present with chronic or subacute bleeding of lesser severity (<ce:cross-ref id="crf0525" refid="b0100">Box 21.17</ce:cross-ref><ce:float-anchor refid="b0100"/>).</ce:para><ce:section id="s0465"><ce:section-title id="st0460">Severe acute lower gastrointestinal bleeding</ce:section-title><ce:para id="p1495">This presents with profuse red or maroon diarrhoea and with shock. Diverticular disease is the most common cause and is often due to erosion of an artery within the mouth of a diverticulum. Bleeding almost always stops spontaneously, but if it does not, the diseased segment of colon should be resected after confirmation of the site by angiography or colonoscopy. Angiodysplasia is a disease of the elderly, in which vascular malformations develop in the proximal colon. Bleeding can be acute and profuse; it usually stops spontaneously but commonly recurs. Diagnosis is often difficult. Colonoscopy may reveal characteristic vascular spots and, in the acute phase, visceral angiography can show bleeding into the intestinal lumen and an abnormal large, draining vein. In some patients, diagnosis is achieved only by laparotomy with on-table colonoscopy. The treatment of choice is endoscopic thermal ablation but resection of the affected bowel may be required if bleeding continues. Bowel ischaemia due to occlusion of the inferior mesenteric artery can present with abdominal colic and rectal bleeding. It should be considered in patients (particularly the elderly) who have evidence of generalised atherosclerosis. The diagnosis is made at colonoscopy. Resection is required only in the presence of peritonitis. Meckel's diverticulum with ectopic gastric epithelium may ulcerate and erode into a major artery. The diagnosis should be considered in children or adolescents who present with profuse or recurrent lower gastrointestinal bleeding. A Meckel's <ce:sup loc="post">99m</ce:sup>Tc-pertechnetate scan is sometimes positive but the diagnosis is commonly made only by laparotomy, at which time the diverticulum is excised.</ce:para></ce:section><ce:section id="s0470"><ce:section-title id="st0465">Subacute or chronic lower gastrointestinal bleeding</ce:section-title><ce:para id="p1500">This can occur at all ages and is usually due to haemorrhoids or anal fissure. Haemorrhoidal bleeding is bright red and occurs during or after defecation. Proctoscopy can be used to make the diagnosis, but subjects who have altered bowel habit and those who present over the age of 40 years should undergo colonoscopy to exclude coexisting colorectal cancer. Anal fissure should be suspected when fresh rectal bleeding and anal pain occur during defecation.</ce:para></ce:section></ce:section><ce:section id="s0475"><ce:section-title id="st0470">Major gastrointestinal bleeding of unknown cause</ce:section-title><ce:para id="p1505">In some patients who present with major gastrointestinal bleeding, upper endoscopy and colonoscopy fail to reveal a diagnosis. When severe life-threatening bleeding continues, urgent CT mesenteric angiography is indicated. This will usually identify the site if the bleeding rate exceeds 1 mL/min and then formal angiographic embolisation can often stop the bleeding. If angiography is negative or bleeding is less severe, push or double balloon enteroscopy can visualise the small intestine (<ce:cross-ref id="crf0530" refid="f0125">Fig. 21.21</ce:cross-ref><ce:float-anchor refid="f0125"/>) and treat the bleeding source. Wireless capsule endoscopy is often used to define a source of bleeding prior to enteroscopy. When all else fails, laparotomy with on-table endoscopy is indicated.</ce:para></ce:section><ce:section id="s0480"><ce:section-title id="st0475">Chronic occult gastrointestinal bleeding</ce:section-title><ce:para id="p1510">In this context, occult means that blood or its breakdown products are present in the stool but cannot be seen by the naked eye. Occult bleeding may reach 200 mL per day and cause iron deficiency anaemia. Any cause of gastrointestinal bleeding may be responsible but the most important is colorectal cancer, particularly carcinoma of the caecum, which may produce no gastrointestinal symptoms. In clinical practice, investigation of the upper and lower gastrointestinal tract should be considered whenever a patient presents with unexplained iron deficiency anaemia. Testing the stool for the presence of blood is unnecessary and should not influence whether or not the gastrointestinal tract is imaged because bleeding from tumours is often intermittent and a negative faecal occult blood (FOB) test does not exclude the diagnosis. The only value of FOB testing is as a means of population screening for colonic neoplasia in asymptomatic individuals (<ce:cross-ref id="crf9055" refid="s2015">p. 832</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0485"><ce:section-title id="st0480">Diarrhoea</ce:section-title><ce:para id="p1515">Diarrhoea is defined as the passage of more than 200 g of stool daily and measurement of stool volume is helpful in confirming this. The most severe symptom in many patients is urgency of defecation, and faecal incontinence is a common event in acute and chronic diarrhoeal illnesses.</ce:para><ce:section id="s0490"><ce:section-title id="st0485">Acute diarrhoea</ce:section-title><ce:para id="p1520">This is extremely common and is usually caused by faecal–oral transmission of bacteria or their toxins, viruses or parasites (<ce:intra-ref id="ii0065" xlink:href="pii:B978-0-7020-7028-0.00011-1#c00011">Ch. 11</ce:intra-ref>). Infective diarrhoea is usually short-lived and patients who present with a history of diarrhoea lasting more than 10 days rarely have an infective cause. A variety of drugs, including antibiotics, cytotoxic drugs, PPIs and NSAIDs, may be responsible.</ce:para></ce:section><ce:section id="s0495"><ce:section-title id="st0490">Chronic or relapsing diarrhoea</ce:section-title><ce:para id="p1525">The most common cause is irritable bowel syndrome (<ce:cross-ref id="crf9060" refid="s1840">p. 824</ce:cross-ref>), which can present with increased frequency of defecation and loose, watery or pellety stools. Diarrhoea rarely occurs at night and is most severe before and after breakfast. At other times, the patient is constipated and there are other characteristic symptoms of irritable bowel syndrome. The stool often contains mucus but never blood, and 24-hour stool volume is less than 200 g. Chronic diarrhoea can be categorised as being caused by disease of the colon or small bowel, or to malabsorption (<ce:cross-ref id="crf0535" refid="b0105">Box 21.18</ce:cross-ref><ce:float-anchor refid="b0105"/>). Clinical presentation, examination of the stool, routine blood tests and imaging reveal a diagnosis in many cases. A series of negative investigations usually implies irritable bowel syndrome but some patients clearly have organic disease and need more extensive investigations.</ce:para></ce:section></ce:section><ce:section id="s0500"><ce:section-title id="st0495">Malabsorption</ce:section-title><ce:para id="p1580">Diarrhoea and weight loss in patients with a normal diet are likely to be caused by malabsorption. The symptoms are diverse in nature and variable in severity. A few patients have apparently normal bowel habit but diarrhoea is usual and may be watery and voluminous. Bulky, pale and offensive stools that float in the toilet (steatorrhoea) signify fat malabsorption. Abdominal distension, borborygmi, cramps, weight loss and undigested food in the stool may be present. Some patients complain only of malaise and lethargy. In others, symptoms related to deficiencies of specific vitamins, trace elements and minerals may occur (<ce:cross-ref id="crf0540" refid="f0130">Fig. 21.22</ce:cross-ref><ce:float-anchor refid="f0130"/>).</ce:para><ce:section id="s0505"><ce:section id="s0510"><ce:section-title id="st0500">Pathophysiology</ce:section-title><ce:para id="p1585">Malabsorption results from abnormalities of the three processes that are essential to normal digestion:<ce:list id="ulist0300"><ce:list-item id="u1025"><ce:label>•</ce:label><ce:para id="p1590"><ce:italic>Intraluminal maldigestion</ce:italic> occurs when deficiency of bile or pancreatic enzymes results in inadequate solubilisation and hydrolysis of nutrients. Fat and protein malabsorption results. This may also occur with small bowel bacterial overgrowth.</ce:para></ce:list-item><ce:list-item id="u1030"><ce:label>•</ce:label><ce:para id="p1595"><ce:italic>Mucosal malabsorption</ce:italic> results from small bowel resection or conditions that damage the small intestinal epithelium, thereby diminishing the surface area for absorption and depleting brush border enzyme activity.</ce:para></ce:list-item><ce:list-item id="u1035"><ce:label>•</ce:label><ce:para id="p1600"><ce:italic>‘Post-mucosal’ lymphatic obstruction</ce:italic> prevents the uptake and transport of absorbed lipids into lymphatic vessels. Increased pressure in these vessels results in leakage into the intestinal lumen, leading to protein-losing enteropathy.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0515"><ce:section-title id="st0505">Investigations</ce:section-title><ce:para id="p1605">Investigations should be performed both to confirm the presence of malabsorption and to determine the underlying cause. Routine blood tests may show one or more of the abnormalities listed in <ce:cross-ref id="crf0545" refid="b0110">Box 21.19</ce:cross-ref><ce:float-anchor refid="b0110"/>. Tests to confirm fat and protein malabsorption should be performed, as described on <ce:cross-ref id="crf9065" refid="s0310">page 777</ce:cross-ref>. An approach to the investigation of malabsorption is shown in <ce:cross-ref id="crf0550" refid="f0135">Figure 21.23</ce:cross-ref><ce:float-anchor refid="f0135"/>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0530"><ce:section-title id="st0520">Weight loss</ce:section-title><ce:para id="p1660">Weight loss may be physiological, due to dieting, exercise, starvation, or the decreased nutritional intake that accompanies old age. Weight loss of more than 3 kg over 6 months is significant and often indicates the presence of an underlying disease. Hospital and general practice weight records may be valuable in confirming that weight loss has occurred, as may reweighing patients at intervals; sometimes weight is regained or stabilises in those with no obvious cause. Pathological weight loss can be due to psychiatric illness, systemic disease, gastrointestinal causes or advanced disease of many organ systems (<ce:cross-ref id="crf0555" refid="f0140">Fig. 21.24</ce:cross-ref><ce:float-anchor refid="f0140"/>).</ce:para><ce:section id="s0535"><ce:section id="s0540"><ce:section id="s0545"><ce:section-title id="st0525">Physiological causes</ce:section-title><ce:para id="p1665">Weight loss can occur in the absence of serious disease in healthy individuals who have changes in physical activity or social circumstances. It may be difficult to be sure of this diagnosis in older patients, when the dietary history may be unreliable, and professional help from a dietitian is often valuable under these circumstances.</ce:para></ce:section><ce:section id="s0550"><ce:section-title id="st0530">Psychiatric illness</ce:section-title><ce:para id="p1670">Features of anorexia nervosa (<ce:intra-ref id="ii0080" xlink:href="pii:B978-0-7020-7028-0.00028-7#s1085">p. 1203</ce:intra-ref>), bulimia (<ce:intra-ref id="ii0085" xlink:href="pii:B978-0-7020-7028-0.00028-7#p2870">p. 1204</ce:intra-ref>) and affective disorders (<ce:intra-ref id="ii0090" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0785">p. 1198</ce:intra-ref>) may be apparent only after formal psychiatric input. Alcoholic patients lose weight as a consequence of self-neglect and poor dietary intake. Depression may cause weight loss.</ce:para></ce:section><ce:section id="s0555"><ce:section-title id="st0535">Systemic disease</ce:section-title><ce:para id="p1675">Chronic infections, including tuberculosis (<ce:intra-ref id="ii0095" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1030">p. 588</ce:intra-ref>), recurrent urinary or chest infections, and a range of parasitic and protozoan infections (<ce:intra-ref id="ii0100" xlink:href="pii:B978-0-7020-7028-0.00011-1#c00011">Ch. 11</ce:intra-ref>), should be considered. A history of foreign travel, high-risk activities and specific features, such as fever, night sweats, rigors, productive cough and dysuria, must be sought. Promiscuous sexual activity and drug misuse suggest HIV-related illness (<ce:intra-ref id="ii0105" xlink:href="pii:B978-0-7020-7028-0.00012-3#c00012">Ch. 12</ce:intra-ref>). Weight loss is a late feature of disseminated malignancy, but by the time the patient presents, other features of cancer are often present. Chronic inflammatory diseases, such as rheumatoid arthritis (<ce:intra-ref id="ii0110" xlink:href="pii:B978-0-7020-7028-0.00024-X#s0995">p. 1021</ce:intra-ref>) and polymyalgia rheumatica (<ce:intra-ref id="ii0115" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1555">p. 1042</ce:intra-ref>), are often associated with weight loss.</ce:para></ce:section><ce:section id="s0560"><ce:section-title id="st0540">Gastrointestinal disease</ce:section-title><ce:para id="p1680">Almost any disease of the gastrointestinal tract can cause weight loss. Dysphagia and gastric outflow obstruction (<ce:cross-ref id="crf9070" refid="s0335">pp. 778 and 801</ce:cross-ref>) cause weight loss by reducing food intake. Malignancy at any site may cause weight loss by mechanical obstruction, anorexia or cytokine-mediated systemic effects. Malabsorption from pancreatic diseases (<ce:cross-ref id="crf9075" refid="s2175">p. 837</ce:cross-ref>) or small bowel causes may lead to profound weight loss with specific nutritional deficiencies (<ce:intra-ref id="ii0130" xlink:href="pii:B978-0-7020-7028-0.00019-6#p0840">p. 704</ce:intra-ref>). Inflammatory diseases, such as Crohn's disease or ulcerative colitis (<ce:cross-ref id="crf9080" refid="s1565">p. 813</ce:cross-ref>), cause anorexia, fear of eating and loss of protein, blood and nutrients from the gut.</ce:para></ce:section><ce:section id="s0565"><ce:section-title id="st0545">Metabolic disorders and miscellaneous causes</ce:section-title><ce:para id="p1685">Weight loss may occur in association with metabolic disorders, as well as end-stage respiratory and cardiac disease.</ce:para></ce:section></ce:section><ce:section id="s0570"><ce:section-title id="st0550">Investigations</ce:section-title><ce:para id="p1690">In cases where the cause of weight loss is not obvious after thorough history taking and physical examination, or where an existing condition is considered unlikely, the following investigations are indicated: urinalysis for glucose, protein and blood; blood tests, including liver function tests, random blood glucose and thyroid function tests; CRP and ESR (may be raised in unsuspected infections, such as tuberculosis, connective tissue disorders and malignancy); and faecal calprotectin. Sometimes invasive tests, such as bone marrow aspiration or liver biopsy, may be necessary to identify conditions like cryptic miliary tuberculosis (<ce:intra-ref id="ii0140" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1030">p. 588</ce:intra-ref>). Rarely, abdominal and pelvic imaging by CT may be required, but before embarking on invasive or very costly investigations it is always worth revisiting the patient's history and reweighing at intervals.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0575"><ce:section-title id="st0555">Constipation</ce:section-title><ce:para id="p1695">Constipation is defined as infrequent passage of hard stools. Patients may also complain of straining, a sensation of incomplete evacuation and either perianal or abdominal discomfort. Constipation may occur in many gastrointestinal and other medical disorders (<ce:cross-ref id="crf0560" refid="b0115">Box 21.20</ce:cross-ref><ce:float-anchor refid="b0115"/>).</ce:para><ce:section id="s0580"><ce:section id="s0585"><ce:section-title id="st0560">Clinical assessment and management</ce:section-title><ce:para id="p1830">The onset, duration and characteristics are important; for example, a neonatal onset suggests Hirschsprung's disease, while a recent change in bowel activity in middle age should raise the suspicion of an organic disorder, such as colonic carcinoma. The presence of rectal bleeding, pain and weight loss is important, as are excessive straining, symptoms suggestive of irritable bowel syndrome, a history of childhood constipation and emotional distress.</ce:para><ce:para id="p1835">Careful examination contributes more to the diagnosis than extensive investigation. A search should be made for general medical disorders, as well as signs of intestinal obstruction. Neurological disorders, especially spinal cord lesions, should be sought. Perineal inspection and rectal examination are essential and may reveal abnormalities of the pelvic floor (abnormal descent, impaired sensation), anal canal or rectum (masses, faecal impaction, prolapse).</ce:para><ce:para id="p1840">It is neither possible nor appropriate to investigate every person with constipation. Most respond to increased fluid intake, dietary fibre supplementation, exercise and the judicious use of laxatives. Middle-aged or elderly patients with a short history or worrying symptoms (rectal bleeding, pain or weight loss) must be investigated promptly, by either barium enema or colonoscopy. For those with simple constipation, investigation will usually proceed along the lines described below.</ce:para><ce:section id="s0590"><ce:section-title id="st0565">Initial visit</ce:section-title><ce:para id="p1845">Digital rectal examination, proctoscopy and sigmoidoscopy (to detect anorectal disease), routine biochemistry, including serum calcium and thyroid function tests, and a full blood count should be carried out. If these are normal, a 1-month trial of dietary fibre and/or laxatives is justified.</ce:para></ce:section><ce:section id="s0595"><ce:section-title id="st0570">Next visit</ce:section-title><ce:para id="p1850">If symptoms persist, then examination of the colon by barium enema or CT colonography is indicated to look for structural disease.</ce:para></ce:section><ce:section id="s0600"><ce:section-title id="st0575">Further investigation</ce:section-title><ce:para id="p1855">If no cause is found and disabling symptoms are present, then specialist referral for investigation of possible dysmotility may be necessary. The problem may be one of infrequent desire to defecate (‘slow transit’) or else may result from neuromuscular incoordination and excessive straining (‘functional obstructive defecation’, <ce:cross-ref id="crf9085" refid="s1185">p. 803</ce:cross-ref>). Intestinal marker studies, anorectal manometry, electrophysiological studies and magnetic resonance proctography can all be used to define the problem.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0605"><ce:section-title id="st0580">Abdominal pain</ce:section-title><ce:para id="p1860">There are four types of abdominal pain:<ce:list id="ulist0390"><ce:list-item id="u1205"><ce:label>•</ce:label><ce:para id="p1865"><ce:italic>Visceral</ce:italic>. Gut organs are insensitive to stimuli such as burning and cutting but are sensitive to distension, contraction, twisting and stretching. Pain from unpaired structures is usually, but not always, felt in the midline.</ce:para></ce:list-item><ce:list-item id="u1210"><ce:label>•</ce:label><ce:para id="p1870"><ce:italic>Parietal</ce:italic>. The parietal peritoneum is innervated by somatic nerves and its involvement by inflammation, infection or neoplasia causes sharp, well-localised and lateralised pain.</ce:para></ce:list-item><ce:list-item id="u1215"><ce:label>•</ce:label><ce:para id="p1875"><ce:italic>Referred pain</ce:italic>. Gallbladder pain, for example, may be referred to the back or shoulder tip.</ce:para></ce:list-item><ce:list-item id="u1220"><ce:label>•</ce:label><ce:para id="p1880"><ce:italic>Psychogenic</ce:italic>. Cultural, emotional and psychosocial factors influence everyone's experience of pain. In some patients, no organic cause can be found despite investigation, and psychogenic causes (depression or somatisation disorder) may be responsible (<ce:intra-ref id="ii0150" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0785">pp. 1198 and 1202</ce:intra-ref>).</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0610"><ce:section-title id="st0585">The acute abdomen</ce:section-title><ce:para id="p1885">This accounts for approximately 50% of all urgent admissions to general surgical units. The acute abdomen is a consequence of one or more pathological processes (<ce:cross-ref id="crf0565" refid="b0120">Box 21.21</ce:cross-ref><ce:float-anchor refid="b0120"/>):<ce:list id="ulist0430"><ce:list-item id="u1300"><ce:label>•</ce:label><ce:para id="p1970"><ce:italic>Inflammation</ce:italic>. Pain develops gradually, usually over several hours. It is initially rather diffuse until the parietal peritoneum is involved, when it becomes localised. Movement exacerbates the pain; abdominal rigidity and guarding occur.</ce:para></ce:list-item><ce:list-item id="u1305"><ce:label>•</ce:label><ce:para id="p1975"><ce:italic>Perforation</ce:italic>. When a viscus perforates, pain starts abruptly; it is severe and leads to generalised peritonitis.</ce:para></ce:list-item><ce:list-item id="u1310"><ce:label>•</ce:label><ce:para id="p1980"><ce:italic>Obstruction</ce:italic>. Pain is colicky, with spasms that cause the patient to writhe around and double up. Colicky pain that does not disappear between spasms suggests complicating inflammation.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0615"><ce:section-title id="st0590">Initial clinical assessment</ce:section-title><ce:para id="p1985">If there are signs of peritonitis (guarding and rebound tenderness with rigidity), the patient should be resuscitated with oxygen, intravenous fluids and antibiotics. In other circumstances, further investigations are required (<ce:cross-ref id="crf0575" refid="f0145">Fig. 21.25</ce:cross-ref><ce:float-anchor refid="f0145"/>).</ce:para></ce:section><ce:section id="s0620"><ce:section-title id="st0595">Investigations</ce:section-title><ce:para id="p1990">Patients should have a full blood count, urea and electrolytes, glucose and amylase taken to look for evidence of dehydration, leucocytosis and pancreatitis. Urinalysis is useful in suspected renal colic and pyelonephritis. An erect chest X-ray may show air under the diaphragm, suggestive of perforation, and a plain abdominal film may show evidence of obstruction or ileus (see <ce:cross-ref id="crf0580" refid="f0075">Fig. 21.11</ce:cross-ref>). An abdominal ultrasound may help if gallstones or renal stones are suspected. Ultrasonography is also useful in the detection of free fluid and any possible intra-abdominal abscess. Contrast studies, by either mouth or anus, are useful in the further evaluation of intestinal obstruction, and essential in the differentiation of pseudo-obstruction from mechanical large-bowel obstruction. Other investigations commonly used include CT (seeking evidence of pancreatitis, retroperitoneal collections or masses, including an aortic aneurysm or renal calculi) and angiography (mesenteric ischaemia).</ce:para><ce:para id="p1995">Diagnostic laparotomy should be considered when the diagnosis has not been revealed by other investigations. All patients must be carefully and regularly re-assessed (every 2–4 hours) so that any change in condition that might alter both the suspected diagnosis and clinical decision can be observed and acted on early.<ce:display><ce:textbox id="b0125" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0280" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000214/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1325" role="short">Image 80</ce:alt-text></ce:inline-figure> 21.22</ce:label><ce:alt-text id="atte1330" role="short">21.22</ce:alt-text><ce:textbox-head><ce:title id="tit0130">Acute abdominal pain in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2000"><ce:list id="ulist0435"><ce:list-item id="u1315"><ce:label>•</ce:label><ce:para id="p2005"><ce:bold>Presentation</ce:bold>: severity and localisation may blunt with age. Presentation may be atypical, e.g. with delirium, collapse and/or immobility.</ce:para></ce:list-item><ce:list-item id="u1320"><ce:label>•</ce:label><ce:para id="p2010"><ce:bold>Cancer</ce:bold>: a more common cause of acute pain in those over 70 years of age than in those under 50 years. Older people with vague abdominal symptoms should therefore be carefully assessed.</ce:para></ce:list-item><ce:list-item id="u1325"><ce:label>•</ce:label><ce:para id="p2015"><ce:bold>Non-specific symptoms</ce:bold>: intra-abdominal inflammatory conditions, such as diverticulitis, may present with non-specific symptoms, such as delirium or anorexia and relatively little abdominal tenderness. The reasons for this are not clear but may stem from altered sensory perception.</ce:para></ce:list-item><ce:list-item id="u1330"><ce:label>•</ce:label><ce:para id="p2020"><ce:bold>Outcome of abdominal surgery</ce:bold>: determined by how frail the patient is and whether surgery is elective or emergency, rather than by chronological age.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section><ce:section id="s0625"><ce:section-title id="st0600">Management</ce:section-title><ce:para id="p2025">The general approach is to close perforations, treat inflammatory conditions with antibiotics or resection, and relieve obstructions. The speed of intervention and the necessity for surgery depend on the organ that is involved and on a number of other factors, of which the presence or absence of peritonitis is the most important. A treatment summary of some of the more common surgical conditions follows.</ce:para><ce:section id="s0630"><ce:section-title id="st0605">Acute appendicitis</ce:section-title><ce:para id="p2030">This should be treated by early surgery, since there is a risk of perforation and recurrent attacks with non-operative treatment. The appendix can be removed through a conventional right iliac fossa skin crease incision or by laparoscopic techniques.</ce:para></ce:section><ce:section id="s0635"><ce:section-title id="st0610">Acute cholecystitis</ce:section-title><ce:para id="p2035">This can be successfully treated non-operatively but the high risk of recurrent attacks and the low morbidity of surgery have made early laparoscopic cholecystectomy the treatment of choice.</ce:para></ce:section><ce:section id="s0640"><ce:section-title id="st0615">Acute diverticulitis</ce:section-title><ce:para id="p2040">Conservative therapy is standard but if perforation has occurred, resection is advisable. Depending on peritoneal contamination and the state of the patient, primary anastomosis is preferable to a Hartmann's procedure (oversew of rectal stump and end-colostomy).</ce:para></ce:section><ce:section id="s0645"><ce:section-title id="st0620">Small bowel obstruction</ce:section-title><ce:para id="p2045">If the cause is obvious and surgery inevitable (such as with a strangulated hernia), an early operation is appropriate. If the suspected cause is adhesions from previous surgery, only those patients who do not resolve within the first 48 hours or who develop signs of strangulation (colicky pain becoming constant, peritonitis, tachycardia, fever, leucocytosis) should have surgery.</ce:para></ce:section><ce:section id="s0650"><ce:section-title id="st0625">Large bowel obstruction</ce:section-title><ce:para id="p2050">Pseudo-obstruction should be treated non-operatively. Some patients benefit from colonoscopic decompression but mechanical obstruction merits resection, usually with a primary anastomosis. Differentiation between the two is made by water-soluble contrast enema.</ce:para></ce:section><ce:section id="s0655"><ce:section-title id="st0630">Perforated peptic ulcer</ce:section-title><ce:para id="p2055">Surgical closure of the perforation is standard practice but some patients without generalised peritonitis can be treated non-operatively once a water-soluble contrast meal has confirmed spontaneous sealing of the perforation. Adequate and aggressive resuscitation with intravenous fluids, antibiotics and analgesia is mandatory before surgery.</ce:para><ce:para id="p2060">For a more detailed discussion of acute abdominal pain, the reader is referred to the sister volume of this text, <ce:italic>Principles and Practice of Surgery</ce:italic>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0660"><ce:section-title id="st0635">Chronic or recurrent abdominal pain</ce:section-title><ce:para id="p2065">It is essential to take a detailed history, paying particular attention to features of the pain and any associated symptoms (<ce:cross-ref id="crf0585" refid="b0130">Boxes 21.23</ce:cross-ref><ce:float-anchor refid="b0130"/> and <ce:cross-ref id="crf0590" refid="b0135">21.24</ce:cross-ref><ce:float-anchor refid="b0135"/>).</ce:para><ce:para id="p2225">Note should be made of the patient's general demeanour, mood and emotional state, signs of weight loss, fever, jaundice or anaemia. If a thorough abdominal and rectal examination is normal, a careful search should be made for evidence of disease affecting other structures, particularly the vertebral column, spinal cord, lungs and cardiovascular system.</ce:para><ce:para id="p2230">Investigations will depend on the clinical features elicited during the history and examination:<ce:list id="ulist0515"><ce:list-item id="u1480"><ce:label>•</ce:label><ce:para id="p2235">Endoscopy and ultrasound are indicated for epigastric pain, and for dyspepsia and symptoms suggestive of gallbladder disease.</ce:para></ce:list-item><ce:list-item id="u1485"><ce:label>•</ce:label><ce:para id="p2240">Colonoscopy is indicated for patients with altered bowel habit, rectal bleeding or features of obstruction suggesting colonic disease.</ce:para></ce:list-item><ce:list-item id="u1490"><ce:label>•</ce:label><ce:para id="p2245">CT or MR angiography should be considered when pain is provoked by food in a patient with widespread atherosclerosis, since this may indicate mesenteric ischaemia.</ce:para></ce:list-item><ce:list-item id="u1495"><ce:label>•</ce:label><ce:para id="p2250">Persistent symptoms require exclusion of colonic or small bowel disease. However, young patients with pain relieved by defecation, bloating and alternating bowel habit are likely to have irritable bowel syndrome (<ce:cross-ref id="crf9090" refid="s1840">p. 824</ce:cross-ref>). Simple investigations (blood tests, faecal calprotectin and sigmoidoscopy) are sufficient in the absence of rectal bleeding, weight loss and abnormal physical findings.</ce:para></ce:list-item><ce:list-item id="u1500"><ce:label>•</ce:label><ce:para id="p2255">Ultrasound, CT and faecal elastase are required for patients with upper abdominal pain radiating to the back. A history of alcohol misuse, weight loss and diarrhoea suggests chronic pancreatitis or pancreatic cancer.</ce:para></ce:list-item><ce:list-item id="u1505"><ce:label>•</ce:label><ce:para id="p2260">Recurrent attacks of pain in the loins radiating to the flanks with urinary symptoms should prompt investigation for renal or ureteric stones by abdominal X-ray, ultrasound and computed tomography of the kidneys, ureters and bladder (CT KUB).</ce:para></ce:list-item><ce:list-item id="u1510"><ce:label>•</ce:label><ce:para id="p2265">A past history of psychiatric disturbance, repeated negative investigations or vague symptoms that do not fit any disease or organ pattern suggest a psychological origin for the pain. Careful review of case notes and previous investigations, along with open and honest discussion with the patient, reduces the need for further cycles of unnecessary and invasive tests. Care must always be taken, however, not to miss rare pathology, such as acute intermittent porphyria (<ce:intra-ref id="ii0160" xlink:href="pii:B978-0-7020-7028-0.00014-7#s0735">p. 378</ce:intra-ref>), or atypical presentations of common diseases.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0665"><ce:section-title id="st0640">Constant abdominal pain</ce:section-title><ce:para id="p2270">Patients with chronic pain that is constant or nearly always present usually have features to suggest the underlying diagnosis. No cause will be found in a minority, despite thorough investigation, leading to the diagnosis of ‘chronic functional abdominal pain’. In these patients, there appears to be abnormal CNS processing of normal visceral afferent sensory input and psychosocial factors are often operative (<ce:intra-ref id="ii0165" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0325">p. 1186</ce:intra-ref>); the most important tasks are to provide symptom control, if not relief, and to minimise the effects of the pain on social, personal and occupational life. Patients are best managed in specialised pain clinics where, in addition to psychological support, appropriate use of drugs, including tricyclic antidepressants, gabapentin or pregabalin, ketamine and opioids, may be necessary.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0670"><ce:section-title id="st0645">Diseases of the mouth and salivary glands</ce:section-title><ce:section id="s0675"><ce:section id="s0680"><ce:section-title id="st0650">Aphthous ulceration</ce:section-title><ce:para id="p2275">Aphthous ulcers are superficial and painful; they occur in any part of the mouth. Recurrent ulcers afflict up to 30% of the population and are particularly common in women prior to menstruation. The cause is unknown, but in severe cases other causes of oral ulceration must be considered (<ce:cross-ref id="crf0595" refid="b0140">Box 21.25</ce:cross-ref><ce:float-anchor refid="b0140"/>). Biopsy is occasionally necessary for diagnosis.</ce:para><ce:para id="p2385">Management is with topical glucocorticoids (such as 0.1% triamcinolone in Orabase) or choline salicylate (8.7%) gel. Symptomatic relief is achieved using local anaesthetic mouthwashes. Rarely, patients with very severe, recurrent aphthous ulcers may need oral glucocorticoids.</ce:para></ce:section><ce:section id="s0685"><ce:section-title id="st0655">Oral cancer</ce:section-title><ce:para id="p2390">Squamous carcinoma of the oral cavity is common worldwide and the incidence has increased by 25% in the last decade in the UK. The mortality rate is around 50%, largely as a result of late diagnosis. Poor diet, alcohol excess and smoking or tobacco chewing are the traditional risk factors but high-risk, oncogenic strains of human papillomavirus (HPV-16 and HPV-18) have been identified as being responsible for much of the recent increase in incidence, especially in cases affecting the base of tongue, soft palate and tonsils. In parts of Asia, the disease is common among people who chew areca nuts wrapped in leaves of the betel plant (‘betel nuts’).</ce:para><ce:para id="p2395">Oral cancer may present in many ways (<ce:cross-ref id="crf0600" refid="b0145">Box 21.26</ce:cross-ref><ce:float-anchor refid="b0145"/>) and a high index of suspicion is required. All possible sources of local trauma or infection should be treated in patients with suspicious lesions and they should be reviewed after 2 weeks, with biopsy if the lesion persists. Small cancers can be resected but extensive surgery, with neck dissection to remove involved lymph nodes, may be necessary. Some patients can be treated with radical radiotherapy alone, and sometimes radiotherapy is also given after surgery to treat microscopic residual disease. Some tumours may be amenable to photodynamic therapy (PDT), avoiding the need for surgery.</ce:para></ce:section><ce:section id="s0690"><ce:section-title id="st0660">Candidiasis</ce:section-title><ce:para id="p2440">The yeast <ce:italic>Candida albicans</ce:italic> is a normal mouth commensal but it may proliferate to cause thrush. This occurs in babies, debilitated patients, people receiving glucocorticoid or antibiotic therapy, individuals with diabetes and immunosuppressed patients, especially those receiving cytotoxic therapy and those with HIV infection. White patches are seen on the tongue and buccal mucosa. Odynophagia or dysphagia suggests pharyngeal and oesophageal candidiasis. A clinical diagnosis is sufficient to instigate therapy, although brushings or biopsies can be obtained for mycological examination. Oral thrush is treated using nystatin or amphotericin suspensions or lozenges. Resistant cases or immunosuppressed patients may require oral fluconazole.</ce:para></ce:section><ce:section id="s0695"><ce:section-title id="st0665">Parotitis</ce:section-title><ce:para id="p2445">Parotitis is caused by viral or bacterial infection. Mumps causes a self-limiting acute parotitis (<ce:intra-ref id="ii0190" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0650">p. 240</ce:intra-ref>). Bacterial parotitis usually occurs as a complication of major surgery. It is a consequence of dehydration and poor oral hygiene, and can be avoided by good post-operative care. Patients present with painful parotid swelling and this can be complicated by abscess formation. Broad-spectrum antibiotics are required, while surgical drainage is necessary for abscesses. Other causes of salivary gland enlargement are listed in <ce:cross-ref id="crf0605" refid="b0150">Box 21.27</ce:cross-ref><ce:float-anchor refid="b0150"/>.<ce:display><ce:textbox id="b0155" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0310" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000214/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1335" role="short">Image 81</ce:alt-text></ce:inline-figure> 21.28</ce:label><ce:alt-text id="atte1340" role="short">21.28</ce:alt-text><ce:textbox-head><ce:title id="tit0160">Oral health in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2505"><ce:list id="ulist0610"><ce:list-item id="u1695"><ce:label>•</ce:label><ce:para id="p2510"><ce:bold>Dry mouth</ce:bold>: affects around 40% of healthy older people.</ce:para></ce:list-item><ce:list-item id="u1700"><ce:label>•</ce:label><ce:para id="p2515"><ce:bold>Gustatory and olfactory sensation</ce:bold>: declines and chewing power is diminished.</ce:para></ce:list-item><ce:list-item id="u1705"><ce:label>•</ce:label><ce:para id="p2520"><ce:bold>Salivation</ce:bold>: baseline salivary flow falls but stimulated salivation is unchanged.</ce:para></ce:list-item><ce:list-item id="u1710"><ce:label>•</ce:label><ce:para id="p2525"><ce:bold>Root caries and periodontal disease</ce:bold>: common partly because oral hygiene deteriorates with increasing frailty.</ce:para></ce:list-item><ce:list-item id="u1715"><ce:label>•</ce:label><ce:para id="p2530"><ce:bold>Bacteraemia and sepsis</ce:bold>: may complicate Gram-negative anaerobic infection in the periodontal pockets of the very frail.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section></ce:section></ce:section><ce:section id="s0700"><ce:section-title id="st0670">Diseases of the oesophagus</ce:section-title><ce:section id="s0705"><ce:section-title id="st0675">Gastro-oesophageal reflux disease</ce:section-title><ce:para id="p2535">Gastro-oesophageal reflux resulting in heartburn affects approximately 30% of the general population.</ce:para><ce:section id="s0710"><ce:section id="s0715"><ce:section-title id="st0680">Pathophysiology</ce:section-title><ce:para id="p2540">Occasional episodes of gastro-oesophageal reflux are common in healthy individuals. Reflux is normally followed by oesophageal peristaltic waves that efficiently clear the gullet, alkaline saliva neutralises residual acid and symptoms do not occur. Gastro-oesophageal reflux disease develops when the oesophageal mucosa is exposed to gastroduodenal contents for prolonged periods of time, resulting in symptoms and, in a proportion of cases, oesophagitis. Several factors are known to be involved in the development of gastro-oesophageal reflux disease and these are shown in <ce:cross-ref id="crf0610" refid="f0150">Figure 21.26</ce:cross-ref><ce:float-anchor refid="f0150"/>.</ce:para><ce:section id="s0720"><ce:section-title id="st0685">Abnormalities of the lower oesophageal sphincter</ce:section-title><ce:para id="p2545">The lower oesophageal sphincter is tonically contracted under normal circumstances, relaxing only during swallowing (<ce:cross-ref id="crf9095" refid="s0015">p. 766</ce:cross-ref>).</ce:para><ce:para id="p2550">Some patients with gastro-oesophageal reflux disease have reduced lower oesophageal sphincter tone, permitting reflux when intra-abdominal pressure rises. In others, basal sphincter tone is normal but reflux occurs in response to frequent episodes of inappropriate sphincter relaxation.</ce:para></ce:section><ce:section id="s0725"><ce:section-title id="st0690">Hiatus hernia</ce:section-title><ce:para id="p2555">Hiatus hernia (<ce:cross-ref id="crf0615" refid="b0160">Box 21.29</ce:cross-ref><ce:float-anchor refid="b0160"/> and <ce:cross-ref id="crf0620" refid="f0155">Fig. 21.27</ce:cross-ref><ce:float-anchor refid="f0155"/>) causes reflux because the pressure gradient is lost between the abdominal and thoracic cavities, which normally pinches the hiatus. In addition, the oblique angle between the cardia and oesophagus disappears. Many patients who have large hiatus hernias develop reflux symptoms but the relationship between the presence of a hernia and symptoms is poor. Hiatus hernia is very common in individuals who have no symptoms, and some symptomatic patients have only a very small or no hernia. Nevertheless, almost all patients who develop oesophagitis, Barrett's oesophagus or peptic strictures have a hiatus hernia.</ce:para></ce:section><ce:section id="s0730"><ce:section-title id="st0695">Delayed oesophageal clearance</ce:section-title><ce:para id="p2590">Defective oesophageal peristaltic activity is commonly found in patients who have oesophagitis. It is a primary abnormality, since it persists after oesophagitis has been healed by acid-suppressing drug therapy. Poor oesophageal clearance leads to increased acid exposure time.</ce:para></ce:section><ce:section id="s0735"><ce:section-title id="st0700">Gastric contents</ce:section-title><ce:para id="p2595">Gastric acid is the most important oesophageal irritant and there is a close relationship between acid exposure time and symptoms. Pepsin and bile also contribute to mucosal injury.</ce:para></ce:section><ce:section id="s0740"><ce:section-title id="st0705">Defective gastric emptying</ce:section-title><ce:para id="p2600">Gastric emptying is delayed in patients with gastro-oesophageal reflux disease. The reason is unknown.</ce:para></ce:section><ce:section id="s0745"><ce:section-title id="st0710">Increased intra-abdominal pressure</ce:section-title><ce:para id="p2605">Pregnancy and obesity are established predisposing causes. Weight loss may improve symptoms.</ce:para></ce:section><ce:section id="s0750"><ce:section-title id="st0715">Dietary and environmental factors</ce:section-title><ce:para id="p2610">Dietary fat, chocolate, alcohol, tea and coffee relax the lower oesophageal sphincter and may provoke symptoms. The foods that trigger symptoms vary widely between affected individuals.</ce:para></ce:section><ce:section id="s0755"><ce:section-title id="st0720">Patient factors</ce:section-title><ce:para id="p2615">Visceral sensitivity and patient vigilance play a role in determining symptom severity and consulting behaviour in individual patients.</ce:para></ce:section></ce:section><ce:section id="s0760"><ce:section-title id="st0725">Clinical features</ce:section-title><ce:para id="p2620">The major symptoms are heartburn and regurgitation, often provoked by bending, straining or lying down. ‘Waterbrash’, which is salivation due to reflex salivary gland stimulation as acid enters the gullet, is often present. The patient is often overweight. Some patients are woken at night by choking as refluxed fluid irritates the larynx. Others develop odynophagia or dysphagia. A variety of other features have been described, such as atypical chest pain that may be severe and can mimic angina; it may be due to reflux-induced oesophageal spasm. Others include hoarseness (‘acid laryngitis’), recurrent chest infections, chronic cough and asthma. The true relationship of these features to gastro-oesophageal reflux disease remains unclear.</ce:para></ce:section><ce:section id="s0765"><ce:section-title id="st0730">Complications</ce:section-title><ce:section id="s0770"><ce:section-title id="st0735">Oesophagitis</ce:section-title><ce:para id="p2625">A range of endoscopic findings is recognised, from mild redness to severe bleeding ulceration with stricture formation, although appearances may be completely normal (<ce:cross-ref id="crf0625" refid="f0160">Fig. 21.28</ce:cross-ref><ce:float-anchor refid="f0160"/>). There is a poor correlation between symptoms and histological and endoscopic findings.</ce:para></ce:section><ce:section id="s0775"><ce:section-title id="st0740">Barrett's oesophagus</ce:section-title><ce:para id="p2630">Barrett's oesophagus is a pre-malignant condition, in which the normal squamous lining of the lower oesophagus is replaced by columnar mucosa (columnar lined oesophagus; CLO) that may contain areas of intestinal metaplasia (<ce:cross-ref id="crf0630" refid="f0165">Fig. 21.29</ce:cross-ref><ce:float-anchor refid="f0165"/>). It is an adaptive response to chronic gastro-oesophageal reflux and is found in 10% of patients undergoing gastroscopy for reflux symptoms. Community-based epidemiological studies suggest that the true prevalence may be up to 1.5–5% of the population, as the condition is often asymptomatic until discovered when the patient presents with oesophageal cancer. The relative risk of oesophageal cancer is increased 40–120-fold but the absolute risk is low (0.1–0.5% per year). The epidemiology and aetiology of Barrett's oesophagus are poorly understood. The prevalence is increasing, and it is more common in men (especially white), the obese and those over 50 years of age. It is weakly associated with smoking but not alcohol intake. The risk of cancer seems to relate to the severity and duration of reflux rather than the presence of Barrett's oesophagus per se, and it has been suggested that duodenogastro-oesophageal reflux of bile, pancreatic enzymes and pepsin, as well as gastric acid, may be important in the pathogenesis. The molecular events underlying progression of Barrett's oesophagus to dysplasia and cancer are incompletely understood but inactivation of the tumour suppression protein p16 by loss of heterozygosity or promoter hypermethylation is a key event, followed by somatic inactivation of <ce:italic>TP53</ce:italic>, which promotes aneuploidy and tumour progression. Studies are in progress to develop biomarkers that will allow detection of those at higher cancer risk.</ce:para><ce:section id="s0780"><ce:section-title id="st0745">Diagnosis</ce:section-title><ce:para id="p2635">This requires multiple systematic biopsies to maximise the chance of detecting intestinal metaplasia and/or dysplasia.</ce:para></ce:section><ce:section id="s0785"><ce:section-title id="st0750">Management</ce:section-title><ce:para id="p2640">Neither potent acid suppression nor anti-reflux surgery stops progression or induces regression of Barrett's oesophagus, and treatment is indicated only for symptoms of reflux or complications, such as stricture. Endoscopic therapies, such as radiofrequency ablation or photodynamic therapy, can induce regression but at present are used only for those with dysplasia or intramucosal cancer. Regular endoscopic surveillance can detect dysplasia at an early stage and may improve survival but, because most Barrett's oesophagus is undetected until cancer develops, surveillance strategies are unlikely to influence the overall mortality rate of oesophageal cancer. Surveillance is expensive and cost-effectiveness studies have been conflicting. It is currently recommended that patients with Barrett's oesophagus with intestinal metaplasia, but without dysplasia, should undergo endoscopy at 3–5-yearly intervals if the length of the Barrettic segment is less than 3 cm and at 2–3-yearly intervals if the length is greater than 3 cm. Those with low-grade dysplasia should be endoscoped at 6-monthly intervals.</ce:para><ce:para id="p2645">For those with high-grade dysplasia or intramucosal carcinoma, the treatment options are either oesophagectomy or endoscopic therapy, with a combination of endoscopic resection of any visibly abnormal areas and radiofrequency ablation of the remaining Barrett's mucosa, as an ‘organ-preserving’ alternative to surgery. These cases should be discussed in a multidisciplinary team meeting and managed in specialist centres.</ce:para></ce:section></ce:section><ce:section id="s0790"><ce:section-title id="st0755">Anaemia</ce:section-title><ce:para id="p2650">Iron deficiency anaemia can occur as a consequence of occult blood loss from long-standing oesophagitis. Most patients have a large hiatus hernia and bleeding can stem from subtle erosions in the neck of the sac (‘Cameron lesions’). Nevertheless, hiatus hernia is very common and other causes of blood loss, particularly colorectal cancer, must be considered in anaemic patients, even when endoscopy reveals oesophagitis.</ce:para></ce:section><ce:section id="s0795"><ce:section-title id="st0760">Benign oesophageal stricture</ce:section-title><ce:para id="p2655">Fibrous strictures can develop as a consequence of long-standing oesophagitis, especially in the elderly and those with poor oesophageal peristaltic activity. The typical presentation is with dysphagia that is worse for solids than for liquids. Bolus obstruction following ingestion of meat causes absolute dysphagia. A history of heartburn is common but not invariable; many elderly patients presenting with strictures have no preceding heartburn.</ce:para><ce:para id="p2660">Diagnosis is by endoscopy, when biopsies of the stricture can be taken to exclude malignancy. Endoscopic balloon dilatation or bouginage is helpful. Subsequently, long-term therapy with a PPI drug at full dose should be started to reduce the risk of recurrent oesophagitis and stricture formation. The patient should be advised to chew food thoroughly and it is important to ensure adequate dentition.</ce:para></ce:section><ce:section id="s0800"><ce:section-title id="st0765">Gastric volvulus</ce:section-title><ce:para id="p2665">Occasionally, a massive intrathoracic hiatus hernia may twist on itself, leading to a gastric volvulus. This gives rise to complete oesophageal or gastric obstruction and the patient presents with severe chest pain, vomiting and dysphagia. The diagnosis is made by chest X-ray (air bubble in the chest) and barium swallow (see <ce:cross-ref id="crf0635" refid="f0155">Fig. 21.27B</ce:cross-ref>). Most cases spontaneously resolve but recurrence is common, and surgery is usually advised after the acute episode has been treated by nasogastric decompression.</ce:para></ce:section></ce:section><ce:section id="s0805"><ce:section-title id="st0770">Investigations</ce:section-title><ce:para id="p2670">Young patients who present with typical symptoms of gastro-oesophageal reflux, without worrying features such as dysphagia, weight loss or anaemia, can be treated empirically without investigation. Investigation is advisable if patients present over the age of 50–55 years, if symptoms are atypical or if a complication is suspected. Endoscopy is the investigation of choice. This is performed to exclude other upper gastrointestinal diseases that can mimic gastro-oesophageal reflux and to identify complications. A normal endoscopy in a patient with compatible symptoms should not preclude treatment for gastro-oesophageal reflux disease.</ce:para><ce:para id="p2675">Twenty-four-hour pH monitoring is indicated if the diagnosis is unclear or surgical intervention is under consideration. This involves tethering a slim catheter with a terminal radiotelemetry pH-sensitive probe above the gastro-oesophageal junction. The intraluminal pH is recorded while the patient undergoes normal activities, and episodes of symptoms are noted and related to pH. A pH of less than 4 for more than 6–7% of the study time is diagnostic of reflux disease. In a few patients with difficult reflux, impedance testing can detect weakly acidic or alkaline reflux that is not revealed by standard pH testing.</ce:para></ce:section><ce:section id="s0810"><ce:section-title id="st0775">Management</ce:section-title><ce:para id="p2680">A treatment algorithm for gastro-oesophageal reflux is outlined in <ce:cross-ref id="crf0640" refid="f0170">Figure 21.30</ce:cross-ref><ce:float-anchor refid="f0170"/>. Lifestyle advice should be given, including weight loss, avoidance of dietary items that the patient finds worsen symptoms, elevation of the bed head in those who experience nocturnal symptoms, avoidance of late meals and cessation of smoking. Patients who fail to respond to these measures should be offered PPIs, which are usually effective in resolving symptoms and healing oesophagitis. Recurrence of symptoms is common when therapy is stopped and some patients require life-long treatment at the lowest acceptable dose. When dysmotility features are prominent, domperidone can be helpful. There is no evidence that <ce:italic>H. pylori</ce:italic> eradication has any therapeutic value. Proprietary antacids and alginates can also provide symptomatic benefit. H<ce:inf loc="post">2</ce:inf>-receptor antagonist drugs relieve symptoms without healing oesophagitis.</ce:para><ce:para id="p2685">Long-term PPI therapy is associated with reduced absorption of iron, B<ce:inf loc="post">12</ce:inf> and magnesium, and a small but increased risk of osteoporosis and fractures (odds ratio 1.2–1.5). The drugs also predispose to enteric infections with <ce:italic>Salmonella</ce:italic>, <ce:italic>Campylobacter</ce:italic> and possibly <ce:italic>Clostridium difficile</ce:italic>, and have recently been shown to have an undesirable impact on the composition of the gut microbiota. Long-term therapy increases the risk of <ce:italic>Helicobacter</ce:italic>-associated progression of gastric mucosal atrophy (see below) and <ce:italic>H. pylori</ce:italic> eradication is advised in patients requiring PPIs for more than 1 year.<ce:display><ce:textbox id="b0165" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0345" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000214/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1345" role="short">Image 82</ce:alt-text></ce:inline-figure> 21.30</ce:label><ce:alt-text id="atte1350" role="short">21.30</ce:alt-text><ce:textbox-head><ce:title id="tit0170">Gastro-oesophageal reflux disease in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2690"><ce:list id="ulist0620"><ce:list-item id="u1745"><ce:label>•</ce:label><ce:para id="p2695"><ce:bold>Prevalence</ce:bold>: higher.</ce:para></ce:list-item><ce:list-item id="u1750"><ce:label>•</ce:label><ce:para id="p2700"><ce:bold>Severity of symptoms</ce:bold>: does not correlate with the degree of mucosal inflammation.</ce:para></ce:list-item><ce:list-item id="u1755"><ce:label>•</ce:label><ce:para id="p2705"><ce:bold>Complications</ce:bold>: late complications, such as peptic strictures or bleeding from oesophagitis, are more common.</ce:para></ce:list-item><ce:list-item id="u1760"><ce:label>•</ce:label><ce:para id="p2710"><ce:bold>Recurrent pneumonia</ce:bold>: consider aspiration from occult gastro-oesophageal reflux disease.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para><ce:para id="p2715">Patients who fail to respond to medical therapy, those who are unwilling to take long-term PPIs and those whose major symptom is severe regurgitation should be considered for laparoscopic anti-reflux surgery (see <ce:italic>Principles and Practice of Surgery</ce:italic>). Although heartburn and regurgitation are alleviated in most patients, a small minority develop complications, such as inability to vomit and abdominal bloating (‘gas-bloat’ syndrome').</ce:para></ce:section></ce:section><ce:section id="s0815"><ce:section-title id="st0780">Other causes of oesophagitis</ce:section-title><ce:section id="s0820"><ce:section id="s0825"><ce:section-title id="st0785">Infection</ce:section-title><ce:para id="p2720">Oesophageal candidiasis occurs in debilitated patients and those taking broad-spectrum antibiotics or cytotoxic drugs. It is a particular problem in patients with HIV/AIDS, who are also susceptible to a spectrum of other oesophageal infections (<ce:intra-ref id="ii0205" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0160">p. 316</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0830"><ce:section-title id="st0790">Corrosives</ce:section-title><ce:para id="p2725">Suicide attempt by ingestion of strong household bleach or battery acid is followed by painful burns of the mouth and pharynx and by extensive erosive oesophagitis (<ce:intra-ref id="ii0210" xlink:href="pii:B978-0-7020-7028-0.00007-X#p1895">p. 147</ce:intra-ref>). This may be complicated by oesophageal perforation with mediastinitis and by stricture formation. At the time of presentation, treatment is conservative, based on analgesia and nutritional support; vomiting and endoscopy should be avoided because of the high risk of oesophageal perforation. After the acute phase, a barium swallow should be performed to demonstrate the extent of stricture formation. Endoscopic dilatation is usually necessary but it is difficult and hazardous because strictures are often long, tortuous and easily perforated.</ce:para></ce:section><ce:section id="s0835"><ce:section-title id="st0795">Drugs</ce:section-title><ce:para id="p2730">Potassium supplements and NSAIDs may cause oesophageal ulcers when the tablets are trapped above an oesophageal stricture. Liquid preparations of these drugs should be used in such patients. Bisphosphonates cause oesophageal ulceration and should be used with caution in patients with known oesophageal disorders.</ce:para></ce:section><ce:section id="s0840"><ce:section-title id="st0800">Eosinophilic oesophagitis</ce:section-title><ce:para id="p2735">This is more common in children but increasingly recognised in young adults. It occurs more often in atopic individuals and is characterised by eosinophilic infiltration of the oesophageal mucosa. Patients present with dysphagia or food bolus obstruction more often than heartburn, and other symptoms, such as chest pain and vomiting, may be present. Endoscopy is usually normal but mucosal rings (that sometimes need endoscopic dilatation), strictures or a narrow-calibre oesophagus can occur. Children may respond to elimination diets but these are less successful in adults, who should first be treated with PPIs. The condition can be treated with 8–12 weeks of therapy with topical glucocorticoids, such as fluticasone or betamethasone. The usual approach is to prescribe a metered-dose inhaler but to tell the patient to spray this into the mouth and swallow it rather than inhale it. Refractory symptoms sometimes respond to montelukast, a leukotriene inhibitor.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0845"><ce:section-title id="st0805">Motility disorders</ce:section-title><ce:section id="s0850"><ce:section-title id="st0810">Pharyngeal pouch</ce:section-title><ce:para id="p2740">This occurs because of incoordination of swallowing within the pharynx, which leads to herniation through the cricopharyngeus muscle and formation of a pouch. It is rare, affecting 1 in 100 000 people; it usually develops in middle life but can arise at any age. Many patients have no symptoms but regurgitation, halitosis and dysphagia can be present. Some notice gurgling in the throat after swallowing. The investigation of choice is a barium swallow (see <ce:cross-ref id="crf0645" refid="f0080">Fig. 21.12A</ce:cross-ref>), which demonstrates the pouch and reveals incoordination of swallowing, often with pulmonary aspiration. Endoscopy may be hazardous, since the instrument may enter and perforate the pouch. Surgical myotomy (‘diverticulotomy’), with or without resection of the pouch, is indicated in symptomatic patients.</ce:para></ce:section><ce:section id="s0855"><ce:section-title id="st0815">Achalasia of the oesophagus</ce:section-title><ce:section id="s0860"><ce:section-title id="st0820">Pathophysiology</ce:section-title><ce:para id="p2745">Achalasia is characterised by:<ce:list id="ulist0625"><ce:list-item id="u1765"><ce:label>•</ce:label><ce:para id="p2750">a hypertonic lower oesophageal sphincter, which fails to relax in response to the swallowing wave</ce:para></ce:list-item><ce:list-item id="u1770"><ce:label>•</ce:label><ce:para id="p2755">failure of propagated oesophageal contraction, leading to progressive dilatation of the gullet.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2760">The cause is unknown. Defective release of nitric oxide by inhibitory neurons in the lower oesophageal sphincter has been reported, and there is degeneration of ganglion cells within the sphincter and the body of the oesophagus. Loss of the dorsal vagal nuclei within the brainstem can be demonstrated in later stages. Infection with <ce:italic>Trypanosoma cruzi</ce:italic> in Chagas' disease (<ce:intra-ref id="ii0215" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2110">p. 279</ce:intra-ref>) causes a syndrome that is clinically indistinguishable from achalasia.</ce:para></ce:section><ce:section id="s0865"><ce:section-title id="st0825">Clinical features</ce:section-title><ce:para id="p2765">The presentation is with dysphagia. This develops slowly, is initially intermittent, and is worse for solids and eased by drinking liquids and by standing and moving around after eating. Heartburn does not occur because the closed oesophageal sphincter prevents gastro-oesophageal reflux. Some patients experience episodes of chest pain due to oesophageal spasm. As the disease progresses, dysphagia worsens, the oesophagus empties poorly and nocturnal pulmonary aspiration develops. Achalasia predisposes to squamous carcinoma of the oesophagus.</ce:para></ce:section><ce:section id="s0870"><ce:section-title id="st0830">Investigations</ce:section-title><ce:para id="p2770">Endoscopy should always be carried out because carcinoma of the cardia can mimic the presentation and radiological and manometric features of achalasia (‘pseudo-achalasia’). A barium swallow shows tapered narrowing of the lower oesophagus and, in late disease, the oesophageal body is dilated, aperistaltic and food-filled (<ce:cross-ref id="crf0650" refid="f0175">Fig. 21.31A</ce:cross-ref><ce:float-anchor refid="f0175"/>). Manometry confirms the high-pressure, non-relaxing lower oesophageal sphincter with poor contractility of the oesophageal body (<ce:cross-ref id="crf0660" refid="f0175">Fig. 21.31B</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0875"><ce:section-title id="st0835">Management</ce:section-title><ce:section id="s0880"><ce:section-title id="st0840">Endoscopic</ce:section-title><ce:para id="p2775">Forceful pneumatic dilatation using a 30–35-mm-diameter, fluoroscopically positioned balloon disrupts the oesophageal sphincter and improves symptoms in 80% of patients. Some patients require more than one dilatation but those needing frequent dilatation are best treated surgically. Endoscopically directed injection of botulinum toxin into the lower oesophageal sphincter induces clinical remission but relapse is common. Recently, a complex endoscopic technique has been developed in specialist centres (peroral endoscopic myotomy, POEM).</ce:para></ce:section><ce:section id="s0885"><ce:section-title id="st0845">Surgical</ce:section-title><ce:para id="p2780">Surgical myotomy (Heller's operation), performed either laparoscopically or as an open operation, is effective but is more invasive than endoscopic dilatation. Both pneumatic dilatation and myotomy may be complicated by gastro-oesophageal reflux, and this can lead to severe oesophagitis because oesophageal clearance is so poor. For this reason, Heller's myotomy is accompanied by a partial fundoplication anti-reflux procedure. PPI therapy is often necessary after surgery.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0890"><ce:section-title id="st0850">Other oesophageal motility disorders</ce:section-title><ce:para id="p2785">Diffuse oesophageal spasm presents in late middle age with episodic chest pain that may mimic angina but is sometimes accompanied by transient dysphagia. Some cases occur in response to gastro-oesophageal reflux. Treatment is based on the use of PPI drugs when gastro-oesophageal reflux is present. Oral or sublingual nitrates or nifedipine may relieve attacks of pain. The results of drug therapy are often disappointing, as are the alternatives: pneumatic dilatation and surgical myotomy. ‘Nutcracker’ oesophagus is a condition in which extremely forceful peristaltic activity leads to episodic chest pain and dysphagia. Treatment is with nitrates or nifedipine. Some patients present with oesophageal motility disorders that do not fit into a specific disease entity. The patients are usually elderly and present with dysphagia and chest pain. Manometric abnormalities, ranging from poor peristalsis to spasm, occur. Treatment is with dilatation and/or vasodilators for chest pain.</ce:para></ce:section><ce:section id="s0895"><ce:section-title id="st0855">Secondary causes of oesophageal dysmotility</ce:section-title><ce:para id="p2790">In systemic sclerosis or CREST syndrome (<ce:intra-ref id="ii0225" xlink:href="pii:B978-0-7020-7028-0.00024-X#p4895">p. 1037</ce:intra-ref>), the muscle of the oesophagus is replaced by fibrous tissue, which causes failure of peristalsis leading to heartburn and dysphagia. Oesophagitis is often severe and benign fibrous strictures occur. These patients require long-term therapy with PPIs. Dermatomyositis, rheumatoid arthritis and myasthenia gravis may also cause dysphagia.</ce:para></ce:section><ce:section id="s0900"><ce:section-title id="st0860">Benign oesophageal stricture</ce:section-title><ce:para id="p2795">Benign oesophageal stricture is usually a consequence of gastro-oesophageal reflux disease (<ce:cross-ref id="crf0665" refid="b0170">Box 21.31</ce:cross-ref><ce:float-anchor refid="b0170"/>) and occurs most often in elderly patients who have poor oesophageal clearance. Rings, caused by submucosal fibrosis, are found at the oesophago-gastric junction (‘Schatzki ring’) and cause intermittent dysphagia, often starting in middle age. A post-cricoid web is a rare complication of iron deficiency anaemia (Paterson–Kelly or Plummer–Vinson syndrome), and may be complicated by the development of squamous carcinoma. Benign strictures can be treated by endoscopic dilatation, in which wire-guided bougies or balloons are used to disrupt the fibrous tissue of the stricture.</ce:para></ce:section></ce:section><ce:section id="s0905"><ce:section-title id="st0865">Tumours of the oesophagus</ce:section-title><ce:section id="s0910"><ce:section-title id="st0870">Benign tumours</ce:section-title><ce:para id="p2855">The most common is a leiomyoma. This is usually asymptomatic but may cause bleeding or dysphagia.</ce:para></ce:section><ce:section id="s0915"><ce:section-title id="st0875">Carcinoma of the oesophagus</ce:section-title><ce:para id="p2860">Squamous oesophageal cancer (<ce:cross-ref id="crf0670" refid="b0175">Box 21.32</ce:cross-ref><ce:float-anchor refid="b0175"/>) is relatively rare in Caucasians (4 : 100 000) but is more common in Iran, parts of Africa and China (200 : 100 000). Squamous cancer can occur in any part of the oesophagus and almost all tumours in the upper oesophagus are squamous cancers. Adenocarcinomas typically arise in the lower third of the oesophagus from Barrett's oesophagus or from the cardia of the stomach. The incidence is increasing and is now approximately 5: 100 000 in the UK; this is possibly because of the high prevalence of gastro-oesophageal reflux and Barrett's oesophagus in Western populations. Despite modern treatment, the overall 5-year survival of patients presenting with oesophageal cancer is only 13%.</ce:para><ce:section id="s0920"><ce:section-title id="st0880">Clinical features</ce:section-title><ce:para id="p2910">Most patients have a history of progressive, painless dysphagia for solid foods. Others present acutely because of food bolus obstruction. In the late stages, weight loss is often extreme; chest pain or hoarseness suggests mediastinal invasion. Fistulation between the oesophagus and the trachea or bronchial tree leads to coughing after swallowing, pneumonia and pleural effusion. Physical signs may be absent but, even at initial presentation, cachexia, cervical lymphadenopathy or other evidence of metastatic spread is common.</ce:para></ce:section><ce:section id="s0925"><ce:section-title id="st0885">Investigations</ce:section-title><ce:para id="p2915">The investigation of choice is upper gastrointestinal endoscopy (<ce:cross-ref id="crf0675" refid="f0180">Fig. 21.32</ce:cross-ref><ce:float-anchor refid="f0180"/>) with biopsy. A barium swallow demonstrates the site and length of the stricture but adds little useful information. Once a diagnosis has been made, investigations should be performed to stage the tumour and define operability. Thoracic and abdominal CT, often combined with positron emission tomography (PET-CT), should be carried out to identify metastatic spread and local invasion (<ce:cross-ref id="crf0680" refid="f0185">Fig. 21.33</ce:cross-ref><ce:float-anchor refid="f0185"/>). Invasion of the aorta, major airways or coeliac axis usually precludes surgery, but patients with resectable disease on imaging should undergo EUS to determine the depth of penetration of the tumour into the oesophageal wall and to detect locoregional lymph node involvement (<ce:cross-ref id="crf0685" refid="f0190">Fig. 21.34</ce:cross-ref><ce:float-anchor refid="f0190"/>). These investigations will define the TNM stage of the disease (<ce:intra-ref id="ii0230" xlink:href="pii:B978-0-7020-7028-0.00033-0#p0545">p. 1322</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0930"><ce:section-title id="st0890">Management</ce:section-title><ce:para id="p2920">The treatment of choice is surgery if the patient presents at a point at which resection is possible. For very early superficial tumours, endoscopic submucosal dissection may offer an alternative to surgery but is not widely used outside of Japan and Korea. Patients with tumours that have extended beyond the wall of the oesophagus (T3) or that have lymph node involvement (N1) carry a 5-year survival of around 10%. This figure improves significantly, however, if the tumour is confined to the oesophageal wall and there is no spread to lymph nodes. Overall survival following ‘potentially curative’ surgery (all macroscopic tumour removed) is about 30% at 5 years but recent studies have suggested that this can be improved by neoadjuvant chemotherapy. Although squamous carcinomas are radiosensitive, radiotherapy alone is associated with a 5-year survival of only 5% but combined chemoradiotherapy for these tumours can achieve 5-year survival rates of 25–30%.</ce:para><ce:para id="p2925">Approximately 70% of patients have extensive disease at presentation; in these, treatment is palliative and should focus on relief of dysphagia and pain. Endoscopic laser therapy or self-expanding metallic stents can be used to improve swallowing. Palliative radiotherapy may induce shrinkage of both squamous cancers and adenocarcinomas but symptomatic response may be slow. Quality of life can be improved by nutritional support and appropriate analgesia.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0935"><ce:section-title id="st0895">Perforation of the oesophagus</ce:section-title><ce:para id="p2930">The most common cause is endoscopic perforation complicating dilatation or intubation. Malignant, corrosive or post-radiotherapy strictures are more likely to be perforated than peptic strictures. A perforated peptic stricture is managed conservatively using broad-spectrum antibiotics and parenteral nutrition; most cases heal within days. Malignant, caustic and radiotherapy stricture perforations require resection or stenting.</ce:para><ce:para id="p2935">Spontaneous oesophageal perforation (‘Boerhaave's syndrome’) results from forceful vomiting and retching. Severe chest pain and shock occur as oesophago-gastric contents enter the mediastinum and thoracic cavity. Subcutaneous emphysema, pleural effusions and pneumothorax develop. The diagnosis can be made using a water-soluble contrast swallow but, in difficult cases, both CT and careful endoscopy (usually in an intubated patient) may be required. Treatment is surgical. Delay in diagnosis is a key factor in the high mortality associated with this condition.</ce:para></ce:section></ce:section><ce:section id="s0940"><ce:section-title id="st0900">Diseases of the stomach and duodenum</ce:section-title><ce:section id="s0945"><ce:section-title id="st0905">Gastritis</ce:section-title><ce:para id="p2940">Gastritis is a histological diagnosis, although it can also be recognised at endoscopy.</ce:para><ce:section id="s0950"><ce:section-title id="st0910">Acute gastritis</ce:section-title><ce:para id="p2945">Acute gastritis is often erosive and haemorrhagic. Neutrophils are the predominant inflammatory cell in the superficial epithelium. Many cases result from alcohol, aspirin or NSAID ingestion (<ce:cross-ref id="crf0690" refid="b0180">Box 21.33</ce:cross-ref><ce:float-anchor refid="b0180"/>). Acute gastritis often produces no symptoms but may cause dyspepsia, anorexia, nausea or vomiting, and haematemesis or melaena. Many cases resolve quickly and do not merit investigation; in others, endoscopy and biopsy may be necessary to exclude peptic ulcer or cancer. Treatment should be directed at the underlying cause. Short-term symptomatic therapy with antacids, and acid suppression using PPIs, prokinetics (domperidone) or antiemetics (metoclopramide) may be necessary.</ce:para></ce:section><ce:section id="s0970"><ce:section-title id="st0930">Chronic gastritis due to <ce:italic>Helicobacter pylori</ce:italic> infection</ce:section-title><ce:para id="p3040">This is the most common cause of chronic gastritis (<ce:cross-ref id="crf0695" refid="b0180">Box 21.33</ce:cross-ref>). The predominant inflammatory cells are lymphocytes and plasma cells. Correlation between symptoms and endoscopic or pathological findings is poor. Most patients are asymptomatic and do not require treatment but patients with dyspepsia may benefit from <ce:italic>H. pylori</ce:italic> eradication.</ce:para></ce:section><ce:section id="s0975"><ce:section-title id="st0935">Autoimmune chronic gastritis</ce:section-title><ce:para id="p3045">This involves the body of the stomach but spares the antrum; it results from autoimmune damage to parietal cells. The histological features are diffuse chronic inflammation, atrophy and loss of fundic glands, intestinal metaplasia and sometimes hyperplasia of enterochromaffin-like (ECL) cells. Circulating antibodies to parietal cell and intrinsic factor may be present. In some patients, the degree of gastric atrophy is severe and loss of intrinsic factor secretion leads to pernicious anaemia (<ce:intra-ref id="ii0240" xlink:href="pii:B978-0-7020-7028-0.00023-8#s0720">p. 944</ce:intra-ref>). The gastritis itself is usually asymptomatic. Some patients have evidence of other organ-specific autoimmunity, particularly thyroid disease. In the long term, there is a two- to threefold increase in the risk of gastric cancer (see also <ce:cross-ref id="crf9100" refid="s1185">p. 803</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0980"><ce:section-title id="st0940">Ménétrier's disease</ce:section-title><ce:para id="p3050">In this rare condition, the gastric pits are elongated and tortuous, with replacement of the parietal and chief cells by mucus-secreting cells. The cause is unknown but there is excessive production of transforming growth factor alpha (TGF-α). As a result, the mucosal folds of the body and fundus are greatly enlarged. Most patients are hypochlorhydric. While some patients have upper gastrointestinal symptoms, the majority present in middle or old age with protein-losing enteropathy (<ce:cross-ref id="crf9105" refid="p4310">p. 811</ce:cross-ref>) due to exudation from the gastric mucosa. Endoscopy shows enlarged, nodular and coarse folds, although biopsies may not be deep enough to show all the histological features. Treatment with antisecretory drugs, such as PPIs with or without octreotide, may reduce protein loss and <ce:italic>H. pylori</ce:italic> eradication may be effective, but unresponsive patients require partial gastrectomy.</ce:para></ce:section></ce:section><ce:section id="s0985"><ce:section-title id="st0945">Peptic ulcer disease</ce:section-title><ce:para id="p3055">The term ‘peptic ulcer’ refers to an ulcer in the lower oesophagus, stomach or duodenum, in the jejunum after surgical anastomosis to the stomach or, rarely, in the ileum adjacent to a Meckel's diverticulum. Ulcers in the stomach or duodenum may be acute or chronic; both penetrate the muscularis mucosae but the acute ulcer shows no evidence of fibrosis. Erosions do not penetrate the muscularis mucosae.</ce:para><ce:section id="s0990"><ce:section-title id="st0950">Gastric and duodenal ulcer</ce:section-title><ce:para id="p3060">The prevalence of peptic ulcer (0.1–0.2%) is decreasing in many Western communities as a result of widespread use of <ce:italic>Helicobacter pylori</ce:italic> eradication therapy but it remains high in developing countries. The male-to-female ratio for duodenal ulcer varies from 5 : 1 to 2 : 1, while that for gastric ulcer is 2 : 1 or less. Chronic gastric ulcer is usually single; 90% are situated on the lesser curve within the antrum or at the junction between body and antral mucosa. Chronic duodenal ulcer usually occurs in the first part of the duodenum and 50% are on the anterior wall. Gastric and duodenal ulcers coexist in 10% of patients and more than one peptic ulcer is found in 10–15% of patients.</ce:para><ce:section id="s0995"><ce:section-title id="st0955">Pathophysiology</ce:section-title><ce:section id="s1000"><ce:section-title id="st0960"><ce:italic>H. pylori</ce:italic></ce:section-title><ce:para id="p3065">Peptic ulceration is strongly associated with <ce:italic>H. pylori</ce:italic> infection. The prevalence of the infection in developed nations rises with age and in the UK approximately 50% of people over the age of 50 years are infected. In the developing world infection is more common, affecting up to 90% of adults. These infections are probably acquired in childhood by person-to-person contact. The vast majority of colonised people remain healthy and asymptomatic, and only a minority develop clinical disease. Around 90% of duodenal ulcer patients and 70% of gastric ulcer patients are infected with <ce:italic>H. pylori</ce:italic>. The remaining 30% of gastric ulcers are caused by NSAIDs and this proportion is increasing in Western countries as a result of <ce:italic>H. pylori</ce:italic> eradication strategies.</ce:para><ce:para id="p3070"><ce:italic>H. pylori</ce:italic> is Gram-negative and spiral, and has multiple flagella at one end, which make it motile, allowing it to burrow and live beneath the mucus layer adherent to the epithelial surface. It uses an adhesin molecule (BabA) to bind to the Lewis b antigen on epithelial cells. Here the surface pH is close to neutral and any acidity is buffered by the organism's production of the enzyme urease. This produces ammonia from urea and raises the pH around the bacterium and between its two cell membrane layers. <ce:italic>H. pylori</ce:italic> exclusively colonises gastric-type epithelium and is found in the duodenum only in association with patches of gastric metaplasia. It causes chronic gastritis by provoking a local inflammatory response in the underlying epithelium (<ce:cross-ref id="crf0700" refid="f0195">Fig. 21.35</ce:cross-ref><ce:float-anchor refid="f0195"/>). This depends on numerous factors, notably expression of bacterial <ce:italic>cagA</ce:italic> and <ce:italic>vacA</ce:italic> genes. The CagA gene product is injected into epithelial cells, interacting with numerous cell-signalling pathways involved in cell replication and apoptosis. <ce:italic>H. pylori</ce:italic> strains expressing CagA (CagA<ce:sup loc="post">+</ce:sup>) are more often associated with disease than CagA<ce:sup loc="post">−</ce:sup> strains. Most strains also secrete a large pore-forming protein called VacA, which causes increased cell permeability, efflux of micronutrients from the epithelium, induction of apoptosis and suppression of local immune cell activity. Several forms of VacA exist and pathology is most strongly associated with the s1/ml form of the toxin.</ce:para><ce:para id="p3075">The distribution and severity of <ce:italic>H. pylori</ce:italic>–induced gastritis determine the clinical outcome. In most people, <ce:italic>H. pylori</ce:italic> causes a mild pangastritis with little effect on acid secretion and the majority develop no significant clinical outcomes. In a minority (up to 10% in the West), the infection causes an antral-predominant pattern of gastritis characterised by hypergastrinaemia and a very exaggerated acid production by parietal cells, which could lead to duodenal ulceration (<ce:cross-ref id="crf0705" refid="f0200">Fig. 21.36</ce:cross-ref><ce:float-anchor refid="f0200"/>). In a much smaller number of infected people, <ce:italic>H. pylori</ce:italic> causes a corpus-predominant pattern of gastritis leading to gastric atrophy and hypochlorhydria. This phenotype is much more common in Asian countries, particularly Japan, China and Korea. The hypochlorhydria allows other bacteria to proliferate within the stomach; these other bacteria continue to drive the chronic inflammation and produce mutagenic nitrites from dietary nitrates, predisposing to the development of gastric cancer (<ce:cross-ref id="crf0710" refid="f0205">Fig. 21.37</ce:cross-ref><ce:float-anchor refid="f0205"/>). The effects of <ce:italic>H. pylori</ce:italic> are more complex in gastric ulcer patients compared to those with duodenal ulcers. The ulcer probably arises because of impaired mucosal defence resulting from a combination of <ce:italic>H. pylori</ce:italic> infection, NSAIDs and smoking, rather than excess acid.</ce:para></ce:section><ce:section id="s1005"><ce:section-title id="st0965">NSAIDs</ce:section-title><ce:para id="p3080">Treatment with NSAIDs is associated with peptic ulcers due to impairment of mucosal defences, as discussed on <ce:intra-ref id="ii0255" xlink:href="pii:B978-0-7020-7028-0.00024-X#s0465">page 1002</ce:intra-ref>.</ce:para></ce:section><ce:section id="s1010"><ce:section-title id="st0970">Smoking</ce:section-title><ce:para id="p3085">Smoking confers an increased risk of gastric ulcer and, to a lesser extent, duodenal ulcer. Once the ulcer has formed, it is more likely to cause complications and less likely to heal if the patient continues to smoke.</ce:para></ce:section></ce:section><ce:section id="s1015"><ce:section-title id="st0975">Clinical features</ce:section-title><ce:para id="p3090">Peptic ulcer disease is a chronic condition with spontaneous relapses and remissions lasting for decades, if not for life. The most common presentation is with recurrent abdominal pain that has three notable characteristics: localisation to the epigastrium, relationship to food and episodic occurrence. Occasional vomiting occurs in about 40% of ulcer subjects; persistent daily vomiting suggests gastric outlet obstruction. In one-third, the history is less characteristic, especially in elderly people or those taking NSAIDs. In this situation, pain may be absent or so slight that it is experienced only as a vague sense of epigastric unease. Occasionally, the only symptoms are anorexia and nausea, or early satiety after meals. In some patients, the ulcer is completely ‘silent’, presenting for the first time with anaemia from chronic undetected blood loss, as abrupt haematemesis or as acute perforation; in others, there is recurrent acute bleeding without ulcer pain. The diagnostic value of individual symptoms for peptic ulcer disease is poor; the history is therefore a poor predictor of the presence of an ulcer.</ce:para></ce:section><ce:section id="s1020"><ce:section-title id="st0980">Investigations</ce:section-title><ce:para id="p3095">Endoscopy is the preferred investigation (<ce:cross-ref id="crf0715" refid="f0210">Fig. 21.38</ce:cross-ref><ce:float-anchor refid="f0210"/>). Gastric ulcers may occasionally be malignant and therefore must always be biopsied and followed up to ensure healing. Patients should be tested for <ce:italic>H. pylori</ce:italic> infection. The current options available are listed in <ce:cross-ref id="crf0720" refid="b0185">Box 21.34</ce:cross-ref><ce:float-anchor refid="b0185"/>. Some are invasive and require endoscopy; others are non-invasive. They vary in sensitivity and specificity. Breath tests or faecal antigen tests are best because of accuracy, simplicity and non-invasiveness.</ce:para></ce:section><ce:section id="s1025"><ce:section-title id="st0985">Management</ce:section-title><ce:para id="p3105">The aims of management are to relieve symptoms, induce healing and prevent recurrence. <ce:italic>H. pylori</ce:italic> eradication is the cornerstone of therapy for peptic ulcers, as this will successfully prevent relapse and eliminate the need for long-term therapy in the majority of patients.</ce:para><ce:section id="s1030"><ce:section-title id="st0990"><ce:italic>H. pylori</ce:italic> eradication</ce:section-title><ce:para id="p3110">All patients with proven ulcers who are <ce:italic>H. pylori</ce:italic>-positive should be offered eradication as primary therapy. Treatment is based on a PPI taken simultaneously with two antibiotics (from amoxicillin, clarithromycin and metronidazole) for at least 7 days. High-dose, twice-daily PPI therapy increases efficacy of treatment, as does extending treatment to 10–14 days. Success is achieved in 80–90% of patients, although adherence, side-effects (<ce:cross-ref id="crf0725" refid="b0190">Box 21.35</ce:cross-ref><ce:float-anchor refid="b0190"/>) and antibiotic resistance influence this. Resistance to amoxicillin is rare but rates of metronidazole resistance reach more than 50% in some countries and rates of clarithromycin resistance of 20–40% have recently become common. Where the latter exceed 15%, a quadruple therapy regimen, consisting of omeprazole (or another PPI), bismuth subcitrate, metronidazole and tetracycline (OBMT) for 10–14 days, is recommended. In areas of low clarithromycin resistance, this regimen should also be offered as second-line therapy to those who remain infected after initial therapy, once adherence has been checked. For those who are still colonised after two treatments, the choice lies between a third attempt guided by antimicrobial sensitivity testing, rescue therapy (levofloxacin, PPI and clarithromycin) or long-term acid suppression.</ce:para><ce:para id="p3150"><ce:italic>H. pylori</ce:italic> and NSAIDs are independent risk factors for ulcer disease and patients requiring long-term NSAID therapy should first undergo eradication therapy to reduce ulcer risk. Subsequent co-prescription of a PPI along with the NSAID is advised but is not always necessary for patients being given low-dose aspirin, in whom the risk of ulcer complications is lower.</ce:para><ce:para id="p3155">Other indications for <ce:italic>H. pylori</ce:italic> eradication are shown in <ce:cross-ref id="crf0730" refid="b0195">Box 21.36</ce:cross-ref><ce:float-anchor refid="b0195"/>. Eradication of the infection has proven benefits in several extragastric disorders, including unexplained B<ce:inf loc="post">12</ce:inf> deficiency and iron deficiency anaemia, once sources of gastrointestinal bleeding have been looked for and excluded. Platelet counts improve and may normalise after eradication therapy in patients with idiopathic thrombocytopenic purpura (<ce:intra-ref id="ii0260" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1830">p. 979</ce:intra-ref>); the mechanism for this is unclear.</ce:para></ce:section><ce:section id="s1045"><ce:section-title id="st1005">General measures</ce:section-title><ce:para id="p3240">Cigarette smoking, aspirin and NSAIDs should be avoided. Alcohol in moderation is not harmful and no special dietary advice is required.</ce:para></ce:section><ce:section id="s1050"><ce:section-title id="st1010">Maintenance treatment</ce:section-title><ce:para id="p3245">Continuous maintenance treatment should not be necessary after successful <ce:italic>H. pylori</ce:italic> eradication. For the minority who do require it, the lowest effective dose of PPI should be used.</ce:para></ce:section><ce:section id="s1055"><ce:section-title id="st1015">Surgical treatment</ce:section-title><ce:para id="p3250">Surgery is now rarely required for peptic ulcer disease but it is needed in some cases (<ce:cross-ref id="crf0750" refid="b0200">Box 21.37</ce:cross-ref><ce:float-anchor refid="b0200"/>).</ce:para><ce:para id="p3290">The operation of choice for a chronic non-healing gastric ulcer is partial gastrectomy, preferably with a Billroth I anastomosis, in which the ulcer itself and the ulcer-bearing area of the stomach are resected. The reason for this is to exclude an underlying cancer. In an emergency, ‘under-running’ the ulcer for bleeding or ‘oversewing’ (patch repair) for perforation is all that is required, in addition to taking a biopsy. For giant duodenal ulcers, partial gastrectomy using a ‘Polya’ or Billroth II reconstruction may be required.</ce:para></ce:section><ce:section id="s1070"><ce:section-title id="st1030">Complications of gastric resection or vagotomy</ce:section-title><ce:para id="p3295">Up to 50% of patients who undergo gastric surgery for peptic ulcer surgery experience long-term adverse effects. In most cases these are minor but in 10% they significantly impair quality of life.</ce:para><ce:section id="s1075"><ce:section-title id="st1035">Dumping</ce:section-title><ce:para id="p3300">Rapid gastric emptying leads to distension of the proximal small intestine as the hypertonic contents draw fluid into the lumen. This leads to abdominal discomfort and diarrhoea after eating. Autonomic reflexes release a range of gastrointestinal hormones that provoke vasomotor features, such as flushing, palpitations, sweating, tachycardia and hypotension. Patients should therefore avoid large meals with high carbohydrate content.</ce:para></ce:section><ce:section id="s1080"><ce:section-title id="st1040">Chemical (bile reflux) gastropathy</ce:section-title><ce:para id="p3305">Duodenogastric bile reflux leads to chronic gastropathy. Treatment with aluminium-containing antacids or sucralfate may be effective. A few patients require revisional surgery with creation of a Roux en Y loop to prevent bile reflux.</ce:para></ce:section><ce:section id="s1085"><ce:section-title id="st1045">Diarrhoea and maldigestion</ce:section-title><ce:para id="p3310">Diarrhoea may develop after any peptic ulcer operation and usually occurs 1–2 hours after eating. Poor mixing of food in the stomach, with rapid emptying, inadequate mixing with pancreaticobiliary secretions, rapid transit and bacterial overgrowth, may lead to malabsorption. Diarrhoea often responds to small, dry meals with a reduced intake of refined carbohydrates. Antidiarrhoeal drugs, such as codeine phosphate (15–30 mg 4–6 times daily) or loperamide (2 mg after each loose stool), are helpful.</ce:para></ce:section><ce:section id="s1090"><ce:section-title id="st1050">Weight loss</ce:section-title><ce:para id="p3315">Most patients lose weight shortly after surgery and 30–40% are unable to regain all the weight that is lost. The usual cause is reduced intake because of a small gastric remnant but diarrhoea and mild steatorrhoea also contribute.</ce:para></ce:section><ce:section id="s1095"><ce:section-title id="st1055">Anaemia</ce:section-title><ce:para id="p3320">Anaemia is common many years after subtotal gastrectomy. Iron deficiency is the most common cause; folic acid and B<ce:inf loc="post">12</ce:inf> deficiency are much less frequent. Inadequate dietary intake of iron and folate, lack of acid and intrinsic factor secretion, mild chronic low-grade blood loss from the gastric remnant and recurrent ulceration are responsible.</ce:para></ce:section><ce:section id="s1100"><ce:section-title id="st1060">Metabolic bone disease</ce:section-title><ce:para id="p3325">Both osteoporosis and osteomalacia can occur as a consequence of calcium and vitamin D malabsorption.</ce:para></ce:section><ce:section id="s1105"><ce:section-title id="st1065">Gastric cancer</ce:section-title><ce:para id="p3330">An increased risk of gastric cancer has been reported from several epidemiological studies. Surgery itself is an independent risk factor for late development of malignancy in the gastric remnant but the risk is higher in those with hypochlorhydria, duodenogastric reflux of bile, smoking and <ce:italic>H. pylori</ce:italic> infection. Although the relative risk is increased, the absolute risk of cancer remains low and endoscopic surveillance is not indicated following gastric surgery.<ce:display><ce:textbox id="b0205" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0425" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000214/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1355" role="short">Image 83</ce:alt-text></ce:inline-figure> 21.38</ce:label><ce:alt-text id="atte1360" role="short">21.38</ce:alt-text><ce:textbox-head><ce:title id="tit0210">Peptic ulcer disease in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3335"><ce:list id="ulist0685"><ce:list-item id="u2055"><ce:label>•</ce:label><ce:para id="p3340"><ce:bold>Gastroduodenal ulcers</ce:bold>: have a greater incidence, admission rate and mortality.</ce:para></ce:list-item><ce:list-item id="u2060"><ce:label>•</ce:label><ce:para id="p3345"><ce:bold>Causes</ce:bold>: high prevalence of <ce:italic>H. pylori</ce:italic>, use of non-steroidal anti-inflammatory drugs and impaired defence mechanisms.</ce:para></ce:list-item><ce:list-item id="u2065"><ce:label>•</ce:label><ce:para id="p3350"><ce:bold>Atypical presentations</ce:bold>: pain and dyspepsia are frequently absent or atypical. Older people often develop complications, such as bleeding or perforation, without a dyspeptic history.</ce:para></ce:list-item><ce:list-item id="u2070"><ce:label>•</ce:label><ce:para id="p3355"><ce:bold>Bleeding</ce:bold>: older patients require more intensive management because they have more limited reserve to withstand hypovolaemia.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section></ce:section></ce:section><ce:section id="s1110"><ce:section-title id="st1070">Complications of peptic ulcer disease</ce:section-title><ce:section id="s1115"><ce:section-title id="st1075">Perforation</ce:section-title><ce:para id="p3360">When perforation occurs, the contents of the stomach escape into the peritoneal cavity, leading to peritonitis. This is more common in duodenal than in gastric ulcers and is usually found with ulcers on the anterior wall. About one-quarter of all perforations occur in acute ulcers and NSAIDs are often incriminated. Perforation can be the first sign of ulcer and a history of recurrent epigastric pain is uncommon. The most striking symptom is sudden, severe pain; its distribution follows the spread of the gastric contents over the peritoneum. The pain initially develops in the upper abdomen and rapidly becomes generalised; shoulder tip pain is caused by irritation of the diaphragm. The pain is accompanied by shallow respiration, due to limitation of diaphragmatic movements, and by shock. The abdomen is held immobile and there is generalised ‘board-like’ rigidity. Bowel sounds are absent and liver dullness to percussion decreases due to the presence of gas under the diaphragm. After some hours, symptoms may improve, although abdominal rigidity remains. Later, the patient's condition deteriorates as general peritonitis develops. In at least 50% of cases, an erect chest X-ray shows free air beneath the diaphragm (see <ce:cross-ref id="crf0755" refid="f0075">Fig. 21.11B</ce:cross-ref>, <ce:cross-ref id="crf9110" refid="s0150">p. 773</ce:cross-ref>). If not, a water-soluble contrast swallow will confirm leakage of gastroduodenal contents. After resuscitation, the acute perforation should be treated surgically, either by simple closure or by conversion of the perforation into a pyloroplasty if it is large. On rare occasions, a ‘Polya’ partial gastrectomy is required. Following surgery, <ce:italic>H. pylori</ce:italic> should be treated (if present) and NSAIDs avoided. Perforation carries a mortality of 25%, reflecting the advanced age and significant comorbidity of the population that are affected.</ce:para></ce:section><ce:section id="s1120"><ce:section-title id="st1080">Gastric outlet obstruction</ce:section-title><ce:para id="p3365">The causes are shown in <ce:cross-ref id="crf0760" refid="b0210">Box 21.39</ce:cross-ref><ce:float-anchor refid="b0210"/>. The most common is an ulcer in the region of the pylorus. The presentation is with nausea, vomiting and abdominal distension. Large quantities of gastric content are often vomited and food eaten 24 hours or more previously may be recognised. Physical examination may show evidence of wasting and dehydration. A succussion splash may be elicited 4 hours or more after the last meal or drink. Visible gastric peristalsis is diagnostic of gastric outlet obstruction. Loss of acidic gastric contents leads to alkalosis and dehydration with low serum chloride and potassium and raised serum bicarbonate and urea concentrations (hypochloraemic metabolic alkalosis). Paradoxical aciduria occurs because of enhanced renal absorption of Na<ce:sup loc="post">+</ce:sup> in exchange for H<ce:sup loc="post">+</ce:sup>. Endoscopy should be performed after the stomach has been emptied using a wide-bore nasogastric tube. Intravenous correction of dehydration is undertaken and, in severe cases, at least 4 L of isotonic saline and 80 mmol of potassium may be necessary during the first 24 hours. In some patients, PPI drugs heal ulcers, relieve pyloric oedema and overcome the need for surgery. Endoscopic balloon dilatation of benign stenoses may be possible in some patients but in others partial gastrectomy is necessary; this is best done after a 7-day period of nasogastric aspiration, which enables the stomach to return to normal size. A gastroenterostomy is an alternative operation but, unless this is accompanied by vagotomy, patients will require long-term PPI therapy to prevent stomal ulceration.</ce:para></ce:section><ce:section id="s1125"><ce:section-title id="st1085">Bleeding</ce:section-title><ce:para id="p3375">See <ce:cross-ref id="crf9115" refid="s0390">page 780</ce:cross-ref>.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1130"><ce:section-title id="st1090">Zollinger–Ellison syndrome</ce:section-title><ce:para id="p3380">This is a rare disorder characterised by the triad of severe peptic ulceration, gastric acid hypersecretion and a neuro-endocrine tumour (<ce:intra-ref id="ii0275" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1305">p. 678</ce:intra-ref>) of the pancreas or duodenum (‘gastrinoma’). It probably accounts for about 0.1% of all cases of duodenal ulceration. The syndrome occurs in either sex at any age, although it is most common between 30 and 50 years of age.</ce:para><ce:section id="s1135"><ce:section-title id="st1095">Pathophysiology</ce:section-title><ce:para id="p3385">The tumour secretes gastrin, which stimulates acid secretion to its maximal capacity and increases the parietal cell mass three- to sixfold. The acid output may be so great that it reaches the upper small intestine, reducing the luminal pH to 2 or less. Pancreatic lipase is inactivated and bile acids are precipitated. Diarrhoea and steatorrhoea result. Around 90% of tumours occur in the pancreatic head or proximal duodenal wall. At least half are multiple and tumour size can vary from 1 mm to 20 cm. Approximately one-half to two-thirds are malignant but are often slow-growing. Between 20% and 60% of patients have multiple endocrine neoplasia (MEN) type 1 (<ce:intra-ref id="ii0280" xlink:href="pii:B978-0-7020-7028-0.00018-4#p5315">p. 688</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1140"><ce:section-title id="st1100">Clinical features</ce:section-title><ce:para id="p3390">The presentation is with severe and often multiple peptic ulcers in unusual sites, such as the post-bulbar duodenum, jejunum or oesophagus. There is a poor response to standard ulcer therapy. The history is usually short, and bleeding and perforations are common. Diarrhoea is seen in one-third or more of patients and can be the presenting feature.</ce:para></ce:section><ce:section id="s1145"><ce:section-title id="st1105">Investigations</ce:section-title><ce:para id="p3395">Hypersecretion of acid under basal conditions, with little increase following pentagastrin, may be confirmed by gastric aspiration. Serum gastrin levels are grossly elevated (10- to 1000-fold). Injection of the hormone secretin normally causes no change or a slight decrease in circulating gastrin concentrations, but in Zollinger–Ellison syndrome it produces a paradoxical and dramatic increase in gastrin. Tumour localisation (and staging) is best achieved by a combination of CT and EUS; radio-labelled somatostatin receptor scintigraphy and <ce:sup loc="post">68</ce:sup>gallium DOTATATE PET scanning may also be used for tumour detection and staging.</ce:para></ce:section><ce:section id="s1150"><ce:section-title id="st1110">Management</ce:section-title><ce:para id="p3400">Some 30% of small and single tumours can be localised and resected but many tumours are multifocal (especially in the context of MEN 1). Some patients present with metastatic disease and, in these circumstances, surgery is inappropriate. In the majority of these individuals, continuous therapy with omeprazole or other PPIs can be successful in healing ulcers and alleviating diarrhoea, although double the normal dose is required. The synthetic somatostatin analogue, octreotide, given by subcutaneous injection, reduces gastrin secretion and may be of value. Other treatment options for pancreatic neuro-endocrine tumours are discussed on <ce:intra-ref id="ii0285" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1305">page 678</ce:intra-ref>. Overall 5-year survival is 60–75% and all patients should undergo genetic screening for MEN 1.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1155"><ce:section-title id="st1115">Functional disorders</ce:section-title><ce:section id="s1160"><ce:section-title id="st1120">Functional dyspepsia</ce:section-title><ce:para id="p3405">This is defined as chronic dyspepsia in the absence of organic disease. Other commonly reported symptoms include early satiety, fullness, bloating and nausea. ‘Ulcer-like’ and ‘dysmotility-type’ subgroups are often reported but there is overlap between these and with irritable bowel syndrome.</ce:para><ce:section id="s1165"><ce:section-title id="st1125">Pathophysiology</ce:section-title><ce:para id="p3410">The cause is poorly understood but probably covers a spectrum of mucosal, motility and psychiatric disorders.</ce:para></ce:section><ce:section id="s1170"><ce:section-title id="st1130">Clinical features</ce:section-title><ce:para id="p3415">Patients are usually young (&#x003C; 40 years) and women are affected twice as commonly as men. Abdominal discomfort is associated with a combination of other ‘dyspeptic’ symptoms, the most common being nausea, satiety and bloating after meals. Morning symptoms are characteristic and pain or nausea may occur on waking. Direct enquiry may elicit symptoms suggestive of irritable bowel syndrome. Peptic ulcer disease must be considered, while in older people intra-abdominal malignancy is a prime concern. There are no diagnostic signs, apart from inappropriate tenderness on abdominal palpation, perhaps. Symptoms may appear disproportionate to clinical well-being and there is no weight loss. Patients often appear anxious. A drug history should be taken and the possibility of a depressive illness should be considered. Pregnancy should be ruled out in young women before radiological studies are undertaken. Alcohol misuse should be suspected when early-morning nausea and retching are prominent.</ce:para></ce:section><ce:section id="s1175"><ce:section-title id="st1135">Investigations</ce:section-title><ce:para id="p3420">The history will often suggest the diagnosis. All patients should be checked for <ce:italic>H. pylori</ce:italic> infection and patients over the age of 55 years should undergo endoscopy to exclude mucosal disease. While an ultrasound scan may detect gallstones, these are rarely responsible for dyspeptic symptoms.</ce:para></ce:section><ce:section id="s1180"><ce:section-title id="st1140">Management</ce:section-title><ce:para id="p3425">The most important elements are explanation and reassurance. Possible psychological factors should be explored and the concept of psychological influences on gut function should be explained. Idiosyncratic and restrictive diets are of little benefit but smaller portions and fat restriction may help.</ce:para><ce:para id="p3430">Up to 10% of patients benefit from <ce:italic>H. pylori</ce:italic> eradication therapy and this should be offered to infected individuals. Eradication also removes a major risk factor for peptic ulcers and gastric cancer but at the cost of a small risk of side-effects and worsening symptoms of underlying gastro-oesophageal reflux disease. Drug treatment is not especially successful but merits trial. Antacids, such as hydrotalcite, are sometimes helpful. Prokinetic drugs, such as metoclopramide (10 mg 3 times daily) or domperidone (10–20 mg 3 times daily), may be given before meals if nausea, vomiting or bloating is prominent. Metoclopramide may induce extrapyramidal side-effects, including tardive dyskinesia in young patients. H<ce:inf loc="post">2</ce:inf>-receptor antagonist drugs may be tried if night pain or heartburn is troublesome. Low-dose tricyclic agents, such as amitriptyline, are of value in up to two-thirds.</ce:para><ce:para id="p3435">Symptoms that can be associated with an identifiable cause of stress resolve with appropriate counselling. Some patients have major psychological disorders that result in persistent or recurrent symptoms and need behavioural or other formal psychotherapy (<ce:intra-ref id="ii0290" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0435">p. 1190</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s1185"><ce:section-title id="st1145">Functional causes of vomiting</ce:section-title><ce:para id="p3440">Psychogenic retching or vomiting may arise in anxiety. It typically occurs on wakening or immediately after breakfast, and only rarely later in the day. The disorder is probably a reaction to facing up to the worries of everyday life; in the young, it can be due to school phobia. Early morning vomiting also occurs in pregnancy, alcohol misuse and depression. Although functional vomiting may occur regularly over long periods, there is little or no weight loss. Children, and less often adults, sometimes suffer from acute and recurrent disabling bouts of vomiting for days at a time. The cause of this cyclical vomiting syndrome is unknown but in some adults it is associated with cannabis use.</ce:para><ce:para id="p3445">In all patients it is essential to exclude other common causes (<ce:cross-ref id="crf9120" refid="s0390">p. 780</ce:cross-ref>). Tranquillisers and antiemetic drugs (metoclopramide 10 mg 3 times daily, domperidone 10 mg 3 times daily, prochlor­perazine 5–10 mg 3 times daily) have only a secondary place in management. Antidepressants in full dose may be effective (<ce:intra-ref id="ii0300" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0820">p. 1199</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1190"><ce:section-title id="st1150">Gastroparesis</ce:section-title><ce:para id="p3450">Defective gastric emptying without mechanical obstruction of the stomach or duodenum can occur as a primary event, due to inherited or acquired disorders of the gastric pacemaker, or can be secondary to disorders of autonomic nerves (particularly diabetic neuropathy) or the gastroduodenal musculature (systemic sclerosis, myotonic dystrophies and amyloidosis). Drugs such as opiates, calcium channel antagonists and those with anticholinergic activity (tricyclics, phenothiazines) can also cause gastroparesis. Early satiety and recurrent vomiting are the major symptoms; abdominal fullness and a succussion splash may be present on examination. Treatment is based on small, frequent, low-fat meals and the use of metoclopramide and domperidone. In severe cases, nutritional failure can occur and long-term jejunostomy feeding or total parenteral nutrition is required. Surgical insertion of a gastric neurostimulator has been successful in some cases, especially those complicating diabetic autonomic neuropathy.</ce:para></ce:section></ce:section><ce:section id="s1195"><ce:section-title id="st1155">Tumours of the stomach</ce:section-title><ce:section id="s1200"><ce:section-title id="st1160">Gastric carcinoma</ce:section-title><ce:para id="p3455">Gastric carcinoma is the third leading cause of cancer death worldwide but there is marked geographical variation in incidence. It is most common in China, Japan, Korea (incidence 40/100 000 males), Eastern Europe and parts of South America (20/100 000). Rates in the UK are 12/100 000 for men. In most countries, the incidence is 50% lower in women. In both sexes, it rises sharply after 50 years of age. Studies of Japanese migrants to the USA have revealed a much lower incidence in the second generation, confirming the importance of environmental factors. The overall prognosis is poor, with less than 30% surviving 5 years, and the best hope for improved survival lies in more efficient detection of tumours at an earlier stage.</ce:para><ce:section id="s1205"><ce:section-title id="st1165">Pathophysiology</ce:section-title><ce:para id="p3460">Infection with <ce:italic>H. pylori</ce:italic> plays a key pathogenic role and the infection has been classified by the International Agency for Research on Cancer (IARC) as a definite human carcinogen. It is associated with chronic atrophic gastritis, gastric mucosal atrophy and gastric cancer (<ce:cross-ref id="crf0765" refid="f0215">Fig. 21.39</ce:cross-ref><ce:float-anchor refid="f0215"/>). It has been estimated that <ce:italic>H. pylori</ce:italic> infection may contribute to the occurrence of gastric cancer in 70% of cases. Although the majority of <ce:italic>H. pylori-</ce:italic>infected individuals have normal or increased acid secretion, a few become hypo- or achlorhydric and these people are thought to be at greatest risk. <ce:italic>H. pylori</ce:italic>-induced chronic inflammation with generation of reactive oxygen species and depletion of the normally abundant antioxidant ascorbic acid are also important. There is strong evidence that <ce:italic>H. pylori</ce:italic> eradication, especially if achieved before irreversible pre-neoplastic changes (atrophy and intestinal metaplasia) have developed, reduces the risk of cancer development in high-risk populations and is cost-effective.</ce:para><ce:para id="p3465">Diets rich in salted, smoked or pickled foods and the consumption of nitrites and nitrates may increase cancer risk. Carcinogenic <ce:italic>N</ce:italic>-nitroso-compounds are formed from nitrates by the action of nitrite-reducing bacteria that colonise the achlorhydric stomach. Diets lacking in fresh fruit and vegetables, as well as vitamins C and A, may also contribute. Other risk factors are listed in <ce:cross-ref id="crf0770" refid="b0215">Box 21.40</ce:cross-ref><ce:float-anchor refid="b0215"/>. No predominant genetic abnormality has been identified, although cancer risk is increased two- to threefold in first-degree relatives of patients, and links with blood group A have been reported. Some host genetic factors related to inflammatory genes and prostate stem cell antigen have recently been associated with increased risk of gastric caner. Rarely, gastric cancer may be inherited in an autosomal dominant manner in association with mutations of the <ce:italic>E-cadherin</ce:italic> (<ce:italic>CDH1</ce:italic>) gene.</ce:para><ce:para id="p3525">Virtually all tumours are adenocarcinomas arising from mucus-secreting cells in the base of the gastric crypts. Most develop on a background of chronic atrophic gastritis with intestinal metaplasia and dysplasia. Cancers are either ‘intestinal’, arising from areas of intestinal metaplasia with histological features reminiscent of intestinal epithelium, or ‘diffuse’, arising from normal gastric mucosa. Intestinal carcinomas are more common and arise against a background of chronic mucosal injury. Diffuse cancers tend to be poorly differentiated and occur in younger patients. In the developing world, 50% of gastric cancers develop in the antrum; 20–30% occur in the gastric body, often on the greater curve; and 20% are found in the cardia. In Western populations, however, proximal gastric tumours are becoming more common than those arising in the body and distal stomach. This change in disease pattern may be a reflection of changes in lifestyle or the decreasing prevalence of <ce:italic>H. pylori</ce:italic> in the West. Diffuse submucosal infiltration by a scirrhous cancer (linitis plastica) is uncommon. Early gastric cancer is defined as cancer confined to the mucosa or submucosa. It is more often recognised in Japan, where widespread screening is practised. Some cases can be cured by endoscopic mucosal or submucosal resection. The majority of patients (&#x003E; 80%) in the West, however, present with advanced gastric cancer.</ce:para></ce:section><ce:section id="s1210"><ce:section-title id="st1170">Clinical features</ce:section-title><ce:para id="p3530">Early gastric cancer is usually asymptomatic but may be discovered during endoscopy for investigation of dyspepsia. Two-thirds of patients with advanced cancers have weight loss and 50% have ulcer-like pain. Anorexia and nausea occur in one-third, while early satiety, haematemesis, melaena and dyspepsia alone are less common. Dysphagia occurs in tumours of the gastric cardia that obstruct the gastro-oesophageal junction. Anaemia from occult bleeding is also common. Examination may reveal no abnormalities but signs of weight loss, anaemia and a palpable epigastric mass are not infrequent. Jaundice or ascites signifies metastatic spread. Occasionally, tumour spread occurs to the supraclavicular lymph nodes (Troisier's sign), umbilicus (Sister Joseph's nodule) or ovaries (Krukenberg tumour). Paraneoplastic phenomena, such as acanthosis nigricans, thrombophlebitis (Trousseau's sign) and dermatomyositis, occur rarely. Metastases arise most commonly in the liver, lungs, peritoneum and bone marrow.</ce:para></ce:section><ce:section id="s1215"><ce:section-title id="st1175">Investigations</ce:section-title><ce:para id="p3535">Upper gastrointestinal endoscopy is the investigation of choice (<ce:cross-ref id="crf0775" refid="f0220">Fig. 21.40</ce:cross-ref><ce:float-anchor refid="f0220"/>) and should be performed promptly in any dyspeptic patient with ‘alarm features’ (see <ce:cross-ref id="crf0780" refid="b0090">Box 21.15</ce:cross-ref>, <ce:cross-ref id="crf9125" refid="s0380">p. 779</ce:cross-ref>). Multiple biopsies from the edge and base of a gastric ulcer are required. Barium meal is a poor alternative, since any abnormalities must be followed by endoscopy and biopsy. Once the diagnosis is made, further imaging is necessary for staging and assessment of resectability. CT will provide evidence of intra-abdominal spread or liver metastases. Even with these techniques, laparoscopy with peritoneal washings is required to determine whether the tumour is resectable, as it is the only modality that will reliably detect peritoneal spread.</ce:para></ce:section><ce:section id="s1220"><ce:section-title id="st1180">Management</ce:section-title><ce:section id="s1225"><ce:section-title id="st1185">Surgery</ce:section-title><ce:para id="p3540">Resection offers the only hope of cure and this can be achieved in about 90% of patients with early gastric cancer. For the majority of patients with locally advanced disease, total gastrectomy with lymphadenectomy is the operation of choice, preserving the spleen if possible. Proximal tumours involving the oesophago-gastric junction also require a distal oesophagectomy. Small, distally sited tumours can be managed by a partial gastrectomy with lymphadenectomy and either a Billroth I or a Roux en Y reconstruction. More extensive lymph node resection may increase survival rates but carries greater morbidity. Even for those who cannot be cured, palliative resection may be necessary when patients present with bleeding or gastric outflow obstruction. Following surgery, recurrence is much more likely if serosal penetration has occurred, although complete removal of all macroscopic tumour combined with lymphadenectomy will achieve a 50–60% 5-year survival. Perioperative chemotherapy with epirubicin, cisplatin and fluorouracil (ECF) improves survival rates.</ce:para></ce:section><ce:section id="s1230"><ce:section-title id="st1190">Palliative treatment</ce:section-title><ce:para id="p3545">In patients with inoperable tumours, survival can be improved and palliation of symptoms achieved with chemotherapy using 5-fluorouracil and cisplatin, ECF or other platinum- and taxane-based regimens. The biological agent trastuzumab may benefit some patients whose tumours over-express HER2 (<ce:intra-ref id="ii0315" xlink:href="pii:B978-0-7020-7028-0.00033-0#p0545">p. 1322</ce:intra-ref>). Endoscopic laser ablation for control of dysphagia or recurrent bleeding benefits some patients. Carcinomas at the cardia or pylorus may require endoscopic dilatation or insertion of expandable metallic stents for relief of dysphagia or vomiting. A nasogastric tube may offer temporary relief of vomiting due to gastric outlet obstruction (<ce:cross-ref id="crf0785" refid="b0220">Box 21.41</ce:cross-ref><ce:float-anchor refid="b0220"/>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s1250"><ce:section-title id="st1210">Gastric lymphoma</ce:section-title><ce:para id="p3670">This is a rare tumour, accounting for less than 5% of all gastric malignancies. The stomach is, however, the most common site for extranodal non-Hodgkin lymphoma and 60% of all primary gastrointestinal lymphomas occur at this site. Lymphoid tissue is not found in the normal stomach but lymphoid aggregates develop in the presence of <ce:italic>H. pylori</ce:italic> infection. Indeed, <ce:italic>H. pylori</ce:italic> infection is closely associated with the development of a low-grade lymphoma (classified as extranodal marginal-zone lymphomas of MALT type). EUS plays an important role in staging these lesions by accurately defining the depth of invasion into the gastric wall.</ce:para><ce:para id="p3675">The clinical presentation is similar to that of gastric cancer and endoscopically the tumour appears as a polypoid or ulcerating mass. While initial treatment of low-grade lesions confined to the superficial layers of the gastric wall consists of <ce:italic>H. pylori</ce:italic> eradication and close observation, 25% contain t(11 : 18) chromosomal translocations. In these cases, additional radiotherapy or chemotherapy is usually necessary. High-grade B-cell lymphomas should be treated by a combination of rituximab, chemotherapy (<ce:intra-ref id="ii0320" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1335">p. 962</ce:intra-ref>), surgery and radiotherapy. The choice depends on the site and extent of tumour, the presence of comorbid illnesses, and other factors, such as symptoms of bleeding and gastric outflow obstruction. The prognosis depends on the stage at diagnosis. Features predicting a favourable prognosis are stage I or II disease, small resectable tumours, tumours with low-grade histology, and age below 60 years.</ce:para></ce:section><ce:section id="s1255"><ce:section-title id="st1215">Other tumours of the stomach</ce:section-title><ce:para id="p3680">Gastrointestinal stromal cell tumours (GISTs), arising from the interstitial cells of Cajal, are occasionally found at upper gastrointestinal endoscopy. They are differentiated from other mesenchymal tumours by expression of the <ce:italic>c-kit</ce:italic> proto-oncogene, which encodes a tyrosine kinase receptor. These tumours, particularly the smaller lesions of less than 2 cm, are usually benign and asymptomatic, but the larger ones may have malignant potential and may occasionally be responsible for dyspepsia, ulceration and gastrointestinal bleeding. Small lesions (&#x003C; 2 cm) are usually followed by endoscopy, while larger ones require surgical resection. Very large lesions should be treated pre-operatively with imatinib (a tyrosine kinase inhibitor) to reduce their size and make surgery easier. Imatinib can also provide prolonged control of metastatic GISTs.</ce:para><ce:para id="p3685">A variety of polyps occur. Hyperplastic polyps and fundic cystic gland polyps are common and of no consequence. Adenomatous polyps are rare but have malignant potential and should be removed endoscopically.</ce:para><ce:para id="p3690">Occasionally, gastric carcinoid tumours are seen in the fundus and body in patients with long-standing pernicious anaemia. These benign tumours arise from ECL or other endocrine cells, and are often multiple but rarely invasive. Unlike carcinoid tumours arising elsewhere in the gastrointestinal tract, they usually run a benign and favourable course. Large (&#x003E; 2 cm) carcinoids may, however, metastasise and should be removed. Rarely, small nodules of ectopic pancreatic exocrine tissue are found. These ‘pancreatic rests’ may be mistaken for gastric neoplasms and usually cause no symptoms. EUS is the most useful investigation.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1260"><ce:section-title id="st1220">Diseases of the small intestine</ce:section-title><ce:section id="s1265"><ce:section-title id="st1225">Disorders causing malabsorption</ce:section-title><ce:section id="s1270"><ce:section-title id="st1230">Coeliac disease</ce:section-title><ce:para id="p3695">Coeliac disease is an inflammatory disorder of the small bowel occurring in genetically susceptible individuals, which results from intolerance to wheat gluten and similar proteins found in rye, barley and, to a lesser extent, oats. It can result in malabsorption and responds to a gluten-free diet. The condition occurs worldwide but is more common in northern Europe. The prevalence in the UK is approximately 1%, although 50% of these people are asymptomatic. These include both undiagnosed ‘silent’ cases of the disease and cases of ‘latent’ coeliac disease – genetically susceptible people who may later develop clinical coeliac disease.</ce:para><ce:section id="s1275"><ce:section-title id="st1235">Pathophysiology</ce:section-title><ce:para id="p3700">The precise mechanism of mucosal damage is unclear but immunological responses to gluten play a key role (<ce:cross-ref id="crf0790" refid="f0225">Fig. 21.41</ce:cross-ref><ce:float-anchor refid="f0225"/>). There is a strong genetic component, with around 10% of first-degree relatives of an index case affected, and there is strong (approximately 75%) concordance in monozygotic twins. There is a strong association with human leukocyte antigen (HLA)-DQ2/DQ8. Dysbiosis of the intestinal microbiota has been identified but it is unclear if this is pathological or a response to the underlying mucosal changes.</ce:para></ce:section><ce:section id="s1280"><ce:section-title id="st1240">Clinical features</ce:section-title><ce:para id="p3705">Coeliac disease can present at any age. In infancy, it occurs after weaning on to cereals and typically presents with diarrhoea, malabsorption and failure to thrive. In older children, it may present with non-specific features, such as delayed growth. Features of malnutrition are found on examination and mild abdominal distension may be present. Affected children have growth and pubertal delay, leading to short stature in adulthood.</ce:para><ce:para id="p3710">In adults, the disease usually presents during the third or fourth decade and females are affected twice as often as males. The presentation is highly variable, depending on the severity and extent of small bowel involvement. Some have florid malabsorption, while others develop non-specific symptoms, such as tiredness, weight loss, folate deficiency or iron deficiency anaemia. Other presentations include oral ulceration, dyspepsia and bloating. Unrecognised coeliac disease is associated with mild under-nutrition and osteoporosis.</ce:para><ce:para id="p3715">Coeliac disease is associated with other HLA-linked autoimmune disorders and with certain other diseases (<ce:cross-ref id="crf0795" refid="b0225">Box 21.42</ce:cross-ref><ce:float-anchor refid="b0225"/>). In some centres, people at higher risk of developing coeliac disease, such as those with type 1 diabetes, may undergo periodic antibody screening. Such screening may identify people with asymptomatic or minimally symptomatic disease; there is controversy about the optimum management strategy for such individuals.</ce:para></ce:section><ce:section id="s1285"><ce:section-title id="st1245">Investigations</ce:section-title><ce:para id="p3835">These are performed to confirm the diagnosis and to look for consequences of malabsorption.</ce:para><ce:section id="s1290"><ce:section-title id="st1250">Duodenal biopsy</ce:section-title><ce:para id="p3840">Endoscopic small bowel biopsy is the gold standard. Endoscopic appearances should not preclude biopsy, as the mucosa usually looks normal. As the histological changes can be patchy, an adequate number of biopsies – currently, more than four biopsies from the second part of the duodenum plus one from the duodenal bulb – should be retrieved. The histological features are usually characteristic but other causes of villous atrophy should be considered (<ce:cross-ref id="crf0800" refid="b0230">Box 21.43</ce:cross-ref><ce:float-anchor refid="b0230"/> and <ce:cross-ref id="crf0805" refid="f0230">Fig. 21.42</ce:cross-ref><ce:float-anchor refid="f0230"/>). Sometimes the villi appear normal but there are excess numbers of intra-epithelial lymphocytes (lymphocytic duodenosis).</ce:para></ce:section><ce:section id="s1295"><ce:section-title id="st1255">Antibodies</ce:section-title><ce:para id="p3900">Antibody tests constitute a valuable screening tool in patients with diarrhoea or other suggestive symptoms but are not a diagnostic substitute for small bowel biopsy at present. Tissue transglutaminase (tTG) is now recognised as the autoantigen for anti-endomysial antibodies. If the antibody screen is positive, adult patients should remain on a gluten-containing diet until duodenal biopsies are taken. High-titre serology in children can be diagnostic without the need for endoscopy and biopsy. Antibody titres usually become negative with successful treatment.</ce:para><ce:para id="p3905">Anti-endomysial antibodies of the IgA class are detectable by immunofluorescence in most untreated cases. They are sensitive (85–95%) and specific (approximately 99%) for the diagnosis, except in very young infants. IgG antibodies, however, must be analysed in patients with coexisting IgA deficiency. The tTG assay has become the serological test of choice in many countries, as it is easier to perform, is semi-quantitative, has more than 95% sensitivity and specificity, and is more accurate in patients with IgA deficiency.</ce:para></ce:section><ce:section id="s1300"><ce:section-title id="st1260">Haematology and biochemistry</ce:section-title><ce:para id="p3910">A full blood count may show microcytic or macrocytic anaemia from iron or folate deficiency and features of hyposplenism (target cells, spherocytes and Howell–Jolly bodies). Biochemical tests may reveal reduced concentrations of calcium, magnesium, total protein, albumin or vitamin D. Serum IgA measurement is required to ensure an appropriate IgA response and to allow analysis of serological testing.</ce:para></ce:section><ce:section id="s1305"><ce:section-title id="st1265">Other investigations</ce:section-title><ce:para id="p3915">Measurement of bone density should be considered to look for evidence of osteoporosis, especially in older patients and post-menopausal women.</ce:para></ce:section></ce:section><ce:section id="s1310"><ce:section-title id="st1270">Management</ce:section-title><ce:para id="p3920">The aims are to correct existing deficiencies of micronutrients, such as iron, folate, calcium and/or vitamin D, and to achieve mucosal healing through a life-long gluten-free diet. This requires the exclusion of wheat, rye, barley and initially oats, although oats may be re-introduced safely in most patients after 6–12 months. Initially, frequent dietary counselling is required to make sure the diet is being observed, as the most common reason for failure to improve with dietary treatment is accidental or unrecognised gluten ingestion. Mineral and vitamin supplements are also given when indicated but are seldom necessary when a strict gluten-free diet is adhered to. Booklets produced by coeliac societies in many countries, containing diet sheets and recipes for the use of gluten-free flour, are of great value. Dietetic follow-up is key to management. Patients should be followed up after initiation of a gluten-free diet, with assessment of symptoms, weight and nutritional status, and blood should be taken for measurement of tTG or anti-endomysial antibodies. There are currently no additional non-invasive tests to assess small bowel mucosal healing. Repeat small bowel biopsies are not required routinely but should be considered in patients whose symptoms fail to improve and those in whom antibody levels remain high. In these circumstances, if the diet is satisfactory, then other conditions, such as pancreatic insufficiency or microscopic colitis, should be sought, as should complications of coeliac disease, such as ulcerative jejunitis or enteropathy-associated T-cell lymphoma. There remain a small number of patients who fail to respond adequately to a gluten-free diet and they require therapy with glucocorticoids or immunosuppressive drugs.</ce:para></ce:section><ce:section id="s1315"><ce:section-title id="st1275">Complications</ce:section-title><ce:para id="p3925">A twofold-increased risk of malignancy, particularly of enteropathy-associated T-cell lymphoma, small bowel carcinoma and squamous carcinoma of the oesophagus, has been reported.</ce:para><ce:para id="p3930">A few patients develop ulcerative jejuno-ileitis. This may present with fever, pain, obstruction or perforation. This diagnosis can be made by barium studies or enteroscopy but laparotomy and full-thickness biopsy may be required. Treatment is difficult. Glucocorticoids are used with mixed success and some patients require surgical resection and parenteral nutrition. The course is often progressive.</ce:para><ce:para id="p3935">Osteoporosis and osteomalacia may occur in patients with long-standing, poorly controlled coeliac disease. These complications are less common in those who adhere strictly to a gluten-free diet.</ce:para></ce:section></ce:section><ce:section id="s1320"><ce:section-title id="st1280">Dermatitis herpetiformis</ce:section-title><ce:para id="p3940">This is characterised by crops of intensely itchy blisters over the elbows, knees, back and buttocks (<ce:intra-ref id="ii0325" xlink:href="pii:B978-0-7020-7028-0.00029-9#p2915">p. 1256</ce:intra-ref>). Immunofluorescence shows granular or linear IgA deposition at the dermo-epidermal junction. Almost all patients have partial villous atrophy on duodenal biopsy, identical to that seen in coeliac disease, even though they usually have no gastrointestinal symptoms. In contrast, fewer than 10% of coeliac patients have evidence of dermatitis herpetiformis, although both disorders are associated with the same histocompatibility antigen groups. The rash usually responds to a gluten-free diet but some patients require additional treatment with dapsone (100–150 mg daily).</ce:para></ce:section><ce:section id="s1325"><ce:section-title id="st1285">Tropical sprue</ce:section-title><ce:para id="p3945">Tropical sprue is defined as chronic, progressive malabsorption in a patient in or from the tropics, associated with abnormalities of small intestinal structure and function. The disease occurs mainly in the West Indies and in southern India, Malaysia and Indonesia.</ce:para><ce:section id="s1330"><ce:section-title id="st1290">Pathophysiology</ce:section-title><ce:para id="p3950">The epidemiological pattern and occasional epidemics suggest that an infective agent may be involved. Although no single bacterium has been isolated, the condition often begins after an acute diarrhoeal illness. Small bowel bacterial overgrowth with <ce:italic>Escherichia coli</ce:italic>, <ce:italic>Enterobacter</ce:italic> and <ce:italic>Klebsiella</ce:italic> is frequently seen. The changes closely resemble those of coeliac disease.</ce:para></ce:section><ce:section id="s1335"><ce:section-title id="st1295">Clinical features</ce:section-title><ce:para id="p3955">There is diarrhoea, abdominal distension, anorexia, fatigue and weight loss. In visitors to the tropics, the onset of severe diarrhoea may be sudden and accompanied by fever. When the disorder becomes chronic, the features of megaloblastic anaemia (vitamin B<ce:inf loc="post">12</ce:inf> and folic acid malabsorption) and other deficiencies, including ankle oedema, glossitis and stomatitis, are common. Remissions and relapses may occur. The differential diagnosis in the indigenous tropical population is an infective cause of diarrhoea. The important differential diagnosis in visitors to the tropics is giardiasis (<ce:intra-ref id="ii0330" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2335">p. 287</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1340"><ce:section-title id="st1300">Management</ce:section-title><ce:para id="p3960">Tetracycline (250 mg 4 times daily for 28 days) is the treatment of choice and brings about long-term remission or cure. In most patients, pharmacological doses of folic acid (5 mg daily) improve symptoms and jejunal morphology. In some cases, treatment must be prolonged before improvement occurs and occasionally patients must leave the tropics.</ce:para></ce:section></ce:section><ce:section id="s1345"><ce:section-title id="st1305">Small bowel bacterial overgrowth (‘blind loop syndrome’)</ce:section-title><ce:para id="p3965">The normal duodenum and jejunum contain fewer than 10<ce:sup loc="post">4</ce:sup>/mL organisms, which are usually derived from saliva. The count of coliform organisms never exceeds 10<ce:sup loc="post">3</ce:sup>/mL. In bacterial overgrowth, there may be 10<ce:sup loc="post">8</ce:sup>–10<ce:sup loc="post">10</ce:sup>/mL organisms, most of which are normally found only in the colon. Disorders that impair the normal physiological mechanisms controlling bacterial proliferation in the intestine predispose to bacterial overgrowth (<ce:cross-ref id="crf0810" refid="b0235">Box 21.44</ce:cross-ref><ce:float-anchor refid="b0235"/>). The most important are loss of gastric acidity, impaired intestinal motility and structural abnormalities that allow colonic bacteria to gain access to the small intestine or provide a secluded haven from the peristaltic stream.</ce:para><ce:section id="s1350"><ce:section-title id="st1310">Pathophysiology</ce:section-title><ce:para id="p3975">Bacterial overgrowth can occur in patients with small bowel diverticuli. Another cause is diabetic autonomic neuropathy (<ce:intra-ref id="ii0335" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0855">p. 760</ce:intra-ref>), which reduces small bowel motility and affects enterocyte secretion. In systemic sclerosis, bacterial overgrowth arises because the circular and longitudinal layers of the intestinal muscle are fibrosed and motility is abnormal. In idiopathic hypogammaglobulinaemia (<ce:intra-ref id="ii0340" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0345">p. 78</ce:intra-ref>), bacterial overgrowth occurs because the IgA and IgM levels in serum and jejunal secretions are reduced. Chronic diarrhoea and malabsorption occur because of bacterial overgrowth and recurrent gastrointestinal infections (particularly giardiasis, <ce:intra-ref id="ii0345" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2335">p. 287</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1355"><ce:section-title id="st1315">Clinical features</ce:section-title><ce:para id="p3980">The patient presents with watery diarrhoea and/or steatorrhoea, and with anaemia due to B<ce:inf loc="post">12</ce:inf> deficiency. These arise because of deconjugation of bile acids, which impairs micelle formation, and because of bacterial utilisation of vitamin B<ce:inf loc="post">12</ce:inf>. There may also be symptoms from the underlying intestinal cause.</ce:para></ce:section><ce:section id="s1360"><ce:section-title id="st1320">Investigations</ce:section-title><ce:para id="p3985">The diagnosis of blind loops or fistulae can often be made by barium small bowel meal and follow-through or small bowel MRI enterography. Endoscopic duodenal biopsies are useful in excluding coeliac disease. Jejunal contents for bacteriological examination can also be aspirated at endoscopy but laboratory analysis requires anaerobic and aerobic culture techniques. Bacterial overgrowth can also be diagnosed non-invasively using hydrogen breath tests, although they lack sensitivity. These simple, non-radioactive tests involve serial measurement of breath samples for hydrogen after oral ingestion of 50 g of glucose or lactulose. If bacteria are present within the small bowel, they rapidly metabolise the glucose, causing an early rise in exhaled hydrogen, in advance of that normally resulting from metabolism by colonic flora. Biochemical analysis may reveal low serum levels of vitamin B<ce:inf loc="post">12</ce:inf>, with normal or elevated folate levels because the bacteria produce folic acid. Hypogammaglobulinaemia can be diagnosed by measurement of serum immunoglobulins and by intestinal biopsy, which shows reduced or absent plasma cells and nodular lymphoid hyperplasia.<ce:display><ce:textbox id="b0240" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0485" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000214/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1365" role="short">Image 84</ce:alt-text></ce:inline-figure> 21.45</ce:label><ce:alt-text id="atte1370" role="short">21.45</ce:alt-text><ce:textbox-head><ce:title id="tit0245">Malabsorption in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3990"><ce:list id="ulist0725"><ce:list-item id="u2390"><ce:label>•</ce:label><ce:para id="p3995"><ce:bold>Coeliac disease</ce:bold>: symptoms such as dyspepsia tend to be vague; only 25% present classically with diarrhoea and weight loss. Metabolic bone disease, folate or iron deficiency, coagulopathy and small bowel lymphoma are more common.</ce:para></ce:list-item><ce:list-item id="u2395"><ce:label>•</ce:label><ce:para id="p4000"><ce:bold>Small bowel bacterial overgrowth</ce:bold>: more common due to atrophic gastritis, resulting in hypo- or achlorhydria, increased prevalence of jejunal diverticulosis and long-term adverse effects of gastric surgery for ulcer disease.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section><ce:section id="s1365"><ce:section-title id="st1325">Management</ce:section-title><ce:para id="p4005">The underlying cause of small bowel bacterial overgrowth should be addressed, where possible. A course of broad-spectrum antibiotic for 2 weeks is the first-line treatment, although there is no consensus on agent or dose. Examples include tetracycline (250 mg 4 times daily), metronidazole (400 mg 3 times daily), amoxicillin (250 mg 3 times daily) or ciprofloxacin (250 mg twice daily). If breath testing reveals high methane production, addition of neomycin (500 mg twice daily) may be beneficial. Up to 50% of patients do not respond adequately and relapse rates are high. Some patients require up to 4 weeks of treatment and, in a few, continuous rotating courses of antibiotics are necessary. Consideration should be given to the risk of emerging antimicrobial resistance. Intramuscular vitamin B<ce:inf loc="post">12</ce:inf> supplementation may be needed in chronic cases, as the bacteria utilise vitamin B<ce:inf loc="post">12</ce:inf>. Patients with motility disorders, such as diabetes and systemic sclerosis, can sometimes benefit from antidiarrhoeal drugs (diphenoxylate (5 mg 3 times daily orally) or loperamide (2 mg 4–6 times daily) orally). Giardiasis should be controlled in patients with hypogammaglobulinaemia using metronidazole or tinidazole, but if symptoms fail to respond adequately, immunoglobulin infusions may be required.</ce:para></ce:section></ce:section><ce:section id="s1370"><ce:section-title id="st1330">Whipple's disease</ce:section-title><ce:para id="p4010">This rare condition is characterised by infiltration of small intestinal mucosa by ‘foamy’ macrophages, which stain positive with periodic acid–Schiff (PAS) reagent. The disease is a multisystem one and almost any organ can be affected, sometimes long before gastrointestinal involvement becomes apparent (<ce:cross-ref id="crf0825" refid="b0245">Box 21.46</ce:cross-ref><ce:float-anchor refid="b0245"/>).</ce:para><ce:section id="s1375"><ce:section-title id="st1335">Pathophysiology</ce:section-title><ce:para id="p4145">Whipple's disease is caused by infection with the Gram-positive bacillus <ce:italic>Tropheryma whipplei</ce:italic>, which becomes resident within macrophages in the bowel mucosa. Villi are widened and flattened, containing densely packed macrophages in the lamina propria, which obstruct lymphatic drainage and cause fat malabsorption.</ce:para></ce:section><ce:section id="s1380"><ce:section-title id="st1340">Clinical features</ce:section-title><ce:para id="p4150">Middle-aged Caucasian men are most frequently affected and presentation depends on the pattern of organ involvement. Low-grade fever is common and most patients have joint symptoms to some degree, often as the first manifestation. Occasionally, neurological manifestations may predominate and CNS involvement is the most serious consequence.</ce:para></ce:section><ce:section id="s1385"><ce:section-title id="st1345">Investigations</ce:section-title><ce:para id="p4155">Diagnosis is made by the characteristic features on small bowel biopsy, with characterisation of the bacillus by polymerase chain reaction (PCR).</ce:para></ce:section><ce:section id="s1390"><ce:section-title id="st1350">Management</ce:section-title><ce:para id="p4160">Whipple's disease is often fatal if untreated but responds well, at least initially, to intravenous ceftriaxone (2 g daily for 2 weeks), followed by oral co-trimoxazole for at least 1 year. Symptoms usually resolve quickly and biopsy changes revert to normal in a few weeks. Long-term follow-up is essential, as clinical relapse occurs in up to one-third of patients, often within the CNS; in this case, the same therapy is repeated or else treatment with doxycycline and hydroxychloroquine is necessary.</ce:para></ce:section></ce:section><ce:section id="s1395"><ce:section-title id="st1355">Bile acid diarrhoea</ce:section-title><ce:para id="p4165">Bile acid diarrhoea can occur idiopathically (type 1), as a complication of small bowel resection, post cholecystectomy (type 2) or in association with other conditions such as microscopic colitis, chronic pancreatitis, coeliac disease, small intestinal bacterial overgrowth or diabetes mellitus. The population prevalence is estimated at around 1% and the disease is often under-diagnosed. It is now appreciated that many patients diagnosed with diarrhoea-predominant irritable bowel syndrome have evidence of bile acid diarrhoea. The most common scenario is in patients with Crohn's disease who have undergone ileal resection, which can also lead to other malabsorptive manifestations (<ce:cross-ref id="crf0830" refid="f0235">Fig. 21.43</ce:cross-ref><ce:float-anchor refid="f0235"/>). Unabsorbed bile salts pass into the colon, stimulating water and electrolyte secretion and causing diarrhoea. If hepatic synthesis of new bile acids cannot keep pace with faecal losses, fat malabsorption occurs. Another consequence is the formation of lithogenic bile, leading to gallstones. Renal calculi, rich in oxalate, develop. Normally, oxalate in the colon is bound to and precipitated by calcium. Unabsorbed bile salts preferentially bind calcium, leaving oxalate to be absorbed, with development of urinary oxalate calculi.</ce:para><ce:para id="p4170">Patients have urgent watery diarrhoea or mild steatorrhoea. Contrast studies and tests of B<ce:inf loc="post">12</ce:inf> and bile acid absorption, such as the <ce:sup loc="post">75</ce:sup>Se-homocholic acid taurine (SeHCAT) test (<ce:cross-ref id="crf9130" refid="s0310">p. 777</ce:cross-ref>), are useful investigations but are not available throughout the world due to use of synthetic radio-labelled compound. An elevated serum 7α-hydroxycholestenone is a useful non-invasive marker of bile acid diarrhoea. Diarrhoea usually responds well to bile acid sequestrants, such as colestyramine or colesevelam, which bind bile salts in the intestinal lumen. Aluminium hydroxide can be used as an alternative.</ce:para></ce:section><ce:section id="s1400"><ce:section-title id="st1360">Short bowel syndrome</ce:section-title><ce:para id="p4175">This is discussed in detail on <ce:intra-ref id="ii0355" xlink:href="pii:B978-0-7020-7028-0.00019-6#s0365">page 708</ce:intra-ref>.</ce:para></ce:section><ce:section id="s1405"><ce:section-title id="st1365">Radiation enteritis and proctocolitis</ce:section-title><ce:para id="p4180">Intestinal damage occurs in 10–15% of patients undergoing radiotherapy for abdominal or pelvic malignancy. The risk varies with total dose, dosing schedule and the use of concomitant chemotherapy.</ce:para><ce:section id="s1410"><ce:section-title id="st1370">Pathophysiology</ce:section-title><ce:para id="p4185">The rectum, sigmoid colon and terminal ileum are most frequently involved. Radiation causes acute inflammation, shortening of villi, oedema and crypt abscess formation. These usually resolve completely but some patients develop an obliterative endarteritis affecting the endothelium of submucosal arterioles over 2–12 months. In the longer term, this can provoke a fibrotic reaction, leading to adhesions, ulceration, strictures, obstruction or fistula to adjacent organs.</ce:para></ce:section><ce:section id="s1415"><ce:section-title id="st1375">Clinical features</ce:section-title><ce:para id="p4190">In the acute phase, there is nausea, vomiting, cramping abdominal pain and diarrhoea. When the rectum and colon are involved, rectal mucus, bleeding and tenesmus occur. The chronic phase develops after 5–10 years in some patients and produces one or more of the problems listed in <ce:cross-ref id="crf0835" refid="b0250">Box 21.47</ce:cross-ref><ce:float-anchor refid="b0250"/>.</ce:para></ce:section><ce:section id="s1420"><ce:section-title id="st1380">Investigations</ce:section-title><ce:para id="p4230">In the acute phase, the rectal changes at sigmoidoscopy resemble ulcerative proctitis (see <ce:cross-ref id="crf0840" refid="f0285">Fig. 21.53</ce:cross-ref>, <ce:cross-ref id="crf9135" refid="s1710">p. 819</ce:cross-ref>). An endoscopic biopsy from the rectal wall is associated with a 2% risk of fistula formation. The extent of the lesion can be assessed by colonoscopy. Barium follow-through or MRI enterography can be of diagnostic value in showing small bowel strictures, ulcers and fistulae.</ce:para></ce:section><ce:section id="s1425"><ce:section-title id="st1385">Management</ce:section-title><ce:para id="p4235">Diarrhoea in the acute phase should be treated with codeine phosphate, diphenoxylate or loperamide. Antibiotics may be required for bacterial overgrowth. Nutritional supplements are necessary when malabsorption is present. Colestyramine or colesevelam is useful for bile acid diarrhoea. Surgery should be avoided, if possible, because the injured intestine is difficult to resect and anastomose, but may be necessary for obstruction, perforation or fistula.</ce:para><ce:para id="p4240">In radiation proctitis, the underlying pathophysiology is tissue ischaemia rather than inflammation; glucocorticoid enemas are therefore not effective. Traditionally, endoscopic argon plasma coagulation therapy was used but this is of limited benefit and can induce fistula, stricture or perforation. Effective treatments include sucralfate enema and hyperbaric oxygen.</ce:para></ce:section></ce:section><ce:section id="s1430"><ce:section-title id="st1390">Abetalipoproteinaemia</ce:section-title><ce:para id="p4245">This rare autosomal recessive disorder is caused by deficiency of apolipoprotein B, which results in failure of chylomicron formation. It leads to fat malabsorption and deficiency of fat-soluble vitamins. Jejunal biopsy reveals enterocytes distended with resynthesised triglyceride and normal villous morphology. Serum cholesterol and triglyceride levels are low. A number of other abnormalities occur in this syndrome, including acanthocytosis, retinitis pigmentosa and a progressive neurological disorder with cerebellar and dorsal column signs. Symptoms may be improved by a low-fat diet supplemented with medium-chain triglycerides and vitamins A, D, E and K.</ce:para></ce:section></ce:section><ce:section id="s1435"><ce:section-title id="st1395">Motility disorders</ce:section-title><ce:section id="s1440"><ce:section-title id="st1400">Chronic intestinal pseudo-obstruction</ce:section-title><ce:para id="p4250">Small intestinal motility is disordered in conditions that affect the smooth muscle or nerves of the intestine. Many cases are ‘primary’ (idiopathic), while others are ‘secondary’ to a variety of disorders or drugs (<ce:cross-ref id="crf0845" refid="b0255">Box 21.48</ce:cross-ref><ce:float-anchor refid="b0255"/>).</ce:para><ce:section id="s1455"><ce:section-title id="st1415">Clinical features</ce:section-title><ce:para id="p4300">There are recurrent episodes of nausea, vomiting, abdominal discomfort and distension, often worse after food. Alternating constipation and diarrhoea occur and weight loss results from malabsorption (due to bacterial overgrowth) and fear of eating. There may also be symptoms of dysmotility affecting other parts of the gastrointestinal tract, such as dysphagia, and features of bladder dysfunction in primary cases. Some patients develop severe abdominal pain for reasons that are poorly understood and this can be difficult to manage.</ce:para></ce:section><ce:section id="s1460"><ce:section-title id="st1420">Investigations</ce:section-title><ce:para id="p4305">The diagnosis is often delayed and a high index of suspicion is needed. Plain X-rays show distended loops of bowel and air–fluid levels but barium studies demonstrate no mechanical obstruction. Laparotomy is sometimes required to exclude obstruction and to obtain full-thickness biopsies of the intestine. Examination of biopsy material using specialised techniques, such as electron microscopy, and immunohistochemistry can diagnose the many rare diseases of enteric smooth muscle and nerves that can cause this syndrome.</ce:para></ce:section><ce:section id="s1465"><ce:section-title id="st1425">Management</ce:section-title><ce:para id="p4310">This is often difficult. Underlying causes should be addressed and further surgery avoided. Metoclopramide or domperidone may enhance motility and antibiotics are given for bacterial overgrowth. Nutritional and psychological support is also necessary.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1470"><ce:section-title id="st1430">Miscellaneous disorders of the small intestine</ce:section-title><ce:section id="s1475"><ce:section-title id="st1435">Protein-losing enteropathy</ce:section-title><ce:para id="p4315">This term is used when there is excessive loss of protein into the gut lumen, sufficient to cause hypoproteinaemia. Protein-losing enteropathy occurs in many gut disorders but is most common in those in which ulceration occurs (<ce:cross-ref id="crf0850" refid="b0260">Box 21.49</ce:cross-ref><ce:float-anchor refid="b0260"/>). In other disorders, protein loss can result from increased mucosal permeability or obstruction of intestinal lymphatic vessels. Patients present with peripheral oedema and hypoproteinaemia in the presence of normal liver function, low albumin and globulin, and without proteinuria. The diagnosis can be confirmed by measurement of faecal clearance of α<ce:inf loc="post">1</ce:inf>-antitrypsin or <ce:sup loc="post">51</ce:sup>Cr-labelled albumin after intravenous injection. Other investigations should be performed to determine the underlying cause. Treatment is that of the underlying disorder, with nutritional support and measures to control peripheral oedema.</ce:para></ce:section><ce:section id="s1480"><ce:section-title id="st1440">Intestinal lymphangiectasia</ce:section-title><ce:para id="p4400">This may be primary, resulting from congenital malunion of lymphatics, or secondary to lymphatic obstruction due to lymphoma, filariasis or constrictive pericarditis. Impaired drainage of intestinal lymphatic vessels leads to discharge of protein and fat-rich lymph into the gastrointestinal lumen. The condition presents with peripheral lymphoedema, pleural effusions or chylous ascites, and steatorrhoea. Investigations reveal hypoalbuminaemia, lymphopenia and reduced serum immunoglobulin concentrations. The diagnosis can be made by CT scanning and by enteroscopy with jejunal biopsy, which shows greatly dilated lacteals. Treatment consists of a low-fat diet with medium-chain triglyceride supplements.</ce:para></ce:section><ce:section id="s1485"><ce:section-title id="st1445">Ulceration of the small intestine</ce:section-title><ce:para id="p4405">Small bowel ulcers are uncommon and are either idiopathic or secondary to underlying intestinal disorders (<ce:cross-ref id="crf0855" refid="b0265">Box 21.50</ce:cross-ref><ce:float-anchor refid="b0265"/>). Ulcers are more common in the ileum and cause bleeding, perforation, stricture formation or obstruction. Barium studies and enteroscopy confirm the diagnosis.</ce:para></ce:section><ce:section id="s1490"><ce:section-title id="st1450">NSAID-associated small intestinal toxicity</ce:section-title><ce:para id="p4450">These drugs cause a spectrum of small intestinal lesions ranging from erosions and ulcers to mucosal webs, strictures and, rarely, a condition known as ‘diaphragm disease’, in which intense submucosal fibrosis results in circumferential stricturing. The condition can present with pain, obstruction, bleeding or anaemia, and may mimic Crohn's disease, carcinoma or lymphoma. Enteroscopy or capsule endoscopy can reveal the diagnosis but sometimes this is discovered only at laparotomy.</ce:para></ce:section><ce:section id="s1495"><ce:section-title id="st1455">Eosinophilic gastroenteritis</ce:section-title><ce:para id="p4455">This disorder of unknown aetiology can affect any part of the gastrointestinal tract; it is characterised by eosinophil infiltration involving the gut wall, in the absence of parasitic infection or eosinophilia of other tissues. It may be mucosal, muscular or subserosal. Peripheral blood eosinophilia is present in 80% of cases.</ce:para><ce:section id="s1500"><ce:section-title id="st1460">Clinical features</ce:section-title><ce:para id="p4460">There are features of obstruction and inflammation, such as colicky pain, nausea and vomiting, diarrhoea and weight loss. Protein-losing enteropathy occurs and up to 50% of patients have a history of other allergic disorders. Serosal involvement may produce eosinophilic ascites.</ce:para></ce:section><ce:section id="s1505"><ce:section-title id="st1465">Investigations and management</ce:section-title><ce:para id="p4465">The diagnosis is made by histological assessment of multiple endoscopic biopsies, although full-thickness biopsies are occasionally required. Other investigations should be performed to exclude parasitic infection and other causes of eosinophilia. The serum IgE concentration is often raised. Dietary manipulations are rarely effective, although elimination diets, especially of milk, may benefit a few patients. Severe symptoms are treated with prednisolone (20–40 mg daily) and/or sodium cromoglicate, which stabilises mast cell membranes. The prognosis is good in the majority of patients.</ce:para></ce:section></ce:section><ce:section id="s1510"><ce:section-title id="st1470">Meckel's diverticulum</ce:section-title><ce:para id="p4470">This is the most common congenital anomaly of the gastrointestinal tract and occurs in 0.3–3% of people, but the vast majority of affected individuals are asymptomatic throughout life. The diverticulum results from failure of closure of the vitelline duct, with persistence of a blind-ending sac arising from the anti-mesenteric border of the ileum; it usually occurs within 100 cm of the ileocaecal valve and is up to 5 cm long. Approximately 50% contain ectopic gastric mucosa; rarely, colonic, pancreatic or endometrial tissue is present. Complications most commonly occur in the first 2 years of life but are occasionally seen in young adults. Bleeding can result from ulceration of ileal mucosa adjacent to the ectopic parietal cells and presents as recurrent melaena or altered blood per rectum. The diagnosis can be made by scanning the abdomen using a gamma counter following an intravenous injection of <ce:sup loc="post">99m</ce:sup>Tc-pertechnetate, which is concentrated by ectopic parietal cells. Other complications include intestinal obstruction, diverticulitis, intussusception and perforation. Intervention is unnecessary unless complications occur.</ce:para></ce:section></ce:section><ce:section id="s1515"><ce:section-title id="st1475">Adverse food reactions</ce:section-title><ce:para id="p4475">Adverse food reactions are common and are subdivided into food intolerance and food allergy, the former being much more common. In food intolerance, there is an adverse reaction to food that is not immune-mediated and results from pharmacological (histamine, tyramine or monosodium glutamate), metabolic (lactase deficiency) or other mechanisms (toxins or chemical contaminants in food).</ce:para><ce:section id="s1520"><ce:section-title id="st1480">Lactose intolerance</ce:section-title><ce:para id="p4480">Human milk contains around 200 mmol/L (68 g/L) of lactose, which is normally digested to glucose and galactose by the brush border enzyme lactase prior to absorption. In most populations, enterocyte lactase activity declines throughout childhood. The enzyme is deficient in up to 90% of adult Africans, Asians and South Americans but only 5% of northern Europeans.</ce:para><ce:para id="p4485">In cases of genetically determined (primary) lactase deficiency, jejunal morphology is normal. ‘Secondary’ lactase deficiency occurs as a consequence of disorders that damage the jejunal mucosa, such as coeliac disease and viral gastroenteritis. Unhydrolysed lactose enters the colon, where bacterial fermentation produces volatile short-chain fatty acids, hydrogen and carbon dioxide.</ce:para><ce:section id="s1525"><ce:section-title id="st1485">Clinical features</ce:section-title><ce:para id="p4490">In most people, lactase deficiency is completely asymptomatic. However, some complain of colicky pain, abdominal distension, increased flatus, borborygmi and diarrhoea after ingesting milk or milk products. Irritable bowel syndrome may be suspected but the correct diagnosis is suggested by clinical improvement on lactose withdrawal. The lactose hydrogen breath test is a useful non-invasive investigation.</ce:para><ce:para id="p4495">Dietary exclusion of lactose is recommended, although most sufferers are able to tolerate small amounts of milk without symptoms. Addition of commercial lactase preparations to milk has been effective in some studies but is costly.</ce:para></ce:section></ce:section><ce:section id="s1530"><ce:section-title id="st1490">Intolerance of other sugars</ce:section-title><ce:para id="p4500">‘Osmotic’ diarrhoea can be caused by sorbitol, an unabsorbable carbohydrate that is used as an artificial sweetener. Fructose contained within fruit juices may also cause diarrhoea if it is consumed in greater quantities than can be absorbed.</ce:para></ce:section><ce:section id="s1535"><ce:section-title id="st1495">Food allergy</ce:section-title><ce:para id="p4505">Food allergies are immune-mediated disorders, most commonly due to type I hypersensitivity reactions with production of IgE antibodies, although type IV delayed hypersensitivity reactions are also seen (<ce:intra-ref id="ii0365" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0550">p. 83</ce:intra-ref>). Up to 20% of the population perceive themselves as suffering from food allergy but only 1–2% of adults and 5–7% of children have genuine food allergies. The most common culprits are peanuts, milk, eggs, soya and shellfish.</ce:para><ce:para id="p4510">Clinical manifestations occur immediately on exposure and range from trivial to life-threatening or even fatal anaphylaxis. The common oral allergy syndrome results from contact with benzoic acid in certain fresh fruit juices, leading to urticaria and angioedema of the lips and oropharynx. This is not, however, an immune-mediated reaction. ‘Allergic gastroenteropathy’ has features similar to eosinophilic gastroenteritis, while ‘gastro­intestinal anaphylaxis’ consists of nausea, vomiting, diarrhoea and sometimes cardiovascular and respiratory collapse. Fatal reactions to trace amounts of peanuts are well documented.</ce:para><ce:para id="p4515">The diagnosis of food allergy is difficult to prove or refute. Skin-prick tests and measurements of antigen-specific IgE antibodies in serum have limited predictive value. Double-blind placebo-controlled food challenges are the gold standard but are laborious and are not readily available. In many cases, clinical suspicion and trials of elimination diets are used.</ce:para><ce:para id="p4520">Treatment of proven food allergy consists of detailed patient education and awareness, strict elimination of the offending antigen, and, in some cases, antihistamines or sodium cromoglicate. Anaphylaxis should be treated as a medical emergency with resuscitation, airway support and intravenous adrenaline (epinephrine). Teachers and other carers of affected children should be trained to deal with this. Patients should wear an information bracelet and be taught to carry and use a preloaded adrenaline syringe.</ce:para></ce:section></ce:section><ce:section id="s1540"><ce:section-title id="st1500">Infections of the small intestine</ce:section-title><ce:section id="s1545"><ce:section-title id="st1505">Travellers' diarrhoea, giardiasis and amoebiasis</ce:section-title><ce:para id="p4525">See <ce:intra-ref id="ii0370" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0480">pages 232</ce:intra-ref>, 287 and 286.</ce:para></ce:section><ce:section id="s1550"><ce:section-title id="st1510">Abdominal tuberculosis</ce:section-title><ce:para id="p4530"><ce:italic>Mycobacterium tuberculosis</ce:italic> is a rare cause of abdominal disease in Caucasians but must be considered in people in and from the developing world and in AIDS patients. Gut infection usually results from human <ce:italic>M. tuberculosis</ce:italic>, which is swallowed after coughing. Many patients have no pulmonary symptoms and a normal chest X-ray.</ce:para><ce:para id="p4535">The area most commonly affected is the ileocaecal region. The presentation and radiological findings may be very similar to those of Crohn's disease. Abdominal pain can be acute or of several months' duration but diarrhoea is less common in tuberculosis than in Crohn's disease. Low-grade fever is common but not invariable. Like Crohn's disease, tuberculosis can affect any part of the gastrointestinal tract and perianal disease with fistula is recognised. Peritoneal tuberculosis may result in peritonitis with exudative ascites, associated with abdominal pain and fever. Granulomatous hepatitis occurs.</ce:para><ce:section id="s1555"><ce:section-title id="st1515">Investigations</ce:section-title><ce:para id="p4540">Abdominal tuberculosis causes an elevated ESR; a raised serum alkaline phosphatase concentration suggests hepatic involvement. Histological confirmation should be sought by endoscopy, laparoscopy or liver biopsy. Caseation of granulomas is not always seen and acid- and alcohol-fast bacteria are often scanty. Culture may be helpful but identification of the organism may take 6 weeks and diagnosis is now possible on biopsy specimens using PCR-based techniques.</ce:para></ce:section><ce:section id="s1560"><ce:section-title id="st1520">Management</ce:section-title><ce:para id="p4545">When the presentation is very suggestive of abdominal tuberculosis, chemotherapy with multiple anti-tuberculous drugs should be commenced, even if bacteriological or histological proof is lacking. Isoniazid, pyrazinamide and ethambutol is a common standard regime (<ce:intra-ref id="ii9000" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1080">p. 590</ce:intra-ref>), though the precise choice will be dependent on local drug resistance patterns.</ce:para></ce:section></ce:section><ce:section id="s1565"><ce:section-title id="st1525">Cryptosporidiosis</ce:section-title><ce:para id="p4550">Cryptosporidiosis and other protozoal infections, including cystoisosporiasis (<ce:italic>Cystoisospora belli</ce:italic>) and microsporidiosis, are dealt with on <ce:intra-ref id="ii0380" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2335">pages 287 and 317</ce:intra-ref>.</ce:para></ce:section></ce:section><ce:section id="s1570"><ce:section-title id="st1530">Tumours of the small intestine</ce:section-title><ce:para id="p4555">The small intestine is rarely affected by neoplasia and fewer than 5% of all gastrointestinal tumours occur at this site.</ce:para><ce:section id="s1575"><ce:section-title id="st1535">Benign tumours</ce:section-title><ce:para id="p4560">The most common are adenomas, GISTs, lipomas and hamartomas. Adenomas are most often found in the periampullary region and are usually asymptomatic, although occult bleeding or obstruction due to intussusception may occur. Transformation to adenocarcinoma is rare. Multiple adenomas are common in the duodenum of patients with familial adenomatous polyposis (FAP), who merit regular endoscopic surveillance. Hamartomatous polyps with almost no malignant potential occur in Peutz–Jeghers syndrome (<ce:cross-ref id="crf9140" refid="p5830">p. 829</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1580"><ce:section-title id="st1540">Malignant tumours</ce:section-title><ce:para id="p4565">These are rare and include, in decreasing order of frequency, adenocarcinoma, neuro-endocrine tumours, malignant GIST and lymphoma. The majority occur in middle age or later. Kaposi's sarcoma of the small bowel may arise in patients with AIDS.</ce:para><ce:section id="s1585"><ce:section-title id="st1545">Adenocarcinomas</ce:section-title><ce:para id="p4570">Adenocarcinomas occur with increased frequency in patients with FAP, coeliac disease, small bowel Crohn's disease and Peutz–Jeghers syndrome. This is a rare cancer, accounting for less than 5% of all gastrointestinal malignancies. The non-specific presentation and rarity of these lesions often lead to a delay in diagnosis. Despite advances in imaging and endoscopic techniques, early diagnosis is difficult. Barium follow-through examination or small bowel enterography studies demonstrate most lesions of this type. Enteroscopy, capsule endoscopy, mesenteric angiography and CT also play a role in investigation. Treatment is by surgical resection.</ce:para></ce:section><ce:section id="s1590"><ce:section-title id="st1550">Neuro-endocrine tumours</ce:section-title><ce:para id="p4575">These are discussed in detail on <ce:intra-ref id="ii0390" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1305">page 678</ce:intra-ref>.</ce:para></ce:section><ce:section id="s1595"><ce:section-title id="st1555">Lymphoma</ce:section-title><ce:para id="p4580">Non-Hodgkin lymphoma (<ce:intra-ref id="ii0395" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1350">p. 964</ce:intra-ref>) may involve the gastrointestinal tract as part of more generalised disease or may rarely arise in the gut, the small intestine being most commonly affected. Lymphomas occur with increased frequency in patients with coeliac disease, HIV/AIDS and other immunodeficiency states. Most are of B-cell origin, although lymphoma associated with coeliac disease is derived from T cells (enteropathy-associated T-cell lymphoma).</ce:para><ce:para id="p4585">Colicky abdominal pain, obstruction and weight loss are the presenting features and perforation is also seen occasionally. Malabsorption is a feature of diffuse bowel involvement and hepatosplenomegaly is rare.</ce:para><ce:para id="p4590">The diagnosis is made by small bowel biopsy, radiological contrast studies and CT. Staging investigations should be performed as for lymphomas occurring elsewhere (<ce:intra-ref id="ii0400" xlink:href="pii:B978-0-7020-7028-0.00023-8#s1335">p. 962</ce:intra-ref>). Surgical resection, where possible, is the treatment of choice, with radiotherapy and combination chemotherapy reserved for those with advanced disease. The prognosis depends largely on the stage at diagnosis, cell type, patient age and the presence of ‘B’ symptoms (fever, weight loss, night sweats).</ce:para></ce:section><ce:section id="s1600"><ce:section-title id="st1560">Immunoproliferative small intestinal disease</ce:section-title><ce:para id="p4595">Immunoproliferative small intestinal disease (IPSID), also known as alpha heavy chain disease, is a rare condition occurring mainly in Mediterranean countries, the Middle East, India, Pakistan and North America. It is a variant of B-cell lymphoma of MALT type and often associated with <ce:italic>Campylobacter jejuni</ce:italic> infection. The condition varies in severity from relatively benign to frankly malignant.</ce:para><ce:para id="p4600">The small intestinal mucosa is diffusely affected, especially proximally, by a dense lymphoplasmacytic infiltrate. Enlarged mesenteric lymph nodes are also common. Most patients are young adults who present with malabsorption, anorexia and fever. Serum electrophoresis confirms the presence of alpha heavy chains (from the F<ce:inf loc="post">c</ce:inf> portion of IgA). Prolonged remissions can be obtained with long-term antibiotic therapy but chemotherapy is required for those who fail to respond or who have aggressive disease.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1605"><ce:section-title id="st1565">Inflammatory bowel disease</ce:section-title><ce:para id="p4605">Ulcerative colitis and Crohn's disease are chronic inflammatory bowel diseases that pursue a protracted relapsing and remitting course, usually extending over years. The diseases have many similarities and it is sometimes impossible to differentiate between them. One crucial distinction is that ulcerative colitis involves only the colon, while Crohn's disease can involve any part of the gastrointestinal tract from mouth to anus. A summary of the main features of ulcerative colitis and Crohn's disease is provided in <ce:cross-ref id="crf0860" refid="b0270">Box 21.51</ce:cross-ref><ce:float-anchor refid="b0270"/>.</ce:para><ce:para id="p4615">The incidence of inflammatory bowel disease (IBD) varies widely between populations. There was a dramatic increase in the incidence of both ulcerative colitis and Crohn's disease in the Western world, starting in the second half of the last century and coinciding with the introduction of a more ‘hygienic’ environment with the advent of domestic refrigeration and the widespread use of antibiotics. The developing world has seen similar patterns, as these countries adopt an increasingly Westernised lifestyle.</ce:para><ce:para id="p4620">In the West, the incidence of ulcerative colitis is stable at 10–20 per 100 000, with a prevalence of 100–200 per 100 000, while the incidence of Crohn's disease is increasing and is now 5–10 per 100 000, with a prevalence of 50–100 per 100 000. Both diseases most commonly start in the second and third decades of life, with a second smaller incidence peak in the seventh decade. Approximately 240 000 people are affected by IBD in the UK (approximately 1.4 million in the USA), equating to a prevalence of about 1 in 250. Life expectancy in patients with IBD is similar to that of the general population. Although many patients require surgery and admission to hospital for other reasons, with substantial associated morbidity, the majority have an excellent work record and pursue a normal life.</ce:para><ce:section id="s1610"><ce:section id="s1615"><ce:section id="s1620"><ce:section-title id="st1570">Pathophysiology</ce:section-title><ce:para id="p4625">IBD has both environmental and genetic components, and evidence from genome-wide association studies suggests that genetic variants that predispose to Crohn's disease may have undergone positive selection by protecting against infectious diseases, including tuberculosis (<ce:cross-ref id="crf0865" refid="b0275">Box 21.52</ce:cross-ref><ce:float-anchor refid="b0275"/>). It is thought that IBD develops because these genetically susceptible individuals mount an abnormal inflammatory response to environmental triggers, such as intestinal bacteria. This leads to inflammation of the intestine with involvement of a wide array of innate and adaptive immune cell responses, with release of inflammatory mediators, including TNF-α, IL-12 and IL-23, which cause tissue damage (<ce:cross-ref id="crf0870" refid="f0240">Fig. 21.44</ce:cross-ref><ce:float-anchor refid="f0240"/>). There is an association between microbial dysbiosis and IBD. For example, there is a reduced diversity, primarily of Firmicutes and in particular, <ce:italic>Faecalibacterium prausnitzii</ce:italic>. Functional changes in the bacteria are important and include a reduction of anti-inflammatory metabolites, such as butyrate and other short-chain fatty acids. There is emerging evidence that the virome and mycobiome (fungal species) may be important in the development of IBD. In both diseases, the intestinal wall is infiltrated with acute and chronic inflammatory cells, but there are important differences between the conditions in the distribution of lesions and in histological features (<ce:cross-ref id="crf0875" refid="f0245">Fig. 21.45</ce:cross-ref><ce:float-anchor refid="f0245"/>).</ce:para><ce:section id="s1635"><ce:section-title id="st1585">Ulcerative colitis</ce:section-title><ce:para id="p4715">Inflammation invariably involves the rectum (proctitis) and spreads proximally in a continuous manner to involve the entire colon in some cases (pancolitis). In long-standing pancolitis, the bowel can become shortened and post-inflammatory ‘pseudopolyps’ develop; these are normal or hypertrophied residual mucosa within areas of atrophy (<ce:cross-ref id="crf0880" refid="f0250">Fig. 21.46</ce:cross-ref><ce:float-anchor refid="f0250"/>). The inflammatory process is limited to the mucosa and spares the deeper layers of the bowel wall (<ce:cross-ref id="crf0885" refid="f0255">Fig. 21.47</ce:cross-ref><ce:float-anchor refid="f0255"/>). Both acute and chronic inflammatory cells infiltrate the lamina propria and the crypts (‘cryptitis’). Crypt abscesses are typical. Goblet cells lose their mucus and, in long-standing cases, glands become distorted. Dysplasia, characterised by heaping of cells within crypts, nuclear atypia and increased mitotic rate, may herald the development of colon cancer.</ce:para></ce:section><ce:section id="s1640"><ce:section-title id="st1590">Crohn's disease</ce:section-title><ce:para id="p4720">The sites most commonly involved are, in order of frequency, the terminal ileum and right side of colon, colon alone, terminal ileum alone, ileum and jejunum. The entire wall of the bowel is oedematous and thickened, and there are deep ulcers that often appear as linear fissures; thus the mucosa between them is described as ‘cobblestone’. These may penetrate through the bowel wall to initiate abscesses or fistulae involving the bowel, bladder, uterus, vagina and skin of the perineum. The mesenteric lymph nodes are enlarged and the mesentery is thickened. Crohn's disease has a patchy distribution and the inflammatory process is interrupted by islands of normal mucosa. On histological examination, the bowel wall is thickened with a chronic inflammatory infiltrate throughout all layers (<ce:cross-ref id="crf0890" refid="f0260">Fig. 21.48</ce:cross-ref><ce:float-anchor refid="f0260"/>).</ce:para></ce:section></ce:section><ce:section id="s1645"><ce:section-title id="st1595">Clinical features</ce:section-title><ce:section id="s1650"><ce:section-title id="st1600">Ulcerative colitis</ce:section-title><ce:para id="p4725">The cardinal symptoms are rectal bleeding with passage of mucus and bloody diarrhoea. The presentation varies, depending on the site and severity of the disease (see <ce:cross-ref id="crf0895" refid="f0245">Fig. 21.45</ce:cross-ref>), as well as the presence of extra-intestinal manifestations. The first attack is usually the most severe and is followed by relapses and remissions. Emotional stress, intercurrent infection, gastroenteritis, antibiotics or NSAID therapy may all provoke a relapse. Proctitis causes rectal bleeding and mucus discharge, accompanied by tenesmus. Some patients pass frequent, small-volume fluid stools, while others pass pellety stools due to constipation upstream of the inflamed rectum. Constitutional symptoms do not occur. Left-sided and extensive colitis causes bloody diarrhoea with mucus, often with abdominal cramps. In severe cases, anorexia, malaise, weight loss and abdominal pain occur and the patient is toxic, with fever, tachycardia and signs of peritoneal inflammation (<ce:cross-ref id="crf0900" refid="b0280">Box 21.53</ce:cross-ref><ce:float-anchor refid="b0280"/>).</ce:para></ce:section><ce:section id="s1655"><ce:section-title id="st1605">Crohn's disease</ce:section-title><ce:para id="p4735">The major symptoms are abdominal pain, diarrhoea and weight loss. Ileal Crohn's disease (<ce:cross-ref id="crf0930" refid="f0265">Figs 21.49</ce:cross-ref><ce:float-anchor refid="f0265"/> and <ce:cross-ref id="crf0935" refid="f0270">21.50</ce:cross-ref><ce:float-anchor refid="f0270"/>) may cause subacute or even acute intestinal obstruction. The pain is often associated with diarrhoea, which is usually watery and does not contain blood or mucus. Almost all patients lose weight because they avoid food, since eating provokes pain. Weight loss may also be due to malabsorption and some patients present with features of fat, protein or vitamin deficiencies. Crohn's colitis presents in an identical manner to ulcerative colitis but rectal sparing and the presence of perianal disease are features that favour a diagnosis of Crohn's disease. Many patients present with symptoms of both small bowel and colonic disease. A few patients present with isolated perianal disease, vomiting from jejunal strictures or severe oral ulceration.</ce:para><ce:para id="p4740">Physical examination often reveals evidence of weight loss, anaemia with glossitis and angular stomatitis. There is abdominal tenderness, most marked over the inflamed area. An abdominal mass may be palpable and is due to matted loops of thickened bowel or an intra-abdominal abscess. Perianal skin tags, fissures or fistulae are found in at least 50% of patients.</ce:para></ce:section></ce:section><ce:section id="s1660"><ce:section-title id="st1610">Differential diagnosis</ce:section-title><ce:para id="p4745">The differential diagnosis is summarised in <ce:cross-ref id="crf0940" refid="b0285">Box 21.54</ce:cross-ref><ce:float-anchor refid="b0285"/>. The most important issue is to distinguish the first attack of acute colitis from infection. In general, diarrhoea lasting longer than 10 days in Western countries is unlikely to be the result of infection, whereas a history of foreign travel, antibiotic exposure (<ce:italic>Clostridium difficile</ce:italic>/pseudomembranous colitis) or homosexual contact increases the possibility of infection, which should be excluded by the appropriate investigations (see below). The diagnosis of Crohn's disease is usually more straightforward and is made on the basis of imaging and clinical presentation, but in atypical cases biopsy or surgical resection is necessary to exclude other diseases (<ce:cross-ref id="crf0945" refid="b0290">Box 21.55</ce:cross-ref><ce:float-anchor refid="b0290"/>).</ce:para></ce:section><ce:section id="s1665"><ce:section-title id="st1615">Complications</ce:section-title><ce:section id="s1670"><ce:section-title id="st1620">Life-threatening colonic inflammation</ce:section-title><ce:para id="p4880">This can occur in both ulcerative colitis and Crohn's colitis. In the most extreme cases, the colon dilates (toxic megacolon) and bacterial toxins pass freely across the diseased mucosa into the portal and then systemic circulation. This complication arises most commonly during the first attack of colitis and is recognised by the features described in <ce:cross-ref id="crf0960" refid="b0280">Box 21.53</ce:cross-ref>. An abdominal X-ray should be taken daily because, when the transverse colon is dilated to more than 6 cm (<ce:cross-ref id="crf0965" refid="f0275">Fig. 21.51</ce:cross-ref><ce:float-anchor refid="f0275"/>), there is a high risk of colonic perforation, although this complication can also occur in the absence of toxic megacolon. Severe colonic inflammation with toxic dilatation is a surgical emergency and most often requires colectomy.</ce:para></ce:section><ce:section id="s1675"><ce:section-title id="st1625">Haemorrhage</ce:section-title><ce:para id="p4885">Haemorrhage due to erosion of a major artery is rare but can occur in both conditions.</ce:para></ce:section><ce:section id="s1680"><ce:section-title id="st1630">Fistulae</ce:section-title><ce:para id="p4890">These are specific to Crohn's disease. Enteroenteric fistulae can cause diarrhoea and malabsorption due to blind loop syndrome. Enterovesical fistulation causes recurrent urinary infections and pneumaturia. An enterovaginal fistula causes a faeculent vaginal discharge. Fistulation from the bowel may also cause perianal or ischiorectal abscesses, fissures and fistulae.</ce:para></ce:section><ce:section id="s1685"><ce:section-title id="st1635">Cancer</ce:section-title><ce:para id="p4895">The risk of dysplasia and cancer increases with the duration and extent of uncontrolled colonic inflammation. Thus patients who have long-standing, extensive colitis are at highest risk. Oral mesalazine therapy reduces the risk of dysplasia and neoplasia in ulcerative colitis. Azathioprine also seems to reduce the risk of colorectal cancer in ulcerative colitis and Crohn's colitis. This protective effect probably extends to any medical treatment that results in sustained healing of the colonic mucosa. The cumulative risk for dysplasia in ulcerative colitis may be as high as 20% after 30 years but is probably lower for Crohn's colitis. The risk is particularly high in patients who have concomitant primary sclerosing cholangitis for unknown reasons. Tumours develop in areas of dysplasia and may be multiple. Patients with long-standing colitis are therefore entered into surveillance programmes beginning 10 years after diagnosis. Targeted biopsies of areas that show abnormalities on staining with indigo carmine or methylene blue increase the chance of detecting dysplasia and this technique (termed pancolonic chromo-endoscopy) has replaced colonoscopy with random biopsies taken every 10 cm in screening for malignancy. The procedure allows patients to be stratified into high-, medium- or low-risk groups to determine the interval between surveillance procedures. Family history of colon cancer is also an important factor to consider. If high-grade dysplasia is found, panproctocolectomy is usually recommended because of the high risk of colon cancer.</ce:para></ce:section><ce:section id="s1690"><ce:section-title id="st1640">Extra-intestinal complications</ce:section-title><ce:para id="p4900">Extra-intestinal complications are common in IBD and may dominate the clinical picture. Some of these occur during relapse of intestinal disease; others appear to be unrelated to intestinal disease activity (<ce:cross-ref id="crf0970" refid="f0280">Fig. 21.52</ce:cross-ref><ce:float-anchor refid="f0280"/>).</ce:para></ce:section></ce:section><ce:section id="s1695"><ce:section-title id="st1645">Investigations</ce:section-title><ce:para id="p4905">Investigations are necessary to confirm the diagnosis, define disease distribution and activity, and identify complications. Full blood count may show anaemia resulting from bleeding or malabsorption of iron, folic acid or vitamin B<ce:inf loc="post">12</ce:inf>. Platelet count can also be high as a marker of chronic inflammation. Serum albumin concentration falls as a consequence of protein-losing enteropathy, inflammatory disease or poor nutrition. ESR and CRP are elevated in exacerbations and in response to abscess formation. Faecal calprotectin has a high sensitivity for detecting gastrointestinal inflammation and may be elevated, even when the CRP is normal. It is particularly useful for distinguishing inflammatory bowel disease from irritable bowel syndrome at diagnosis, and for subsequent monitoring of disease activity.</ce:para><ce:section id="s1700"><ce:section-title id="st1650">Bacteriology</ce:section-title><ce:para id="p4910">At initial presentation, stool microscopy, culture and examination for <ce:italic>Clostridium difficile</ce:italic> toxin or for ova and cysts, blood cultures and serological tests should be performed. These investigations should be repeated in established disease to exclude superimposed enteric infection in patients who present with exacerbations of IBD. During acute flares necessitating hospital admission, three separate stool samples should be sent for bacteriology to maximise sensitivity.</ce:para></ce:section><ce:section id="s1705"><ce:section-title id="st1655">Endoscopy</ce:section-title><ce:para id="p4915">Patients who present with diarrhoea plus raised inflammatory markers or alarm features, such as weight loss, rectal bleeding and anaemia, should undergo ileocolonoscopy. Flexible sigmoidoscopy is occasionally performed to make a diagnosis, especially during acute severe presentations when ileocolonoscopy may confer an unacceptable risk; ileocolonoscopy should still be performed at a later date, however, in order to evaluate disease extent. In ulcerative colitis, there is loss of vascular pattern, granularity, friability and contact bleeding, with or without ulceration (<ce:cross-ref id="crf0975" refid="f0285">Fig. 21.53</ce:cross-ref><ce:float-anchor refid="f0285"/>). In Crohn's disease, patchy inflammation, with discrete, deep ulcers, strictures and perianal disease (fissures, fistulae and skin tags), is typically observed, often with rectal sparing. In established disease, colonoscopy may show active inflammation with pseudopolyps or a complicating carcinoma. Biopsies should be taken from each anatomical segment (terminal ileum, right colon, transverse colon, left colon and rectum) to confirm the diagnosis and define disease extent, and also to seek dysplasia in patients with long-standing colitis guided by pancolonic chromo-endoscopy. In Crohn's disease, wireless capsule endoscopy is useful in the identification of small bowel inflammation but should be avoided in the presence of strictures. Enteroscopy may be required to make a histological diagnosis of small bowel Crohn's disease, when the inflamed segment is out of reach of standard endoscopes. All children and most adults with Crohn's disease should have upper gastrointestinal endoscopy and biopsy to complete their staging. Not only is upper gastrointestinal Crohn's disease relatively common in this group, but also it may help to make a definitive diagnosis in patients who otherwise appear to have non-specific colonic inflammation.</ce:para></ce:section><ce:section id="s1710"><ce:section-title id="st1660">Radiology</ce:section-title><ce:para id="p4920">Barium enema is a less sensitive investigation than colonoscopy in patients with colitis and, where colonoscopy is incomplete, a CT colonogram is preferred. Small bowel imaging is essential to complete staging of Crohn's disease. Traditional contrast imaging by barium follow-through demonstrates affected areas of the bowel as narrowed and ulcerated, often with multiple strictures (see <ce:cross-ref id="crf0980" refid="f0270">Fig. 21.50</ce:cross-ref>). This has largely been replaced now by MRI enterography, which does not involve exposure to radiation and is a sensitive way of detecting extra-intestinal manifestations and of assessing pelvic and perineal involvement. These studies use an orally administered small bowel-distending agent and intravenous contrast to provide transmural imaging that can usefully distinguish between predominantly inflammatory strictures (that should respond to anti-inflammatory medical strategies) and fibrotic strictures (that require a mechanical solution, such as surgical resection, stricturoplasty or endoscopic balloon dilatation). A plain abdominal X-ray is essential in the management of patients who present with severe active disease. Dilatation of the colon (see <ce:cross-ref id="crf0985" refid="f0275">Fig. 21.51</ce:cross-ref>), mucosal oedema (thumb-printing) or evidence of perforation may be found. Patients with proctitis may have features of proximal faecal loading. In small bowel Crohn's disease, there may be evidence of intestinal obstruction or displacement of bowel loops by a mass. Ultrasound is a very powerful tool to detect small bowel inflammation and stricture formation but it is operator-dependent. The role of CT is limited to screening for complications, such as perforation or abscess formation, in the acutely unwell.</ce:para></ce:section></ce:section><ce:section id="s1715"><ce:section-title id="st1665">Management</ce:section-title><ce:para id="p4925">Drugs that are used in the treatment of IBD are listed in <ce:cross-ref id="crf0990" refid="b0295">Box 21.56</ce:cross-ref><ce:float-anchor refid="b0295"/>. Although medical therapy plays an important role, optimal management depends on establishing a multidisciplinary team-based approach involving physicians, surgeons, radiologists, nurse specialists and dietitians. Both ulcerative colitis and Crohn's disease are life-long conditions and have important psychosocial implications; specialist nurses, counsellors and patient support groups have key roles in education, reassurance and coping. The key aims of medical therapy are to:<ce:list id="ulist0905"><ce:list-item id="u2890"><ce:label>•</ce:label><ce:para id="p4935">treat acute attacks (induce remission)</ce:para></ce:list-item><ce:list-item id="u2895"><ce:label>•</ce:label><ce:para id="p4940">prevent relapses (maintain remission)</ce:para></ce:list-item><ce:list-item id="u2900"><ce:label>•</ce:label><ce:para id="p4945">prevent bowel damage</ce:para></ce:list-item><ce:list-item id="u2905"><ce:label>•</ce:label><ce:para id="p4950">detect dysplasia and prevent carcinoma</ce:para></ce:list-item><ce:list-item id="u2910"><ce:label>•</ce:label><ce:para id="p4955">select appropriate patients for surgery.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s1720"><ce:section-title id="st1670">Ulcerative colitis</ce:section-title><ce:section id="s1725"><ce:section-title id="st1675">Active proctitis</ce:section-title><ce:para id="p4960">Most patients with ulcerative proctitis respond to a 1 g mesalazine suppository but some will additionally require oral 5-aminosalicylate (5-ASA) therapy. Topical glucocorticoids are less effective and are reserved for patients who are intolerant of topical mesalazine. Patients with resistant disease may require treatment with systemic glucocorticoids and immuno­suppressants. A stool softener may be required to treat proximal constipation.</ce:para></ce:section><ce:section id="s1730"><ce:section-title id="st1680">Active left-sided or extensive ulcerative colitis</ce:section-title><ce:para id="p4965">In mild to moderately active cases, the combination of a once-daily oral and a topical 5-ASA preparation (‘top and tail approach’) is usually effective. The topical preparation (1 g foam or liquid enema) is typically withdrawn after 1 month. The oral 5-ASA is continued long-term to prevent relapse and minimise the risk of dysplasia. In patients who do not respond to this approach within 2–4 weeks, oral prednisolone (40 mg daily, tapered by 5 mg/week over an 8-week total course) is indicated. Glucocorticoids should never be used for maintenance therapy. At the first signs of glucocorticoid resistance (lack of efficacy) or in patients who require recurrent glucocorticoid doses to maintain control, immunosuppressive therapy with a thiopurine should be introduced. Simultaneous calcium and vitamin D supplementation should be given along with glucocorticoids for bone protection.</ce:para></ce:section><ce:section id="s1735"><ce:section-title id="st1685">Severe ulcerative colitis</ce:section-title><ce:para id="p4970">Patients who fail to respond to maximal oral therapy and those who present with acute severe colitis (meeting the Truelove–Witts criteria; see <ce:cross-ref id="crf0995" refid="b0280">Box 21.53</ce:cross-ref>) are best managed in hospital and should be monitored jointly by a physician and surgeon:<ce:list id="ulist0910"><ce:list-item id="u2915"><ce:label>•</ce:label><ce:para id="p4975"><ce:italic>clinically</ce:italic>: for the presence of abdominal pain, temperature, pulse rate, stool blood and frequency</ce:para></ce:list-item><ce:list-item id="u2920"><ce:label>•</ce:label><ce:para id="p4980"><ce:italic>by laboratory testing</ce:italic>: haemoglobin, white cell count, albumin, electrolytes, ESR and CRP, stool culture</ce:para></ce:list-item><ce:list-item id="u2925"><ce:label>•</ce:label><ce:para id="p4985"><ce:italic>radiologically</ce:italic>: for colonic dilatation on plain abdominal X-rays.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4990">All patients should be given supportive treatment with intravenous fluids to correct dehydration and enteral nutritional support should be provided for malnourished patients (<ce:cross-ref id="crf1000" refid="b0300">Box 21.57</ce:cross-ref><ce:float-anchor refid="b0300"/>). Intravenous glucocorticoids (methylprednisolone 60 mg or hydrocortisone 400 mg/day) should be given by intravenous infusion or bolus injection. Topical and oral aminosalicylates have no role to play in the acute severe attack. Response to therapy is judged over the first 3 days. Patients who do not respond promptly to glucocorticoids should be considered for medical rescue therapy with ciclosporin (intravenous infusion or oral) or infliximab (5 mg/kg), which can avoid the need for urgent colectomy in approximately 60% of cases.</ce:para><ce:para id="p5045">Patients who develop colonic dilatation (&#x003E; 6 cm), those whose clinical and laboratory measurements deteriorate and those who do not respond after 7–10 days' maximal medical treatment usually require urgent colectomy. Subtotal colectomy can also be performed laparoscopically, given sufficient local expertise. The surgical and medical teams should liaise early in the disease course and, if possible, the patient should have the opportunity to speak with the stoma nurse prior to colectomy.</ce:para></ce:section><ce:section id="s1740"><ce:section-title id="st1690">Maintenance of remission</ce:section-title><ce:para id="p5050">Life-long maintenance therapy is recommended for all patients with left-sided or extensive disease but is not necessary in those with proctitis (although 20% of these patients will develop proximal ‘extension’ over the lifetime of their disease). Once-daily oral 5-aminosalicylates are the preferred first-line agents. Sulfasalazine has a higher incidence of side-effects but is equally effective and can be considered in patients with coexistent arthropathy. Patients who frequently relapse despite aminosalicylate drugs should be treated with thiopurines (azathioprine or 6-mercaptopurine). Biologic therapy with anti-TNF antibodies (infliximab or adalimumab) or anti-α4β7 integrin antibodies (vedolizumab) can also be considered for maintenance treatment in patients with moderate to severe ulcerative colitis who are intolerant of or non-responsive to thiopurine immunosuppression.</ce:para></ce:section></ce:section><ce:section id="s1745"><ce:section-title id="st1695">Crohn's disease</ce:section-title><ce:section id="s1750"><ce:section-title id="st1700">Principles of treatment</ce:section-title><ce:para id="p5055">Crohn's disease is a progressive condition that may result in stricture or fistula formation if suboptimally treated. It is therefore important to agree long-term treatment goals with the patient; these are to induce remission and then maintain glucocorticoid-free remission with a normal quality of life. Treatment should focus on monitoring the patient carefully for evidence of disease activity and complications (<ce:cross-ref id="crf1005" refid="b0305">Box 21.58</ce:cross-ref><ce:float-anchor refid="b0305"/>), and ensuring that mucosal healing is achieved.</ce:para></ce:section><ce:section id="s1755"><ce:section-title id="st1705">Induction of remission</ce:section-title><ce:para id="p5115">Glucocorticoids remain the mainstay of treatment for active Crohn's disease. The drug of first choice in patents with ileal disease is budesonide, since it undergoes 90% first-pass metabolism in the liver and has very little systemic toxicity. A typical regimen is 9 mg once daily for 6 weeks, with a gradual reduction in dose over the subsequent 2 weeks when therapy is stopped. If there is no response to budesonide within 2 weeks, the patient should be switched to prednisolone, which has greater potency. This is typically given in a dose of 40 mg daily, reducing by 5 mg/week over 8 weeks, at which point treatment is stopped. Oral prednisolone in the dose regimen described above is the treatment of choice for inducing remission in colonic Crohn's disease. Calcium and vitamin D supplements should be co-prescribed in patients who are on glucocorticoids, to try to compensate for their inhibitory effect on intestinal calcium absorption.</ce:para><ce:para id="p5120">As an alternative to glucocorticoid therapy, enteral nutrition with either an elemental (constituent amino acids) or polymeric (liquid protein) diet may induce remission. Both types of diet are equally effective but the polymeric one is more palatable when taken by mouth. It is particularly effective in children, in whom equal efficacy to glucocorticoids has been demonstrated, and in extensive ileal disease in adults. As well as resting the gut and providing excellent nutritional support, it also has a direct anti-inflammatory effect. It is an effective bridge to urgent staging investigations at first presentation and can be given by mouth or by nasogastric tube. With sufficient explanation, encouragement and motivation, most patients will tolerate it well.</ce:para><ce:para id="p5125">Some individuals with severe colonic disease require admission to hospital for intravenous glucocorticoids. In severe ileal or panenteric disease, induction therapy with an anti-TNF agent is appropriate, provided that acute perforating complications, such as abscess, have not arisen. Both infliximab and adalimumab are licensed for use in the UK. Randomised trials have demonstrated that combination therapy with an anti-TNF antibody and a thiopurine is the most effective strategy for inducing and maintaining remission in luminal Crohn's patients. This strategy is more effective than anti-TNF monotherapy, which, in turn, is more effective than thiopurine monotherapy. Following induction of remission, a substantial proportion of patients (20–30%) remain well without the requirement for maintenance therapy. Patients with evidence of persistently active disease require further treatment (see below).</ce:para></ce:section><ce:section id="s1760"><ce:section-title id="st1710">Maintenance therapy</ce:section-title><ce:para id="p5130">Immunosuppressive treatment with thiopurines (azathioprine and mercaptopurine) forms the core of maintenance therapy but methotrexate is also effective and can be given once weekly, either orally or by subcutaneous injection. Women and men of child-bearing potential who are prescribed methotrexate must use a robust contraceptive method, and should be counselled to plan pregnancy with a 3-month methotrexate-free period prior to conception since it is teratogenic. Combination therapy with an immunosuppressant and an anti-TNF antibody is the most effective strategy but costs are high and there is an increased risk of serious adverse effects. In the UK, the use of anti-TNF therapy is limited to specific patient subgroups with severe disease (<ce:cross-ref id="crf1010" refid="b0310">Box 21.59</ce:cross-ref><ce:float-anchor refid="b0310"/>). Vedolizumab is a possible option in patients who have not responded to anti-TNF therapy. It is a humanised monoclonal antibody against anti-α4β7 integrin. The α4β7 is expressed on a specific subset of CD4<ce:sup loc="post">+</ce:sup> leucocytes; vedolizumab binds to this integrin and blocks interaction with MAdCAM-1, expressed on gut endothelial cells, resulting in a reduced influx of immune cells to the inflamed gut mucosa. Serious systemic adverse effects, including progressive multifocal leukoencephalopathy, have been seen with other anti-integrin drugs (such as natalizumab) but this has not emerged with vedolizumab due to its gut specificity. Emerging novel medical therapies for Crohn's disease are currently in phase III clinical trials and are likely to be available for clinical use in the near future. These include ustekinumab (anti-p40, inhibiting both IL-12 and IL-23) and tofacitinib (a Janus kinase inhibitor that blocks pro-inflammatory cytokine signalling).</ce:para><ce:para id="p5180">Cigarette smokers with Crohn's disease should be strongly counselled to stop smoking at every possible opportunity. Those that do not manage to stop smoking fare much worse, with increased rates of relapse and surgical intervention. Careful monitoring of disease activity (see <ce:cross-ref id="crf1015" refid="b0305">Box 21.58</ce:cross-ref>) is the key to maintaining sustained remission and preventing the accumulation of bowel damage in Crohn's disease.</ce:para></ce:section><ce:section id="s1765"><ce:section-title id="st1715">Fistulae and perianal disease</ce:section-title><ce:para id="p5185">Fistulae may develop in relation to active Crohn's disease and are often associated with sepsis. The first step is to define the site by imaging (usually MRI of the pelvis). Surgical exploration by an examination under anaesthetic is usually then required, to delineate the anatomy and drain abscesses. Seton sutures can be inserted through fistula tracts to ensure adequate drainage and to prevent future sepsis. Glucocorticoids are ineffective. Use of antibiotics, such as metronidazole and/or ciprofloxacin, can aid healing as an adjunctive treatment. Thiopurines can be used in chronic disease but do not usually result in fistula healing. Infliximab and adalimumab can heal fistulae and perianal disease in many patients and are indicated when the measures described above have been ineffective. Other options for refractory perianal disease are proctectomy or diverting colostomy.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1770"><ce:section-title id="st1720">Surgical treatment</ce:section-title><ce:section id="s1775"><ce:section-title id="st1725">Ulcerative colitis</ce:section-title><ce:para id="p5190">Up to 60% of patients with extensive ulcerative colitis eventually require surgery. The indications are listed in <ce:cross-ref id="crf1020" refid="b0315">Box 21.60</ce:cross-ref><ce:float-anchor refid="b0315"/>. Impaired quality of life, with its impact on occupation and social and family life, is the most important of these. Surgery involves removal of the entire colon and rectum, and cures the patient. One-third of those with pancolitis undergo colectomy within 5 years of diagnosis. Before surgery, patients must be counselled by doctors, stoma nurses and patients who have undergone similar surgery. The choice of procedure is either panproctocolectomy with ileostomy, or proctocolectomy with ileal–anal pouch anastomosis. The sister text to this book, <ce:italic>Principles and Practice of Surgery</ce:italic>, should be consulted for further details.</ce:para></ce:section><ce:section id="s1800"><ce:section-title id="st1745">Crohn's disease</ce:section-title><ce:para id="p5250">The indications for surgery are similar to those for ulcerative colitis. Operations are often necessary to deal with fistulae, abscesses and perianal disease, and may also be required to relieve small or large bowel obstruction. In contrast to ulcerative colitis, surgery is not curative and disease recurrence is the rule. The only method that has consistently been shown to reduce post-operative recurrence is smoking cessation. Antibiotics are effective in the short term only. Use of thiopurines post-surgery is suggested if there are indicators of a high chance of recurrence, i.e. more than one resection or evidence of penetrating disease, such as fistulae or abscess. Otherwise, it is common to undertake colonoscopy 6 months after surgery to inspect and biopsy the anastomosis and neo-terminal ileum. Patients with endoscopic recurrence are then prescribed thiopurines.</ce:para><ce:para id="p5255">Surgery should be as conservative as possible in order to minimise the loss of viable intestine and to avoid the creation of a short bowel syndrome (<ce:intra-ref id="ii0415" xlink:href="pii:B978-0-7020-7028-0.00019-6#s0365">p. 708</ce:intra-ref>). Obstructing or fistulating small bowel disease may require resection of affected tissue. Patients who have localised segments of Crohn's colitis may be managed by segmental resection and/or multiple stricturoplasties, in which the stricture is not resected but instead incised in its longitudinal axis and sutured transversely. Others who have extensive colitis require total colectomy but ileal–anal pouch formation should be avoided because of the high risk of recurrence within the pouch and subsequent fistulae, abscess formation and pouch failure.</ce:para><ce:para id="p5260">Historical datasets show that around 80% of Crohn's patients undergo surgery at some stage and 70% of these require more than one operation during their lifetime. Clinical recurrence following resectional surgery is present in 50% of all cases at 10 years. Emerging data demonstrate that aggressive medical therapy, coupled with intense monitoring, probably reduces the requirement for surgery substantially.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1805"><ce:section-title id="st1750">IBD in special circumstances</ce:section-title><ce:section id="s1810"><ce:section-title id="st1755">Childhood</ce:section-title><ce:para id="p5265">Chronic ill health in childhood or adolescent IBD may result in growth failure, metabolic bone disease and delayed puberty. Loss of schooling and social contact, as well as frequent hospitalisation, can have important psychosocial consequences. Treatment is similar to that described for adults and may require glucocorticoids, immunosuppressive drugs, biological agents and surgery. Monitoring of height, weight and sexual development is crucial. Children with IBD should be managed by specialised paediatric gastroenterologists and transitioned to adult care in dedicated clinics (<ce:cross-ref id="crf1025" refid="b0320">Box 21.61</ce:cross-ref><ce:float-anchor refid="b0320"/>).</ce:para></ce:section><ce:section id="s1815"><ce:section-title id="st1760">Pregnancy</ce:section-title><ce:para id="p5300">A women's ability to become pregnant is adversely affected by active IBD. Pre-conceptual counselling should focus on optimising disease control. During pregnancy, the rule of thirds applies: roughly one-third of women improve, one-third get worse and one-third remain stable with active disease. In the post-partum period, these changes sometimes reverse spontaneously. Drug therapy, including aminosalicylates, glucocorticoids and azathioprine, can be safely continued throughout pregnancy but methotrexate must be avoided, both during pregnancy and if the patient is trying to conceive (<ce:cross-ref id="crf1030" refid="b0325">Box 21.62</ce:cross-ref><ce:float-anchor refid="b0325"/>). Anti-TNF agents are transmitted through the placenta (but not breast milk) and are omitted during the last trimester.</ce:para></ce:section><ce:section id="s1840"><ce:section-title id="st1785">Metabolic bone disease</ce:section-title><ce:para id="p5420">Patients with IBD are prone to developing osteoporosis due to the effects of chronic inflammation, glucocorticoids, weight loss, malnutrition and malabsorption. Osteomalacia can also occur in Crohn's disease that is complicated by malabsorption, but is less common than osteoporosis. The risk of osteoporosis increases with age and with the dose and duration of glucocorticoid therapy.</ce:para></ce:section></ce:section><ce:section id="s1845"><ce:section-title id="st1790">Refractory Crohn's disease</ce:section-title><ce:para id="p5425">Crohn's disease can be progressive despite maximal medical therapy and extensive surgery. There are several other immunomodulatory drugs in the clinical trial pipeline (see above).</ce:para></ce:section><ce:section id="s1850"><ce:section-title id="st1795">Microscopic colitis</ce:section-title><ce:para id="p5430">Microscopic colitis, which comprises two related conditions called lymphocytic colitis and collagenous colitis, has no known cause. The presentation is with watery diarrhoea. The colonoscopic appearances are normal but histological examination of biopsies shows a range of abnormalities. It is therefore recommended that biopsies of the right and left colon plus the terminal ileum should be undertaken in all patients undergoing colonoscopy for diarrhoea. Collagenous colitis is characterised by the presence of a submucosal band of collagen, often with a chronic inflammatory infiltrate. The disease is more common in women and may be associated with rheumatoid arthritis, diabetes, coeliac disease and some drug therapies, such as NSAIDs or PPIs. Treatment with budesonide or 5-aminosalicylates is usually effective but the condition will recur in some patients on discontinuation of therapy.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1855"><ce:section-title id="st1800">Irritable bowel syndrome</ce:section-title><ce:para id="p5435">Irritable bowel syndrome (IBS) is characterised by recurrent abdominal pain in association with abnormal defecation in the absence of a structural abnormality of the gut. About 10–15% of the population are affected at some time but only 10% of these consult their doctors because of symptoms. Nevertheless, IBS is the most common cause of gastrointestinal referral and accounts for frequent absenteeism from work and impaired quality of life. Young women are affected 2–3 times more often than men. Coexisting conditions, such as non-ulcer dyspepsia, chronic fatigue syndrome, dysmenorrhoea and fibromyalgia, are common. IBS is sometimes associated with a history of physical or sexual abuse and this is an important aspect of the history as these patients benefit from psychologically based therapy.</ce:para><ce:section id="s1860"><ce:section id="s1865"><ce:section id="s1870"><ce:section-title id="st1805">Pathophysiology</ce:section-title><ce:para id="p5440">The cause of IBS is incompletely understood but biopsychosocial factors are thought to play an important role, along with luminal factors, such as diet and the gut microbiota, as discussed below.</ce:para><ce:section id="s1875"><ce:section-title id="st1810">Behavioural and psychosocial factors</ce:section-title><ce:para id="p5445">Most patients seen in general practice do not have psychological problems but about 50% of patients referred to hospital have a psychiatric illness, such as anxiety, depression, somatisation and neurosis. Panic attacks are also common. Acute psychological stress and overt psychiatric disease are known to alter visceral perception and gastrointestinal motility. There is an increased prevalence of abnormal illness behaviour, with frequent consultations for minor symptoms and reduced coping ability (<ce:intra-ref id="ii0420" xlink:href="pii:B978-0-7020-7028-0.00028-7#s1025">p. 1202</ce:intra-ref>). These factors contribute to but do not cause IBS.</ce:para></ce:section><ce:section id="s1880"><ce:section-title id="st1815">Physiological factors</ce:section-title><ce:para id="p5450">There is some evidence that IBS may be a serotoninergic (5-HT) disorder, as evidenced by relatively excessive release of 5-HT in diarrhoea-predominant IBS (D-IBS) and relative deficiency with constipation-predominant IBS (C-IBS). Accordingly, 5-HT<ce:inf loc="post">3</ce:inf> receptor antagonists are effective in D-IBS, while 5-HT<ce:inf loc="post">4</ce:inf> agonists improve bowel function in C-IBS. There is some evidence that IBS may represent a state of low-grade gut inflammation or immune activation, not detectable by tests, with raised numbers of mucosal mast cells that sensitise enteric neurons by releasing histamine and tryptase. Some patients respond positively to mast cell stabilisers, such as ketotifen, which supports a pathogenic role of mast cells in at least some patients. Immune activation may be associated with altered CNS processing of visceral pain signals. This is more common in women and in D-IBS, and may be triggered by a prior episode of gastroenteritis with <ce:italic>Salmonella</ce:italic> or <ce:italic>Campylobacter</ce:italic> species.</ce:para></ce:section><ce:section id="s1885"><ce:section-title id="st1820">Luminal factors</ce:section-title><ce:para id="p5455">Both quantitative and qualitative alterations in intestinal bacterial microbiota have been reported. Small intestinal bacterial overgrowth (SIBO) may be present in some patients and lead to symptoms. This ‘gut dysbiosis’ may explain the response to probiotics or the non-absorbable antibiotic rifaximin.</ce:para><ce:para id="p5460">Dietary factors are also important. Some patients have chemical food intolerances (not allergy) to poorly absorbed, short-chain carbohydrates (lactose, fructose and sorbitol, among others), collectively known as FODMAPs (fermentable oligo-, di- and monosaccharides, and polyols). Their fermentation in the colon leads to bloating, pain, wind and altered bowel habit. Non-coeliac gluten sensitivity (negative coeliac serology and normal duodenal biopsies) seems to be present in some IBS patients, while others may be intolerant of chemicals such as salicylates or benzoates, found in certain foods.</ce:para></ce:section></ce:section><ce:section id="s1890"><ce:section-title id="st1825">Clinical features</ce:section-title><ce:para id="p5465">The most common presentation is that of recurrent abdominal discomfort (<ce:cross-ref id="crf1035" refid="b0330">Box 21.63</ce:cross-ref><ce:float-anchor refid="b0330"/>). This is usually colicky or cramping in nature, felt in the lower abdomen and relieved by defecation. Abdominal bloating worsens throughout the day; the cause is unknown but it is not due to excessive intestinal gas. The bowel habit is variable. Most patients alternate between episodes of diarrhoea and constipation but it is useful to classify them as having predominantly constipation or predominantly diarrhoea. Those with constipation tend to pass infrequent pellety stools, usually in association with abdominal pain or proctalgia. Those with diarrhoea have frequent defecation but produce low-volume stools and rarely have nocturnal symptoms. Passage of mucus is common but rectal bleeding does not occur. Patients do not lose weight and are constitutionally well. Physical examination is generally unremarkable, with the exception of variable tenderness to palpation.</ce:para></ce:section><ce:section id="s1895"><ce:section-title id="st1830">Investigations</ce:section-title><ce:para id="p5490">The diagnosis is clinical in nature and can be made confidently in most patients using the Rome criteria combined with the absence of alarm symptoms, without resorting to complicated tests (<ce:cross-ref id="crf1040" refid="b0335">Box 21.64</ce:cross-ref><ce:float-anchor refid="b0335"/>). Full blood count and faecal calprotectin, with or without sigmoidoscopy, are usually done and are normal in IBS. Colonoscopy should be undertaken in older patients (over 40 years of age) to exclude colorectal cancer. Endoscopic examination is also required in patients who report rectal bleeding to exclude colon cancer and IBD. Those who present atypically require investigations to exclude other gastrointestinal diseases. Diarrhoea-predominant patients justify investigations to exclude coeliac disease (<ce:cross-ref id="crf9145" refid="s1250">p. 805</ce:cross-ref>), microscopic colitis (<ce:cross-ref id="crf9150" refid="s1840">p. 824</ce:cross-ref>), lactose intolerance (<ce:cross-ref id="crf9155" refid="s1510">p. 812</ce:cross-ref>), bile acid diarrhoea (<ce:cross-ref id="crf9160" refid="s1370">p. 809</ce:cross-ref>), thyrotoxicosis (<ce:intra-ref id="ii0445" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0095">p. 635</ce:intra-ref>) and, in developing countries, parasitic infection.</ce:para></ce:section><ce:section id="s1900"><ce:section-title id="st1835">Management</ce:section-title><ce:para id="p5550">The most important steps are to make a positive diagnosis and reassure the patient. Many people are concerned that they have developed cancer. A cycle of anxiety leading to colonic symptoms, which further heighten anxiety, can be broken by explaining that symptoms are not due to a serious underlying disease but instead are the result of behavioural, psychosocial, physiological and luminal factors. In individuals who fail to respond to reassurance, treatment is traditionally tailored to the predominant symptoms (<ce:cross-ref id="crf1045" refid="f0290">Fig. 21.54</ce:cross-ref><ce:float-anchor refid="f0290"/>). Dietary management is effective for many patients (<ce:cross-ref id="crf1050" refid="b0340">Box 21.65</ce:cross-ref><ce:float-anchor refid="b0340"/>).</ce:para><ce:para id="p5610">Up to 20% may benefit from a wheat-free diet, some may respond to lactose exclusion, and excess intake of caffeine or artificial sweeteners, such as sorbitol, should be addressed. A more restrictive, ‘low-FODMAP’ diet, supervised by a dietitian, with gradual re-introduction of different food groups, may help some patients, as may a trial of a gluten-free diet. Probiotics, in capsule form, can be effective if taken for several months, although the optimum combination of bacterial strains and dose have yet to be clarified.</ce:para><ce:para id="p5615">Patients with intractable symptoms sometimes benefit from several months of therapy with a tricyclic antidepressant, such as amitriptyline or imipramine (10–25 mg orally at night). Side-effects include dry mouth and drowsiness but these are usually mild and the drug is generally well tolerated, although patients with features of somatisation tolerate the drug poorly and lower doses should be used. It may act by reducing visceral sensation and by altering gastrointestinal motility. Anxiety and affective disorders may also require specific treatment (<ce:intra-ref id="ii0450" xlink:href="pii:B978-0-7020-7028-0.00028-7#p2385">pp. 1200 and 1198</ce:intra-ref>). The 5-HT<ce:inf loc="post">4</ce:inf> agonist prucalopride, the guanylate cyclase-C receptor agonist linaclotide, and chloride channel activators, such as lubiprostone, can be effective in constipation-predominant IBS.</ce:para><ce:para id="p5620">Trials of anti-inflammatory agents, such as ketotifen or mesalazine, and the antibiotic rifaximin may be considered in some patients with difficult symptoms but are best prescribed only after specialist referral.</ce:para><ce:para id="p5625">Psychological interventions, such as cognitive behavioural therapy, relaxation and gut-directed hypnotherapy, should be reserved for the most difficult cases. A range of complementary and alternative therapies exist; most lack a good evidence base but are popular and help some patients (<ce:cross-ref id="crf1055" refid="b0345">Box 21.66</ce:cross-ref><ce:float-anchor refid="b0345"/>).</ce:para><ce:para id="p5680">Most patients have a relapsing and remitting course. Exac­erbations often follow stressful life events, occupational dissatisfaction and difficulties with interpersonal relationships.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1930"><ce:section-title id="st1865">HIV/AIDS and the gastrointestinal tract</ce:section-title><ce:para id="p5685">Patients with HIV/AIDS may develop several symptoms referable to the gastrointestinal tract, as discussed in detail on <ce:intra-ref id="ii0455" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0160">page 316</ce:intra-ref>. HIV testing should be considered in all patients with atypical or unexplained gastrointestinal symptoms and in those resident in areas of high prevalence.</ce:para></ce:section><ce:section id="s1935"><ce:section-title id="st1870">Ischaemic gut injury</ce:section-title><ce:para id="p5690">Ischaemic gut injury is usually the result of arterial occlusion. Severe hypotension and venous insufficiency are less frequent causes. The presentation is variable, depending on the different vessels involved and the acuteness of the event. Diagnosis is often difficult.</ce:para><ce:section id="s1940"><ce:section id="s1945"><ce:section-title id="st1875">Acute small bowel ischaemia</ce:section-title><ce:para id="p5695">An embolus from the heart or aorta to the superior mesenteric artery is responsible for 40–50% of cases, thrombosis of underlying atheromatous disease for approximately 25%, and non-occlusive ischaemia due to hypotension complicating myocardial infarction, heart failure, arrhythmias or sudden blood loss for approximately 25%. Vasculitis and venous occlusion are rare causes. The clinical spectrum ranges from transient alteration of bowel function to transmural haemorrhagic necrosis and gangrene. Patients usually have evidence of cardiac disease and arrhythmia. Almost all develop abdominal pain that is more impressive than the physical findings. In the early stages, the only physical signs may be a silent, distended abdomen or diminished bowel sounds, with peritonitis developing only later.</ce:para><ce:para id="p5700">Leucocytosis, metabolic acidosis, hyperphosphataemia and hyperamylasaemia are typical. Plain abdominal X-rays show ‘thumb-printing’ due to mucosal oedema. Mesenteric or CT angiography reveals an occluded or narrowed major artery with spasm of arterial arcades, although most patients undergo laparotomy on the basis of a clinical diagnosis without angiography. Resuscitation, management of cardiac disease and intravenous antibiotic therapy, followed by laparotomy, are key steps. If treatment is instituted early, embolectomy and vascular reconstruction may salvage some small bowel. In these rare cases, a ‘second look’ laparotomy should be undertaken 24 hours later and further necrotic bowel resected. In patients at high surgical risk, thrombolysis may sometimes be effective. The results of therapy depend on early intervention; patients treated late have a 75% mortality rate. Survivors often have nutritional failure from short bowel syndrome (<ce:intra-ref id="ii0460" xlink:href="pii:B978-0-7020-7028-0.00019-6#s0365">p. 708</ce:intra-ref>) and require intensive nutritional support, including home parenteral nutrition and anticoagulation. Small bowel transplantation can be considered in selected patients. Patients with mesenteric venous thrombosis also require surgery if there are signs of peritonitis but are otherwise treated with anticoagulation. Investigations for underlying prothrombotic disorders should be performed (<ce:intra-ref id="ii0465" xlink:href="pii:B978-0-7020-7028-0.00023-8#u4055">p. 978</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1950"><ce:section-title id="st1880">Acute colonic ischaemia</ce:section-title><ce:para id="p5705">The splenic flexure and descending colon have little collateral circulation and lie in ‘watershed’ areas of arterial supply. The spectrum of injury ranges from reversible colopathy to transient colitis, colonic stricture, gangrene and fulminant pancolitis. Arterial thromboembolism is usually responsible but colonic ischaemia can also follow severe hypotension, colonic volvulus, strangulated hernia, systemic vasculitis or hypercoagulable states. Ischaemia of the descending and sigmoid colon is also a complication of abdominal aortic aneurysm surgery (where the inferior mesenteric artery is ligated). The patient is usually elderly and presents with sudden onset of cramping, left-sided, lower abdominal pain and rectal bleeding. Symptoms usually resolve spontaneously over 24–48 hours and healing occurs in 2 weeks. Some may develop a fibrous stricture or segment of colitis. A minority develop gangrene and peritonitis. The diagnosis is established by colonoscopy within 48 hours of presentation; otherwise, mucosal ulceration may have resolved. Resection is required for peritonitis.</ce:para></ce:section><ce:section id="s1955"><ce:section-title id="st1885">Chronic mesenteric ischaemia</ce:section-title><ce:para id="p5710">This results from atherosclerotic stenosis of the coeliac axis, superior mesenteric artery and inferior mesenteric artery. At least two of the three vessels must be affected for symptoms to develop. The typical presentation is with dull but severe mid- or upper abdominal pain developing about 30 minutes after eating. Weight loss is common because patients are reluctant to eat and some experience diarrhoea. Physical examination shows evidence of generalised arterial disease. An abdominal bruit is sometimes audible but is non-specific. The diagnosis is made by mesenteric angiography. Treatment is by vascular reconstruction or percutaneous angioplasty, if the patient's clinical condition permits. The condition is frequently complicated by intestinal infarction, if left untreated.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1960"><ce:section-title id="st1890">Disorders of the colon and rectum</ce:section-title><ce:section id="s1965"><ce:section-title id="st1895">Tumours of the colon and rectum</ce:section-title><ce:section id="s1970"><ce:section-title id="st1900">Polyps and polyposis syndromes</ce:section-title><ce:para id="p5715">Polyps may be neoplastic or non-neoplastic. The latter include hamartomas, metaplastic (‘hyperplastic’) polyps and inflammatory polyps. These have no malignant potential. Polyps may be single or multiple and vary from a few millimetres to several centimetres in size.</ce:para><ce:para id="p5720">Colorectal adenomas are extremely common in the Western world and the prevalence rises with age; 50% of people over 60 years of age have adenomas, and in half of these the polyps are multiple. They are more common in the rectum and distal colon and are either pedunculated or sessile. Histologically, they are classified as either tubular, villous or tubulovillous, according to the glandular architecture. Nearly all forms of colorectal carcinoma develop from adenomatous polyps, although not all polyps carry the same degree of risk. Features associated with a higher risk of subsequent malignancy are listed in <ce:cross-ref id="crf1075" refid="b0350">Box 21.67</ce:cross-ref><ce:float-anchor refid="b0350"/>.</ce:para><ce:para id="p5750">Adenomas are usually asymptomatic and discovered incidentally. Occasionally, they cause bleeding and anaemia. Villous adenomas can secrete large amounts of mucus, causing diarrhoea and hypokalaemia.</ce:para><ce:para id="p5755">Discovery of a polyp at sigmoidoscopy is an indication for colonoscopy because proximal polyps are present in 40–50% of such patients. Colonoscopic polypectomy should be carried out wherever possible, as this considerably reduces subsequent colorectal cancer risk (<ce:cross-ref id="crf1080" refid="f0295">Fig. 21.55</ce:cross-ref><ce:float-anchor refid="f0295"/>). Very large or sessile polyps can sometimes be removed safely by endoscopic mucosal resection (EMR) but many require surgery. Once all polyps have been removed, surveillance colonoscopy should be undertaken at 3–5-year intervals, as new polyps develop in 50% of patients. Patients over 75 years of age do not require repeated colon­oscopies, as their subsequent lifetime cancer risk is low.</ce:para><ce:para id="p5760">Between 10% and 20% of polyps show histological evidence of malignancy. When cancer cells are found within 2 mm of the resection margin of the polyp, when the polyp cancer is poorly differentiated or when lymphatic invasion is present, segmental colonic resection is recommended because residual tumour or lymphatic spread (in up to 10%) may be present. Malignant polyps without these features can be followed up by surveillance colonoscopy.</ce:para><ce:para id="p5765">Polyposis syndromes are classified by histopathology (<ce:cross-ref id="crf1085" refid="b0355">Box 21.68</ce:cross-ref><ce:float-anchor refid="b0355"/>). It is important to note that, while the hamartomatous polyps in Peutz–Jeghers syndrome and juvenile polyposis are not themselves neoplastic, these disorders are associated with an increased risk of malignancy of the breast, colon, ovary and thyroid.</ce:para><ce:section id="s1975"><ce:section-title id="st1905">Familial adenomatous polyposis</ce:section-title><ce:para id="p5775">Familial adenomatous polyposis (FAP) is an uncommon autosomal dominant disorder affecting 1 in 13 000 of the population and accounting for 1% of all colorectal cancers. It results from germline mutation of the tumour suppressor <ce:italic>APC</ce:italic> gene, followed by acquired mutation of the remaining allele (<ce:intra-ref id="ii0470" xlink:href="pii:B978-0-7020-7028-0.00003-2#c00003">Ch. 3</ce:intra-ref>). The <ce:italic>APC</ce:italic> gene is large and over 1400 different mutations have been reported, but most are loss-of-function mutations resulting in a truncated APC protein. This protein normally binds to and sequesters β-catenin but is unable to do so when mutated, allowing β-catenin to translocate to the nucleus, where it up-regulates the expression of many genes.</ce:para><ce:para id="p5780">Around 20% of cases arise as new mutations and have no family history. Hundreds to thousands of adenomatous colonic polyps develop in 80% of patients by age 15 (<ce:cross-ref id="crf1105" refid="f0300">Fig. 21.56</ce:cross-ref><ce:float-anchor refid="f0300"/>), with symptoms such as rectal bleeding beginning a few years later. In those affected, cancer will develop within 10–15 years of the appearance of adenomas and 90% of patients will develop colorectal cancer by the age of 50 years. Despite surveillance, approximately 1 in 4 patients with FAP have cancer by the time they undergo colectomy.</ce:para><ce:para id="p5785">A second gene involved in base excision repair (MutY homolog, <ce:italic>MUTYH</ce:italic>) has been identified and may give rise to colonic polyposis. <ce:italic>MUTYH</ce:italic> displays autosomal recessive inheritance and leads to tens to hundreds of polyps and proximal colon cancer. This variant is referred to as <ce:italic>MUTYH</ce:italic>-associated polyposis (MAP).</ce:para><ce:para id="p5790">Non-neoplastic cystic fundic gland polyps occur in the stomach but adenomatous polyps also arise uncommonly. Duodenal adenomas are found in over 90% and are most common around the ampulla of Vater. Malignant transformation to adenocarcinoma takes place in 10% and is the leading cause of death in those who have had prophylactic colectomy. Many extra-intestinal features are also seen in FAP (<ce:cross-ref id="crf1110" refid="b0360">Box 21.69</ce:cross-ref><ce:float-anchor refid="b0360"/>).</ce:para><ce:para id="p5830">Desmoid tumours occur in up to one-third of patients and usually arise in the mesentery or abdominal wall. Although benign, they may become very large, causing compression of adjacent organs, intestinal obstruction or vascular compromise, and are difficult to remove. They sometimes respond to hormonal therapy with tamoxifen, and the NSAID sulindac may bring about regression in some, by unknown mechanisms. Congenital hypertrophy of the retinal pigment epithelium (CHRPE) occurs in some cases and is seen as dark, round, pigmented retinal lesions. When present in an at-risk individual, these are 100% predictive of the presence of FAP. A variant, Turcot's syndrome, is characterised by FAP with primary CNS tumours (astrocytoma or medulloblastoma).</ce:para><ce:para id="p5835">Early identification of affected individuals before symptoms develop is essential. The diagnosis can be excluded if sigmoidoscopy is normal. In newly diagnosed cases, genetic testing should be carried out to confirm the diagnosis and identify the causal mutation. Subsequently, all first-degree relatives should also undergo testing (<ce:intra-ref id="ii0475" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0105">p. 46</ce:intra-ref>). In families with known FAP, adolescents should undergo mutation testing at 13–14 years of age and patients who are found to have the mutation should be offered colectomy after school or college education has been completed. The operation of choice is total proctocolectomy with ileal pouch–anal anastomosis. Periodic upper gastrointestinal endoscopy every 1–3 years is recommended to detect and monitor duodenal and periampullary adenomas. If large, these may be amenable to endoscopic resection.</ce:para></ce:section><ce:section id="s1980"><ce:section-title id="st1910">Peutz–Jeghers syndrome</ce:section-title><ce:para id="p5840">Multiple hamartomatous polyps occur in the small intestine and colon, as well as melanin pigmentation of the lips, mouth and digits (<ce:cross-ref id="crf1130" refid="f0305">Fig. 21.57</ce:cross-ref><ce:float-anchor refid="f0305"/>). Most cases are asymptomatic, although chronic bleeding, anaemia or intussusception can occur. There is a significant risk of small bowel or colonic adenocarcinoma and of cancer of the pancreas, lung, testis, ovary, breast and endometrium. Peutz–Jeghers syndrome is an autosomal dominant disorder, most commonly resulting from truncating mutations in a serine–threonine kinase gene on chromosome 19p (<ce:italic>STK11</ce:italic>)<ce:italic>.</ce:italic> Diagnosis requires two of the three following features:<ce:list id="ulist1035"><ce:list-item id="u3400"><ce:label>•</ce:label><ce:para id="p5845">small bowel polyposis</ce:para></ce:list-item><ce:list-item id="u3405"><ce:label>•</ce:label><ce:para id="p5850">mucocutaneous pigmentation</ce:para></ce:list-item><ce:list-item id="u3410"><ce:label>•</ce:label><ce:para id="p5855">a family history suggesting autosomal dominant inheritance.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5860">The diagnosis can be made by genetic testing but this may be inconclusive, since mutations in genes other than <ce:italic>STK11</ce:italic> can cause the disorder. Affected people should undergo regular upper endoscopy, colonoscopy and small bowel and pancreatic imaging. Polyps greater than 1 cm in size should be removed. Testicular examination is essential for men, while women should undergo pelvic examination, cervical smears and regular mammography. Asymptomatic relatives of affected patients should also undergo screening.</ce:para></ce:section><ce:section id="s1985"><ce:section-title id="st1915">Juvenile polyposis</ce:section-title><ce:para id="p5865">In juvenile polyposis, tens to hundreds of mucus-filled hamar­tomatous polyps are found in the colorectum. One-third of cases are inherited in an autosomal dominant manner and up to one-fifth develop colorectal cancer before the age of 40. The criteria for diagnosis are:<ce:list id="ulist1040"><ce:list-item id="u3415"><ce:label>•</ce:label><ce:para id="p5870">ten or more colonic juvenile polyps</ce:para></ce:list-item><ce:list-item id="u3420"><ce:label>•</ce:label><ce:para id="p5875">juvenile polyps elsewhere in the gut, <ce:italic>or</ce:italic></ce:para></ce:list-item><ce:list-item id="u3425"><ce:label>•</ce:label><ce:para id="p5880">any polyps in those with a family history.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5885">Germline mutations in the <ce:italic>SMAD4</ce:italic> gene are often found, as are <ce:italic>PTEN</ce:italic> mutations. Colonoscopy with polypectomy should be performed every 1–3 years and colectomy considered for extensive involvement.</ce:para></ce:section></ce:section><ce:section id="s1990"><ce:section-title id="st1920">Colorectal cancer</ce:section-title><ce:para id="p5890">Although relatively rare in the developing world, colorectal cancer is the second most common malignancy and the second leading cause of cancer deaths in Western countries. In the UK, the incidence is 50–60 per 100 000, equating to 30 000 cases per year. The condition becomes increasingly common over the age of 50 years.</ce:para><ce:section id="s1995"><ce:section-title id="st1925">Pathophysiology</ce:section-title><ce:para id="p5895">Both environmental and genetic factors are important in colorectal carcinogenesis (<ce:cross-ref id="crf1135" refid="f0310">Fig. 21.58</ce:cross-ref><ce:float-anchor refid="f0310"/>). Environmental factors account for the wide geographical variation in incidence and the decrease in risk seen in migrants who move from high- to low-risk countries. Dietary factors are most important and these are summarised in <ce:cross-ref id="crf1140" refid="b0365">Box 21.70</ce:cross-ref><ce:float-anchor refid="b0365"/>; other recognised risk factors are listed in <ce:cross-ref id="crf1160" refid="b0370">Box 21.71</ce:cross-ref><ce:float-anchor refid="b0370"/>.</ce:para><ce:para id="p5975">Colorectal cancer development results from the accumulation of multiple genetic mutations. There are also associated epigenetic influences, such as microRNA expression signature, and potential influences from non-coding genetic variation. Currently, there are three main pathways of genetic instability and each is associated with histological, clinical and prognostic parameters:<ce:list id="ulist1055"><ce:list-item id="u3485"><ce:label>•</ce:label><ce:para id="p5980"><ce:italic>Chromosomal instability</ce:italic>. Mutations or deletions of portions of chromosomes arise, with loss of heterozygosity (LOH) and inactivation of specific tumour suppressor genes. In LOH, one allele of a gene is deleted but gene inactivation occurs only when a subsequent unrelated mutation affects the other allele. Chromosomal instability (CIN) occurs in around 85% of colorectal cancers. <ce:cross-ref id="crf1165" refid="f0315">Figure 21.59</ce:cross-ref><ce:float-anchor refid="f0315"/> outlines some of the common genes affected by CIN.</ce:para></ce:list-item><ce:list-item id="u3490"><ce:label>•</ce:label><ce:para id="p5985"><ce:italic>Microsatellite instability</ce:italic>. This involves germline mutations in one of six genes encoding enzymes involved in repairing errors that occur normally during DNA replication (DNA mismatch repair); these genes are designated <ce:italic>hMSH2</ce:italic>, <ce:italic>hMSH6</ce:italic>, <ce:italic>hMLH1</ce:italic>, <ce:italic>hMLH3</ce:italic>, <ce:italic>hPMS1</ce:italic> and <ce:italic>hPMS2</ce:italic>. Replication errors accumulate and can be detected in ‘microsatellites’ of repetitive DNA sequences. They also occur in important regulatory genes, resulting in a genetically unstable phenotype and accumulation of multiple somatic mutations throughout the genome that eventually lead to cancer. Around 15% of sporadic cancers develop this way, as do most cases of hereditary non-polyposis colon cancer (HNPCC).</ce:para></ce:list-item><ce:list-item id="u3495"><ce:label>•</ce:label><ce:para id="p5990"><ce:italic>CpG island methylator phenotype (CIMP)</ce:italic>. This phenotype is found in approximately 20–30% of colorectal cancers and results in widespread gene hypermethylation. The result is functional loss of tumour suppressor genes.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5995">With the advent of sophisticated sequencing methodologies, such as whole-exome or whole-genome sequencing, it is becoming clear that colorectal cancer displays molecular heterogeneity resulting from both common and rare genetic variants, all displaying differing levels of penetrance.</ce:para><ce:para id="p6000">About 5–10% of colon cancers are caused by HNPCC. Pedigrees with this disorder have an autosomal dominant mode of inheritance and a positive family history of colon cancer occurring at a young age. The lifetime risk in affected individuals is 80%, with a mean age at cancer development of 45 years. In contrast to sporadic colon cancer, two-thirds of tumours occur proximally. The diagnostic criteria are listed in <ce:cross-ref id="crf1170" refid="b0375">Box 21.72</ce:cross-ref><ce:float-anchor refid="b0375"/>. In a subset of patients, there is also an increased incidence of cancers of the endometrium, ovary, urinary tract, stomach, pancreas, small intestine and CNS, related to inheritance of different mismatch repair gene mutations. Those who fulfil the criteria for HNPCC should be referred for pedigree assessment, genetic testing (see above) and colonoscopy. These should begin around 25 years of age or 5–10 years earlier than the youngest case of cancer in the family. Colonoscopy needs to be repeated every 1–2 years but, even then, interval cancers can still occur.</ce:para><ce:para id="p6030">A family history of colorectal cancer can be obtained in 20% of patients who do not fulfil the criteria for HNPCC. In these families, the lifetime risk of developing colon cancer is 1 in 12 and 1 in 6, respectively, when one or two first-degree relatives are affected. The risk is even higher if relatives were affected at an early age. The genes responsible for these cases are, however, unknown.</ce:para><ce:para id="p6035">Most colorectal cancers are ‘sporadic’ and arise from malignant transformation of a benign adenomatous polyp. Over 65% occur in the rectosigmoid and a further 15% occur in the caecum or ascending colon. Synchronous tumours are present in 2–5% of patients. Spread occurs through the bowel wall. Rectal cancers may invade the pelvic viscera and side walls. Lymphatic invasion is common at presentation, as is spread through both portal and systemic circulations to reach the liver and, less commonly, the lungs. Tumour stage at diagnosis is the most important determinant of prognosis (<ce:cross-ref id="crf1180" refid="f0320">Fig. 21.60</ce:cross-ref><ce:float-anchor refid="f0320"/>).</ce:para></ce:section><ce:section id="s2010"><ce:section-title id="st1940">Clinical features</ce:section-title><ce:para id="p6040">Symptoms vary, depending on the site of the carcinoma. In tumours of the left colon, fresh rectal bleeding is common and obstruction occurs early. Tumours of the right colon present with anaemia from occult bleeding or with altered bowel habit, but obstruction is a late feature. Colicky lower abdominal pain is present in two-thirds of patients and rectal bleeding occurs in 50%. A minority present with features of either obstruction or perforation, leading to peritonitis, localised abscess or fistula formation. Carcinoma of the rectum usually causes early bleeding, mucus discharge or a feeling of incomplete emptying. Between 10% and 20% of patients present with iron deficiency anaemia or weight loss. On examination, there may be a palpable mass, signs of anaemia or hepatomegaly from metastases. Low rectal tumours may be palpable on digital examination.</ce:para></ce:section><ce:section id="s2015"><ce:section-title id="st1945">Investigations</ce:section-title><ce:para id="p6045">Colonoscopy is the investigation of choice because it is more sensitive and specific than barium enema. Furthermore, lesions can be biopsied and polyps removed. Patients in whom colonoscopy is incomplete and those who are at high risk of complications can be investigated by CT colonography (virtual colonoscopy). This is a sensitive and non-invasive technique for diagnosing tumours and polyps of more than 6 mm diameter. When the diagnosis of colon cancer has been made, CT of the chest, abdomen and pelvis should be performed as a staging investigation, particularly to detect hepatic metastases. Pelvic MRI or endoanal ultrasound should be used for local staging of rectal cancer. Measurement of serum carcinoembryonic antigen (CEA) levels are of limited value in diagnosis, since values are normal in many patients, but CEA testing can be helpful during follow-up to monitor for recurrence.</ce:para></ce:section><ce:section id="s2020"><ce:section-title id="st1950">Management</ce:section-title><ce:section id="s2025"><ce:section-title id="st1955">Surgery</ce:section-title><ce:para id="p6050">All patients should be discussed at a multidisciplinary team meeting. Those with locally advanced rectal cancer should be offered neoadjuvant radiotherapy or chemoradiotherapy to increase the subsequent chance of a complete (R0) surgical resection. A 1-week course of radiotherapy just prior to surgery reduces the risk of local recurrence in operable rectal cancer. The tumour should be removed, along with adequate resection margins and pericolic lymph nodes. Continuity should be restored by direct anastomosis, wherever possible. Carcinomas within 2 cm of the anal verge may require abdominoperineal resection and formation of a colostomy. All patients should be counselled pre-operatively about the possible need for a stoma. Total mesorectal excision reduces recurrence rates and increases survival in rectal cancer. Metastatic disease confined to liver or lung should be considered for resection, as this can be potentially curative if there is truly no disease at other sites. Post-operatively, patients should undergo colonoscopy after 6–12 months and then at 5 years to search for local recurrence or development of new lesions, which occur in 6% of cases.</ce:para></ce:section><ce:section id="s2030"><ce:section-title id="st1960">Adjuvant therapy</ce:section-title><ce:para id="p6055">About 30–40% of patients have lymph node involvement at presentation (<ce:cross-ref id="crf1185" refid="f0320">Fig. 21.60</ce:cross-ref>) and are therefore at risk of recurrence. Most recurrences are within 3 years of diagnosis and affect the liver, lung, distant lymph nodes and peritoneum. Adjuvant chemotherapy with 5-fluorouracil/folinic acid or capecitabine, preferably in combination with oxaliplatin, can reduce the risk of recurrence in patients with Dukes stage C cancers and some high-risk Dukes B cancers. Post-operative radiotherapy reduces the risk of local recurrence in rectal cancer if operative resection margins are involved.</ce:para></ce:section><ce:section id="s2035"><ce:section-title id="st1965">Palliation of advanced disease</ce:section-title><ce:para id="p6060">Surgical resection of the primary tumour is appropriate for some patients with metastases to treat obstruction, bleeding or pain. Palliative chemotherapy with 5-fluorouracil/folinic acid, capecitabine, oxaliplatin or irinotecan improves survival. Patients with advanced metastatic disease may be treated with mono­clonal antibodies using bevacizumab or cetuximab, either alone or together with chemotherapy. Pelvic radiotherapy is sometimes useful for distressing rectal symptoms, such as pain, bleeding or severe tenesmus. Endoscopic laser therapy or insertion of an expandable metal stent can be used to relieve obstruction (<ce:cross-ref id="crf1190" refid="f0325">Fig. 21.61</ce:cross-ref><ce:float-anchor refid="f0325"/>).</ce:para></ce:section></ce:section><ce:section id="s2040"><ce:section-title id="st1970">Prevention and screening</ce:section-title><ce:para id="p6065">Secondary prevention aims to detect and remove lesions at an early or pre-malignant stage by screening the asymptomatic general population. Several potential methods exist:<ce:list id="ulist1065"><ce:list-item id="u3520"><ce:label>•</ce:label><ce:para id="p6070">Population-based screening of people over the age of 50 years by regular <ce:italic>faecal occult blood (FOB) testing</ce:italic> reduces colorectal cancer mortality and increases the proportion of early cancers detected. The sensitivity and specificity of these tests need to be improved. Traditionally, serial stool testing with or without subsequent colonoscopy is the screening method of choice in the UK.</ce:para></ce:list-item><ce:list-item id="u3525"><ce:label>•</ce:label><ce:para id="p6075"><ce:italic>Colonoscopy</ce:italic> remains the gold standard and allows preventative polypectomy but is expensive, requires bowel preparation and carries risks (perforation approximately 1 : 1000). Many countries lack the resources to offer this form of screening.</ce:para></ce:list-item><ce:list-item id="u3530"><ce:label>•</ce:label><ce:para id="p6080"><ce:italic>Flexible sigmoidoscopy</ce:italic> is an alternative option and has been shown to reduce overall colorectal cancer mortality by approximately 35% (70% for cases arising in the rectosigmoid). It is recommended in the USA every 5 years in all persons over the age of 50.</ce:para></ce:list-item><ce:list-item id="u3535"><ce:label>•</ce:label><ce:para id="p6085">Screening for high-risk patients by <ce:italic>molecular genetic analysis</ce:italic> is an exciting prospect but is not yet available.</ce:para></ce:list-item><ce:list-item id="u3540"><ce:label>•</ce:label><ce:para id="p6090"><ce:italic>CT colonography</ce:italic> is fast and low-risk, and offers equivalent sensitivity to colonoscopy. Disadvantages include reduced sensitivity to detect polyps of less than 6 mm, the requirement for bowel preparation, exposure to ionising radiation and its inability to offer therapeutic intent.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:section><ce:section id="s2045"><ce:section-title id="st1975">Diverticulosis</ce:section-title><ce:para id="p6095">Diverticula are acquired and are most common in the sigmoid and descending colon of middle-aged people. Asymptomatic diverticula (diverticulosis) are present in over 50% of people above the age of 70 years. Symptomatic diverticular disease supervenes in 10–25% of cases, while complicated diverticulosis (acute diverticulitis, pericolic abscess, bleeding, perforation or stricture) is uncommon.</ce:para><ce:section id="s2050"><ce:section id="s2055"><ce:section-title id="st1980">Pathophysiology</ce:section-title><ce:para id="p6100">A life-long refined diet with a relative deficiency of fibre is widely thought to be responsible and the condition is rare in populations with a high dietary fibre intake, such as in Asia, where it more often affects the right side of the colon. It is postulated that small-volume stools require high intracolonic pressures for propulsion and this leads to herniation of mucosa between the taeniae coli (<ce:cross-ref id="crf1195" refid="f0330">Fig. 21.62</ce:cross-ref><ce:float-anchor refid="f0330"/>). Diverticula consist of protrusions of mucosa covered by peritoneum. There is commonly hypertrophy of the circular muscle coat. Inflammation is thought to result from impaction of diverticula with faecoliths. This may resolve spontaneously or progress to cause haemorrhage, perforation, local abscess formation, fistula and peritonitis. Repeated attacks of inflammation lead to thickening of the bowel wall, narrowing of the lumen and eventual obstruction.</ce:para></ce:section><ce:section id="s2060"><ce:section-title id="st1985">Clinical features</ce:section-title><ce:para id="p6105">Symptoms are usually the result of associated constipation or spasm. Colicky pain is suprapubic or felt in the left iliac fossa. The sigmoid colon may be palpable and, in attacks of diverticulitis, there is local tenderness, guarding, rigidity (‘left-sided appendicitis’) and sometimes a palpable mass. During these episodes, there may be diarrhoea, rectal bleeding or fever. The differential diagnosis includes colorectal cancer, ischaemic colitis, IBD and infection. Diverticular disease may be complicated by perforation, pericolic abscess, fistula formation (usually colovesical) or acute rectal bleeding. These complications are more common in patients who take NSAIDs or aspirin. After one attack of diverticulitis, the recurrence rate is around 3% per year. Over 10–30 years, perforation, obstruction or bleeding may occur, each affecting 5% of patients.</ce:para></ce:section><ce:section id="s2065"><ce:section-title id="st1990">Investigations</ce:section-title><ce:para id="p6110">Investigations are usually performed to exclude colorectal neoplasia. Diverticula can be seen during colonoscopy or on imaging modalities such as CT scan, CT colonography or barium enema (see <ce:cross-ref id="crf1200" refid="f0080">Fig. 21.12C</ce:cross-ref>, <ce:cross-ref id="crf9165" refid="s0150">p. 773</ce:cross-ref>). In severe diverticulosis, colonoscopy requires expertise and carries a risk of perforation. CT is used to assess complications, such as perforation or pericolic abscess.</ce:para></ce:section><ce:section id="s2070"><ce:section-title id="st1995">Management</ce:section-title><ce:para id="p6115">Diverticular disease that is asymptomatic and discovered coincidentally requires no treatment. Constipation can be relieved by a high-fibre diet, with or without a bulking laxative (ispaghula husk, 1–2 sachets daily), taken with plenty of fluids. Stimulant laxatives (see <ce:cross-ref id="crf1205" refid="b0380">Box 21.73</ce:cross-ref> below) should be avoided. Antispasmodics may sometimes help. Acute attacks of diverticulitis can be treated with antibiotics active against Gram-negative and anaerobic organisms. Severe cases require intravenous fluids, intravenous antibiotics, analgesia and nasogastric suction, but randomised trials show no benefit from acute resection compared to conservative management. Emergency surgery is reserved for severe haemorrhage or perforation. Percutaneous drainage of acute paracolic abscesses can be effective and avoids the need for emergency surgery. Patients who have repeated attacks of obstruction should undergo elective surgery once the acute episode has settled, in order to resect the affected segment of bowel with restoration of continuity by primary anastomosis.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2075"><ce:section-title id="st2000">Constipation and disorders of defecation</ce:section-title><ce:para id="p6120">The clinical approach to patients with constipation and its aetiology have been described on <ce:cross-ref id="crf9170" refid="s0570">page 786</ce:cross-ref>.</ce:para><ce:section id="s2080"><ce:section-title id="st2005">Simple constipation</ce:section-title><ce:para id="p6125">Simple constipation is extremely common and does not signify underlying organic disease. It usually responds to increased dietary fibre or the use of bulking agents; an adequate fluid intake is also essential. Many types of laxative are available, and these are listed in <ce:cross-ref id="crf1210" refid="b0380">Box 21.73</ce:cross-ref><ce:float-anchor refid="b0380"/>.</ce:para></ce:section><ce:section id="s2085"><ce:section-title id="st2010">Severe idiopathic constipation</ce:section-title><ce:para id="p6135">This occurs almost exclusively in young women and often begins in childhood or adolescence. The cause is unknown but some have ‘slow transit’ with reduced motor activity in the colon. Others have ‘obstructed defecation’, resulting from inappropriate contraction of the external anal sphincter and puborectalis muscle (anismus). The condition is often resistant to treatment. Bulking agents may exacerbate symptoms but prokinetic agents or balanced solutions of polyethylene glycol ‘3350’ benefit some patients with slow transit. Glycerol suppositories and biofeedback techniques are used for those with obstructed defecation. Others benefit from agents such as prucalopride or linaclotide. Rarely, subtotal colectomy may be necessary as a last resort.</ce:para></ce:section><ce:section id="s2090"><ce:section-title id="st2015">Faecal impaction</ce:section-title><ce:para id="p6140">In faecal impaction, a large, hard mass of stool fills the rectum. This tends to occur in disabled, immobile or institutionalised patients, especially the frail elderly or those with dementia. Constipating drugs, autonomic neuropathy and painful anal conditions also contribute. Megacolon, intestinal obstruction and urinary tract infections may supervene. Perforation and bleeding from pressure-induced ulceration are occasionally seen. Treatment involves adequate hydration and careful digital disimpaction after softening the impacted stool with arachis oil enemas. Stimulants should be avoided.<ce:display><ce:textbox id="b0385" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0740" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000214/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1375" role="short">Image 85</ce:alt-text></ce:inline-figure> 21.74</ce:label><ce:alt-text id="atte1380" role="short">21.74</ce:alt-text><ce:textbox-head><ce:title id="tit0390">Constipation in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6145"><ce:list id="ulist1070"><ce:list-item id="u3545"><ce:label>•</ce:label><ce:para id="p6150"><ce:bold>Evaluation</ce:bold>: particular attention should be paid to immobility, dietary fluid and fibre intake, drugs and depression.</ce:para></ce:list-item><ce:list-item id="u3550"><ce:label>•</ce:label><ce:para id="p6155"><ce:bold>Immobility</ce:bold>: predisposes to constipation by increasing the colonic transit time; the longer this is, the greater the fluid absorption and the harder the stool.</ce:para></ce:list-item><ce:list-item id="u3555"><ce:label>•</ce:label><ce:para id="p6160"><ce:bold>Bulking agents</ce:bold>: can make matters worse in patients with slow transit times and should be avoided.</ce:para></ce:list-item><ce:list-item id="u3560"><ce:label>•</ce:label><ce:para id="p6165"><ce:bold>Overflow diarrhoea</ce:bold>: if faecal impaction develops, paradoxical overflow diarrhoea may occur. If antidiarrhoeal agents are given, the underlying impaction may worsen and result in serious complications, such as stercoral ulceration and bleeding.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section><ce:section id="s2095"><ce:section-title id="st2020">Melanosis coli and laxative misuse syndromes</ce:section-title><ce:para id="p6170">Long-term consumption of stimulant laxatives leads to accu­mulation of lipofuscin pigment in macrophages in the lamina propria. This imparts a brown discoloration to the colonic mucosa, often described as resembling ‘tiger skin’. The condition is benign and resolves when the laxatives are stopped. Prolonged laxative use may rarely result in megacolon or ‘cathartic colon’, in which barium enema demonstrates a featureless mucosa, loss of haustra and shortening of the bowel. Surreptitious laxative misuse is a psychiatric condition seen in young women, some of whom have a history of bulimia or anorexia nervosa (<ce:intra-ref id="ii0500" xlink:href="pii:B978-0-7020-7028-0.00028-7#s1085">pp. 1203 and 1204</ce:intra-ref>). They complain of refractory watery diarrhoea. Laxative use is usually denied and may continue, even when patients are undergoing investigation. Screening of urine for laxatives may reveal the diagnosis.</ce:para></ce:section><ce:section id="s2100"><ce:section-title id="st2025">Hirschsprung's disease</ce:section-title><ce:para id="p6175">This disease is characterised by constipation and colonic dilatation (megacolon) due to congenital absence of ganglion cells in the large intestine. The incidence is approximately 1 : 5000. About one-third of patients have a positive family history and, in these families, the disease is inherited in an autosomal dominant manner with incomplete penetrance. About 50% of familial cases and 15% of sporadic cases have mutations affecting the <ce:italic>RET</ce:italic> proto-oncogene, which is also implicated in multiple endocrine neoplasia (MEN) types 2 and 3 (also known as MEN 2a and 2b, respectively; <ce:intra-ref id="ii0505" xlink:href="pii:B978-0-7020-7028-0.00018-4#p5315">p. 688</ce:intra-ref>). Unlike MEN 2 and 3, which are caused by activating <ce:italic>RET</ce:italic> mutations, Hirschsprung's disease is caused by loss-of-function mutations. In some kindreds, Hirschsprung's disease and MEN can actually co-segregate and this presumably represents both ‘switch off’ and ‘switch on’ of <ce:italic>RET</ce:italic> in different tissues. Although <ce:italic>RET</ce:italic> is the most important susceptibility gene, some patients with <ce:italic>RET</ce:italic> mutations do not develop clinical Hirschsprung's disease, and mutations in other genes have been identified that interact to cause the disease. All of the genes implicated in Hirschsprung's disease are involved in the regulation of enteric neurogenesis, and the mutations cause failure of migration of neuroblasts into the gut wall during embryogenesis. Ganglion cells are absent from nerve plexuses, most commonly in a short segment of the rectum and/or sigmoid colon. As a result, the internal anal sphincter fails to relax. Constipation, abdominal distension and vomiting usually develop immediately after birth but a few cases do not present until childhood or adolescence. The rectum is empty on digital examination.</ce:para><ce:para id="p6180">A plain abdominal X-ray or barium enema shows a small rectum and colonic dilatation above the narrowed segment. Full-thickness biopsies are required to demonstrate nerve plexuses and confirm the absence of ganglion cells. Histochemical stains for acetylcholinesterase are also used. Anorectal manometry demonstrates failure of the rectum to relax with balloon distension. Treatment involves resection of the affected segment.</ce:para></ce:section><ce:section id="s2105"><ce:section-title id="st2030">Acquired megacolon</ce:section-title><ce:para id="p6185">This may develop in childhood as a result of voluntary withholding of stool during toilet training. In such cases, it presents after the first year of life and is distinguished from Hirschsprung's disease by the urge to defecate and the presence of stool in the rectum. It usually responds to osmotic laxatives.</ce:para><ce:para id="p6190">In adults, acquired megacolon has several causes. It is seen in patients with depression or dementia, either as part of the condition or as a side-effect of antidepressant drugs. Prolonged misuse of stimulant laxatives may cause degeneration of the myenteric plexus, while interruption of sensory or motor innervation may be responsible in a number of neurological disorders. Patients taking large doses of opioid analgesics can develop a megacolon: so-called ‘narcotic bowel syndrome’. Systemic sclerosis and hypothyroidism are other recognised causes.</ce:para><ce:para id="p6195">Most patients can be managed conservatively by treatment of the underlying cause, high-residue diets, laxatives and the judicious use of enemas. Prokinetics are helpful in a minority of patients. Opioid-associated constipation can be treated with the specific peripheral opioid receptor antagonist naloxegol. Subtotal colectomy is a last resort for the most severely affected patients.</ce:para></ce:section><ce:section id="s2110"><ce:section-title id="st2035">Acute colonic pseudo-obstruction</ce:section-title><ce:para id="p6200">Acute colonic pseudo-obstruction (Ogilvie's syndrome) has many causes (<ce:cross-ref id="crf1225" refid="b0390">Box 21.75</ce:cross-ref><ce:float-anchor refid="b0390"/>) and is characterised by sudden onset of painless, massive enlargement of the proximal colon; there are no features of mechanical obstruction. Bowel sounds are normal or high-pitched, rather than absent. Left untreated, it may progress to perforation, peritonitis and death.</ce:para><ce:para id="p6245">Abdominal X-rays show colonic dilatation with air extending to the rectum. Caecal diameter greater than 10 cm is associated with a high risk of perforation. Single-contrast or water-soluble barium enemas demonstrate the absence of mechanical obstruction.</ce:para><ce:para id="p6250">Management consists of treating the underlying disorder and correcting any biochemical abnormalities. The anticholinesterase neostigmine is effective in enhancing parasympathetic activity and gut motility. Decompression, with either a rectal tube or colonoscope, may be effective but needs to be repeated until the condition resolves. In severe cases, surgical or fluoroscopic defunctioning caecostomy is necessary.</ce:para></ce:section></ce:section><ce:section id="s2115"><ce:section-title id="st2040">Anorectal disorders</ce:section-title><ce:section id="s2120"><ce:section-title id="st2045">Faecal incontinence</ce:section-title><ce:para id="p6255">The normal control of anal continence is described on <ce:cross-ref id="crf9175" refid="s0090">page 770</ce:cross-ref>. Common causes of incontinence are listed in <ce:cross-ref id="crf1230" refid="b0395">Box 21.76</ce:cross-ref><ce:float-anchor refid="b0395"/>. High-risk patients include frail older people, women after childbirth and those with severe neurological/spinal disorders, learning difficulties or cognitive impairment.</ce:para><ce:para id="p6295">Patients are often embarrassed to admit incontinence and may complain only of ‘diarrhoea’. A careful history and examination, especially of the anorectum and perineum, may help to establish the underlying cause. Endoanal ultrasound is valuable for defining the integrity of the anal sphincters, while anorectal physiology and MR proctography are also useful investigations.</ce:para><ce:section id="s2125"><ce:section-title id="st2050">Management</ce:section-title><ce:para id="p6300">This is often very difficult. Underlying disorders should be treated and diarrhoea managed with loperamide, diphenoxylate or codeine phosphate. Attention must be paid to a proper diet and adequate fluid intake. Pelvic floor exercises, biofeedback and bowel retraining techniques help some patients, and those with confirmed anal sphincter defects may benefit from sphincter repair operations. Where sphincter repair is not appropriate, a trial of sacral nerve stimulation is undertaken with a view to insertion of a permanent stimulator but, if unsuccessful, creation of a neo-sphincter may be possible, by graciloplasty or by an artificial anal sphincter.</ce:para></ce:section></ce:section><ce:section id="s2130"><ce:section-title id="st2055">Haemorrhoids</ce:section-title><ce:para id="p6305">Haemorrhoids (commonly known as piles) arise from congestion of the internal and/or external venous plexuses around the anal canal. They are extremely common in adults. The aetiology is unknown, although they are associated with constipation and straining, and may develop for the first time during pregnancy. First-degree piles bleed, while second-degree piles prolapse but retract spontaneously. Third-degree piles are those that require manual replacement after prolapsing. Bright red rectal bleeding occurs after defecation. Other symptoms include pain, pruritus ani and mucus discharge; thrombosis can occur in prolapsed piles, which can be very painful (<ce:cross-ref id="crf1235" refid="f0335">Fig. 21.63</ce:cross-ref><ce:float-anchor refid="f0335"/>). Treatment involves measures to prevent constipation and straining. Band ligation is effective for many but a minority of patients require haemorrhoidectomy, which is usually curative. Haemorrhoidal artery ligation operation (HALO) procedures have been developed and may replace surgery. HALO involves using Doppler ultrasound to identify all the arteries feeding the haemorrhoids and ligating them.</ce:para></ce:section><ce:section id="s2135"><ce:section-title id="st2060">Pruritus ani</ce:section-title><ce:para id="p6310">This is common and can stem from many causes (<ce:cross-ref id="crf1240" refid="b0400">Box 21.77</ce:cross-ref><ce:float-anchor refid="b0400"/>), most of which result in contamination of the perianal skin with faecal contents.</ce:para><ce:para id="p6375">Itching may be severe and results in an itch–scratch–itch cycle that exacerbates the problem. When no underlying cause is found, all local barrier ointments and creams must be stopped. Good personal hygiene is essential, with careful washing after defecation. The perineal area must be kept dry and clean. Bulk-forming laxatives may reduce faecal soiling.</ce:para></ce:section><ce:section id="s2140"><ce:section-title id="st2065">Solitary rectal ulcer syndrome</ce:section-title><ce:para id="p6380">This is most common in young adults and occurs on the anterior rectal wall. It is thought to result from localised chronic trauma and/or ischaemia associated with disordered puborectalis function and mucosal prolapse. The ulcer is seen at sigmoidoscopy and biopsies show a characteristic accumulation of collagen.</ce:para><ce:para id="p6385">Symptoms include minor bleeding and mucus per rectum, tenesmus and perineal pain. Treatment is often difficult but avoidance of straining at defecation is important and treatment of constipation may help. Marked mucosal prolapse is treated surgically.</ce:para></ce:section><ce:section id="s2145"><ce:section-title id="st2070">Anal fissure</ce:section-title><ce:para id="p6390">In this common problem, traumatic or ischaemic damage to the anal mucosa results in a superficial mucosal tear, most commonly in the midline posteriorly. Spasm of the internal anal sphincter exacerbates the condition. Severe pain occurs on defecation and there may be minor bleeding, mucus discharge and pruritus. The skin may be indurated and an oedematous skin tag, or ‘sentinel pile’, adjacent to the fissure is common.</ce:para><ce:para id="p6395">Avoidance of constipation with bulk-forming laxatives and increased fluid intake is important. Relaxation of the internal sphincter is normally mediated by nitric oxide, and 0.2% glyceryl trinitrate, which donates nitric oxide and improves mucosal blood flow, is effective in 60–80% of patients. Diltiazem cream (2%) can be used as an alternative. Resistant cases may respond to injection of botulinum toxin into the internal anal sphincter to induce relaxation. Manual dilatation under anaesthesia leads to long-term incontinence and should not be considered. The majority of cases can be treated without surgery, but where these measures fail, healing can be achieved surgically by lateral internal anal sphincterotomy or advancement anoplasty.</ce:para></ce:section><ce:section id="s2150"><ce:section-title id="st2075">Anorectal abscesses and fistulae</ce:section-title><ce:para id="p6400">Perianal abscesses develop between the internal and external anal sphincters and may point at the perianal skin. Ischiorectal abscesses occur lateral to the sphincters in the ischiorectal fossa. They usually result from infection of anal glands by normal intestinal bacteria. Crohn's disease (<ce:cross-ref id="crf9180" refid="s1565">p. 813</ce:cross-ref>) is sometimes responsible.</ce:para><ce:para id="p6405">Patients complain of extreme perianal pain, fever and/or discharge of pus. Spontaneous rupture may lead to the development of fistulae. These may be superficial or track through the anal sphincters to reach the rectum. Abscesses are drained surgically and superficial fistulae are laid open with care to avoid sphincter damage.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2155"><ce:section-title id="st2080">Diseases of the peritoneal cavity</ce:section-title><ce:section id="s2160"><ce:section-title id="st2085">Peritonitis</ce:section-title><ce:para id="p6410">Surgical peritonitis occurs as the result of a ruptured viscus (for details see this book's companion text, <ce:italic>Principles and Practice of Surgery</ce:italic>). Peritonitis may also complicate ascites in chronic liver disease (spontaneous bacterial peritonitis, <ce:intra-ref id="ii0520" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0370">p. 864</ce:intra-ref>) or may occur in children in the absence of ascites, due to infection with <ce:italic>Streptococcus pneumoniae</ce:italic> or β-haemolytic streptococci (<ce:intra-ref id="ii0525" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1170">p. 253</ce:intra-ref>).</ce:para><ce:para id="p6415">Chlamydial peritonitis is a complication of pelvic inflammatory disease (<ce:intra-ref id="ii0530" xlink:href="pii:B978-0-7020-7028-0.00013-5#s0105">p. 336</ce:intra-ref>). The patient presents with right upper quadrant pain, pyrexia and a hepatic rub (the Fitz-Hugh–Curtis syndrome). Tuberculosis may cause peritonitis and ascites (<ce:intra-ref id="ii0535" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1030">p. 588</ce:intra-ref>).</ce:para></ce:section><ce:section id="s2165"><ce:section-title id="st2090">Tumours</ce:section-title><ce:para id="p6420">The most common is secondary adenocarcinoma from the ovary or gastrointestinal tract. Mesothelioma is a rare tumour complicating asbestos exposure. It presents as a diffuse abdominal mass, due to omental infiltration, and with ascites. The prognosis is extremely poor.</ce:para></ce:section></ce:section><ce:section id="s2170"><ce:section-title id="st2095">Other disorders</ce:section-title><ce:section id="s2175"><ce:section-title id="st2100">Endometriosis</ce:section-title><ce:para id="p6425">Ectopic endometrial tissue can become embedded on the serosal aspect of the intestine, most frequently in the sigmoid and rectum. The overlying mucosa is usually intact. Cyclical engorgement and inflammation result in pain, bleeding, diarrhoea, constipation and adhesions or obstruction. Low backache is frequent. The onset is usually between 20 and 45 years and the condition is more common in nulliparous women. Bimanual examination may reveal tender nodules in the pouch of Douglas. Endoscopic studies reveal the diagnosis only if carried out during menstruation, when a bluish mass with intact overlying mucosa is apparent. In some patients, laparoscopy is required. Treatment options include laparoscopic diathermy and hormonal therapy with progestogens (e.g. norethisterone), gonadotrophin-releasing hormone analogues or danazol.</ce:para></ce:section><ce:section id="s2180"><ce:section-title id="st2105">Pneumatosis cystoides intestinalis</ce:section-title><ce:para id="p6430">In this rare condition, multiple gas-filled submucosal cysts line the colonic and small bowel walls. The cause is unknown but the condition may be seen in patients with chronic cardiac or pulmonary disease, pyloric obstruction, systemic sclerosis or dermatomyositis. Most patients are asymptomatic, although there may be abdominal cramp, diarrhoea, tenesmus, rectal bleeding and mucus discharge. The cysts are recognised on sigmoidoscopy, plain abdominal X-rays or barium enema. Therapies reported to be effective include prolonged high-flow oxygen, elemental diets and antibiotics.</ce:para></ce:section></ce:section><ce:section id="s2185"><ce:section-title id="st2110">Diseases of the pancreas</ce:section-title><ce:section id="s2190"><ce:section-title id="st2115">Acute pancreatitis</ce:section-title><ce:para id="p6435">Acute pancreatitis accounts for 3% of all cases of abdominal pain admitted to hospital. It affects 2–28 per 100 000 of the population and is increasing in incidence. It is a potentially serious condition with an overall mortality of 10%. About 80% of all cases are mild and have a favourable outcome. Approximately 98% of deaths from pancreatitis occur in the 20% of patients with severe disease and about one-third of these arise within the first week, usually from multi-organ failure. After this time, the majority of deaths result from sepsis, especially that complicating infected necrosis. At admission, it is possible to predict patients at risk of these complications (<ce:cross-ref id="crf1245" refid="b0405">Box 21.78</ce:cross-ref><ce:float-anchor refid="b0405"/>). Individuals who are predicted to have severe pancreatitis (<ce:cross-ref id="crf1255" refid="b0410">Box 21.79</ce:cross-ref><ce:float-anchor refid="b0410"/>) and those with necrosis or other complications should be managed in a specialist centre with an intensive care unit and multidisciplinary hepatobiliary specialists.</ce:para><ce:section id="s2210"><ce:section id="s2215"><ce:section-title id="st2135">Pathophysiology</ce:section-title><ce:para id="p6580">Acute pancreatitis occurs as a consequence of premature intracellular trypsinogen activation, releasing proteases that digest the pancreas and surrounding tissue. Triggers for this are many, including alcohol, gallstones and pancreatic duct obstruction (<ce:cross-ref id="crf1265" refid="f0340">Fig. 21.64</ce:cross-ref><ce:float-anchor refid="f0340"/>). There is simultaneous activation of nuclear factor kappa B (NFκB), leading to mitochondrial dysfunction, autophagy and a vigorous inflammatory response. The normal pancreas has only a poorly developed capsule, and adjacent structures, including the common bile duct, duodenum, splenic vein and transverse colon, are commonly involved in the inflammatory process. The severity of acute pancreatitis is dependent on the balance between the activity of released proteolytic enzymes and antiproteolytic factors. The latter comprise an intracellular pancreatic trypsin inhibitor protein and circulating β<ce:inf loc="post">2</ce:inf>-macroglobulin, α<ce:inf loc="post">1</ce:inf>-antitrypsin and C1-esterase inhibitors. The causes of acute pancreatitis are listed in <ce:cross-ref id="crf1270" refid="b0415">Box 21.80</ce:cross-ref><ce:float-anchor refid="b0415"/>. Acute pancreatitis is often self-limiting, but in some patients with severe disease, local complications, such as necrosis, pseudocyst or abscess, occur, as well as systemic complications that lead to multi-organ failure.</ce:para></ce:section><ce:section id="s2230"><ce:section-title id="st2150">Clinical features</ce:section-title><ce:para id="p6680">The typical presentation is with severe, constant upper abdominal pain, of increasing intensity over 15–60 minutes, which radiates to the back. Nausea and vomiting are common. There is marked epigastric tenderness, but in the early stages (and in contrast to a perforated peptic ulcer), guarding and rebound tenderness are absent because the inflammation is principally retroperitoneal. Bowel sounds become quiet or absent as paralytic ileus develops. In severe cases, the patient becomes hypoxic and develops hypovolaemic shock with oliguria. Discoloration of the flanks (Grey Turner's sign) or the periumbilical region (Cullen's sign) is a feature of severe pancreatitis with haemorrhage. The differential diagnosis includes a perforated viscus, acute cholecystitis and myocardial infarction. Various complications may occur and these are listed in <ce:cross-ref id="crf1275" refid="b0420">Box 21.81</ce:cross-ref><ce:float-anchor refid="b0420"/>.</ce:para><ce:para id="p6690">A collection of fluid and debris may develop in the lesser sac, following inflammatory rupture of the pancreatic duct; this is known as a pancreatic fluid collection. It is initially contained within a poorly defined, fragile wall of granulation tissue, which matures over a 6-week period to form a fibrous capsule (<ce:cross-ref id="crf1280" refid="f0345">Fig. 21.65</ce:cross-ref><ce:float-anchor refid="f0345"/>). Such ‘pseudocysts’ are common and usually asymptomatic, resolving as the pancreatitis recovers. Pseudocysts greater than 6 cm in diameter seldom disappear spontaneously and can cause constant abdominal pain and compress or erode surrounding structures, including blood vessels, to form pseudoaneurysms. Large pseudocysts can be detected clinically as a palpable abdominal mass.</ce:para><ce:para id="p6695">Pancreatic ascites occurs when fluid leaks from a disrupted pancreatic duct into the peritoneal cavity. Leakage into the thoracic cavity can result in a pleural effusion or a pleuro-pancreatic fistula.</ce:para></ce:section><ce:section id="s2235"><ce:section-title id="st2155">Investigations</ce:section-title><ce:para id="p6700">The diagnosis is based on raised serum amylase or lipase concentrations and ultrasound or CT evidence of pancreatic swelling. Plain X-rays should be taken to exclude other diagnoses, such as perforation or obstruction, and to identify pulmonary complications. Amylase is efficiently excreted by the kidneys and concentrations may have returned to normal if measured 24–48 hours after the onset of pancreatitis. A persistently elevated serum amylase concentration suggests pseudocyst formation. Peritoneal amylase concentrations are massively elevated in pancreatic ascites. Serum amylase concentrations are also elevated (but less so) in intestinal ischaemia, perforated peptic ulcer and ruptured ovarian cyst, while the salivary isoenzyme of amylase is elevated in parotitis. If available, serum lipase measurements are preferable to amylase, as they have greater diagnostic accuracy for acute pancreatitis.</ce:para><ce:para id="p6705">Ultrasound scanning can confirm the diagnosis, although in the earlier stages the gland may not be grossly swollen. The ultrasound scan is also useful because it may show gallstones, biliary obstruction or pseudocyst formation.</ce:para><ce:para id="p6710">Contrast-enhanced pancreatic CT performed 6–10 days after admission can be useful in assessing viability of the pancreas if persisting organ failure, sepsis or clinical deterioration is present, since these features may indicate that pancreatic necrosis has occurred. Necrotising pancreatitis is associated with decreased pancreatic enhancement on CT, following intravenous injection of contrast material. The presence of gas within necrotic material (<ce:cross-ref id="crf1285" refid="f0350">Fig. 21.66</ce:cross-ref><ce:float-anchor refid="f0350"/>) suggests infection and impending abscess formation, in which case percutaneous aspiration of material for bacterial culture should be carried out and appropriate antibiotics prescribed. Involvement of the colon, blood vessels and other adjacent structures by the inflammatory process is best seen by CT.</ce:para><ce:para id="p6715">Certain investigations stratify the severity of acute pancreatitis and have important prognostic value at the time of presentation (see <ce:cross-ref id="crf1290" refid="b0405">Boxes 21.78</ce:cross-ref> and <ce:cross-ref id="crf1295" refid="b0410">21.79</ce:cross-ref>). In addition, serial assessment of CRP is a useful indicator of progress. A peak CRP of &#x003E; 210 mg/L in the first 4 days predicts severe acute pancreatitis with 80% accuracy. It is worth noting that the serum amylase concentration has no prognostic value.</ce:para></ce:section><ce:section id="s2240"><ce:section-title id="st2160">Management</ce:section-title><ce:para id="p6720">Management comprises several related steps:<ce:list id="ulist1155"><ce:list-item id="u3880"><ce:label>•</ce:label><ce:para id="p6725">establishing the diagnosis and disease severity</ce:para></ce:list-item><ce:list-item id="u3885"><ce:label>•</ce:label><ce:para id="p6730">early resuscitation, according to whether the disease is mild or severe</ce:para></ce:list-item><ce:list-item id="u3890"><ce:label>•</ce:label><ce:para id="p6735">detection and treatment of complications</ce:para></ce:list-item><ce:list-item id="u3895"><ce:label>•</ce:label><ce:para id="p6740">treatment of the underlying cause.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p6745">Opiate analgesics should be given to treat pain and hypovolaemia should be corrected using normal saline or other crystalloids. All severe cases should be managed in a high-dependency or intensive care unit. A central venous line and urinary catheter should be inserted to monitor patients with shock. Oxygen should be given to hypoxic patients, and those who develop systemic inflammatory response syndrome (SIRS) may require ventilatory support. Hyperglycaemia should be corrected using insulin and hypocalcaemia by intravenous calcium injection.</ce:para><ce:para id="p6750">Nasogastric aspiration is required only if paralytic ileus is present. Enteral feeding, if tolerated, should be started at an early stage in patients with severe pancreatitis because they are in a severely catabolic state and need nutritional support. Enteral feeding decreases endotoxaemia and so may reduce systemic complications. Nasogastric feeding is just as effective as feeding by the nasojejunal route. Prophylaxis of thromboembolism with subcutaneous low-molecular-weight heparin is also advisable. The use of prophylactic, broad-spectrum intravenous antibiotics to prevent infection of pancreatic necrosis is not indicated, but infected necrosis is treated with antibiotics that penetrate necrotic tissue, e.g. carbapenems or quinolones, and metronidazole.</ce:para><ce:para id="p6755">Patients who present with cholangitis or jaundice in association with severe acute pancreatitis should undergo urgent ERCP to diagnose and treat choledocholithiasis. In less severe cases of gallstone pancreatitis, biliary imaging (using MRCP or EUS) can be carried out after the acute phase has resolved. If the liver function tests return to normal and ultrasound has not demonstrated a dilated biliary tree, laparoscopic cholecystectomy with an on-table cholangiogram is appropriate because any common bile duct stones have probably passed. When the operative cholangiogram detects residual common bile duct stones, these should be removed by laparoscopic exploration of the duct or by post-operative ERCP. Cholecystectomy should be undertaken within 2 weeks of resolution of pancreatitis – and preferably during the same admission – to prevent further potentially fatal attacks of pancreatitis. Patients with infected pancreatic necrosis or pancreatic abscess require urgent endoscopic drainage or minimally invasive retroperitoneal pancreatic (MIRP) necrosectomy to debride all cavities of necrotic material. Pancreatic pseudocysts can be treated by drainage into the stomach or duodenum. This is usually performed after an interval of at least 6 weeks, once a pseudocapsule has matured, by surgical or endoscopic cystogastrostomy.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2245"><ce:section-title id="st2165">Chronic pancreatitis</ce:section-title><ce:para id="p6760">Chronic pancreatitis is a chronic inflammatory disease char­acterised by fibrosis and destruction of exocrine pancreatic tissue. Diabetes mellitus occurs in advanced cases because the islets of Langerhans are involved (<ce:intra-ref id="ii0555" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0280">p. 733</ce:intra-ref>).</ce:para><ce:section id="s2250"><ce:section id="s2255"><ce:section-title id="st2170">Pathophysiology</ce:section-title><ce:para id="p6765">Around 80% of cases in Western countries result from alcohol misuse. In southern India, severe chronic calcific pancreatitis occurs in non-alcoholics, possibly as a result of malnutrition, deficiency of trace elements and micronutrients, and cassava consumption. Other causes are listed in <ce:cross-ref id="crf1300" refid="b0425">Box 21.82</ce:cross-ref><ce:float-anchor refid="b0425"/>. The pathophysiology of chronic pancreatitis is shown in <ce:cross-ref id="crf1310" refid="f0355">Figure 21.67</ce:cross-ref><ce:float-anchor refid="f0355"/>.</ce:para></ce:section><ce:section id="s2260"><ce:section-title id="st2175">Clinical features</ce:section-title><ce:para id="p6855">Chronic pancreatitis predominantly affects middle-aged alcoholic men. Almost all present with abdominal pain. In 50%, this occurs as episodes of ‘acute pancreatitis’, although each attack results in a degree of permanent pancreatic damage. Relentless, slowly progressive chronic pain without acute exacerbations affects 35% of patients, while the remainder have no pain but present with diarrhoea. Pain is due to a combination of increased pressure within the pancreatic ducts and direct involvement of peripancreatic nerves by the inflammatory process. Pain may be relieved by leaning forwards or by drinking alcohol. Approximately one-fifth of patients chronically consume opiate analgesics. Weight loss is common and results from a combination of anorexia, avoidance of food because of post-prandial pain, malabsorption and/or diabetes. Steatorrhoea occurs when more than 90% of the exocrine tissue has been destroyed; protein malabsorption develops only in the most advanced cases. Overall, 30% of patients have (secondary) diabetes but this figure rises to 70% in those with chronic calcific pancreatitis. Physical examination reveals a thin, malnourished patient with epigastric tenderness. Skin pigmentation over the abdomen and back is common and results from chronic use of a hot water bottle (erythema ab igne). Many patients have features of other alcohol- and smoking-related diseases. Complications are listed in <ce:cross-ref id="crf1315" refid="b0430">Box 21.83</ce:cross-ref><ce:float-anchor refid="b0430"/>.</ce:para></ce:section></ce:section><ce:section id="s2265"><ce:section-title id="st2180">Investigations</ce:section-title><ce:para id="p6890">Investigations (<ce:cross-ref id="crf1320" refid="b0435">Box 21.84</ce:cross-ref><ce:float-anchor refid="b0435"/> and <ce:cross-ref id="crf1330" refid="f0360">Fig. 21.68</ce:cross-ref><ce:float-anchor refid="f0360"/>) are carried out to:<ce:list id="ulist1235"><ce:list-item id="u4050"><ce:label>•</ce:label><ce:para id="p6955">make a diagnosis of chronic pancreatitis</ce:para></ce:list-item><ce:list-item id="u4055"><ce:label>•</ce:label><ce:para id="p6960">define pancreatic function</ce:para></ce:list-item><ce:list-item id="u4060"><ce:label>•</ce:label><ce:para id="p6965">demonstrate anatomical abnormalities prior to surgical intervention.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2285"><ce:section-title id="st2200">Management</ce:section-title><ce:section id="s2290"><ce:section id="s2295"><ce:section-title id="st2205">Alcohol misuse</ce:section-title><ce:para id="p6970">Alcohol avoidance is crucial in halting progression of the disease and reducing pain.</ce:para></ce:section><ce:section id="s2300"><ce:section-title id="st2210">Pain relief</ce:section-title><ce:para id="p6975">A range of analgesic drugs, particularly NSAIDs, are valuable but the severe and unremitting nature of the pain often leads to opiate use with the risk of addiction. Analgesics, such as pregabalin and tricyclic antidepressants at a low dose, may be effective. Oral pancreatic enzyme supplements suppress pancreatic secretion and their regular use reduces analgesic consumption in some patients. Patients who are abstinent from alcohol and who have severe chronic pain that is resistant to conservative measures should be considered for surgical or endoscopic pancreatic therapy (<ce:cross-ref id="crf1335" refid="b0440">Box 21.85</ce:cross-ref><ce:float-anchor refid="b0440"/>). Coeliac plexus neurolysis sometimes produces long-lasting pain relief, although relapse occurs in the majority of cases. In some patients, MRCP does not show a surgically or endoscopically correctable abnormality and, in these individuals, the only surgical approach is total pancreatectomy. Unfortunately, even after this operation, some continue to experience pain. Moreover, the procedure causes diabetes, which may be difficult to control, with a high risk of hypoglycaemia (since both insulin and glucagon are absent) and significant morbidity and mortality.</ce:para></ce:section><ce:section id="s2315"><ce:section-title id="st2225">Malabsorption</ce:section-title><ce:para id="p7015">This is treated by dietary fat restriction (with supplementary medium-chain triglyceride therapy in malnourished patients) and oral pancreatic enzyme supplements. A PPI is added to optimise duodenal pH for pancreatic enzyme activity.</ce:para></ce:section><ce:section id="s2320"><ce:section-title id="st2230">Management of complications</ce:section-title><ce:para id="p7020">Surgical or endoscopic therapy may be necessary for the management of pseudocysts, pancreatic ascites, common bile duct or duodenal stricture and the consequences of portal hypertension. Many patients with chronic pancreatitis also require treatment for other alcohol- and smoking-related diseases and for the consequences of self-neglect and malnutrition.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2325"><ce:section-title id="st2235">Autoimmune pancreatitis</ce:section-title><ce:para id="p7025">Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis that can mimic cancer but which responds to glucocorticoids. It is characterised by abdominal pain, weight loss or obstructive jaundice, without acute attacks of pancreatitis. Blood tests reveal increased serum IgG or IgG4 and the presence of other autoantibodies. Imaging shows a diffusely enlarged pancreas, narrowing of the pancreatic duct and stricturing of the lower bile duct. AIP may occur alone or with other autoimmune disorders, such as Sjögren's syndrome, primary sclerosing cholangitis or IBD. The response to glucocorticoids is usually excellent but some patients require azathioprine.</ce:para></ce:section></ce:section><ce:section id="s2330"><ce:section-title id="st2240">Congenital abnormalities affecting the pancreas</ce:section-title><ce:section id="s2335"><ce:section-title id="st2245">Pancreas divisum</ce:section-title><ce:para id="p7030">This is due to failure of the primitive dorsal and ventral ducts to fuse during embryonic development of the pancreas. As a consequence, most of the pancreatic drainage occurs through the smaller accessory ampulla rather than through the major ampulla. The condition occurs in 7–10% of the normal population and is usually asymptomatic, but some patients develop acute pancreatitis, chronic pancreatitis or atypical abdominal pain.</ce:para></ce:section><ce:section id="s2340"><ce:section-title id="st2250">Annular pancreas</ce:section-title><ce:para id="p7035">In this congenital anomaly, the pancreas encircles the second/third part of the duodenum, leading to gastric outlet obstruction. Annular pancreas is associated with malrotation of the intestine, atresias and cardiac anomalies.</ce:para></ce:section><ce:section id="s2345"><ce:section-title id="st2255">Cystic fibrosis</ce:section-title><ce:para id="p7040">This disease is considered in detail on <ce:intra-ref id="ii0565" xlink:href="pii:B978-0-7020-7028-0.00017-2#s0715">page 580</ce:intra-ref>. The major gastrointestinal manifestations are pancreatic insufficiency and meconium ileus. Peptic ulcer and hepatobiliary disease may also occur. In cystic fibrosis, pancreatic secretions are protein- and mucus-rich. The resultant viscous juice forms plugs that obstruct the pancreatic ductules, leading to progressive destruction of acinar cells. Steatorrhoea is universal and the large-volume bulky stools predispose to rectal prolapse. Malnutrition is compounded by the metabolic demands of respiratory failure and by diabetes, which develops in 40% of patients by adolescence.</ce:para><ce:para id="p7045">Nutritional counselling and supervision are important to ensure intake of high-energy foods, providing 120–150% of the recommended intake for normal subjects. Fats are an important calorie source and, despite the presence of steatorrhoea, fat intake should not be restricted. Supplementary fat-soluble vitamins are also necessary. High-dose oral pancreatic enzymes are required, in doses sufficient to control steatorrhoea and stool frequency. A PPI aids fat digestion by producing an optimal duodenal pH.</ce:para><ce:section id="s2350"><ce:section-title id="st2260">Meconium ileus</ce:section-title><ce:para id="p7050">Mucus-rich plugs within intestinal contents can obstruct the small or large intestine of a newborn child. Meconium ileus is treated by the mucolytic agent <ce:italic>N</ce:italic>-acetylcysteine, given either orally, by Gastrografin enema or by gut lavage using polyethylene glycol. In resistant cases of meconium ileus, surgical resection may be necessary.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2355"><ce:section-title id="st2265">Tumours of the pancreas</ce:section-title><ce:section id="s2360"><ce:section-title id="st2270">Adenocarcinoma of the pancreas</ce:section-title><ce:para id="p7055">Some 90% of pancreatic neoplasms are adenocarcinomas that arise from the pancreatic ducts. These tumours involve local structures and metastasise to regional lymph nodes at an early stage. Most patients have advanced disease at the time of presentation. Neuro-endocrine tumours also arise in the pancreas but tend to grow more slowly and have a better prognosis; these are discussed in detail on <ce:intra-ref id="ii0570" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1305">page 678</ce:intra-ref>. Pancreatic adenocarcinoma affects 10–15 per 100 000 in Western populations, rising to 100 per 100 000 in those over the age of 70. Men are affected twice as often as women. The disease is associated with increasing age, smoking and chronic pancreatitis. Between 5% and 10% of patients have a genetic predisposition: hereditary pancreatitis, HNPCC and familial atypical mole multiple melanoma syndrome (FAMMM). Overall survival is only 3–5%, with a median survival of 6–10 months for those with locally advanced disease and 3–5 months if metastases are present.</ce:para><ce:section id="s2365"><ce:section-title id="st2275">Clinical features</ce:section-title><ce:para id="p7060">Many patients are asymptomatic until an advanced stage, when they present with central abdominal pain, weight loss and obstructive jaundice (<ce:cross-ref id="crf1340" refid="f0365">Fig. 21.69</ce:cross-ref><ce:float-anchor refid="f0365"/>). The pain results from invasion of the coeliac plexus and is characteristically incessant and gnawing. It often radiates from the upper abdomen through to the back and may be eased a little by bending forwards. Almost all patients lose weight and many are cachectic. Around 60% of tumours arise from the head of the pancreas, and involvement of the common bile duct results in the development of obstructive jaundice, often with severe pruritus. A few patients present with diarrhoea, vomiting from duodenal obstruction, diabetes mellitus, recurrent venous thrombosis, acute pancreatitis or depression. Physical examination reveals clear evidence of weight loss. An abdominal mass due to the tumour itself, a palpable gallbladder or hepatic metastasis is commonly found. A palpable gallbladder in a jaundiced patient is usually the consequence of distal biliary obstruction by a pancreatic cancer (Courvoisier's sign).</ce:para></ce:section><ce:section id="s2370"><ce:section-title id="st2280">Investigations</ce:section-title><ce:para id="p7065">The diagnosis is usually made by ultrasound and contrast-enhanced CT (<ce:cross-ref id="crf1345" refid="f0370">Fig. 21.70</ce:cross-ref><ce:float-anchor refid="f0370"/>). Diagnosis in non-jaundiced patients is often delayed because presenting symptoms are relatively non-specific. Fit patients with small, localised tumours should undergo staging to define operability. EUS or laparoscopy with laparoscopic ultrasound will define tumour size, involvement of blood vessels and metastatic spread. In patients unsuitable for surgery because of advanced disease, frailty or comorbidity, EUS- or CT-guided cytology or biopsy can be used to confirm the diagnosis (<ce:cross-ref id="crf1350" refid="f0370">Fig. 21.70</ce:cross-ref>). MRCP and ERCP are sensitive methods of diagnosing pancreatic cancer and are valuable when the diagnosis is in doubt, although differentiation between cancer and localised chronic pancreatitis can be difficult. The main role of ERCP is to insert a stent into the common bile duct to relieve obstructive jaundice in inoperable patients.</ce:para></ce:section><ce:section id="s2375"><ce:section-title id="st2285">Management</ce:section-title><ce:para id="p7070">Surgical resection is the only method of effecting cure, and 5-year survival in patients undergoing a complete resection is around 12%. Clinical trials have demonstrated improved survival (21–29%) with adjuvant chemotherapy using gemcitabine. Unfortunately, only 10–15% of tumours are resectable for cure, since most are locally advanced at the time of diagnosis. For the great majority of patients, treatment is palliative. Chemotherapy with FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) improves median survival to 11 months. Pain relief can be achieved using analgesics but, in some patients, coeliac plexus neurolysis may be required. Jaundice can be relieved by choledochojejunostomy in fit patients, whereas percutaneous or endoscopic stenting is preferable in the elderly and those with very advanced disease. Ampullary or periampullary adenocarcinomas are rare neoplasms that arise from the ampulla of Vater or adjacent duodenum. They are often polypoid and may ulcerate; they frequently infiltrate the duodenum but behave less aggressively than pancreatic adenocarcinoma. Around 25% of patients undergoing resection of ampullary or periampullary tumours survive for 5 years, in contrast to patients with pancreatic ductal cancer.</ce:para></ce:section></ce:section><ce:section id="s2380"><ce:section-title id="st2290">Incidental pancreatic mass</ce:section-title><ce:para id="p7075">Cystic neoplasms of the pancreas are increasingly being seen with widespread use of CT. These are a heterogeneous group; serous cystadenomas rarely, if ever, become malignant and do not require surgery. Mucinous cysts occur more often in women, are usually in the pancreatic tail and display a spectrum of behaviour from benign to frankly malignant. Aspiration of the cyst contents for cytology and measurement of CEA and amylase concentrations in fluid obtained at EUS can help determine whether a lesion is mucinous or not. In fit patients, all mucinous lesions should be resected. A variant, called intraductal papillary mucinous neoplasia (IPMN), is often discovered coincidentally on CT, frequently in elderly men. This may affect the main pancreatic duct with marked dilatation and plugs of mucus, or may involve a side branch. The histology varies from villous adenomatous change to dysplasia or carcinoma. Since IPMN is a pre-malignant but indolent condition, the decision to resect or to monitor depends on age and fitness of the patient and location, size and evolution of lesions.</ce:para></ce:section></ce:section></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st2295">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st2300">Books and journal articles</ce:section-title><ce:bib-reference id="bib1"><ce:label>Canard et al, 2011</ce:label><sb:reference id="sr0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>JM</ce:given-name><ce:surname>Canard</ce:surname></sb:author><sb:author><ce:given-name>J-C</ce:given-name><ce:surname>Letard</ce:surname></sb:author><sb:author><ce:given-name>L</ce:given-name><ce:surname>Palazzo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Gastrointestinal endoscopy in practice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:book><sb:date>2011</sb:date><sb:publisher><sb:name>Churchill Livingstone</sb:name><sb:location>Edinburgh</sb:location></sb:publisher></sb:book></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>Feldman, Friedman, Brandt, 2015</ce:label><sb:reference id="sr0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M</ce:given-name><ce:surname>Feldman</ce:surname></sb:author><sb:author><ce:given-name>LS</ce:given-name><ce:surname>Friedman</ce:surname></sb:author><sb:author><ce:given-name>LJ</ce:given-name><ce:surname>Brandt</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Sleisenger and Fordtran's Gastrointestinal and liver disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:book><sb:edition>10th edn</sb:edition><sb:date>2015</sb:date><sb:publisher><sb:name>Elsevier Saunders</sb:name><sb:location>Philadelphia</sb:location></sb:publisher></sb:book></sb:host></sb:reference></ce:bib-reference></ce:further-reading-sec><ce:further-reading-sec id="fs0015"><ce:section-title id="st2305">Websites</ce:section-title><ce:bib-reference id="bib3"><ce:label>,</ce:label><sb:reference id="sr0020"><sb:host><sb:e-host><ce:inter-ref id="iw0010" xlink:href="http://bsg.org.uk">bsg.org.uk</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0635"><ce:italic>British Society of Gastroenterology.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>,</ce:label><sb:reference id="sr0025"><sb:host><sb:e-host><ce:inter-ref id="iw0015" xlink:href="http://crohnsandcolitis.org.uk">crohnsandcolitis.org.uk</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0640"><ce:italic>Crohn's and Colitis UK.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>,</ce:label><sb:reference id="sr0030"><sb:host><sb:e-host><ce:inter-ref id="iw0020" xlink:href="http://coeliac.org.uk">coeliac.org.uk</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0645"><ce:italic>Coeliac UK.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>,</ce:label><sb:reference id="sr9000"><sb:host><sb:e-host><ce:inter-ref id="iw9000" xlink:href="http://coeliac.org.uk">ecco-ibd.eu</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0650"><ce:italic>European Crohn's and Colitis Organisation.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>,</ce:label><sb:reference id="sr0035"><sb:host><sb:e-host><ce:inter-ref id="iw0025" xlink:href="http://gastro.org">gastro.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0655"><ce:italic>American Gastroenterological Association and American Digestive Health Foundation.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>,</ce:label><sb:reference id="sr0040"><sb:host><sb:e-host><ce:inter-ref id="iw0030" xlink:href="http://isg.org.in">isg.org.in</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0660"><ce:italic>Indian Society of Gastroenterology.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>